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A major challenge in paediatric urology is determining which children with antenatally 
detected hydronephrosis and pelvi-ureteric junction obstruction (PUJO) need a pyeloplasty 
to relieve obstruction, and which do not. In part this is because the pathophysiology 
underpinning why children develop ‘safe’ or ‘damaging’ PUJO is not well understood. This 
research investigates whether aquaporins, as mediators of water-reabsorption from the renal 
tract, explain the mechanism behind these differing clinical outcomes. Furthermore, this 
research explores whether urinary aquaporin levels are good biomarkers to direct surgical 
management. A dual approach was employed involving interrogating an in vivo neonatal rat 
partial unilateral ureteric obstruction model, and implementing a complementary childhood 
PUJO study.  
The rodent model demonstrated that kidneys with moderate hydronephrosis had normal renal 
architecture and raised intra-renal pelvis pressure, whereas severely hydronephrotic kidneys 
displayed obstructive nephropathy. While renal aquaporin isoform expression was 
maintained in moderate hydronephrosis, several, but not all, renal aquaporin isoforms were 
downregulated in severe hydronephrosis. Following characterisation of the aquaporin 
isoforms expressed by whole normal rodent and human renal pelvis, aquaporins 1 and 3 were 
localised to the vascular endothelium and the urothelium in both species respectively. The 
rat model established that aquaporins 1 and 3 were downregulated in obstructed renal pelvis. 
Downregulation was inversely related to hydronephrosis severity and, contrary to renal 
expression, was exhibited in both moderate and severe hydronephrosis. These findings may 
indicate that reduced urothelial aquaporin expression diminishes the urinary tract’s ability to 
mitigate pressure rises, ultimately leading to severe hydronephrosis and renal damage.  
Rodent urinary aquaporin 1 excretion was unchanged between obstructed and sham rats, 
questioning the ability of this test as a non-invasive biomarker in the management of PUJO. 
A childhood PUJO study with full ethical approval is currently underway, having recruited 
18 patients thus far. This study will investigate the same parameters as the rodent model, 
confirming whether results translate to the human scenario.  
In conclusion, improving our understanding of the mechanism of renal injury through studies 
such as this will enable earlier diagnosis and better management of this important condition 










This work could not have been completed without the assistance and support of many people 
both within and outside the Bristol Renal Group. Many thanks particularly to my 
supervisors; Mr Mark Woodward for his work as the site investigator for the childhood study 
and his vital clinical and technical expertise with all surgical facets of this project. Professor 
Richard Coward for his exceptional guidance and patience through all aspects of this 
research, particularly in helping me to focus my ideas, my research direction and my writing. 
Finally, thanks to Dr Gavin Welsh for his invaluable insights into the laboratory aspects of 
the research and advice in preparing this thesis.  
Secondly, many thanks to the funding bodies who have generously supported this research 
and without whom the last 3 years of valuable research experience would not have been 
possible; The Royal College of Surgeons of England, The British Association of Paediatric 
Surgeons and the David Telling Charitable Trust.   
Thanks also to all former and current members of Bristol Renal who have helped me many 
times over the years. A special mention must be made to Jenny Hurcombe and Abi Lay who 
taught me everything I know in terms of laboratory techniques. Also to Fern Barrington who 
very generously gave her time to troubleshoot my difficulties with immunohistochemistry 
staining and went on to stain, image and assess my renal pelvis sections for aquaporin 3. 
Thank you to Hannah Rhodes for her invaluable advice regarding setting up clinical studies, 
Val Kuzmuk who very kindly counted glomeruli and assessed fibrosis in my rodent kidney 
sections and finally Pri Kutilake for his IT wizardry, and for keeping me topped up with 
copious volumes of confectionary and sweet treats.  Thanks also to Dr Anne-Marie O’Carroll 
whose equipment I used to measure rodent intra-renal pelvis pressures and Dr Phil Griffiths 
who very kindly instructed me on how to use this equipment and the computer software.   
Finally, I could not have completed this work without the incredible and unfailing support 
of my family and friends. Words cannot express my immense gratitude to my husband Dave, 
and my mum Janet, who have given so much of their time and energy to make this possible 
for me. Last, but not least, I must thank my daughter Isla, whose smile and laughter brightens 












Some of the text in this thesis is taken directly from the paper “The molecular biology of 
pelvi-ureteric junction obstruction. Pediatr Nephrol. 2017 March 13. doi10.1007/s00467-
017-3629-0” which I wrote, and which was edited by Mr Mark Woodward and Professor 
Richard Coward. 
I declare that the work in this dissertation was carried out in accordance with the 
requirements of the University’s Regulations and Code of Practice for Research Degree 
Programmes and that it has not been submitted for any other academic award. Except where 
indicated by specific reference in the text, the work is the candidate’s own work. Work done 
in collaboration with, or with the assistance of, others, is indicated as such. Any views 
expressed in the dissertation are those of the author. 
 
 










CONTENTS IN BRIEF…………………………………………………………………...iv 
TABLE OF CONTENTS………………………………………………………………….v 
TABLE OF FIGURES…………………………………………………………………..xiv 
TABLE OF TABLES…………………………………………………………………..xxiii 
LIST OF ABBREVIATIONS…………………………………………………………..xxv 
CHAPTER 1. INTRODUCTION………………………………………………………..0 
CHAPTER 2. MATERIALS AND METHODS……………………………………….59 
CHAPTER 3. ESTABLISHING AND OPTIMISING MOLECULAR BIOLOGICAL        
TECHNIQUES TO ANALYSE AQUAPORIN EXPRESSION………………………84 
CHAPTER 4. ESTABLISHING A NEONATAL RAT PARTIAL UNILATERAL 
URETERIC OBSTRUCTION MODEL………………………………………………146 
CHAPTER 5. AQUAPORIN EXPRESSION AND URINARY EXCRETION IN A       
NEONATAL RAT PARTIAL UNILATERAL URETERIC OBSTRUCTION 
MODEL…………………………………………………………………………………. 179 
CHAPTER 6. CHILDHOOD CROSS-SECTIONAL STUDY OF PELVI-
URETERIC JUNCTION OBSTRUCTION…………………………………………..249 
CHAPTER 7. CONCLUSIONS AND FUTURE WORK……………………………292 
CHAPTER 8. PUBLICATIONS AND PRESENTATIONS………………………...304 
CHAPTER 9. REFERENCES………………………………………………………...305 















CONTENTS IN BRIEF…………………………………………………………………...iv 
TABLE OF CONTENTS…………………………………………………………………v 
TABLE OF FIGURES…………………………………………………………………..xiii 
TABLE OF TABLES…………………………………………………………………...xxii 
LIST OF ABBREVIATIONS………………………………………………………….xxiv 
CHAPTER 1. INTRODUCTION ................................................................................................ 0 
1.1 GENERAL INTRODUCTION ............................................................................................................... 0 
1.2 ANTENATALLY DETECTED HYDRONEPHROSIS ................................................................................ 0 
1.2.1 Definition and grading of hydronephrosis ................................................................. 0 
1.2.2 Incidence of antenatal hydronephrosis ...................................................................... 1 
1.2.3 Aetiology of antenatal hydronephrosis ...................................................................... 2 
1.2.4 Management of antenatally detected hydronephrosis ................................................ 3 
1.3 THE PELVI-URETERIC JUNCTION .................................................................................................... 4 
1.3.1 Embryology of the pelvi-ureteric junction ................................................................. 4 
1.3.2 Anatomy and function of the pelvi-ureteric junction .................................................. 6 
1.4 PELVI-URETERIC JUNCTION OBSTRUCTION .................................................................................... 8 
1.4.1 Definition and aetiology of pelvi-ureteric junction obstruction ................................. 8 
1.4.2 Demographics of pelvi-ureteric junction obstruction ................................................ 9 
1.4.3 Diagnosis of pelvi-ureteric junction obstruction ....................................................... 9 
1.4.4 Surgical management of pelvi-ureteric junction obstruction ................................... 12 
1.4.5 Histopathological features of intrinsic pelvi-ureteric junction obstruction ............. 13 
1.4.6 Renal histopathological features of pelvi-ureteric junction obstruction .................. 14 
1.4.7 Animal models of pelvi-ureteric junction obstruction .............................................. 15 
1.4.8 Potential molecular mechanisms underpinning pelvi-ureteric junction obstruction 16 
1.4.8.1 Abnormal innervation ....................................................................................................... 16 
1.4.8.2 Myogenic factors ............................................................................................................... 18 
1.4.8.3 Increased pressure, impeded blood supply and hypoxia ................................................... 20 
1.4.8.4 Initiation of proinflammatory cytokines ............................................................................ 24 
1.4.8.4.1 Cytokines in the stenotic PUJ ...................................................................................... 24 







1.4.8.5 Inflammatory infiltrates ..................................................................................................... 25 
1.4.8.6 Profibrotic processes ......................................................................................................... 25 
1.4.8.7 Antifibrotic processes ........................................................................................................ 27 
1.4.8.8 Cellular apoptosis .............................................................................................................. 27 
1.4.8.9 Tubular function impairment............................................................................................. 29 
1.4.9 Genetic mechanistic clues in pelvi-ureteric junction obstruction ............................ 29 
1.4.10 Therapeutic manipulation in rodent unilateral ureteric obstruction ....................... 30 
1.4.10.1 Angiotensin converting enzyme and angiotensin II receptor inhibitors ............................ 30 
1.4.10.2 HMGCoA reductase inhibitors (Statins) ........................................................................... 31 
1.4.10.3 TGF-β modulation ............................................................................................................. 31 
1.4.10.4 COX-2 inhibition .............................................................................................................. 32 
1.4.11 Urinary biomarkers in pelvi-ureteric junction obstruction ...................................... 32 
1.4.11.1 Urinary biomarkers in animal studies ............................................................................... 32 
1.4.11.2 Urinary biomarkers in human studies ............................................................................... 33 
1.5 AQUAPORINS .................................................................................................................................. 36 
1.5.1 Aquaporin structure and function ............................................................................ 36 
1.5.2 Aquaporin expression in the kidney ......................................................................... 41 
1.5.3 Aquaporin regulation ............................................................................................... 47 
1.5.3.1 Regulation of renal aquaporin expression ......................................................................... 47 
1.5.3.2 Inhibition of aquaporin isoform permeability ................................................................... 52 
1.5.3.3 Gating of aquaporins ......................................................................................................... 52 
1.5.4 Aquaporin expression in urinary tract obstruction .................................................. 52 
1.5.5 Regulation of renal aquaporin expression in the presence of urinary tract 
obstruction ............................................................................................................................... 53 
1.5.6 Aquaporin expression in urothelium ........................................................................ 54 
1.5.7 Urinary aquaporin excretion ................................................................................... 54 
1.6 HYPOTHESIS AND AIMS .................................................................................................................. 58 
1.6.1 Hypothesis ................................................................................................................ 58 
1.6.2 Aims .......................................................................................................................... 58 
CHAPTER 2. MATERIALS AND METHODS ...................................................................... 59 
2.1 CELL CULTURE .............................................................................................................................. 59 
2.1.1 General cell culture .................................................................................................. 59 
2.1.2 Passage of cells ........................................................................................................ 59 
2.1.3 Culture on coverslips ............................................................................................... 60 
2.1.4 Cryopreservation of cells ......................................................................................... 60 
2.2 IMMUNOFLUORESCENCE OF CULTURED CELLS ............................................................................ 60 
2.2.1 Fixation of cultured cells ......................................................................................... 61 
2.2.2 Staining of cultured cells .......................................................................................... 61 








2.3.1 TRIzol® homogenisation ........................................................................................... 61 
2.3.2 Phase separation ...................................................................................................... 62 
2.3.3 RNA precipitation..................................................................................................... 62 
2.3.4 RNA wash ................................................................................................................. 62 
2.3.5 Dissolving the RNA .................................................................................................. 62 
2.3.6 Spectrophotometer analysis ..................................................................................... 63 
2.3.7 DNase treatment....................................................................................................... 63 
2.4 RNA EXTRACTION FROM WHOLE TISSUE ≤30 MG ........................................................................ 63 
2.4.1 RNA extraction ......................................................................................................... 63 
2.4.2 Spectrophotometer analysis ..................................................................................... 64 
2.5 REVERSE –TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) .................................... 64 
2.5.1 Reverse transcription ............................................................................................... 64 
2.5.2 Polymerase chain reaction ....................................................................................... 65 
2.5.3 Gel electrophoresis of PCR product ........................................................................ 66 
2.5.4 Imaging of PCR product .......................................................................................... 66 
2.6 REVERSE-TRANSCRIPTION REAL-TIME POLYMERASE CHAIN REACTION (RT-QPCR) 
……………………………………………………………………………………………...………………66 
2.6.1 Reverse transcription ............................................................................................... 66 
2.6.2 Spectrophotometer analysis ..................................................................................... 66 
2.6.3 Real-time polymerase chain reaction ....................................................................... 67 
2.7 EXTRACTION OF PROTEIN ............................................................................................................. 68 
2.7.1 Extraction of protein from whole cells ..................................................................... 68 
2.7.2 Extraction of protein from whole tissue ................................................................... 68 
2.7.3 Extraction of protein from whole tissue ≤30 mg ...................................................... 69 
2.8 BINCINCHONINIC ACID (BCA) PROTEIN ASSAY ........................................................................... 69 
2.9 DEGLYCOSYLATION OF PROTEINS ................................................................................................ 70 
2.10 CONCENTRATION AND FRACTIONATION OF HUMAN URINARY PROTEINS.................................... 70 
2.10.1 Ultrafiltration ........................................................................................................... 70 
2.10.2 Ultrafiltration and chemical precipitation of exosomes ........................................... 71 
2.10.3 Urine lyophilisation ................................................................................................. 71 
2.11 WESTERN BLOTTING – CHEMILUMINESCENT AND FLUORESCENT .............................................. 72 
2.11.1 Apparatus ................................................................................................................. 72 
2.11.2 Preparation of the acrylamide gel ........................................................................... 72 
2.11.3 Sample preparation and loading .............................................................................. 72 
2.11.4 Gel electrophoresis .................................................................................................. 73 
2.11.5 Protein transfer ........................................................................................................ 73 
2.11.6 Blocking of membrane .............................................................................................. 74 








2.11.8 Chemiluminescence imaging .................................................................................... 74 
2.11.9 Fluorescence imaging .............................................................................................. 75 
2.11.10   Membrane stripping and re-probing following western blotting .............................. 75 
2.12 SAMPLE PROCESSING FOR IMMUNOHISTOCHEMISTRY AND HISTOPATHOLOGICAL STAINING ... 75 
2.12.1 Sample fixation ......................................................................................................... 75 
2.12.2 Section cutting .......................................................................................................... 75 
2.13 IMMUNOHISTOCHEMISTRY ........................................................................................................... 76 
2.13.1 Deparaffinisation/hydration ..................................................................................... 76 
2.13.2 Antigen unmasking ................................................................................................... 76 
2.13.3 Blocking ................................................................................................................... 76 
2.13.4 Antibody incubation ................................................................................................. 76 
2.13.5 Staining .................................................................................................................... 77 
2.13.6 Dehydration and mounting ...................................................................................... 77 
2.14 MASSON’S TRICHROME STAIN ...................................................................................................... 77 
2.14.1 Deparaffinisation/hydration ..................................................................................... 77 
2.14.2 Staining .................................................................................................................... 78 
2.14.3 Dehydration and mounting ...................................................................................... 78 
2.15 PERIODIC ACID SCHIFF STAIN ...................................................................................................... 78 
2.15.1 Deparaffinisation/hydration ..................................................................................... 78 
2.15.2 Staining .................................................................................................................... 78 
2.15.3 Dehydration and mounting ...................................................................................... 79 
2.16 MICROSCOPY ................................................................................................................................. 79 
2.16.1 Light microscopy ...................................................................................................... 79 
2.16.1.1 Counting of glomeruli ....................................................................................................... 79 
2.16.1.2 Quantification of renal fibrosis .......................................................................................... 79 
2.16.1.3 Grading of renal pelvis AQP3 staining ............................................................................. 80 
2.16.2 Fluorescent microscopy ........................................................................................... 80 
2.17 URINE SAMPLE COLLECTION, PROCESSING AND STORAGE .......................................................... 80 
2.17.1 Rodent urine ............................................................................................................. 80 
2.17.2 Human urine............................................................................................................. 80 
2.18 URINARY CREATININE ASSAY ........................................................................................................ 81 
2.19 URINARY CREATININE MEASUREMENT ......................................................................................... 81 
2.20 URINARY AQUAPORIN 1 ELISA .................................................................................................... 81 
2.20.1 Antigen coating of plate ........................................................................................... 81 
2.20.2 Blocking of plate ...................................................................................................... 82 
2.20.3 Antibody incubation ................................................................................................. 82 









2.20.5 Plate reading ............................................................................................................ 83 
2.21 STATISTICAL ANALYSIS ................................................................................................................. 83 
CHAPTER 3. ESTABLISHING AND OPTIMISING MOLECULAR BIOLOGICAL        
TECHNIQUES TO ANALYSE AQUAPORIN EXPRESSION ................................................ 84 
3.1 INTRODUCTION .............................................................................................................................. 84 
3.2 REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION (RT-PCR) ...................................... 86 
3.3 REVERSE TRANSCRIPTION REAL TIME POLYMERASE CHAIN REACTION (RT-QPCR) ................ 88 
3.3.1 Primer design for rat aquaporin isoforms ............................................................... 88 
3.3.2 Primer validation ..................................................................................................... 91 
3.3.2.1 Rat aquaporin 1-3 primers ................................................................................................. 91 
3.3.2.2 Rat aquaporin 4 primers .................................................................................................... 93 
3.3.2.3 Rat aquaporin 5 primers .................................................................................................... 95 
3.3.2.4 Rat aquaporin 6 and 7 primers .......................................................................................... 95 
3.3.2.5 Rat aquaporin 8 and 9 primers .......................................................................................... 96 
3.3.2.6 Aquaporin 11 ..................................................................................................................... 97 
3.3.2.7 Endogenous controls ......................................................................................................... 98 
3.4 WESTERN BLOTTING ................................................................................................................... 101 
3.4.1 Aquaporin 1 ............................................................................................................ 101 
3.4.1.1 Western blotting for aquaporin 1 in an immortalised proximal tubular cell line ............. 101 
3.4.1.2 Western blotting for aquaporin 1 expression in human and rat tissue ............................. 103 
3.4.2 Aquaporin 2 ............................................................................................................ 107 
3.4.3 Aquaporin 3 ............................................................................................................ 113 
3.4.4 Aquaporin 4 ............................................................................................................ 114 
3.5 IMMUNOHISTOCHEMISTRY FOR AQUAPORINS IN FORMALIN FIXED PARAFFIN EMBEDDED HUMAN 
TISSUE……................................................................................................................................................ 115 
3.5.1 Aquaporin 1 ............................................................................................................ 115 
3.5.2 Aquaporin 2 ............................................................................................................ 119 
3.5.3 Aquaporin 3 ............................................................................................................ 120 
3.5.4 Aquaporin 4 ............................................................................................................ 121 
3.6 DETECTING URINARY AQUAPORINS ............................................................................................ 123 
3.6.1 Demonstrating urinary aquaporin 1 by western blotting ....................................... 123 
3.6.2 Urinary aquaporin 1 ELISA ................................................................................... 124 
3.6.2.1 Lyophilisation and concentration of urine samples ......................................................... 128 
3.6.2.2 Freeze thaw effect on recombinant aquaporin 1 protein standard and effect of different 
colorimetric based substrates ............................................................................................................ 130 
3.6.2.3 Effect of different colorimetric based substrates on urine AQP1 detection .................... 131 
3.6.2.4 Addition of detergent to urine samples analysed using TMB substrate .......................... 135 








3.7 DISCUSSION .................................................................................................................................. 141 
CHAPTER 4. ESTABLISHING A NEONATAL RAT PARTIAL UNILATERAL 
URETERIC OBSTRUCTION MODEL .................................................................................... 146 
4.1 INTRODUCTION ............................................................................................................................ 146 
4.2 METHODS ..................................................................................................................................... 148 
4.2.1 Training and licensing for animal studies .............................................................. 148 
4.2.2 Surgical access and feasibility studies for the PUUO procedure .......................... 148 
4.2.3 Recoverable neonatal rat anaesthesia ................................................................... 151 
4.2.4 Creation of neonatal rat PUUO ............................................................................. 153 
4.2.4.1 Retrieval of pups from the cage for surgery .................................................................... 153 
4.2.4.2 General anaesthesia ......................................................................................................... 154 
4.2.4.3 Positioning and skin preparation ..................................................................................... 154 
4.2.4.4 Surgical procedure to create left partial ureteric obstruction ........................................... 154 
4.2.4.5 Sham surgery ................................................................................................................... 157 
4.2.5 Post-operative animal care .................................................................................... 157 
4.2.5.1 Post-anaesthetic recovery ................................................................................................ 157 
4.2.5.2 Return of the neonatal rat pup to the mother and litter .................................................... 157 
4.2.5.3 Continuing animal husbandry and monitoring ................................................................ 158 
4.2.5.4 Effect of wire template diameter ..................................................................................... 158 
4.2.5.4.1 PUUO using a 0.3 mm wire template ........................................................................ 159 
4.2.5.4.2 PUUO using a 0.6 mm wire template ........................................................................ 161 
4.2.5.4.3 PUUO using a 0.4 mm wire template ........................................................................ 166 
4.2.6 End of study protocol ............................................................................................. 168 
4.2.6.1 Schedule 1 methods and retrieval of tissues .................................................................... 168 
4.2.6.2 Preparation of samples .................................................................................................... 169 
4.2.6.3 Pressure measurement within the obstructed renal pelvis ............................................... 170 
4.3 DISCUSSION .................................................................................................................................. 175 
CHAPTER 5. AQUAPORIN EXPRESSION AND URINARY EXCRETION IN A       
NEONATAL RAT PARTIAL UNILATERAL URETERIC OBSTRUCTION 
MODEL……………. .................................................................................................................... 179 
5.1 INTRODUCTION ............................................................................................................................ 179 
5.2 METHODS ..................................................................................................................................... 181 
5.2.1 Study protocol ........................................................................................................ 181 
5.2.2 Immunohistochemistry ........................................................................................... 183 
5.2.3 Statistics ................................................................................................................. 183 
5.3 RESULTS ....................................................................................................................................... 184 








5.3.2 Stratification of PUUO rats according to severity of hydronephrosis ................... 184 
5.3.3 The individual wet weight of the obstructed kidney is unchanged compared to the 
sham kidney ............................................................................................................................ 187 
5.3.4 Intra-renal pelvis pressure is increased in moderate hydronephrosis ................... 189 
5.3.5 Reduced numbers of glomeruli and increased renal fibrosis are noted in severe 
hydronephrosis ....................................................................................................................... 193 
5.3.6 Renal aquaporin mRNA expression is reduced in severe hydronephrosis ............. 196 
5.3.7 Renal aquaporin and housekeeping gene protein expression ................................ 199 
5.3.7.1 Β-actin protein expression is regulated in PUUO rats ..................................................... 199 
5.3.7.2 AQP1 protein is expressed by the cortex and medulla of rat kidney ............................... 200 
5.3.7.3 Renal AQP1 protein expression is unchanged in obstructive hydronephrosis compared to 
sham…….. ........................................................................................................................................ 201 
5.3.7.4 AQP2 protein is expressed by the cortex and medulla of rat kidney ............................... 207 
5.3.7.5 Renal AQP2 protein expression is unchanged in obstructive hydronephrosis compared to 
sham……… ...................................................................................................................................... 207 
5.3.7.6 AQP3 protein is expressed by the cortex and medulla of rat kidney ............................... 211 
5.3.7.7 Renal AQP3 protein expression is unchanged in obstructive hydronephrosis compared to 
sham………. ..................................................................................................................................... 212 
5.3.7.8 Renal AQP4 protein expression is reduced in severe hydronephrosis compared to 
sham…….. ........................................................................................................................................ 216 
5.3.8 Renal pelvis aquaporin mRNA expression is reduced in moderate and severe 
hydronephrosis ....................................................................................................................... 220 
5.3.9 Renal pelvis aquaporin protein expression ............................................................ 225 
5.3.10 Urinary AQP1 excretion is unchanged in hydronephrosis .................................... 229 
5.4 DISCUSSION .................................................................................................................................. 232 
CHAPTER 6. CHILDHOOD CROSS-SECTIONAL STUDY OF PELVI-URETERIC 
JUNCTION OBSTRUCTION .................................................................................................... 249 
6.1 INTRODUCTION ............................................................................................................................ 249 
6.2 METHODS – CHILDHOOD CROSS-SECTIONAL STUDY OF PUJ OBSTRUCTION............................. 253 
6.2.1 Study protocol ........................................................................................................ 254 
6.2.1.1 Group 1 – Children undergoing pyeloplasty for PUJ obstruction ................................... 254 
6.2.1.2 Group 2 – Children with hydronephrosis not requiring surgery ...................................... 256 
6.2.1.3 Group 3 – Children with normal kidneys ........................................................................ 256 
6.2.1.4 Inclusion criteria .............................................................................................................. 257 
6.2.1.5 Exclusion criteria ............................................................................................................ 258 
6.2.1.6 Consent for study participation ....................................................................................... 258 
6.2.2 Ethical approval and study amendments ............................................................... 258 
6.2.3 Study documentation .............................................................................................. 260 








6.2.3.2 EDGE clinical management system ................................................................................ 261 
6.2.4 Sample collection ................................................................................................... 261 
6.2.4.1 Group 1 ........................................................................................................................... 261 
6.2.4.2 Group 2 ........................................................................................................................... 262 
6.2.4.3 Group 3 ........................................................................................................................... 263 
6.2.5 Outcome measures ................................................................................................. 263 
6.2.5.1 Primary outcome measure ............................................................................................... 263 
6.2.5.2 Secondary outcome measures ......................................................................................... 263 
6.2.6 Study sample size.................................................................................................... 263 
6.2.7 Statistical analysis .................................................................................................. 264 
6.3 METHODS - WESTERN BLOTTING AND IMMUNOHISTOCHEMISTRY OF HUMAN URINARY TRACT 
SAMPLES UNRELATED TO THE CHILDHOOD STUDY .................................................................................. 264 
6.4 RESULTS - CHILDHOOD CROSS-SECTIONAL STUDY OF PUJ OBSTRUCTION ............................... 265 
6.4.1 Demographic data of study population .................................................................. 265 
6.4.2 Group 1 results ....................................................................................................... 266 
6.4.3 Group 2 results ....................................................................................................... 272 
6.4.4 Group 3 results ....................................................................................................... 272 
6.5 RESULTS - AQUAPORIN EXPRESSION AND EXCRETION BY THE NORMAL HUMAN URINARY TRACT
 ……………………………………………………………………………………………………273 
6.5.1 Aquaporin isoform mRNA expression in normal human kidney, renal pelvis and 
ureter…….. ............................................................................................................................. 273 
6.6 AQUAPORIN PROTEIN EXPRESSION BY HUMAN KIDNEY, RENAL PELVIS AND 
URETER………………………………………………………………………………………… ............... 276 
6.6.1 Aquaporin 1 ............................................................................................................ 276 
6.6.2 Aquaporin 2 ............................................................................................................ 278 
6.6.3 Aquaporin 3 ............................................................................................................ 280 
6.6.4 Aquaporin 4 ............................................................................................................ 282 
6.7 AQUAPORIN PROTEIN EXCRETION IN HUMAN URINE .................................................................. 282 
6.8 DISCUSSION .................................................................................................................................. 284 
CHAPTER 7. CONCLUSIONS AND FUTURE WORK ..................................................... 292 
7.1 CONCLUSIONS .............................................................................................................................. 292 
7.2 FUTURE WORK ............................................................................................................................. 298 
7.2.1 Laboratory techniques ........................................................................................... 298 
7.2.1.1 Immunohistochemistry .................................................................................................... 298 
7.2.1.2 Western blotting .............................................................................................................. 299 
7.2.2 Animal models ........................................................................................................ 299 
7.2.2.1 Current neonatal rat PUUO model .................................................................................. 299 








7.2.2.3 Human study ................................................................................................................... 301 
7.2.2.4 Urine proteomics ............................................................................................................. 301 
7.3 IMPLICATIONS OF THIS WORK ..................................................................................................... 302 
CHAPTER 8. PUBLICATIONS AND PRESENTATIONS ................................................. 304 
8.1 PUBLICATIONS ............................................................................................................................. 304 
8.2 POSTER PRESENTATIONS ............................................................................................................. 304 
8.3 ORAL PRESENTATIONS ................................................................................................................ 304 
CHAPTER 9. REFERENCES ................................................................................................. 305 
CHAPTER 10. APPENDICES .................................................................................................. 331 
10.1 APPENDIX 1 SOLUTION AND GEL RECIPES, CELL CULTURE MEDIA ............................................ 331 
10.1.1 Solution recipes ...................................................................................................... 331 
10.1.2 Western blotting gel recipe .................................................................................... 333 
10.1.3 Cell culture media .................................................................................................. 334 
10.2 APPENDIX 2 PRIMER SEQUENCES AND ANTIBODIES ................................................................... 334 
10.2.1 Primer sequences ................................................................................................... 334 
10.2.1.1 Human primer sequences ................................................................................................ 334 
10.2.1.2 Rat primer sequences ...................................................................................................... 336 
10.2.2 Antibodies ............................................................................................................... 337 
10.2.2.1 Primary antibodies .......................................................................................................... 337 
10.2.2.2 Secondary antibodies....................................................................................................... 337 
10.3 APPENDIX 3 STUDY SPECIFIC DOCUMENTATION ........................................................................ 339 
10.3.1 Study protocol ........................................................................................................ 339 
10.3.2 Patient information leaflets .................................................................................... 368 
10.3.3 Study consent forms ................................................................................................ 407 








Table of figures 
 
Figure 1.1 PUJ and ureteric embryological signalling pathways .......................................... 5 
Figure 1.2 Diagrammatic representation of the pelvi-ureteric junction ................................. 7 
Figure 1.3 Diagrammatic representation of pelvi-ureteric junction obstruction ................... 8 
Figure 1.4 Diagram illustrating the major steps of a dismembered pyeloplasty ................. 13 
Figure 1.5 Pathological features of intrinsic PUJO ............................................................. 14 
Figure 1.6 Pathological features of rodent models of UUO ................................................ 17 
Figure 1.7 Major mechanisms of renal injury in PUJO ....................................................... 21 
Figure 1.8 Major pathways involved in obstructive nephropathy development .................. 28 
Figure 1.9 TGF-β1 signalling via SMAD dependent pathway ............................................ 29 
Figure 1.10 Human extra-renal aquaporin expression ......................................................... 39 
Figure 1.11 A diagrammatic representation of the structure of aquaporin 1 ....................... 40 
Figure 1.12 Assembly of aquaporin monomers ................................................................... 40 
Figure 1.13 Distribution of aquaporin isoforms along the nephron .................................... 42 
Figure 1.14 Regulation of AQP2 trafficking and synthesis in renal collecting duct cells ... 50 
Figure 1.15 The mechanism of urinary exosomal AQP2 generation by renal collecting duct 
cells ...................................................................................................................................... 55 
Figure 3.1 Endpoint PCR using human genomic DNA ....................................................... 86 
Figure 3.2 Genomic DNA contamination of human whole ureter RT-PCR ....................... 87 
Figure 3.3 Ill-defined opacities present on all lanes of PCR gels ........................................ 87 







Figure 3.5 The NCBI database and Primer-BLAST are used to generate potential primer 
sequences for PCR ............................................................................................................... 89 
Figure 3.6 Example of a single primer pair report generated by Primer-BLAST ............... 89 
Figure 3.7 CLC sequence viewer generates the cDNA product sequence for a primer pair90 
Figure 3.8 Mfold .................................................................................................................. 90 
Figure 3.9 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP1 primers ...................................................................................................................... 92 
Figure 3.10 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP2 primers ...................................................................................................................... 92 
Figure 3.11 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP3 primers ...................................................................................................................... 93 
Figure 3.12 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP4 transcript 1 and 2 primers ......................................................................................... 94 
Figure 3.13 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP4 transcript 3 and 4 primers ......................................................................................... 94 
Figure 3.14 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP4 primers ...................................................................................................................... 95 
Figure 3.15 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP6 primers ...................................................................................................................... 96 
Figure 3.16 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
AQP7 primers ...................................................................................................................... 96 
Figure 3.17 Standard curve and melt curves for real-time PCR of rat liver cDNA using AQP8 
primers ................................................................................................................................. 97 
Figure 3.18 Standard curve and melt curves for real-time PCR of rat liver cDNA using AQP9 
primers ................................................................................................................................. 97 
Figure 3.19 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 






Figure 3.20 Standard curve and melt curves for real-time PCR of rat kidney cDNA using β-
actin primers ........................................................................................................................ 99 
Figure 3.21 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
RING 1 primers ................................................................................................................. 100 
Figure 3.22 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
GAPDH primers ................................................................................................................ 100 
Figure 3.23 Standard curve and melt curves for real-time PCR of rat kidney cDNA using 
PGK 1 primers ................................................................................................................... 101 
Figure 3.24 AQP1 is not expressed by conditionally immortalised proximal tubular cells
 ........................................................................................................................................... 102 
Figure 3.25 SV-40 does not switch off in conditionally immortalised proximal tubular cells
 ........................................................................................................................................... 103 
Figure 3.26 Western blot to determine optimum protein loading ...................................... 104 
Figure 3.27 Western blots demonstrating AQP1 in human kidney lysate extracted with RIPA   
buffer .................................................................................................................................. 105 
Figure 3.28 Western blot demonstrating AQP1 in human kidney lysate extracted using 
urea/thiourea buffer ............................................................................................................ 106 
Figure 3.29 Western blot demonstrating AQP1 expression in human and rat urinary tract 
tissues ................................................................................................................................. 107 
Figure 3.30 Western blot of human kidney for AQP2 generates multiple bands .............. 108 
Figure 3.31 Western blotting of human kidney for AQP2 generates multiple bands with 5% 
milk block .......................................................................................................................... 109 
Figure 3.32 Western blot of human kidney with a new AQP2 antibody ........................... 109 
Figure 3.33 Western blot of deglycosylated and non-deglycosylated human kidney samples 
for AQP2 ............................................................................................................................ 110 
Figure 3.34 Western blot of deglycosylated and non-deglycosylated rat kidney for AQP1 






Figure 3.35 Detection of AQP2 on western blotting using AQP2 overexpression lysate . 111 
Figure 3.36 Western blot demonstrating AQP2 expression in human and rat kidney protein 
lysates extracted with different buffers .............................................................................. 112 
Figure 3.37 Western blot demonstrating AQP2 expression in human and rat tissues ....... 113 
Figure 3.38 Western blot demonstrating AQP3 expression by human and rat tissues ...... 114 
Figure 3.39 Western blot demonstrating AQP4 expression by human and rat tissues ...... 114 
Figure 3.40 Immunohistochemistry demonstrating tubular staining of IgG control human 
kidney sections ................................................................................................................... 116 
Figure 3.41 DAB staining of human kidney in the absence of primary and secondary 
antibodies ........................................................................................................................... 117 
Figure 3.42 Human kidney sections do not demonstrate endogenous peroxidase activity 118 
Figure 3.43 Immunohistochemistry demonstrating AQP1 expression by human kidney, renal 
pelvis and ureter ................................................................................................................. 118 
Figure 3.44 Immunohistochemistry demonstrating AQP2 expression by human kidney and 
not by human renal pelvis and ureter ................................................................................. 119 
Figure 3.45 Immunohistochemistry demonstrating AQP3 expression by human kidney, renal 
pelvis and ureter ................................................................................................................. 120 
Figure 3.46 Immunohistochemistry for AQP4 in human kidney medulla using a Santa Cruz 
anti-AQP4 antibody ........................................................................................................... 121 
Figure 3.47 Immunohistochemistry for AQP4 in human kidney medulla using an Alomone 
anti-AQP4 antibody ........................................................................................................... 122 
Figure 3.48 Comparison of different methods of AQP1 isolation from urine ................... 124 
Figure 3.49 Urinary AQP1 ELISA standard curve ............................................................ 125 
Figure 3.50 Urinary AQP1 ELISA standard curve associated with Table 3.2 .................. 127 






Figure 3.52 Urinary AQP1 ELISA standards using ABTS substrate associated with Table 
3.5 ...................................................................................................................................... 133 
Figure 3.53 Urinary AQP1 ELISA standards using TMB substrate associated with Table 3.5
 ........................................................................................................................................... 133 
Figure 3.54 Urinary AQP1 ELISA using 0.1% SDS/PBS standard and sample diluent ... 135 
Figure 3.55 Urinary AQP1 ELISA standard curve using anti- AQP1 at 1 in 60 dilution 
associated with Table 3.9 and Table 3.10 .......................................................................... 139 
Figure 4.1 Certificates of training and licensing in animal procedures ............................. 148 
Figure 4.2 Size of a p2 rat pup ........................................................................................... 149 
Figure 4.3 Left flank incision to access the left kidney and ureter .................................... 150 
Figure 4.4 Stages of procedure to create left partial ureteric obstruction .......................... 152 
Figure 4.5 Creation of PUUO under isoflurane general anaesthetic ................................. 156 
Figure 4.6 Healing left flank wound .................................................................................. 157 
Figure 4.7 Weight of PUUO (0.3 mm wire) versus sham rats ........................................... 159 
Figure 4.8 Outcome of left PUUO created using 0.3 mm wire template .......................... 161 
Figure 4.9 Mean weight of left PUUO (0.6 mm wire) rats versus controls ....................... 162 
Figure 4.10 Outcome of left PUUO created with 0.6 mm wire template .......................... 164 
Figure 4.11 Renal pelvis and proximal ureter dimensions of PUUO (0.6 mm wire template) 
and control rats ................................................................................................................... 165 
Figure 4.12 Hydronephrotic rat kidneys created using a 0.4 mm wire template ............... 167 
Figure 4.13 Rat positioning and incision site for intra-renal pelvis pressure measurement and 
tissue retrieval .................................................................................................................... 169 
Figure 4.14 Injection of dye to confirm ureteric patency .................................................. 169 






Figure 4.16 Equipment set-up to measure intra-renal pelvis pressure ............................... 172 
Figure 4.17 Intra-renal pelvis pressure measurement using a 16G cannula and 
microrenathane tubing ....................................................................................................... 173 
Figure 4.18 Cartoon demonstrating needle insertion technique to measure intra renal pelvis 
pressure .............................................................................................................................. 173 
Figure 4.19 Modified equipment set-up to measure intra-renal pelvis .............................. 174 
Figure 4.20 Digitimer pressure transducer with attached 27G butterfly needle ................ 174 
Figure 4.21 Intra renal pelvis pressure measurement with 27G butterfly needle .............. 175 
Figure 5.1 Urine AQP1 in male versus female rats ........................................................... 182 
Figure 5.2 Timeline of neonatal rat partial unilateral ureteric obstruction model ............. 183 
Figure 5.3 Mean weight of PUUO rats versus sham rats ................................................... 184 
Figure 5.4 Renal pelvis and proximal ureter dimensions of PUUO and sham rats ........... 187 
Figure 5.5 Mean kidney weights of left PUUO rats compared to controls ....................... 188 
Figure 5.6 Intra-renal pelvis pressure traces for hydronephrotic, sham and contralateral 
kidneys ............................................................................................................................... 190 
Figure 5.7 Intra-renal pelvis pressure measurements of PUUO rats compared to sham and 
non-operated rats ................................................................................................................ 191 
Figure 5.8 Scatter plot demonstrating renal pelvis APD and intra-renal pelvis pressure in 
PUUO rats .......................................................................................................................... 192 
Figure 5.9 Mean number of glomeruli per field of view for PUUO and sham kidney sections
 ........................................................................................................................................... 193 
Figure 5.10 Masson’s Trichrome of PUUO versus sham rat kidneys ............................... 194 
Figure 5.11 Relative interstitial fibrosis affecting PUUO compared to sham rats ............ 195 







Figure 5.13 Endpoint PCR demonstrating the AQP isoforms expressed by rat whole kidney
 ........................................................................................................................................... 197 
Figure 5.14 Renal AQP isoform mRNA expression by PUUO rats compared to sham rats
 ........................................................................................................................................... 198 
Figure 5.15 Regulation of reference proteins in PUUO .................................................... 200 
Figure 5.16 Immunohistochemistry demonstrating rat kidney AQP1 expression ............. 201 
Figure 5.17 AQP1 protein expression by rat kidney in PUUO rats compared to sham rats 
from litters 2 and 3 ............................................................................................................. 203 
Figure 5.18 AQP1 protein expression by rat kidney in PUUO rats compared to sham rats 
from litters 4-6 ................................................................................................................... 205 
Figure 5.19 Repeat western blot of selected rat kidney lysates for AQP1 expression ...... 206 
Figure 5.20 Glycosylated and non-glycosylated AQP1 expression in PUUO rats compared 
to sham ............................................................................................................................... 206 
Figure 5.21 Immunohistochemistry demonstrating AQP2 expression by rat kidney ........ 207 
Figure 5.22 AQP2 protein expression by rat kidney in PUUO rats compared to sham rats 
from litters 2 and 3 ............................................................................................................. 209 
Figure 5.23 AQP2 protein expression by rat kidney in PUUO rats compared to sham rats 
litters 4-6 ............................................................................................................................ 210 
Figure 5.24 AQP2 expression in PUUO rats compared to sham rats ................................ 211 
Figure 5.25 Immunohistochemistry demonstrating AQP3 expression by rat kidney ........ 212 
Figure 5.26 AQP3 expression by rat kidney in PUUO rats compared to sham rats litters 2 
and 3 ................................................................................................................................... 213 
Figure 5.27 AQP3 protein expression by rat kidney in PUUO rats compared to sham rats 
litters 4-6 ............................................................................................................................ 215 







Figure 5.29 AQP4 expression by rat kidney in PUUO rats compared to sham rats litters 2 
and 3 ................................................................................................................................... 217 
Figure 5.30 AQP4 protein expression by rat kidney in PUUO rats compared to sham rats 
litters 4-6 ............................................................................................................................ 219 
Figure 5.31 AQP4 expression in PUUO rats compared to sham rats ................................ 220 
Figure 5.32 Endpoint PCR demonstrating the AQP isoforms expressed by rat renal pelvis
 ........................................................................................................................................... 221 
Figure 5.33 Reference genes for normalisation of rat renal pelvis mRNA expression data
 ........................................................................................................................................... 222 
Figure 5.34 Renal pelvis AQP isoform mRNA expression by PUUO rats compared to sham 
rats ...................................................................................................................................... 224 
Figure 5.35 Renal pelvis aquaporin 1, 2 and 3 protein expression .................................... 226 
Figure 5.36 Rat renal pelvis AQP3 staining in obstructed, sham and contralateral systems
 ........................................................................................................................................... 228 
Figure 5.37 Intensity of urothelial AQP3 staining in PUUO compared to sham rats ........ 229 
Figure 5.38 Urinary AQP1 ELISA standard curve associated with Table 5.5 .................. 230 
Figure 5.39 Urinary AQP1 measurements normalized to creatinine in PUUO and sham rats
 ........................................................................................................................................... 232 
Figure 6.1 Equipment used to measure intrarenal pelvis pressure in group 1 patients ...... 256 
Figure 6.2 Summary of childhood cross-sectional study of pelvi-ureteric junction obstruction
 ........................................................................................................................................... 257 
Figure 6.3 Human tissue sample preparation for storage and formalin fixation ............... 262 
Figure 6.4 Demographic details of study population ......................................................... 266 
Figure 6.5 Group 1 demographic details ........................................................................... 268 






Figure 6.7 Intra-renal pelvis pressure measurements from group 1 children .................... 270 
Figure 6.8 AQP isoform mRNA expression by human kidney ......................................... 274 
Figure 6.9 AQP isoform mRNA expression by human renal pelvis ................................. 275 
Figure 6.10 AQP isoform mRNA expression by human ureter ......................................... 275 
Figure 6.11 AQP1 protein expression by human urinary tract tissue ................................ 276 
Figure 6.12 Immunohistochemistry demonstrating the distribution of AQP1 expression 
within human urinary tract tissue ....................................................................................... 277 
Figure 6.13 AQP2 protein expression by human urinary tract tissue ................................ 278 
Figure 6.14 Immunohistochemistry demonstrating the distribution of AQP2 protein 
expression within human urinary tract tissue .................................................................... 279 
Figure 6.15 AQP3 protein expression by human urinary tract tissue ................................ 280 
Figure 6.16 Immunohistochemistry demonstrating the distribution of AQP3 protein 
expression within human urinary tract tissue .................................................................... 281 
Figure 6.17 AQP4 protein expression by human urinary tract tissue ................................ 282 
Figure 6.18 Non-glycosylated AQP1 excretion in human urine ....................................... 283 
Figure 6.19 AQP2 excretion in human urine ..................................................................... 283 
Figure 6.20 Western blot demonstrating lack of AQP3 excretion in human urine ........... 284 











Table of tables 
 
Table 1.1 The Society for Fetal Urology Hydronephrosis Grading System [18] .................. 1 
Table 1.2 Proteins/molecular pathways involved in ureteric and renal pelvis development . 6 
Table 1.3 Genes potentially involved in the pathogenesis of PUJ obstruction .................... 20 
Table 1.4 The major cytokines, growth factors, chemokines, enzymes and cytoskeletal 
proteins demonstrating altered intrarenal regulation in obstructive nephropathy ............... 24 
Table 1.5 Cytokines, growth factors, enzymes and adhesion molecules promoting or 
preventing tubulointerstitial fibrosis in ureteric obstruction ................................................ 26 
Table 1.6 Urinary proteins from studies in children with PUJO ......................................... 35 
Table 1.7 Extra-renal aquaporin expression ........................................................................ 38 
Table 1.8 Aquaporin isoform expression in kidney ............................................................. 46 
Table 1.9 Renal phenotype of murine AQP isoform congenital double knockout models 
[233, 252] ............................................................................................................................. 47 
Table 2.1 - Mastermix components of a single PCR reaction ............................................. 65 
Table 2.2 - Mastermix components of a single qPCR reaction ........................................... 67 
Table 3.1 AQP1 ELISA investigating high background in blank wells ............................ 126 
Table 3.2 Urinary AQP1 ELISA for serial dilutions of a single human urine sample ...... 128 
Table 3.3 AQP1 ELISA of concentrated/fractionated or lyophilised urine ....................... 130 
Table 3.4 Recombinant AQP1 protein standard is rendered unusable by freeze-thawing 131 
Table 3.5 Human urine AQP1 ELISA comparing ABTS and TMB substrates and 
concentrated versus native urine ........................................................................................ 134 
Table 3.6 AQP1 ELISA using TMB substrate and 0.1% SDS/PBS as standard/sample diluent







Table 3.7 AQP1 ELISA to investigate factors responsible for high background in blank wells 
using TMB substrate .......................................................................................................... 137 
Table 3.8 AQP1 ELISA to determine the optimum anti-AQP1 antibody dilution ............ 138 
Table 3.9 Optical densities of AQP1 standards using anti-AQP1 at 1 in 60 dilution ........ 139 
Table 3.10 The AQP1 ELISA detects both human and rat urinary AQP1 ........................ 140 
Table 4.1 Outcome of PUUO created with a 0.3 mm wire template ................................. 160 
Table 4.2 Outcome of PUUO created with a 0.6 mm wire template versus controls ........ 163 
Table 5.1 Outcome of PUUO created with a 0.4 mm wire template versus sham rats ..... 186 
Table 5.2 Mean kidney weights of left PUUO rats ............................................................ 188 
Table 5.3 Renal pelvis APD and intra-renal pelvis pressure in PUUO rats ...................... 192 
Table 5.4 AQP1 ELISA testing different batches of anti-AQP1 antibody and antibody 
dilutions ............................................................................................................................. 230 
Table 5.5 Optical densities of AQP1 standards ................................................................. 231 
Table 5.6 Summary of AQP isoform expression following neonatal PUUO .................... 246 
Table 6.1 Study amendments ............................................................................................. 259 
Table 6.2 Demographic details of group 1 recruits ........................................................... 271 
Table 6.3 Demographic details of group 3 recruits ........................................................... 272 
















ANH Antenatal hydronephrosis 
ANP Atrial natriuretic peptide 
APD Anteroposterior diameter 
AQP  Aquaporin 
ATP Adenosine triphosphate 
BUO Bilateral ureteric obstruction 
COX-2  Cyclooxygenase 2 
CTGF Connective tissue growth factor 
DMSA Dimercaptosuccinic acid 
DTPA Diethylene-triamine-pentaacetate  
ECM Extracellular matrix 
EGF Epidermal growth factor 
EMT Epithelial-mesenchymal transition 
eNOS Endothelial nitric oxide synthase 
ET-1  Endothelin 1 
GFR Glomerular filtration rate 
HSP-70  Heat shock protein 70 
ICAM-1  Intercellular adhesion molecule 1 
IMCD Inner medullary collecting ducts 
IRAS Integrated Research Application System 
MAG 3 Mercapto acetyl tri glycine 
MCP-1 Monocyte chemoattractant protein 1 
MCUG Micturating cystourethrogram 
MIP-1α  Macrophage inflammatory protein 1α 
MMP Matrix metalloproteinase 
NBC1 Electrogenic Na+/HCO3- cotransporter 
NBCn1 Electroneutral Na+/HCO3- cotransporter 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated B cells 
NHE3 Type 3 Na+/H+ exchanger 
NKCC2 Type 1 bumetanide sensitive Na+-K+ (NH4+) -2Cl- cotransporter 
nNOS Neuronal nitric oxide synthase 
NO Nitric oxide 
NOS Nitric oxide synthase 
PAI-1  Plasminogen activator inhibitor 1 
PDGF Platelet-derived growth factor 
PGK1 Phosphoglycerate kinase 1 
PUJ Pelvi-ureteric junction 
PUJO  Pelvi-ureteric junction obstruction 







R + D Research and development 
RANTES Regulated on activation normal T-cell expressed and secreted 
RBF Renal blood flow 
REC Research ethics committee 
ROS Reactive oxygen species 
RP Renal pelvis 
RT Reverse transcriptase 
RT-PCR Reverse transcription-polymerase chain reaction 
SEM Standard error of the mean 
TGF-β  Transforming growth factor-β 
TIMP-1  Tissue inhibitor of metalloproteinases 1 
TNF-α  Tumour necrosis factor-α 
TonE Tonicity-responsive element 
TonEBP Tonicity-responsive enhancer-binding protein 
UUO Unilateral ureteric obstruction 
VCAM-1  Vascular cell adhesion molecule 1 
VEGF Vascular endothelial growth factor 
VUR Vesicoureteric reflux 







































Chapter 1. Introduction 
 
1.1 General Introduction 
Antenatal hydronephrosis is a major clinical issue for paediatric urologists (incidence of 1 
in 200), which has become more commonly recognised, and clinically problematic in infants 
since antenatal scanning became routine. Of these children approximately 1 in 7 will have 
pelviureteric junction obstruction (PUJO), a condition where narrowing of the junction 
between the renal pelvis and ureter obstructs urine drainage from the kidney. The major 
surgical issue is deciding which children require urgent surgery to relieve obstruction and 
limit kidney damage, and which do not. This is because some children with PUJO do not 
damage their kidneys, do not require surgery and ultimately grow out of the problem. Current 
management involves serial radiological imaging including invasive radioisotope scans to 
guide surgical decision making.  The ability of these tests to adequately predict the need for 
surgery has been questioned for many years and unfortunately some children lose function 
in the affected kidney during the period of observation.  Paediatric urologists need a reliable 
non-invasive test to distinguish between those children with high pressure damaging 
obstruction and those with safe non-renal damaging PUJO.   
1.2 Antenatally detected hydronephrosis 
1.2.1 Definition and grading of hydronephrosis 
Hydronephrosis can be defined as renal collecting system dilatation [1]. It is not a diagnosis 
in itself but rather an indicator of potential urological abnormality.  It is possible to detect 
hydronephrosis as early as 12-14 weeks gestation [2], however, in the UK it is usually noted 
on the anomaly scan performed routinely at 18-20 weeks gestation. The degree of 
hydronephrosis is graded ultrasonographically using the appearances or specific 
measurements of the renal parenchyma and collecting system. Various measurements of the 
renal collecting system have been used to identify hydronephrosis, however the maximum 
measurement of the anteroposterior diameter (APD) of the renal pelvis in the transverse 
plane is most popular and is the most widely used for antenatal assessment of hydronephrosis 
[3-5]. Debate continues regarding the threshold at which the antenatal APD is considered 
abnormal [6-8], particularly since measurements may be affected by other factors such as 
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the gestation of the fetus [9, 10] and maternal hydration [11, 12].   It is commonly accepted 
that antenatal hydronephrosis (ANH) diagnosed earlier in gestation [13] or of greater 
severity [3, 14] correlates with postnatal pathology of greater significance and greater 
likelihood of surgical intervention [15].  A large meta-analysis of the literature demonstrated 
the risk of postnatal nephrourological pathology to be 11.9% for mild ANH, 45.1% for 
moderate ANH and 88.3% for severe ANH [3]. It has also been shown that antenatal renal 
pelvic dilatation increases more rapidly as gestation progresses in those with obstructive 
pathology compared to those with non-obstructed kidneys [10]. Published data suggest an 
antenatal APD≥5 mm should instigate post-natal investigation. [6, 16].  
Post-natally, the most commonly used methods to assess the degree of hydronephrosis are 
the maximum measurement of the renal anteroposterior diameter (APD) and the SFU 
(Society for Fetal Urology) grading system. The SFU grading system was first introduced in 
1993 and concentrates on evaluating the appearance of the renal parenchyma and intrarenal 




Pattern of Renal Sinus Splitting Renal 
Parenchyma 
0 No splitting Preserved 
1 Urine in pelvis barely splits sinus Preserved 
2 Urine fills intrarenal pelvis and extrarenal pelvis, 
major calyces dilated 
Preserved 
3 Grade 2 and minor calyces uniformly dilated Preserved 
4 Grade 2 and minor calyces uniformly dilated Thin 
 
Table 1.1 The Society for Fetal Urology Hydronephrosis Grading System [18] 
 
1.2.2 Incidence of antenatal hydronephrosis 
Antenatal detection of a renal abnormality by ultrasound scan was first reported in 1970 by 
Garrett et al. [19]. Over subsequent years, improvements in ultrasound technology and the 
introduction of routine antenatal scanning has resulted in increased detection of fetal 
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anomalies with greater accuracy [20]. Approximately 1-5% of fetuses have an anomaly 
detected on antenatal scanning [21-23] of which a significant proportion relate to the urinary 
tract, particularly hydronephrosis. The largest prospective data collection of non-selected 
pregnant women undergoing antenatal ultrasound at a mean gestation of 25 weeks 
demonstrated hydronephrosis (APD ≥5 mm) in 100/18766 fetuses (0.59%) [16]. More recent 
UK data, albeit with smaller study sizes of 11465 and 7000 fetuses, suggests the prevalence 
may be higher with hydronephrosis in 2.3% (APD ≥4 mm at a gestation of 18-23 weeks) 
[14] and 2% (APD ≥5 mm at a gestation of 20 weeks) [6] respectively.   
 
1.2.3 Aetiology of antenatal hydronephrosis 
The aetiology of ANH and thus the postnatal clinical significance in terms of treatment and 
prognosis is varied.    Most causes of ANH can cause unilateral or bilateral hydronephrosis 
and they may be obstructive or non-obstructive in nature. Causes include; transient 
hydronephrosis, persistent non-obstructive hydronephrosis, vesicoureteric reflux, peli-
ureteric junction obstruction, multicystic dysplastic kidney, megaureter, ureterocoele, 
ectopic ureter, posterior urethral valves and urethral atresia. The majority of patients (36-
66%) [5, 14, 16] with ANH have transient hydronephrosis which is characterized by normal 
post-natal ultrasound scans and is of unclear origin. Immaturity of the urinary tract in relation 
to urine output, fetal ureteric folds and potentially vesicoureteric reflux have been suggested 
as potential causes of transient hydronephrosis [24].   A further 10-43% have persistent 
hydronephrosis with no obstruction [5, 14, 16, 24] and this hydronephrosis resolves 
spontaneously in 47-84% of children within 24 months [5, 14, 16].  
Vesicoureteric reflux is demonstrated post-natally in 10.7-22% [5, 6, 16] of children with 
ANH, with the prevalence being affected by the institutions’ policy regarding post-natal 
micturating cystourethrogram (MCUG).  A micturating cystourethrogram is a test performed 
under x-day guidance which involves instilling radio-opaque contrast into the bladder via a 
urethral catheter followed by voiding of the contrast by the child. This test enables 
visualisation of the bladder and urethra during filling and voiding, and can identify the 
presence of reflux into the ureters. Those centres which favour performing an MCUG in all 
children with ANH, even in the presence of a normal post-natal scan, will undoubtedly 
discover more cases of low grade VUR which may be clinically asymptomatic [6].    
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Pelviureteric junction (PUJ) obstruction occurs in 3.8-12.6% [5, 6, 24] of children with ANH 
and is suspected when hydronephrosis is seen with a normal bladder and no ureteric 
dilatation on postnatal ultrasound scan.  Further radiological investigation is required to 
support this diagnosis and much controversy remains, as will be discussed in section 1.3, 
regarding the timing and indication for surgical intervention.   
Other less common causes of ANH include: megaureter (non-obstructed or obstructed), 
multicystic dysplastic kidney, ureterocoele, posterior urethral valves, ectopic ureter, prune 
belly syndrome, urethral atresia, extrinsic compression from intra-abdominal/pelvic masses 
and neurological abnormalities [24, 25]. 
 
1.2.4 Management of antenatally detected hydronephrosis   
The vast majority of children with ANH do not require intervention at birth but go on to have 
regular radiological imaging, involving serial ultrasound scan, radioisotope scans and 
invasive micturating cystourethrograms. The major aim of postnatal management is to detect 
those at risk of deterioration in kidney function and prevent problems such as pain, urinary 
tract infection and stone formation while avoiding overzealous investigation of those with 
hydronephrosis that poses no future risk.  There is however no agreed evidence-based 
consensus on post-natal investigation of these children [6, 24, 26, 27].   
Unless there is an indication of bladder outlet obstruction or hydronephrosis in a single 
kidney, the first ultrasound scan is usually performed at around 7 days of life.  It is important 
to ensure it is delayed beyond the first 48 hours as during this time the baby is usually 
relatively dehydrated and oliguric, which may underestimate hydronephrosis [24]. Ismaili et 
al. suggest a post-natal renal ultrasound scan should be performed at 5 days and 1 month. 
During their study of 213 infants they demonstrated that if one or both ultrasound scans are 
abnormal (APD≥7mm) then the sensitivity and specificity of finding a nephrourological 
pathology were 96% and 76% respectively with positive and negative predictive values of 
72% and 97% respectively [5].  Dudley et al. define hydronephrosis as an APD≥5mm and 
suggest a further ultrasound scan at 12 months for all children who initially have two normal 
scans at 1 and 6 weeks of age [16]. A follow-up ultrasound at 1 year is supported by the most 
recent consensus statement from the Society for Fetal Urology (SFU) [18] as later re-
presentation with previously resolved hydronephrosis has been documented [28, 29].  
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Hydronephrosis on post-natal ultrasound scan will prompt follow-up ultrasound scans and 
further investigation as detailed below. 
An MCUG may be performed to assess for the presence of vesicoureteric reflux and other 
lower urinary tract pathologies such as posterior urethral valves.  There is no consensus on 
which children should undergo this investigation, thus this test is variably implemented [27]. 
Some advocate an MCUG for all children who have had ANH even in the presence of normal 
post-natal ultrasound scans [6], while others perform an MCUG only when initial ultrasound 
scans have demonstrated hydronephrosis [16, 18].  Given the invasive nature of an MCUG 
and the fact that some of the VUR detected may be of doubtful significance it has been 
suggested MCUG may be safely reserved for children with higher grades of hydronephrosis 
[30].   
When post-natal ultrasound scans demonstrate persistent hydronephrosis (SFU grade 3-4 or 
an APD >10 mm), particularly but not exclusively in the absence of VUR, diuretic 
renography is performed to assess for PUJO [2, 24]. The SFU consensus statement also 
recommends that children diagnosed with severe ANH (>10 mm in the second trimester, or 
>15 mm in the third trimester) should undergo diuretic renography regardless of the grade 
of post-natal hydronephrosis if their MCUG was negative [18].   
Diuretic renography to determine differential function and drainage of the kidney may be 
achieved with both 99mTc-MAG 3 and 99mTc-DTPA radioisotopes.  99mTc-MAG 3 is 
preferred as it requires a smaller dose of radiation and has a much higher initial uptake within 
the kidney due to very high protein binding of the radioisotope, thus providing better 
parenchymal imaging and functional assessment [18, 20]. Diuretic renography should be 
performed around 6-8 weeks of age as renal immaturity may influence results obtained 
before this time [31]. 
1.3 The pelvi-ureteric junction 
1.3.1 Embryology of the pelvi-ureteric junction 
Understanding the normal embryology of PUJ formation is vital when considering where 
development may proceed incorrectly in congenital abnormalities such as PUJO. The kidney 
develops from metanephric mesoderm as far along the nephron as the distal tubules. The 
collecting duct onwards, including the major and minor calyces, renal pelvis, and ureter has 
a different embryological origin arising from the ureteric bud [32, 33]. Thus, the PUJ does 
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not represent an embryological fusion site, but is derived exclusively from the ureteric bud.  
The ureteric bud, consisting of a simple epithelial layer extending into loose mesenchyme, 
arises from the mesonephric duct during the fifth week of gestation in humans [34].  
Epithelial cell proliferation and differentiation to form transitional epithelium leads to 
luminal obliteration, which at the end of the embryonic period is corrected by physiological 
recanalisation of the ureter. Epithelial paracrine and mesenchymal autocrine signalling 
stimulates the formation of smooth muscle cells from mesenchyme which begins at 12 weeks 
gestation in humans [34, 35]. Mouse models have implicated a number of signalling 
molecules in this process of proliferation, aggregation, differentiation and orientation of 
smooth muscle cells as they encircle the urothelial tube. In postnatal mice (equivalent to 
second trimester human) increased urine production matches the development of the renal 
pelvis. This is accompanied by a second phase of muscle differentiation, particularly 
affecting the renal pelvis and proximal ureter, regulated by calcineurin and angiotensin II 
signalling. [36, 37]. The important molecular pathways that form the ureter and PUJ are 
shown in Table 1.2 and Figure 1.1 [34, 38-40].   
 
Figure 1.1 PUJ and ureteric embryological signalling pathways  
The urothelium secretes SHH which activates the PTCH1 receptor on adjacent mesenchyme stimulating 
mesenchymal proliferation. Mesenchymal cells express TBX18 which enables their correct localisation and 
aggregation around the urothelium.  The mesenchymal cells also express BMP4 which acts in an autocrine 
manner to upregulate TSHZ3 and MYOCD. MYOCD enables differentiation of smooth muscle cells by 
increasing the transcription of genes encoding smooth muscle contractile proteins. DLGH1, expressed by 
urothelium and smooth muscle cells, is responsible for the correct orientation of smooth muscle cells around 
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the urothelial tube. The timeline refers to days gestation in mouse models. MD – Mesonephric duct, UB – 
ureteric bud, MC – mesenchymal cells, SMC smooth muscle cells 
 
Protein Full protein name Function Ref 
SHH Sonic Hedgehog Morphogen which stimulates peri-
urothelial mesenchymal cell 
proliferation and regulates timing of 






Receptor for SHH, functions as 
tumour suppressor when unbound 
[41] 
BMP4  Bone morphogenetic 
protein 4 
Growth factor, necessary for smooth 
muscle cell differentiation and 
ureter morphogenesis  
[42] 
TSHZ3 Teashirt zinc finger 
homeobox 3 
Transcription factor-like protein 
necessary for myocardin expression 
and ureteric smooth muscle cell 
differentiation 
[43] 
MYOCD Myocardin Transcriptional co-activator, 
necessary for expression of 
contractile proteins 
[43] 
TBX18 T Box protein 18 Transcription factor necessary for 
correct localisation and aggregation 
of smooth muscle cells around 
ureteric urothelium 
[44] 
DLGH1 Disks large homolog 1 Scaffolding protein, regulates 
smooth muscle cell orientation 
[45] 
 
Table 1.2 Proteins/molecular pathways involved in ureteric and renal pelvis development 
 
1.3.2 Anatomy and function of the pelvi-ureteric junction 
The pelvi-ureteric junction is a region of gradual transition from the funnel-shaped renal 
pelvis to the proximal ureter [39] (Figure 1.2).  It is a physiologic sphincter [46], 
characterised by prominent luminal folds with evidence of increased muscle thickness 
capable of creating a high-pressure zone to regulate urine flow. Similar to the adjacent renal 
pelvis and ureter, the PUJ comprises 3 main layers: inner urothelium, middle smooth muscle, 
and outer adventitia [39]. The muscle fibres of the ureter are primarily helical, however, their 
7 
 
final orientation is determined by the degree of vertical and transverse growth [47] with fibre 
arrangement changing with age from circular fibres in the neonate [48] to reach the mature 
mesh of spiral, longitudinal and transverse fibres. 
The PUJ represents a region of transition from a broader helix proximally to a lengthened 
helix with more vertically orientated fibres distally [47]. Smooth muscle contraction propels 
urine from the renal pelvis to the bladder [49], coordinated by submucosal and intra-
muscular nerve plexi [50] and modulated by autonomic innervation involving a range of 
neurotransmitters. These include; acetyl choline, noradrenaline, substance P, neurokinin A, 
calcitonin gene related peptide, neuropeptide Y, vasoactive intestinal peptide and nitric oxide 
[49]. Denervated ureters maintain peristaltic activity illustrating the ability of the upper 
urinary tract to independently initiate and control peristalsis [49].  Evidence suggests this is 
achieved by pacemaker cells within the muscle layers [49, 51-53], likely interstitial cells 
[39], which gradually reduce in number from the proximal to the distal ureter [54]. 
 
Figure 1.2 Diagrammatic representation of the pelvi-ureteric junction  
The gradual transition from the renal pelvis to the proximal ureter is illustrated as well as increased mucosal 




1.4 Pelvi-ureteric junction obstruction 
1.4.1 Definition and aetiology of pelvi-ureteric junction obstruction 
In the context of neonatal hydronephrosis, obstruction has been defined by Peters as “a 
condition of impaired urinary drainage which, if uncorrected, will limit the ultimate 
functional potential of the developing kidney” [55]. PUJO results from a narrowing of the 
junction between the renal pelvis and the ureter. This impedes urine drainage from the 
collecting system into the proximal ureter, leading to dilation of the collecting system and 
potential renal damage. Intrinsic obstruction due to an adynamic stenotic segment at the PUJ 
is the most common aetiology (75% of cases) where failure of peristalsis produces an 
incomplete, functional obstruction [24].  A further 20% of cases are related to an accessory 
renal artery, this ‘crossing vessel’ causes extrinsic compression of the PUJ impeding urine 
drainage [24]. Other causes include peripelvic fibrosis, abnormal ureteric insertion, 
fibroepithelial polyps, and anatomical variants such as retrocaval ureter, duplex or horseshoe 
kidneys [24, 56-58].  
 




1.4.2 Demographics of pelvi-ureteric junction obstruction 
PUJO has an incidence of 1 in 1000 – 1 in 2000 live births [6, 24, 58] and affects 3.8-12.6% 
of all children with antenatally detected hydronephrosis [5, 6, 24]. PUJO more commonly 
affects the left kidney (67%) [58] and is bilateral in 19-33% [16, 24, 59]. Males are affected 
three times more frequently than females [24].  The aetiology of this difference is currently 
unknown.   
1.4.3 Diagnosis of pelvi-ureteric junction obstruction 
Making the diagnosis of PUJO and deciding when to operate can be problematic, as the 
natural history of ANH is not fully understood. It is clear, however, that renal dilatation is 
not tantamount to obstruction. Prior to routine antenatal scanning most children with PUJO 
presented with symptoms or complications, namely; urinary tract infection (particularly in 
infants), loin/abdominal pain, frank haematuria, and nephrolithiasis. In the presence of 
supportive radiological investigations management was clear-cut, surgical intervention was 
indicated for these children.   
As antenatal diagnosis of hydronephrosis became more common during the 1980’s most 
infants underwent early surgery for PUJO to prevent the perceived potential deterioration in 
renal function.  Disagreement with early surgery subsequently ensued as it was noted many 
infants with PUJO showed spontaneous resolution of hydronephrosis.  Koff and Campbell 
reported their early experience with conservative treatment in the early 1990’s [60, 61].  Koff 
went on to follow 104 children with severe (SFU grades 3 and 4), unilateral hydronephrosis 
of PUJ configuration over a period of 10 years.  All children, regardless of initial degree of 
hydronephrosis or drainage/function on diuretic renogram, were initially managed non-
operatively.  Indications for surgery were increasing hydronephrosis on ultrasound scan 
and/or >10% deterioration of function.  Pyeloplasty was subsequently performed in 23 
children (22%) at a mean age of 4.8 months while eighty-one patients (78%) were managed 
conservatively.  Of those managed conservatively hydronephrosis resolved completely in 
69% and improved in 31%, with mean time to maximum improvement being 2.5 years. In 
terms of differential function on diuretic renogram, 78% of those managed conservatively 
had good initial differential function (>40%) with a final mean differential function of 48%.  
The remaining 22% of conservatively managed kidneys had initial reduced differential 
function with a mean of 25% however this improved spontaneously to achieve a final mean 
differential function of 48% (range 38-53%) for this group [62].  Crucially what this 
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demonstrates is that many children with ANH show spontaneous resolution of 
hydronephrosis, and in a smaller subset of children, while hydronephrosis does not resolve, 
there is no ongoing renal damage and in fact differential function seems to improve. 
Consequently, this research group advised that careful observation using radiological 
monitoring is safe and avoids unnecessary surgery in infants with PUJO.  Due to the fact 
that all pyeloplasties were performed within the first 2 years they identified this period as 
being vitally important for monitoring which children require surgery, and suggested that 
the maximum interval between scans should be 3 months up to 2 years of age.  Other groups 
have reported a similar phenomenon, whereby infants managed non-operatively show 
spontaneous resolution or improvement of hydronephrosis with only 36-52.2% of children 
with PUJO requiring surgery [26, 63].  
There is little literature regarding the long-term outcome of children managed both 
operatively and non-operatively for PUJO. A recently published historical cohort study with 
a 30-year follow-up demonstrated that 0.8% (26/3198) of adolescents with normal renal 
function and a history of congenital anomalies of the kidney and urinary tract developed end-
stage renal disease in adulthood. The risk of end-stage renal disease in these individuals was 
significantly increased (hazard ratio for ESRD, 5.19) compared to those with no history of 
renal disease [64]. 
Currently, approximately 80% of cases of PUJO are first noted on antenatal ultrasound scan 
generating a large pool of asymptomatic children with hydronephrosis.  Unfortunately, the 
available diagnostic tests have changed little over the last 20 years and many have debated 
the ability of radiological investigations to adequately differentiate those children at risk of 
functional deterioration and determine the necessity of surgical intervention.  
Diuretic renograms (99mTc-MAG 3 and 99mTc-DTPA) are performed to assess for the 
presence of obstruction and they generate three main pieces of data which should be analysed 
together; a drainage curve, the time taken for half of the radioisotope activity to clear (t1/2) 
and differential kidney function expressed as a percentage. As previously stated 99mTc-MAG 
3 is generally preferred due to the smaller amount of radiation involved and its superior 
ability to assess function [18, 20].  Furosemide is injected intravenously either at the same 
time (F0) or 20 minutes after (F+20) intravenous injection of the radioisotope.  The creation 
of diuresis aims to aid identification of the truly obstructed system.   
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O’Reilly described four types of drainage curve based on children with equivocal upper 
urinary tract obstruction studied using the F+20 protocol.  Type I curves show normal and 
prompt drainage. Type II curves show no drainage even in response to furosemide.  Type III 
curves initially show no drainage but respond to furosemide with type IIIa showing a good 
response and Type IIIb showing a poor response. The interpretation of these curves was that 
type I shows no evidence of obstruction, type II and type IIIb were likely consistent with 
obstruction and type IIIa were unclear [65]. 
In addition to analyzing the shape of the drainage curve the t1/2, the time taken for half of the 
radioisotope to clear from the renal pelvis, is calculated and provides a quantitative measure 
of drainage.  A t1/2 within 10-15 minutes is considered normal drainage, within 15-20 minutes 
is considered equivocal and a t1/2 beyond 20 minutes suggests obstruction [24]. 
Despite the well-defined parameters described above it has been demonstrated that 
renography is an unreliable indicator of obstruction and predictor of renal damage. Gordon 
et al. reviewed data for 69 children with unilateral hydronephrosis of PUJ configuration who 
were monitored for up to 6 years with between 2 and 6 99mTc-DTPA diuretic renograms.  
Obstructive renograms were observed in 32% of 78 renograms performed on 24 children 
who were managed non-operatively.  None of these children developed a deterioration in 
function during the period of observation implying they did not have a true obstruction [66].  
Similarly, Hafez et al. showed the drainage pattern on initial diuretic renogram has poor 
sensitivity and specificity (63% and 59% respectively) for diagnosing obstruction requiring 
pyeloplasty [26].   
Differential kidney function and degree of hydronephrosis have been advocated as better 
predictors of those requiring a pyeloplasty [2]. Conversely others have demonstrated that 
differential function of <40% on initial diuretic renogram has poor sensitivity and specificity 
(56% and 66% respectively) for diagnosing obstruction.  By logistic regression analysis they 
determined that both differential function and drainage pattern on initial diuretic renogram 
do not predict the subsequent need for pyeloplasty [26].   This is borne out by the 
observations by Ulman and Koff (described previously) that reduced function on initial 
diuretic renogram can improve spontaneously in children treated non-operatively [62]. Hafez 
et al. suggested progression of hydronephrosis on two consecutive renal ultrasound scans 
performed 4-6 weeks apart is an early sign of obstruction and should be an indicator for 
surgery [26], while others suggest that progression of hydronephrosis on serial ultrasounds 
should prompt further diuretic renography [20]. 
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Due to the difficulty in predicting which children need surgery the management of those 
with antenatally detected PUJO is subjective [1].   Usually it takes the form of careful 
observation with repeat radiological tests however there remains debate regarding the 
parameters which indicate clinically significant obstruction requiring intervention. 
Generally, a pyeloplasty is performed for [56]: 
• differential renal function deterioration (differential function <40% or falls by >10% 
on serial MAG 3 renograms)  
• significant hydronephrosis with a renal pelvis anteroposterior diameter >3 cm on 
ultrasound scan  
• increasing hydronephrosis with a rising anteroposterior diameter on serial ultrasound 
scan 
• in symptomatic children   
The drawback with the conservative approach is that despite careful observation there is a 
risk of loss of function in the affected kidney and this has been demonstrated to occur in up 
to 20% - 25% [67]. Although Ulman et al. reported functional improvement in all kidneys 
that required pyeloplasty for functional deterioration [62], others have shown that not all 
patients recover function [68], and that functional recovery is reduced in those who have a 
delayed pyeloplasty after conservative management compared to those who have an early 
pyeloplasty [69].  
 
1.4.4 Surgical management of pelvi-ureteric junction obstruction 
When required, a dismembered pyeloplasty is performed to relieve the obstruction and 
improve kidney drainage. This procedure involves excising the narrowed junction between 
the renal pelvis and proximal ureter, spatulating the ureter and performing a primary 
anastomosis (Fig.2). It may be performed as an open procedure at all ages or laparoscopically 
in the older child and has good results with minimal morbidity.  The re-operation rate is 
approximately 3-5% [70].  Early complications of this procedure include: bleeding from the 
operative site, urine leakage via the anastomosis, urinary tract infection, clot retention and 




Figure 1.4 Diagram illustrating the major steps of a dismembered pyeloplasty  
Adapted from http://www.chennaiurology.com/robotics/Pyeloplasty.html 
 
1.4.5 Histopathological features of intrinsic pelvi-ureteric junction 
obstruction 
The human PUJ in intrinsic obstruction demonstrates reduced luminal mucosal folds, 
inflammatory cell infiltration [72], varying degrees of fibrosis with excess collagen 
deposition [72-75], increased fibronectin and laminin expression [75] and abnormal muscle 
fibre arrangement [48]. Both muscular hypertrophy/hyperplasia [72, 74, 76] and 
atrophy/hypoplasia [48, 72] are reported alongside depletion of the interstitial cells [77, 78] 
and nerves to the muscular layer [73]. Conversely Koleda et al. reported increased interstitial 
cell density in the obstructed PUJ which decreased with the child’s age. The authors 
suggested interstitial cell changes may be compensatory, subsequently failing over time 
rather than being causative of PUJO [79].  
All of these pathological findings are noted when the PUJ is excised at pyeloplasty and 
therefore represent late features of PUJO (Figure 1.5). Although the time course of PUJ 
disease progression is unknown in humans, genetic mouse models of hydronephrosis show 
abnormalities of peri-urothelial mesenchymal organisation as early as E12.5 (equivalent to 
human 35 days gestation) [44] and smooth muscle cell differentiation at E15.5 (equivalent 
to human 12 weeks gestation) [43]. One week postnatally, mice with Id2 haploinsufficiency 
show smooth muscle irregularity and hypertrophy at the PUJ [80], features which are 
common to human PUJO. The possible molecular mechanisms underlying this PUJO are 




Figure 1.5 Pathological features of intrinsic PUJO  
Reduced luminal mucosal folds, excess collagen deposition, depletion of nerves within the muscular layer, 
abnormal muscle fibre arrangement and both muscle hypertrophy/hyperplasia and muscle atrophy/hypoplasia 
are seen at the PUJ in human PUJO 
 
1.4.6 Renal histopathological features of pelvi-ureteric junction obstruction 
Biopsies from children undergoing pyeloplasty show a variety of histological findings 
similar to those seen in animal models of ureteric obstruction (discussed in section 1.4.7). 
The most common are glomerular changes such as glomerulosclerosis seen in 73% of 
biopsies. However; findings may be as subtle as increased glomerular density (reflecting 
decreased tubular mass) and decreased proximal/distal tubule ratio.  Conversely, severe 
tubulointerstitial injury with inflammatory infiltrate, tubular atrophy, capsular thickening 
and interstitial fibrosis [81, 82] may be noted. Interstitial nephropathy is associated with 
earlier antenatal diagnosis, worse drainage on renogram and reduced differential function 
[83]. Overt interstitial fibrosis is seen in 26% of biopsies and is significantly more common 
in children over 1 year of age [82].  While Han et al. did not show an association between 
histological features of obstructive nephropathy and duration of obstruction [84], Valles et 
al. showed increased renal macrophage infiltration is associated with delay in pyeloplasty 
and decreased GFR [81]. Unlike animal models, renal tubular apoptosis [85] does not seem 




1.4.7 Animal models of pelvi-ureteric junction obstruction 
Adult and neonatal rodent models of complete and partial unilateral ureteric obstruction 
(UUO) have been used to investigate the molecular biology of congenital obstructive 
nephropathy.  Neonatal models are particularly helpful because rodent nephrogenesis 
continues for 1 week postnatally and nephron maturation over the subsequent week. Thus, 
at birth and 1 week of age, rodent kidney development is equivalent to humans at the second 
trimester and birth respectively [87]. This gives a window in which surgery can be performed 
on the animals to mimic in utero obstruction in humans. A comprehensive review comparing 
neonatal models with human disease has affirmed their validity for investigating obstructive 
nephropathy [88]. 
Neonatal UUO in rodents causes renal pelvic dilatation, impedes nephron maturation, 
reduces glomerular tuft size and tubular cell proliferation, initiates tubular apoptosis and 
atrophy, and leads to progressive interstitial fibrosis [89-91]. However; the response to UUO 
is not uniform throughout the nephron with features of hypoxia and necrosis suggesting 
ischaemic injury secondary to vasoconstriction in the proximal tubule. In the more compliant 
distal nephron dilatation leads to stretch induced tubular cell apoptosis and peritubular 
fibrosis, both of which significantly correlate with the degree of dilatation [92].  Whether 
obstruction in the neonatal period is complete or partial there is nephron loss [89, 93], 
inhibition of ipsilateral renal growth [90] [94] and compensatory contralateral renal growth 
[87] with the definitive number of nephrons being inversely related to the period of 
obstruction [93].   
Interestingly, adult rats subjected to 5 days of complete UUO followed by release do not 
show reduced nephron numbers. This underlines the susceptibility of the immature kidney 
to obstruction-induced injury during the period of nephrogenesis and renal maturation [93].  
Relief of rat UUO in the neonatal period attenuates the renal injury although glomerular 
numbers remain reduced and there is evidence of hyperfiltration [90]. One year later 
ipsilateral renal growth is impaired, the number of glomeruli are further reduced and GFR 
has reduced to 20%.  Histological features of tubular atrophy, interstitial fibrosis and 
glomerulosclerosis are increased and significantly these findings are also present in the 
contralateral unobstructed kidney [95].    When extrapolated to humans this data has 
implications for the timing of surgery and emphasizes the potential for renal function 
deterioration after pyeloplasty as a result of permanent damage to the immature kidney. 
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The renal pathological findings in neonatal and adult UUO models and the timescale of their 
development are presented in Figure 1.6 [90, 91, 94, 96-101]. 
 
1.4.8 Potential molecular mechanisms underpinning pelvi-ureteric junction 
obstruction 
Below are highlighted some of the molecular steps that may lead to the development of 
intrinsic PUJO and subsequent obstructive nephropathy. Data has been obtained from both 
adult and neonatal models of complete and partial ureteric obstruction alongside evaluation 
of tissue obtained at pyeloplasty for human PUJO.  
1.4.8.1 Abnormal innervation 
Light microscopy reveals reduced innervation within the muscular layer of the PUJ in human 
specimens excised at pyeloplasty for PUJO [73]. This is associated with reduced expression 
of molecular markers including glial cell line-derived neurotrophic factor (GDNF – survival 
factor for neurons), protein gene product 9.5 (general neuronal marker), and nerve growth 




Figure 1.6 Pathological features of rodent models of UUO  
Timeline of the development of renal pathogenic features in neonatal and adult models of UUO. CUUO – 
complete unilateral ureteric obstruction, PUUO – partial unilateral ureteric obstruction 
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Although it is speculated these neuronal changes may contribute to the pathogenesis of PUJO 
there is no evidence to confirm or refute this. Conflicting changes in synaptophysin (major 
synaptic vesicle protein p38) expression in both amount (increased and decreased) and 
distribution (localisation to the nucleus) are reported compared to control and are of 
uncertain significance. S-100 (Schwann cell marker) and neurofilament (neuronal protein) 
expression are unchanged demonstrating there is not a global reduction in neuronal 
components [74, 102].  
1.4.8.2 Myogenic factors 
Together with increased smooth muscle cell apoptosis [103], phenotypic and cytoskeletal 
smooth muscle cell changes are seen in the human PUJ excised at pyeloplasty for PUJO. 
The stenotic PUJ shows significantly increased expression of smooth muscle myosin heavy 
chain (MHC) isoforms 1 and 2 [76] as well as an altered ratio of integrin (transmembrane 
signalling receptors) isoform expression compared to control samples [103]. The preferential 
expression of immature integrins in the stenotic PUJ [103] may indicate developmental delay 
of the smooth muscle cells, potentially contributing to their altered function and increased 
apoptosis in PUJO.  
Supporting a myogenic cause of PUJO, transgenic mouse models targeting smooth muscle 
differentiation generate a PUJ phenotype with hydronephrosis secondary to functional 
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Table 1.3 Genes potentially involved in the pathogenesis of PUJ obstruction   
Evidence derived from animal and human studies. Abbreviations: CNS – central nervous system, CPH – 
congenital progressive hydronephrosis, PUJO – pelvi-ureteric junction obstruction, VUJ – vescio-ureteric 
junction, VUR- vesico-ureteric reflux 
 
1.4.8.3 Increased pressure, impeded blood supply and hypoxia 
Obstructive hydronephrosis is associated with a doubling to trebling of renal pelvis pressure 
[46, 112-114]. The resultant increased intratubular hydrostatic pressure [115] stimulates the 
renopathogenic effects of obstruction via three proposed mechanisms: tubular ischaemia due 
to hypoperfusion, pressure induced mechanical stretch/compression of tubular cells and 
altered urinary shear stress. The latter two are likely the primary inducers of obstructive renal 
injury [88], causing dysregulation of many cytokines, growth factors, enzymes and 
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cytoskeletal proteins (Table 1.4), resulting in early renal haemodynamic changes followed 
by structural and functional alterations to the entire nephron. Figure 1.7 highlights the major 
mechanisms of renal injury in PUJO. 
 
Figure 1.7 Major mechanisms of renal injury in PUJO 
 
Following a short initial increase in renal blood flow related to local vasodilator production 
[88], the intra-renal renin-angiotensin-aldosterone system is activated causing pre and post 
glomerular vasoconstriction and a resultant fall in renal blood flow (RBF), medullary oxygen 
tension and glomerular filtration rate (GFR) [81, 87, 88, 116-119]. Proximal tubular hypoxia 
and necrosis in neonatal rats with UUO suggests vasoconstriction causes segment specific 
ischaemic injury [92]. Accordingly, AT1 receptor inhibition improves tubular function by 
increasing RBF and GFR [120]. 
Reduced urine production, continuing urine drainage by venous and lymphatic systems 
alongside tubular and renal pelvis dilatation results in a subsequent decline in renal pelvic 
pressure [88, 117, 121], which may be a compensatory mechanism to limit damaging 
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Table 1.4 The major cytokines, growth factors, chemokines, enzymes and cytoskeletal proteins 
demonstrating altered intrarenal regulation in obstructive nephropathy  
The timing of changes and their mode of action is presented, and compared to sham animal or control human 
kidney. Change refers to protein expression unless otherwise state. Timing is days after creation of UUO. 
CUUO – complete unilateral ureteric obstruction, CBUO – complete bilateral ureteric obstruction, PUUO – 
partial unilateral ureteric obstruction, ECM – extracellular matrix  
 
1.4.8.4 Initiation of proinflammatory cytokines 
1.4.8.4.1 Cytokines in the stenotic PUJ 
Increased transforming growth factor-β (TGF-β) expression is noted in the human stenotic 
PUJ compared to normal controls [145]. Furthermore, the smooth muscle regulators 
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endothelin-1 (smooth muscle constrictor) and adrenomedullin (smooth muscle relaxant) 
have been shown to be increased and decreased respectively in stenotic PUJ disease [146].  
Analysis of paediatric renal pelvis tissue proximal to PUJO for cytokines that show altered 
renal expression in nephropathy demonstrates increased TGF-β and reduced macrophage 
inflammatory protein-1α (MIP-1α). In contrast epidermal growth factor, monocyte 
chemotactic peptide 1, Interferon-γ-inducible protein 10 and RANTES mRNA expression 
are unchanged suggesting that TGF-β and MIP-1α have important roles in the development 
of PUJO [116, 147].   
1.4.8.4.2 Intrarenal cytokines 
Increased intra-renal angiotensin II activates nuclear factor kappa B (NF-κB) and rho-
associated coiled-coil forming protein kinase (ROCK) leading to cytokine release, interstitial 
macrophage infiltration and activation. Intra-renal selectins, integrins, intercellular-adhesion 
molecule 1, vascular cell adhesion molecule 1, interleukin 1, monocyte chemoattractant 
peptide 1, colony stimulating factor 1 and osteopontin expression are all involved in 
macrophage stimulation [87, 88, 116, 148]. Therefore, it appears that renal signals initiate 
and maintain the injurious inflammatory response to PUJO. Accordingly, both selectin and 
β2-integrin knockout mouse models show reduced macrophage infiltration into the 
obstructed kidney after UUO [99, 100].  
1.4.8.5 Inflammatory infiltrates 
Activated macrophages infiltrate the renal interstitium, sustaining the inflammatory response 
by releasing cytokines such as: TGF-β1, tumour necrosis factor-α (TNF-α), and platelet 
derived growth factor [87, 116]. 
1.4.8.6 Profibrotic processes 
Tubulointerstitial fibrosis is the final common pathway for many chronic kidney disorders 
including obstructive uropathy and is instigated by altered cytokine expression (Table 1.5). 
Activated resident interstitial myofibroblasts [149], expressing α-smooth muscle actin 
(boosts cell contractility) [150], aggregate, proliferate and produce extracellular matrix. 
Extracellular matrix consisting of collagens I, III and IV, fibronectin, laminin and 
proteoglycans accumulates due to increased synthesis and reduced degradation [132, 151, 
152]. Myofibroblasts amplify fibrosis by producing cytokines including TGF-β1 and TNF-
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α [87]. Parenchymal damage and renal dysfunction results, such that in children with PUJO 
the extent of fibrosis significantly correlates with differential renal function [84].  
 
Promote Prevent 
Angiotensin II EGF 
CTGF MMP 







Table 1.5 Cytokines, growth factors, enzymes and adhesion molecules promoting or preventing 
tubulointerstitial fibrosis in ureteric obstruction 
 
Angiotensin II upregulation is central to the pathogenesis of obstructive nephropathy (Figure 
1.8, Figure 1.7) [87, 92, 97, 101, 118, 126, 140, 141, 153-162]. Angiotensinogen murine 
knockout studies show angiotensin II expression is responsible for at least 50% of renal 
fibrosis in chronic neonatal UUO [154].  Acting predominantly via the AT1 receptor [101, 
155, 163]  it regulates cytokine production and stimulates reactive oxygen species (ROS) 
generation, which propagate the proinflammatory, fibrogenic state [88, 154]. Additionally, 
ROS cause proximal tubular degeneration by apoptosis, autophagy and necrosis with 
destruction of the glomerulotubular junction forming atubular glomeruli [97, 159].  
TGF-β1 is a profibrotic cytokine and fibroblast chemo-attractant which has a major role in 
fibrosis development via SMAD dependent and independent pathways (Figure 1.9) [132-
134, 164-168]. Renal TGF-β expression is increased in experimental UUO [140, 153, 155, 
157, 169-171] and children with PUJO, being positively correlated with the histopathologic 
grade, radioisotope drainage half-time (t1/2) and post-void washout, and negatively correlated 
with pre-operative differential renal function [83, 131]. 
Nitric oxide (NO) is an endogenous vasodilator that protects against tubulointerstitial 
fibrosis and proximal tubular oxidant injury in obstructive nephropathy [137, 141, 172]. 
Animal models [161, 173, 174] and human studies of PUJO show altered endothelial nitric 
oxide synthase (eNOS) and inducible nitric oxide synthase (iNOS) expression/activity 
alongside reduced NO production. Lower eNOS expression/activity is associated with worse 
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creatinine clearance, reduced differential renal function [81, 175] and increased fibrosis [81, 
175], oxidant injury and apoptosis [125, 137]. 
Urinary tract infection promotes progression of chronic kidney disease in patients with 
obstructive uropathy. Similarly, in animal studies, infected obstructed kidneys demonstrate 
interstitial nephritis and collagen deposition not detected in non-infected systems.   
1.4.8.7  Antifibrotic processes 
Renal cyclooxygenase 2 (COX-2) expression and prostaglandin production in experimental 
UUO is increased [127] and may be a protective response. COX-2 inhibition worsens 
obstructive nephropathy while prostacyclin analogue (ONO-1301) supplementation 
alleviates UUO induced fibrosis [176]. 
1.4.8.8 Cellular apoptosis 
Apoptosis affects podocytes, endothelial and epithelial cells within the kidney leading to loss 
of glomeruli, peritubular capillaries and tubules [87]. Tubular cell mechanical stretch is a 
potent stimulator of apoptosis [92, 177] mediated via TGF-β1 and TNF-α [126, 160] released 
from tubular cells and infiltrating macrophages [116]. Other pro-apoptotic factors increased 
after UUO include Fas-L [101], p53, caspases and ceramide [87].  
Downregulation of anti-apoptotic factors including epidermal growth factor, eNOS, NO, 
vascular endothelial growth factor, heat shock protein 70 and Wilms tumour-1 compounds 





Figure 1.8 Major pathways involved in obstructive nephropathy development  
Derived from animal and human studies. Urinary tract infection promotes progression of chronic kidney 
disease in patients with obstructive uropathy. Similarly in animal studies, infected obstructed kidneys 
demonstrate interstitial nephritis and increased collagen deposition compared to non-infected systems [179]. 




Figure 1.9 TGF-β1 signalling via SMAD dependent pathway   
UUO induces increased TGF-β1 and transforming growth factor β receptor II (TGFβRII) expression, 
upregulating SMAD 2 and 3 and downregulating SMAD 7 (inhibitory for SMAD 2 and 3). β1-integrin is 
upregulated by both SMAD signaling and mechanical stretch, and contributes to a positive feedback loop 
regulating TGF-β1 expression via c-Src and STAT-3 pathways. EMT – epithelial mesenchymal transformation 
 
1.4.8.9 Tubular function impairment 
Ureteric obstruction leads to reduced renal expression of the V2 (vasopressin) receptor [180], 
renal sodium and urea transporters [181-183] and aquaporins [184-186].   Following relief 
of obstruction this is associated with natriuresis, polyuria and reduced urine concentrating 
ability [187-189]. Aquaporins are discussed in more detail in section 1.5. 
 
1.4.9 Genetic mechanistic clues in pelvi-ureteric junction obstruction 
Phenotypes similar to PUJO have been noted in numerous transgenic mouse models.  Many 
genes involved in ureteric smooth muscle proliferation and differentiation are implicated 
supporting a primary myogenic aetiology. Importantly one of these genes has been 
implicated in human disease (Table 1.3).  
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TBX18 gene mutations are reported in association with congenital anomalies of the kidney 
and urinary tract (CAKUT). In particular, a heterozygous TBX18 truncating mutation 
(c.1010delG) showing autosomal dominant inheritance is described across four generations 
of a family with CAKUT and predominantly PUJO [109]. The transcription factor TBX18 
is necessary for normal smooth muscle cell proliferation, differentiation and localisation 
around the developing urothelial stalk [44]. TBX18 also directs epithelial proliferation and 
when absent leads to an abnormally short ureteric bud [40] 
In the majority of patients, however, PUJO is a polygenic disorder without an obviously 
inherited genetic component [87]. 
 
1.4.10 Therapeutic manipulation in rodent unilateral ureteric obstruction 
Human and animal studies have highlighted a number of potential therapeutic targets that 
could be manipulated to alleviate the nephropathy sustained secondary to PUJO. Several 
drugs targeting these pathways have been assessed in rodent UUO models as described 
below, however, to our knowledge none of these therapies have been trialled in childhood 
human PUJO. 
1.4.10.1 Angiotensin converting enzyme and angiotensin II receptor 
inhibitors 
In adult rodent UUO models ACE inhibitors and AT1 receptor inhibitors given 
prophylactically (for the duration of obstruction) are beneficial in alleviating nephropathy. 
Specifically they reduce TGF-β [171, 190] and TNF-α [156] expression as well as 
macrophage infiltration and tubulointerstitial fibrosis [141, 155, 191].  Additionally, AT1 
receptor inhibitors improve tubular function by improving RBF and GFR and attenuating 
the reduction in sodium transporter and aquaporin 2 expression thus reducing polyuria and 
natriuresis [120, 162]. 
ACE inhibitors reduce both AT1 and AT2 receptor stimulation [192] and indirectly increase 
NO levels via bradykinin generation [141]. This may explain why they confer additional 
benefits, particularly anti-inflammatory, compared to AT1 receptor inhibitors [148].  
Unfortunately, inhibition of angiotensin during either the period of nephrogenesis (first 10 
days after UUO) or renal maturation (second 10 days after UUO) in neonatal partial UUO 
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exacerbates renal injury in both the obstructed and contralateral kidney [193, 194].  These 
studies highlight the importance of these pathways in normal kidney development and 
maturation. 
However, it is important to remember that ACE inhibitors and AT1 receptor inhibitors are 
frequently used in children with chronic kidney disease in whom they significantly reduce 
proteinuria [195], despite not significantly alleviating the natural decline in excretory 
function [196, 197]. They are largely well tolerated with no apparent effect on growth and 
development and a low incidence of side effects such as hyperkalaemia, hypotension and 
renal injury [195].  
1.4.10.2 HMGCoA reductase inhibitors (Statins) 
Statins ameliorate nephropathy when administered prophylactically in adult and neonatal 
rodent UUO models by reducing renal cytokine production (TGF-β, TNF-α), macrophage 
infiltration, oxidative stress, apoptosis and tubulointerstitial fibrosis [142, 198, 199]. These 
pleiotropic effects are achieved through decreased Ras/ERK/Akt signalling [200] and 
increased NO bioavailability [201]. Importantly statins remain beneficial in neonatal rodent 
UUO where an improvement in tubular dilatation and glomerular number and size are also 
seen [125, 137, 142]. Functionally, in UUO models, statins improve GFR and 
microalbuminuria [202], and increase urinary concentrating ability via boosting aquaporin 2 
expression [203]. 
Statins are commonly used and usually well tolerated in adults. Side effects of treatment 
include: hepatic dysfunction, diabetes mellitus, benign proteinuria, peripheral neuropathy, 
myalgia and rhabdomyolysis [204]. Ten-year follow-up of children (≥8 years) treated with 
statins for familial hypercholesterolaemia demonstrated few discontinue therapy due to side 
effects and no serious adverse reactions. Additionally, growth, puberty and educational 
parameters were unaffected compared to controls [205]. 
1.4.10.3 TGF-β modulation 
Prophylactic TGF-β receptor inhibition is renoprotective in adult rodent UUO models 
reducing apoptosis, macrophage infiltration, fibrosis, proximal tubular atrophy and atubular 
glomeruli formation [167, 206].  Similarly, anti-TGF-β antibody treatment increases NOS 
expression while reducing apoptosis and fibrosis [160]. Conversely prophylactic TGF-β 
receptor inhibition in neonatal mouse UUO causes widespread renal necrosis, exacerbating 
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the injury in the obstructed kidney and highlighting the differing responses to signalling 
cascades during renal development [167].    
Anti- TGF-β antibody treatment (GC1008) has been trialled in human oncological disease 
and was generally well tolerated. However side effects included gingivitis, fatigue and skin 
rashes including keratoacanthoma and squamous cell carcinoma development (melanoma 
patients only). GC1008 treatment has not progressed beyond phase II clinical trials as drug 
development was discontinued by the manufacturer [207]. 
1.4.10.4 COX-2 inhibition 
In adult rodent bilateral ureteric obstruction COX-2 inhibition alleviates aquaporin 2 and 
sodium transporter downregulation and improves post-obstructive polyuria, which would 
appear beneficial [127, 208]. However other studies have demonstrated that both genetic 
COX-2 knockout and prophylactic COX-2 inhibition in adult rodent UUO models increases 
tubular injury, apoptosis and fibrosis thereby negating its potential use in the clinical setting 
[128, 209]. 
Chronic celecoxib (COX-2 inhibitor) use in children demonstrates a similar frequency of 
adverse events as non-selective NSAIDS, which are most frequently gastrointestinal side 
effects [210]. 
1.4.11 Urinary biomarkers in pelvi-ureteric junction obstruction 
Identifying early urinary biomarkers in PUJO may be beneficial for the diagnosis, 
management, and prognosis of this condition. Such biomarkers would enable timely 
detection of children with ‘damaging’ hydronephrosis who require surgery to protect renal 
function, while avoiding surgery in those with ‘safe’ hydronephrosis. 
1.4.11.1 Urinary biomarkers in animal studies 
There is little data from animal studies. Proteomics using a rat UUO model demonstrated 
increased urinary and renal levels of alpha-actinin-1 and moesin at 1 week which 
corresponded with histological evidence of tubular injury. Following 3 weeks of UUO urine 
and renal levels of vimentin, annexin A1 and clusterin were significantly elevated, 
corresponding with substantial renal interstitial fibrosis [211]. 
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1.4.11.2 Urinary biomarkers in human studies 
Many urinary cytokines, growth factors, chemokines, tubular enzymes and tubular transport 
proteins have been investigated from children undergoing pyeloplasty for PUJO.  Studies 
with conservatively managed PUJO as a comparator are most useful to identify biomarkers 
able to aid selection of patients for surgery. Potential urinary biomarker proteins measured 
in bladder urine samples are presented in table 5.  
Finding a suitable biomarker test with high sensitivity, specificity and predictive value is 
challenging [116], not least because these markers are excreted in health as well as disease, 
show significant intra and inter patient variation, and may be affected by patient age, the 
presence of urinary tract infection and other renal disorders [212, 213]. Furthermore, in 
PUJO, the transport of a urine biomarker from the affected kidney to the bladder is physically 
impeded, while dilution of proteins of interest in the bladder by urine from the normal 
contralateral kidney further reduces the likelihood of detecting a suitable voided biomarker.  
A recent systematic review of urinary and serum biomarkers included 14 studies, reporting 
data on 380 surgically managed PUJO patients, 174 conservatively managed patients and 
213 controls. This review reported a wide-range of sometimes conflicting results and was 
unable to draw any firm conclusions, attributing this to differences in study design with 
heterogeneous age groups, various or absent control groups and often short durations of 
follow-up [214].  
More successfully, proteomics of neonatal urine identified a panel of 51 peptides which 
distinguish obstruction severity. When implemented in a prospective blinded study it had an 
accuracy of 94% to predict future need for surgery in newborns with PUJO [215]. However; 
beyond one year of age the sensitivity and specificity of this proteome profile diminished 
significantly [216].  
Currently a single biomarker able to guide selection of patients for pyeloplasty has not been 
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TGF-β Pyeloplasty CMP Increased 
pre-op 
Se - 82% 
Sp - 86% 
 [230] 
 
Table 1.6 Urinary proteins from studies in children with PUJO  
Generally, the primary group measured is children undergoing pyeloplasty which are then compared to healthy 
control and/or conservatively managed PUJO (CMP). The exception is labelled PUJO* which includes 
conservatively managed PUJO split into ‘functional’ (t1/2 of renogram < 20 minutes) and ‘obstructed’ (t1/2 of 
renogram > 20 minutes). In these studies voided urine from children undergoing pyeloplasty was only obtained 
42 months post-op. Where applicable sensitivity, specificity and accuracy of the test at best threshold value 
from ROC curve analysis is presented. NGAL – neutrophil gelatinase-associated lipocalin, CyC – cystatin-C, 
OPN – osteopontin, MIP-1α – macrophage inflammatory protein-1α, IP-10 – interferon-γ-inducible protein 10, 
HO-1 – Heme oxygenase-1, KIM-1 – kidney injury molecule-1, NAG – N-acetyl-beta-D-glucosaminidase, 
γGT – gamma-glutamyl transferase, ALP – alkaline phosphatase, Ca19-9 – carbohydrate antigen 19-9. # To 
detect DRF < 40% out of all hydronephrosis cases, $ To detect pyeloplasty cases out of all hydronephrosis 




1.5.1 Aquaporin structure and function 
Aquaporins (AQPs) are an ancient family of transmembrane proteins found in all organisms 
including eubacteria, yeasts, plants and mammals [231]. AQP1 (initially named CHIP 28) 
was the first to be described in 1988 by Agre et al. for which he subsequently received the 
Nobel prize for Chemistry [232]. This discovery finally revealed the mechanism by which 
water moves across the cell membrane along an osmotic gradient [233]. Subsequent studies 
have highlighted the vital role AQPs play in normal physiology alongside their involvement 
in both heritable and non-heritable diseases. There are 13 mammalian isoforms (AQP 0-12) 
[234] which are found in numerous body tissues in different cellular locations (Figure 1.10 
and Table 1.7) [235].  
These small, roughly 30kDa, hydrophobic proteins are classified into classical AQPs which 
are permeable only to water (AQP 0, 1, 2, 4, 5), aquaglyceroporins (AQP 3, 7, 9, 10) which 
transport water, glycerol and other small uncharged molecules and unorthodox AQPs (AQP 
6, 8, 11, 12) made up of structurally and/or functionally distinct AQPs [231, 236-238]. 
Additionally, a number of AQPs have been shown to be permeable to other substances such 
as ammonia, hydrogen peroxide and carbon dioxide [239, 240].  
Structural studies of a number of the AQPs show they have a similar basic structure 
comprising 2 tandem domains each consisting of 3 transmembrane α-helices and a 
hydrophobic loop with a highly conserved NPA (Asp-Pro-Ala) motif (Figure 1.11 and Figure 
1.12) [235, 237, 241]. AQP1 assembles within the lipid bilayer as a homotetramer. Data 
suggests AQPs 2, 3 and 5 also exist as homotetramers however it is likely not all AQPs have 
this arrangement [241]. 
Aquaglyceroporins contain two extra peptide sequences compared to the classical AQPs 
[237] while AQPs 11 and 12 have limited homology with the other AQPs and have a unique 
NPA box [236]. Some AQP isoforms are N-glycosylated however this does not seem to be 
necessary for their function or transport to the membrane [242, 243]. 
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AQP Species Extrarenal location Function Disease Ref 
0 Human Lens of the eye Water transport Human - Missense mutations lead 
to autosomal dominant cataracts 
[244] 
1 Human, rat Capillary endothelium external to brain 
(eg. lung, peritoneum, pancreas), lymphatic 
vessels, erythrocytes, choroid plexus, 
ciliary body, corneal endothelium, 
cholangiocytes, endothelia of dermis, 




Human - AQP1 null – decreased 
pulmonary vascular permeability 
[239, 245-
248] 
2 Human, rat, 
mouse 
Uterus (oestrogen responsive), ureter and 
bladder urothelium, trigeminal ganglia 
? Water transport Rats - ? associated with detrusor 
overactivity 
Mice – AQP2 null, polyuria, 
failure to thrive and neonatal 
death  
Mice - ? associated with pain 
transmisison 
[249-255] 
3 Human, rat, 
mouse 
Keratinocytes, subcutaneous and visceral 
adipocytes, oesphagus, stomach, ileum, 
colon, liver, intervertebral disc, urothelium 
of ureter/bladder 
Water transport, glycerol 
transport (skin/fat/liver) 
Mice - AQP3 null, impaired 
hydration of stratum corneum 
[256-260] 
4 Human, rat, 
mouse 
Glial cells (brain and spinal cord), muscle 
fibres, retina, optic nerve, olfactory 
epithelium, cochlea, cardiomyocytes, 
stomach, small intestine, urothelium of 
ureter/bladder 
Water transport  Mice - AQP4 null, impaired 
olfaction and retinal function, 
reduced brain/spinal cord oedema 
after injury  
Human - anti-AQP4 









5 Human, rat, 
mouse 
Salivary and lacrimal glands, lung, trachea, 
cochlea 
Water transport 
? osmosensor involved in 
regulating cell volume in 
concert with pendrin 
Mice- AQP5 null produce reduced 
amounts of hypertonic saliva  
Human - Defective trafficking to 












6 Human, rat Parotid gland, cochlea, retina Anion transport  
 
 [248, 274, 
275] 
7 Human, rat Subcutaneous and visceral adipocytes, 
testis (spermatids and spermatozoa), 
ovarian granulosa cells, liver, urothelium 
of ureter/bladder 
Water transport, glycerol 
(important in adipose 
metabolism) transport  
Mice – AQP7 null show obesity, 
heightened adipocyte triglyceride 
synthesis, increased adipose 
glycerol kinase activity 
[258, 259, 
276-279] 
8 Human, rat Exocrine pancreas acinar cells, liver, 
ovarian granulosa cells, trachea, bronchi, 
duodenum, jejunum, colon, epididymis, 
testis, salivary glands 
Water transport Mice – AQP8 null have a mild 
phenotype with increased 
testicular weight in males and 
multi-oocyte follicles in females 
[276, 278, 
280-284] 
9 Human, rat Subcutaneous and visceral adipocytes, 
liver, ovarian granulosa cells, peripheral 
leucocytes, spleen, lung, urothelium of 
ureter/bladder, brain 
Water, glycerol (? role in 
metabolism), ammonia, 




Mice- AQP9 null show increased 
plasma glycerol and triglycerides. 
Fasting in AQP9 null db/db mice 
causes reduced blood glucose 
compared to AQP9 +/- db/db 






in rat and 
mouse) 
Adipocytes, duodenum, jejunum, ileum Water, glycerol 
(important in adipose 
metabolism), urea 
transport  
 [260, 288, 
291-293] 
11 Rat Testis, liver, brain, thymus Water transport  [294-296] 
12 Rat, mouse Pancreas Unknown Mice – AQP12 null show more 
pancreatic damage in a 




Table 1.7 Extra-renal aquaporin expression  
Details of the extra-renal location and function of renal aquaporin isoforms are presented. Human and murine diseases resulting from abnormalities/non-expression of 








Figure 1.10 Human extra-renal aquaporin expression  
Picture adapted from Day et al. 2014 [235]. This diagram highlights the extensive distribution of aquaporin 





Figure 1.11 A diagrammatic representation of the structure of aquaporin 1 
Picture taken from Nielsen et al., 2002 [241]. Each aquaporin monomer consists of 6 transmembrane domains 
connected by 3 extracellular loops and 2 intracellular loops. Both NH2 and COOH termini are intracellular. 
The aquaporin protein folds to bring the highly conserved B and E loops together forming an hourglass shaped 
aqueous channel. The hydrophobic NPA motif is vital for water permeability and proton exclusion 
 
Figure 1.12 Assembly of aquaporin monomers 
Picture taken from Nielsen et al., 2002 [241]. Four aquaporin monomers assemble to form a homotetramer. 
Only one subunit carries a large glycan 
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1.5.2 Aquaporin expression in the kidney 
The kidney is vital for physiological water, salt and acid-base balance alongside the 
excretion of waste products. AQPs are intrinsic to renal function and accordingly nine AQP 
isoforms are expressed (AQP1-8 and 11) at various sites along the nephron (Figure 1.13) 
[234, 299]. Within the kidney their primary role is water homeostasis and this is achieved 
predominantly by AQPs 1-4 which enable [255];  
 near iso-osmolar reabsorption of water in the proximal tubule (AQP1) 
 generation of medullary hypertonicity via participation in the counter-current 
exchange mechanism in the loop of Henle (AQP1)  
 water re-absorption in the collecting duct regulated by circulating vasopressin (AQP2 
in the apical membrane and AQPs 3 and 4 in the basolateral membrane)   
The location of all renally expressed AQP isoforms alongside their potential functions and 
regulatory mechanisms are presented in Table 1.8.  
Transgenic mice studies have eloquently demonstrated the renal role of AQP’s as mice with 
deletions of AQP1-4 all show varying degrees of polyuria. Despite AQP4 knockout causing 
a four-fold reduction in the inner medullary collecting duct permeability it only leads to a 
mild polyuria as compared to the severe polyuria seen in the AQP3 knockout where 
membrane permeability is less significantly reduced. The likely explanation is that the 
majority of water reabsorption in the collecting duct is achieved in the connecting tubular 
and cortical collecting ducts and thus via AQP3 in the basolateral membrane (Table 1.9). 
Supporting the data from transgenic studies, mutations in AQP1 and 2 are described in 
humans leading to an inability to concentrate urine in response to water deprivation and 





Figure 1.13 Distribution of aquaporin isoforms along the nephron 
Picture adapted from Tamma et al. 2012 [236]. Up to 2/3 of glomerular filtrate is reabsorbed in the proximal 
tubule [300], the majority of which is achieved by transcellular water flow via apical and basolateral cell 
membrane AQP1 expression. AQP1 expression in the descending thin limb of the loop of Henle and the vasa 
recta also contributes significantly to the counter current exchange mechanism and the development of 
medullary hypertonicity. AQP2 expression in the collecting duct enables vasopressin regulated water 
reabsorption via the apical membrane which then exits the cell via AQPs 3 and 4 in the basolateral membrane. 
AQP3 is expressed in the cortical and inner/outer medullary collecting ducts while AQP4 is predominantly 
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expressed in X. 
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Table 1.8 Aquaporin isoform expression in kidney  
Details of the renal location, subcellular location and function of renal aquaporins are presented. Human renal diseases resulting from abnormalities of these channels 








1 Vasopressin resistant polyuria and polydipsia. 
Smaller then wild-type mice. Likely reduced 
intrauterine survival. 
2 Failure to thrive and death within neonatal period 
with vasopressin insensitive polyuria. Inducible 
adult models show severe vasopressin resistant 
polyuria 
3 Severe polyuria and polydipsia partially 
vasopressin sensitive, concomitant 
downregulation of AQP 2, hydronephrosis 
secondary to polyuria 
4 Mild polyuria 
5 No renal phenotype 
7 Severe glyceroluria 
8 No renal phenotype 
11 Normal intrauterine survival but neonatal death 
due to renal failure resulting from large polycystic 
kidneys (cysts localized to renal cortex) 
 
Table 1.9 Renal phenotype of murine AQP isoform congenital double knockout models [236, 255] 
 
1.5.3 Aquaporin regulation  
1.5.3.1 Regulation of renal aquaporin expression 
The regulation of AQP expression in the kidney is complex and for many of the AQPs is not 
understood.  AQP2 is the most studied as mutations of the AQP2 gene cause hereditary 
nephrogenic diabetes insipidus (NDI) [255]. Mutations causing both autosomal recessive 
(most common) and dominant NDI have been described where the mutant protein is usually 
retained intracellularly and thus rendered non-functional [346, 347]. X-linked nephrogenic 
NDI on the other hand results from mutations in the V2 receptor for vasopressin [348]. More 
commonly NDI is acquired, with concomitant AQP2 downregulation. Causes include: drugs 
(lithium), electrolyte disturbances (hypokalaemia, hypercalcaemia) and urinary tract 
obstruction. [241, 347, 349].  
48 
 
AQP2 expression is upregulated by vasopressin secretion from the posterior pituitary gland 
in response to numerous stimuli including; increases in plasma osmolality, decreased 
circulating blood volume and angiotensin 2 acting via AT1 receptors [180].  Administration 
of an AT1 receptor blocker, for example, reduces vasopressin induced AQP2 expression in 
collecting ducts cells leading to an increased urine output [350].  
In the basal state most AQP2 resides in intracellular vesicles. Acute changes in expression 
(seconds to minutes) occur by AQP2 trafficking from these vesicles to the apical plasma 
membrane of the collecting duct cells [241].  Phosphorylation of Ser-256 in the C-terminal 
cytoplasmic domain of AQP2 by protein kinase A (PKA) enables this vasopressin mediated 
transport. 
Additionally, activated PKA phosphorylates, thus deactivating, the small GTPase Rho 
leading to the depolymerisation of F-actin allowing the intracellular vesicles access to the 
plasma membrane. Upon removal of vasopressin stimulation or following administration of 
a V2 receptor inhibitor, endocytosis of AQP2 from the membrane and back into intracellular 
vesicles quickly occurs [313, 315].  
Long-term regulation (hours to days) of urinary concentration occurs via regulation of gene 
transcription and thus the total AQP2 protein levels [241]. Using the porcine kidney 
epithelial cell line LLC-PK1, Yasui et al. demonstrated that vasopressin acting via the V2 
receptor and the adenylyl cyclase/cAMP/PKA cascade, activates the transcription factors 
CREB (cAMP-response element binding protein) and c-Fos which bind to CRE and AP1 
respectively in the AQP2 gene promoter to upregulate transcription [351].  
Ultimately, vasopressin mediated AQP2 translocation to the apical membrane and 
upregulation of expression results in increased water reabsorption across the collecting duct 
and generation of a more concentrated urine [241, 313]. 
Although vasopressin acting via G-protein coupled V2 receptors is a major regulator of these 
short and long term changes it is not the sole contributor, as AQP2 expression can be altered 
independently of the action of vasopressin.  The other factors involved in regulation are yet 
to be fully elucidated, however, studies suggest a role for prostaglandins by alteration of 
both trafficking to the cell membrane [241] and regulation of expression [352]. PGE2 
supplementation alone to rat renal inner medullary tissue does not alter AQP2 
phosphorylation or its cellular distribution. Increased PGE2 levels do, however, reduce 
vasopressin stimulated AQP2 translocation to the membrane [353]. Tamma et al. described 
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the mechanism behind this observation using primary rat inner medullary collecting duct 
cells (IMCD). PGE2 via EP3 receptors stimulates Rho (independent of increases in cAMP 
and calcium) leading to F-actin formation which physically hinders the translocation of 
AQP2 to the plasma membrane thus reducing apical membrane expression (Figure 1.14) 
[354].  
In vitro studies have shown other molecules such as atrial natriuretic peptide (ANP), 
adenosine triphosphate (ATP), dopamine, nitric oxide and bradykinin counteract the 
vasopressin induced translocation of AQP2 to the apical membrane by various mechanisms. 
These include ubiquitination and internalisation of AQP2 from the apical membrane and 
lysosomal degradation (ATP and dopamine) [318], reduced gene transcription secondary to 
reduced cAMP levels (ATP and dopamine) [318], Rho activation via Gα/G13 protein 
receptors leading to F-actin polymerization (bradykinin) [319], and signalling via cGMP and 
protein kinase G (ANP and NO) [320]. Recent studies show further modulation of AQP2 
trafficking to the membrane may be achieved by integrin signalling. AQP2 is the only AQP 
to contain the RGD integrin binding motif and has been shown to interact with integrin β1 
by co-immunoprecipitation studies [355].  
Furthermore, AQP2 is transcriptionally upregulated and downregulated by hypertonicity 
[356, 357] and hypotonicity respectively [321, 358]. This occurs via pathways independent 
of vasopressin, cAMP, PKA and CREB. Additionally, downregulation due to hypotonicity 
occurs independently of both prostaglandins and nitric oxide [321]. Although it has been 
suggested regulation by tonicity occurs via the known TonE in the AQP2 promoter alongside 
altered Ton EBP activity [357, 358], others have disputed this and propose that alternative 




Figure 1.14 Regulation of AQP2 trafficking and synthesis in renal collecting duct cells 
Picture taken from Chen et al. 2005 [234].Vasopressin binds to the Gs protein coupled V2 receptor which 
stimulates the adenylyl cyclase/cAMP/protein kinase A pathway.  Subsequent phosphorylation of Ser 256 on 
the cytoplasmic c-terminal of AQP2 causes exocytosis of intracellular vesicles and insertion of AQP2 into the 
apical plasma membrane. Alongside this, PKA activation also phosphorylates, thus deactivating, Rho leading 
to the depolymerisation of F-actin allowing the intracellular vesicles access to the plasma membrane. Reduction 
in vasopressin binding to the V2 receptor stimulates endocytosis of AQP2 back into intracellular vesicles. PGE2 
binds to the EP3 receptor on the basolateral membrane of the collecting duct cell and via cAMP/calcium 
independent mechanisms activates Rho causing polymerization of F-actin which physically blocks the 
translocation of AQP2 to the apical membrane. EP3 mediated inhibition of vasopressin stimulated AQP2 
exocytosis is diminished by EP1 receptor stimulation via an unknown mechanism. Vasopressin acting via the 
V2 receptor also achieves long-term regulation of AQP2 expression by phosphorylating CREB which acts on 
the CRE promoter of the AQP2 gene thus upregulating transcription. Three to four percent of AQP2 from the 
apical membrane is shed within exosomes into the urine. Sulprostome is a PGE2 analogue and EP1/EP3 agonist. 
SC19220 is an EP1 receptor antagonist. These compounds have been administered simultaneously during in 
vitro work to achieve selective EP3 stimulation  [234].   
 
Trafficking of AQP2, to and from the apical membrane, is also affected by tonicity. 
Hypotonicity promotes internalisation of AQP2 from the membrane [359], while 
hypertonicity causes accumulation of AQP2 at the apical membrane [357].  
Regulation of the other renal AQPs has been far less thoroughly investigated. In vitro and in 
vivo studies have demonstrated that AQP1 mRNA and protein expression is upregulated in 
rat proximal tubular cells by angiotensin II acting via the AT1 receptor. The response is 
biphasic with dose dependent increases in expression at lower concentrations of angiotensin 
II but suppression of AQP1 mRNA expression at higher strengths [308]. Vasopressin, 
however, does not directly regulate AQP1 expression [325].  
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In vitro studies using rat and human proximal tubular cells have demonstrated that AQP1 is 
also upregulated by extracellular hypertonicity [308, 309]. Using mouse IMCD-3 cells this 
has been demonstrated to occur via ERK, p38 kinase and JNK activation and the 
hypertonicity responsive element (HRE) in the AQP1 promoter [311]. 
AQP3 expression within the renal collecting duct shows long-term but not short-term 
regulation in response to vasopressin in rats [323, 325, 360]. Specifically, AQP3 is 
upregulated in the connecting tubules, cortical collecting ducts, inner stripe of the outer 
medullary collecting ducts and the initial inner medullary collecting ducts (IMCD). 
Interestingly, expression in the more distal IMCD is reduced in response to vasopressin 
[327]. Upregulation of AQP3 expression is also noted in response to hypertonicity, but this 
has only been demonstrated in cultured human keratinocytes [322]. Similarly, insulin and 
leptin have been shown to upregulate AQP3 expression via the PI3K/Akt/mTOR pathways, 
however this was undertaken in cultured human adipocytes and hepatocytes [258]. 
Using long-term vasopressin stimulation in brattleboro (vasopressin deficient) rats, Terris et 
al. demonstrated by immunoblotting that AQP4 protein expression was unchanged in the 
renal medulla and cortex versus control, suggesting AQP4 expression was not regulated by 
vasopressin [325]. Subsequently Poulsen et al. have challenged this view by demonstrating 
a varying response to vasopressin stimulation at different locations along the nephron by 
immunohistochemistry in this same model. In the connecting tubule and the cortical 
collecting duct where constitutional expression of AQP4 is low, the protein abundance of 
AQP4 increased following vasopressin stimulation. AQP4 expression was also increased in 
the inner stripe of the outer medullary collecting ducts and the initial IMCD. More distally 
along the IMCD however AQP4 was downregulated by vasopressin stimulation [327]. 
Furthermore, vasopressin stimulation has been demonstrated to affect the relative expression 
of various splice variants of AQP4 along the nephron [361].  
Similar to the other 3 major renal AQPs, upregulation of AQP4 has been demonstrated in 
response to hyperosmolality in non-renal cells (rat astrocytes) via the p38/MAPK pathway 
[289].  
Table 1.8 indicates regulatory factors identified for the other renal AQPs. 
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1.5.3.2 Inhibition of aquaporin isoform permeability 
There are no specific inhibitors of individual aquaporin isoforms however many are inhibited 
by mecurials, the sensitivity to which is conferred by cysteine residues close to the conserved 
NPA motif for AQPs 1, 2 and 3 [237].  Notable exceptions are aquaporin 4 which is mercury 
insensitive being originally named mercurial insensitive water channel (MIWC) [362] and 
AQP 6 whose usually low water permeability is increased by mercurial treatment. 
Incidentally the permeability of AQP 6 for small anions is also increased by mercurial 
treatment signifying its potential role as an anion channel [335]. 
1.5.3.3 Gating of aquaporins 
Studies of AQPs expressed in X. laevis oocytes demonstrate that external pH changes do not 
affect the water permeability of AQPs 0, 1, 2, 4 and 5 [363]. The water and anion 
permeability of AQP6, however, is promptly increased at pH<5.5.  This phenomenon is 
reversed at physiological pH [335]. AQP3 is permeable to water and glycerol at 
physiological pH while at pH’s around 6.1 it is predominantly permeable to glycerol as the 
water permeability of AQP3 is eradicated by acidic pH [363]. 
 
1.5.4 Aquaporin expression in urinary tract obstruction 
AQP expression is of great interest in the context of PUJO as experimental rat models of 
ureteric obstruction show reduced renal expression of AQPs. Specifically, downregulation 
of AQPs 1, 2, 3 and 4 in the obstructed kidney and AQPs 1 and 2 in the contralateral kidney 
is noted following adult rat UUO suggesting both intrarenal and systemic factors are 
involved in their regulation [184, 186].  Bilateral ureteric obstruction followed by release is 
also associated with decreased renal AQP1, 2 and 3 expression, polyuria and reduced urinary 
concentrating ability [188, 189].  Reduction of AQP expression and significant polyuria 
persists at 30 days following release of bilateral ureteric obstruction and is associated with a 
significant urinary concentrating defect in response to thirst [189].  This suggests that 
reduced AQP expression is involved in the long-term concentrating defect seen after relief 
of urinary tract obstruction in a clinical setting.  AQP expression may change with time in 
urinary tract obstruction as models mimicking congenital obstruction show an initial increase 
suggesting early compensation, followed by subsequent decrease in aquaporin expression 
possibly related to impairment of tubular function [364]. 
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Dysregulation of AQP expression has also been demonstrated in humans.  In children 
undergoing surgery for congenital hydronephrosis secondary to PUJO, renal expression of 
AQPs 1-4 is reduced at the mRNA and protein level compared to controls. The degree of 
reduction correlates with both the severity of hydronephrosis and the degree of functional 
impairment [187].   
 
1.5.5 Regulation of renal aquaporin expression in the presence of urinary 
tract obstruction 
In health, the administration of an AT1 blocker reduces vasopressin induced expression of 
AQP2 in collecting duct cells leading to an increased urine output [350]. In the context of 
ureteric obstruction however the administration of an AT1 receptor inhibitor attenuates the 
reduction in expression of AQP2 and improves the post-obstructive diuresis encountered 
following release of obstruction [162].  Similar to regulation of expression in the non-
obstructed state, studies have shown that changes in expression of AQPs in obstruction may 
be regulated by other factors than angiotensin.   
Renal levels of prostaglandin E2 and COX-2 are increased in animal models of ureteric 
obstruction alongside a reduction in expression of AQP2 and 3.  This downregulation of 
AQP2 and 3 is not observed in COX-2 deficient mice with ureteric obstruction, suggesting 
upregulation of COX-2 and increased prostaglandin production is involved in reducing renal 
expression of AQPs in ureteric obstruction [352]  This is supported by observations that 
selective COX-2 inhibition prevents AQP2 dysregulation and is associated with 
improvement of post-obstructive diuresis in a model of ureteric obstruction followed by 
release [127, 208]. 
Angiotensin-2 inhibition reduces COX-2 expression in ureteric obstruction and it is likely it 
is via this route which AT1 receptor blockers have their protective effect on AQP expression 
[162].  These effects are not confined to animal models, increased prostaglandin E2 excretion 
has been documented in children’s urine alongside reduced urinary exosomal AQP2 levels 
in the post-operative period after pyeloplasty for PUJO [365]. 
Local renal production of metabolites (such as prostaglandins) resulting in reduced levels of 
AQPs would be consistent with the observation that in unilateral ureteric obstruction AQPs 
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are reduced to a far greater extent in the obstructed kidney as opposed to the unobstructed 
contralateral kidney [186].  
 
1.5.6 Aquaporin expression in urothelium 
The role of AQPs in the urinary tract is not confined to the kidney.  Traditionally urothelium, 
the specialised barrier epithelium of the urinary tract, has been considered impervious to 
urine.  However studies suggest it is able to mediate solute and water transport [366] and 
AQPs have been implicated in this process.  Expression of AQPs 1, 2 and 3 have been 
demonstrated in rat bladder and ureter with expression of AQPs 2 and 3 being significantly 
increased in the presence of dehydration.  Immunocytochemistry localises AQP2 and 3 to 
the urothelial cells while AQP1 is demonstrated in the vascular endothelial cells of the blood 
vessels [249, 367, 368]. 
Human urothelium expresses AQPs 3, 4, 7 and 9 at the mRNA and protein level.  When 
cultured in vitro, human urothelial cells respond to changes in osmolality by regulating 
AQP3 and to a lesser extent AQP9 expression.  Permeability of the urothelial cells to water 
and urea increases in response to an osmotic gradient, while non-selective blockade of AQP 
with mercuric chloride in the same model leads to reduced permeability.  The authors suggest 
that urothelium responds to urine hypertonicity in order to regulate diffusion of water and 
urea [259, 369].  
Alterations in AQP expression in response to urinary tract obstruction are not confined to 
renal tissue.  In a rat model of partial bladder outlet obstruction AQP1 expression in the 
capillaries, arterioles and venules of bladder tissue was increased compared to controls [367] 
while AQP2 and 3 expression was increased in the bladder urothelial cells alongside the 
NOS isoforms eNOS and nNOS [368]. Currently there is no other reported work 
investigating changes in rodent or human urothelial AQP expression in response to urinary 
tract obstruction.  
1.5.7 Urinary aquaporin excretion 
Measuring proteins of interest in the urine is an exciting avenue of research, as it is non-
invasive and offers the potential of developing biomarkers to aid in the diagnosis of disease, 
selection of patients for surgery and to inform clinicians and families about prognosis. 
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AQPs 1 and 2 are excreted in the urine of healthy humans, approximately 40-45% of which 
is membrane bound in extracellular vesicles [370, 371]. Conversely, in a rat model 97% of 
urinary AQP2 was membrane bound [372]. It is likely urinary excretion occurs via an apical 
pathway rather than whole cell shedding as minimal AQPs are found in urinary cellular 
debris and AQP3 (basolateral collecting duct expression) is absent in the urine [371, 372]. 
Excreted AQPs are associated with various sizes of membrane fragments, potentially 
representing shed plasma membrane, apoptotic bodies, microvesicles and multivesicular 
bodies, however, the major mode of membrane bound excretion is via exosomes [371-374]. 
Exosomes are nanovesicles (30-100 nm diameter) secreted by cells into the extracellular 
space or into body fluids such as urine. They are formed when a multivesicular body (MVB) 
fuses with the cell membrane and contain proteins indicating their cell of origin as well as 
mRNA and microRNA [375, 376]. This process is mediated by the endosomal sorting 
complex required for transport (ESCRT) machinery, although ESCRT independent 
generation of exosomes is also reported (Figure 1.15) [373].  
 
Figure 1.15 The mechanism of urinary exosomal AQP2 generation by renal collecting duct cells  
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Picture taken from Oshikawa et al., 2016 [373] Vasopressin via V2 receptors and the cAMP/PKA pathway 
stimulates AQP2 trafficking to the membrane from intracellular vesicles, and upregulation of AQP2 gene 
transcription via the phosphorylation of CREB. Ubiquitination of apical AQP2 results in its endocytosis after 
which it is processed by the cytoplasmic ESCRT machinery. The ubiquitinated AQP2 is recognised and 
retained by ESCRT-0 (including HRS). ESCRT I (including TSG101), ESCRT II, and ESCRT III along with 
other proteins such as ALIX and VPS4 process the endosomes until the AQP2 is present in the membrane of 
intraluminal vesicles within the multivesicular body [373, 375]. The internalised AQP2 maintains the same 
orientation (cytoplasmic side inward) in the intraluminal vesicle membrane as it had on the cell plasma 
membrane. This is in contrast to endosomes where the orientation is inverted [374, 375]. Once within the 
multivesicular body the protein may be destined for the lysosomal pathway or exosomal release.  The 
regulatory factors controlling this are not currently well known [375]. CREB – Cre binding protein, ESCRT – 
endosomal sorting complex required for transport, HRS – hepatocyte growth factor-regulated tyrosine kinase 
substrate, TSG101 – tumor susceptibility gene 101, ALIX – apoptosis-linked gene 2-interacting protein X, 
VPS4 – vacuolar protein sorting 4, MVB – multivesticular body 
 
Exosomes have been detected from every cell type that contacts the urinary lumen along the 
nephron as well as urothelial cells from the lower urinary tract [374, 375].  Most urinary 
exosomal research has concentrated on biomarker discovery, however, exosomes have been 
implicated in both physiological and pathological roles including immune modulation and 
promoting cancer pathogenicity respectively [375, 377, 378]. The exact function of 
exosomal AQPs is unknown, although recent in vitro work highlights a role in intercellular 
signalling to the distal nephron and/or distal urinary tract. Street el al. demonstrated 
increased AQP2 expression and water permeability in unstimulated mCCDc11 (murine 
cortical collecting duct) cells incubated with exosomes containing AQP2.  These results 
indicate the exosomal transfer of either signalling molecules upregulating endogenous AQP2 
expression or functioning AQP2 channels to the recipient cells [379]. Subsequent in vitro 
and in vivo work confirmed vasopressin regulation of this process [380].  
Broadly speaking the urinary excretion of both AQP1 and AQP2 parallel changes in renal 
expression. Total kidney AQP1 expression correlates with urinary excretion 96 hours 
following renal ischaemia/reperfusion in a rodent model [381].  Interestingly, acetazolamide 
treatment causes an increase in apical and a decrease in basolateral expression of AQP1 in 
proximal tubular cells which is associated with increased urinary exosomal AQP1 excretion 
[382].   
Absolute excretion of AQP2 is the same for men and women and is unaffected by age in the 
adult population.  AQP2/Creatinine ratios are, however, higher for women than men due to 
the generally lower amount of creatinine excreted in the urine [383]. Whether exogenous or 
endogenous (dehydration or hypertonic saline), increased levels of vasopressin result in 
increased urinary AQP2 excretion [371, 384, 385] mirroring the changes seen in whole 
kidney. On the contrary, water loading leads to reduced urinary AQP2 excretion [384, 385]. 
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Additionally, data from rat studies suggests daily urinary excreted AQP2 represents 
approximately 3-4% of total kidney AQP2. However; while Rai et al. demonstrated this 
fraction was relatively unaffected by dehydration, Wen et al. showed that in response to 
changes in vasopressin urinary AQP2 levels closely follow those of AQP2 expression in the 
apical membrane rather than total kidney expression [372, 383]. Studies of patients with 
disorders of water homeostasis confirm the relationship between AQP2 excretion and 
vasopressin secretion whereby patients with congestive cardiac failure and cirrhosis have 
increased AQP2 excretion while patients with central diabetes insipidus have reduced 
urinary AQP2 levels [234].    
Urinary excreted AQPs therefore show promise as non-invasive biomarkers of renal disease. 
Accordingly, post-operative urinary levels of urinary exosomal AQP1 [386] and AQP2 [365] 
are significantly reduced (64% and 54% respectively) in urine obtained from the obstructed 
kidney compared to the normal contralateral kidney in children who have had a pyeloplasty 
for PUJO. The reduction of AQP expression is noted for up to 4 days post-operatively, and 
is associated with a marked polyuria and significant decrease in urine osmolality from the 
obstructed kidney which persists for at least 4 days post-operatively [365]. Urinary TGF-β1 
[386] and prostaglandin E2 [365] excretion is increased in urine from the obstructed kidney 
suggesting that changes in their production may be associated with the downregulation of 
aquaporins seen in urinary tract obstruction.  
Proteomic studies have demonstrated the presence of exosomal AQPs 5 and 7, in addition to 
AQPs 1 and 2, in the urine of healthy humans [387] however this has not been confirmed by 
immunoblotting or ELISA.  
We currently do not know what normal urinary AQP levels are in children.  Additionally, 
there are no reports documenting urinary aquaporin levels in children being monitored for 
hydronephrosis with a PUJ configuration or pre-operatively in children undergoing 





1.6 Hypothesis and aims 
1.6.1 Hypothesis 
The central hypothesis for this project is that: 
Urinary tract aquaporin expression and excretion predicts the severity of disease in 
human and rodent models of PUJO.  
 
1.6.2 Aims 
The specific aims of this project are to: 
❖ Measure the distribution and quantity of AQPs in the kidney and lower urinary tract 
in rodent and human models of neonatal PUJO and compare this with non-obstructed 
kidneys. AQP expression will be correlated with renal pelvis pressure measurements 
and markers of kidney function. 
• Clinical application - Future manipulation of AQP expression in the kidney 
and lower urinary tract may lead to the development of new therapeutic 
approaches for PUJO and other obstructive uropathies. 
❖ Establish the urinary AQP profile in high pressure (damaging) and low pressure 
(non-damaging) PUJO in rodents and humans 
• Clinical application - Defining AQP levels in the urine may lead to the 




Chapter 2. Materials and Methods 
 
2.1 Cell culture 
2.1.1 General cell culture 
Cell culture work was performed using aseptic technique in a Microflow Biological Safety 
Cabinet (MDH, Andover, UK). All equipment, media and solutions used were sterile, either 
by autoclaving before use (Prior Clave, London) or as standard when purchased from the 
manufacturer.  Additionally, the cabinet and all equipment were sanitised with 70% 
industrial methylated spirit prior to use.   
Conditionally immortalised proximal tubular cells with a thermosensitive SV-40 construct 
[388] were grown in adherent culture in either T75 cm2 (156499, Nunclon, Thermoscientific, 
Waltham, MA, USA) or T25 cm2 (156367, Nunclon, Thermoscientific, Waltham, MA, 
USA) flasks containing 10 ml and 3 ml of modified RPMI 1640 media respectively (see 
appendix 1, section 10.1.3).  Cells were viewed daily, and prior to passage and 
cryopreservation, using an inverted microcope (Nikon TMS, Japan) to assess the degree of 
confluence and ensure there was no bacterial or fungal contamination. Culture medium was 
aspirated and replaced with fresh modified RPMI medium every 3 days.  Cells were 
incubated in a Hereus Function Line CO2 incubator (Hereus, NJ, USA) in 5% CO2 at either 
33°C to produce cell proliferation or 37°C to stop proliferation and induce cell 
differentiation. 
2.1.2 Passage of cells 
Cell passage was performed when cells had reached 70% confluence.  The medium was 
aspirated from the culture flask and the cell monolayer washed with sterile PBS using a 
volume equal to half the volume of culture medium. The PBS was aspirated, and the wash 
step repeated. Trypsin in EDTA (T3924, Sigma-Aldrich, St-Louis, MO, USA) was pipetted 
onto the cell monolayer, the flask rotated to ensure complete coverage and then placed in the 
33°C incubator for 3-5 minutes.  Following incubation, the flask was tapped to release any 
remaining attached cells and then assessed using the inverted microscope to ensure all cells 
were rounded and detached.  The cells were resuspended in fresh modified RPMI 1640 
medium and reseeded into fresh flasks at a cell density required for ongoing experiments. 
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Flasks were then placed in the 33°C incubator to allow cell proliferation.  After each cell 
passage the passage number was increased by 1.  The passage number of the cells used for 
each specific experiment will be noted alongside the results.   
2.1.3 Culture on coverslips 
Cell seeding onto coverslips was performed using trypsinised cells generated during cell 
passage.  A single sterile coverslip was placed in each well of a 6-well plate (657160, 
Cellstar®, Greiner bio-one, Stonehouse, UK). Trypsinised cells were resuspended in fresh 
modified RPMI 1640 medium and 2 ml of the cell suspension added to each well of the 6-
well plate.  Plates were incubated at 33°C until 70% confluence was reached and then the 
cells thermoswitched by placing the plates in the 37°C incubator to achieve cell 
differentiation.    
2.1.4 Cryopreservation of cells 
Cell cryopreservation was performed when cells had reached 80-90% confluence.  
Trypsinisation to detach cells from the flask was performed in the same way as for cell 
passage (section 2.1.2).  Cells were then resuspended in a volume of fresh modified RPMI 
1640 medium at least equivalent to the volume of trypsin and then centrifuged at 1500 rpm 
for 5 minutes.  Supernatant was aspirated, and the pellet washed with fresh medium.  The 
cell suspension was centrifuged again at 1500 rpm for 5 minutes and the supernatant 
aspirated. Cells were resuspended in freeze medium (see appendix 1, section 10.1) and 1 ml 
aliquots of cell suspension placed in cryoprotective ampoules (10-500-25, Fisher Scientific, 
Loughborough, UK).  Generally, cells retrieved from a single T75 flask would be split into 
2-3 cryoprotective ampoules.  Ampoules were placed in a passive freezer (Nalgene® Cryo 
1°C, 5100-0001, Thermoscientific, Waltham, MA, USA) containing 100% isopropanol and 
placed in the -80°C freezer overnight allowing a gradual decline in temperature.  Frozen 
ampoules were then transferred to liquid nitrogen storage.   
2.2 Immunofluorescence of cultured cells 
All incubations were carried out at room temperature unless otherwise stated.  Details of 
primary and secondary antibody concentrations used can be found in the relevant chapters.  
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2.2.1 Fixation of cultured cells  
Cells used for immunofluorescence were grown on coverslips in a 6 well plate (657160, 
Cellstar®, Greiner bio-one, Stonehouse, UK). Media was removed from cells, they were 
washed once with PBS, and then fixed in 4% paraformaldehyde (200 µl/well) for 15 minutes. 
A further ice-cold PBS wash was performed before permeabilising the cells by adding 0.2% 
Triton X-100 in PBS (1 ml/well) for 5 minutes.  Cells were washed again with ice-cold PBS 
before treatment with 1 ml of sodium borohydride in PBS (1 mg/ml) for 10 minutes to 
quench any remaining paraformaldehyde and reduce cellular autofluorescence.  Three 
further ice-cold PBS washes were performed.  
2.2.2  Staining of cultured cells  
The PBS wash was removed and primary antibody (see chapter 3 for dilutions and appendix 
2, section 10.2.2 for specific antibody details) in 1% BSA/PBS was added to the surface of 
the coverslip (100 µl/well) and incubated performed for either 1 hour at room temperature 
or overnight at 4°C.  Control cells not treated with primary antibody were incubated with 
1% BSA/PBS only.  Three further PBS washes were performed followed by addition of 
fluorochrome-labelled secondary antibody (see chapter 3 for dilutions and appendix 2, 
section 10.2.2 for specific antibody details) in sterile filtered PBS (100 µl/well) to the surface 
of the coverslip.  Cells were incubated with secondary antibodies in the dark for 45 minutes.  
Three PBS washes were performed followed by a short rinse in distilled water to remove 
PBS associated salts.  Coverslips were mounted onto glass slides using Vectashield® 
Hardset™ mounting medium with DAPI (H-1500, Vector Laboratories, Burlingame, CA, 
USA).  Slides were then imaged using a fluorescent microscope. 
2.3 RNA extraction from whole tissue 
Whole tissue applies to all kidney samples and human renal pelvis and ureter samples 
2.3.1 TRIzol® homogenisation 
Whole human tissue samples were obtained with consent and appropriate ethical approval. 
Whole rat tissues were obtained under the regulations of an appropriate animal licence.   
Samples were immediately washed in ice-cold PBS five times, snap-frozen and stored at 
minus 80°C for later RNA extraction.    Previously frozen samples were retrieved, weighed 
and ground to a powder under liquid nitrogen in a pre-cooled pestle and mortar (Z247464, 
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Z247502, Sigma-Aldrich, St-Louis, MO, USA).  Tissues were homogenised with a hand 
glass homogeniser (11522443, Fisher Scientific, Loughborough, UK) for 10 minutes in 
TRIzol® reagent (15596018, Invitrogen, Paisley, Scotland, UK) using 1 ml TRIzol /100 mg 
tissue.  This method of homogenisation was modified when processing samples obtained 
from the rat model (October 2016 onwards). Previously frozen samples were retrieved, 
weighed, transferred quickly from liquid nitrogen into TRIzol® reagent (15596018, 
Invitrogen, Paisley, Scotland, UK) (1 ml/100 mg tissue) and homogenised using an Ultra-
Turrax homogeniser (TP18/10, Janke and Kunkel, IKA Works, Staufen, Germany). 
Following both homogenisation methods samples were incubated for a further 10 minutes at 
room temperature in TRIzol, then transferred to RNase/DNase free eppendorfs in 1 ml 
aliquots and either stored at -80°C or used directly for RNA isolation. 
2.3.2 Phase separation 
Unless proceeding directly from TRIzol homogenisation the RNA/TRIzol samples were 
retrieved from -80°C storage and thawed on ice.  200 µl of chloroform was added and the 
eppendorf shaken vigorously for 15 seconds.  The sample was incubated at room temperature 
for 3 minutes and then centrifuged at 13500 rpm for 15 minutes at 4°C (5415R 
Microcentrifuge, Eppendorf, Hamburg, Germany).  The clear aqueous phase was aspirated 
and transferred to a new 1.5 ml RNase/DNase free eppendorf. 
2.3.3 RNA precipitation 
500 µl of isopropanol was added to the aqueous phase, the eppendorfs inverted to mix and 
incubated at room temperature for 10 minutes.  Following centrifugation at 13500 rpm for 
10 minutes at 4°C the RNA was visible as a pellet within the eppendorf. 
2.3.4 RNA wash 
The supernatant was carefully removed and 1 ml of ice cold 75% ethanol added to the 
eppendorf.  The sample was vortexed to mix and then centrifuged at 13500 rpm for 5 minutes 
at 4°C.  This wash step was repeated ensuring that all supernatant was carefully and 
completely removed after the second wash. 
2.3.5 Dissolving the RNA 
The pellet was air dried for 5 minutes and then re-suspended in ultrapure RNase/DNase free 
water (Milli-Q Integral water purification system with BioPak, Merck Millipore, Billerica, 
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MA, USA).  The RNA suspension was incubated at 55°C in the hotblock (Accublock™, 
Labnet International, New Jersey, USA) for 10 minutes and then immediately transferred to 
ice.  The RNA suspension was separated in 10 µl aliquots in RNase/DNase free tubes (3412, 
Molecular Bioproducts, San Diego, CA, USA) which were either stored at -80°C or used for 
spectrophotometer analysis and reverse transcription to cDNA. 
2.3.6 Spectrophotometer analysis 
Estimation of the quantity and quality (A260/280 ratio) of RNA was made using the 
Nanodrop spectrophotometer (ND-1000, Thermoscientific, Waltham, MA, USA). 
2.3.7 DNase treatment 
DNase treatment was undertaken using a Primerdesign Precision DNase kit according to the 
manufacturers’ instructions (DNASE-50, PrimerDesign, Southampton, UK). Briefly, 5 µl of 
Precision DNase reaction buffer and 1 µl of Precision DNase enzyme were added to 50 µl 
of RNA sample on ice.  Samples were incubated in the thermal cycler at 30°C for 10 minutes 
followed by 55°C for 5 minutes.  Samples then proceeded to reverse transcription. 
2.4 RNA extraction from whole tissue ≤30 mg 
Tissue ≤30 mg applies to all rat renal pelvis and ureter samples.   
2.4.1 RNA extraction 
Tissue samples were obtained under the regulations of an appropriate animal licence. 
Samples were immediately washed in ice-cold PBS five times, snap-frozen and stored at 
minus 80°C for later RNA extraction. RNA was extracted using an RNeasy Mini Kit (74104, 
Qiagen, Austin, Texas, USA) following the manufacturer’s instructions. Briefly, previously 
frozen samples were retrieved, transferred quickly from liquid nitrogen into 600 µl buffer 
RLT (1 µl β-mercaptoethanol/100 µl buffer RLT) and homogenised using an Ultra-Turrax 
homogeniser (TP18/10, Janke and Kunkel, IKA Works, Staufen, Germany). The lysate was 
centrifuged at 16000 x g for 3 minutes and the supernatant retrieved into a fresh 
RNase/DNase free Eppendorf whereupon 600 µl of 70% ethanol was added and mixed by 
pipetting. Up to 700 µl of sample was added to an RNeasy Mini spin column placed in a 2 
ml collection tube. The sample was centrifuged for 15 seconds at 14000 x g (1-14, Sigma-
Aldrich, St-Louis, MO, USA) and the flow through discarded. This step was repeated using 
64 
 
the same spin column for any remaining sample/70% ethanol mix. Buffer RW1 (350 µl) was 
added to the column and the column centrifuged at 14000 x g for 15 seconds. RNase free 
DNase 1 (79254, Qiagen, Austin, Texas, USA) was made up as per the manufacturer’s 
instructions and then 80 µl added directly to the column membrane and allowed to incubate 
at room temperature for 15 minutes. A further 350 µl of buffer RW1 was added to the column 
which was then centrifuged at 14000 x g and the flow-through discarded. Buffer RPE (500 
µl) was then added to the column followed by centrifugation at 14000 x g for 15 seconds.  
The flow-through was discarded. A further 500 µl of buffer RPE was added to the spin 
column followed by centrifugation at 14000 x g for 2 minutes.  The RNeasy column was 
then placed in a new 2 ml collection tube and centrifuged for 1 minute at 16000 x g to dry 
the membrane. The column was then placed into a new 1.5 ml collection tube and 30 µl of 
RNase free water added directly to the membrane. The column was centrifuged at 16000 x 
g to elute the RNA. The flow-through was carefully pipetted out of the collection tube and 
reapplied to the column membrane. A further centrifugation step at 16000 x g for 1 minute 
was performed to increase the RNA yield and the collection tube containing the RNA 
suspension was transferred to ice. The RNA suspension was separated in 10 µl aliquots in 
RNase/DNase free tubes (3412, Molecular Bioproducts, San Diego, CA, USA) which were 
either stored at -80°C or used for spectrophotometer analysis and reverse transcription to 
cDNA. 
2.4.2 Spectrophotometer analysis 
Estimation of the quantity and quality (A260/280 ratio) of RNA was made using the 
Nanodrop spectrophotometer (ND-1000, Thermoscientific, Waltham, MA, USA). 
2.5 Reverse –transcription polymerase chain reaction (RT-PCR) 
Following reverse transcription samples were either stored at -20°C for later use or used 
directly for end-point PCR analysis. 
2.5.1 Reverse transcription 
Reverse transcription was undertaken using the Applied Biosystems® high capacity RNA to 
cDNA™ kit (4387406, Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s instructions. Positive (with enzyme) and negative (without enzyme) reverse 
transcription reactions were mixed on ice with up to 1 µg of RNA being added to each 20 µl 
total reaction mix.  Tubes were vortexed and underwent a brief centrifuge before being 
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placed in the thermal cycler (Sensoquest labcycler, Gottingen, Germany).  Incubations were 
performed at 37°C for 60 minutes and the reaction was stopped by heating to 95°C for 5 
minutes. 
2.5.2 Polymerase chain reaction 
Forward and reverse primers (MWG Eurofins, Germany) were dissolved in ultrapure 
RNase/DNase free water (Milli-Q with BioPak, Merck Millipore, Billerica, MA, USA) to a 
stock concentration of 100 µM and stored at -20°C.  Forward and reverse primers were then 
mixed and diluted with ultrapure RNase/DNase free water to create a 10 µM working 
solution which was stored at -20°C.  PCR mastermix was prepared on ice as per Table 2.1. 
Mastermix (23.5 µl) was added to each RNase/DNase free PCR tube (3412, Molecular 
Bioproducts, San Diego, CA, USA) to which 1 µl of 10 mM primers and 0.5 µl of cDNA or 
0.3 μl genomic DNA (11691112001, Roche, Sussex, UK) was added to complete a single 
25 µl reaction mix.  Tubes were vortexed to mix and spun in the microfuge (1-14, Sigma-
Aldrich, St-Louis, MO, USA) briefly to eliminate air bubbles. A negative ‘no template’ 
control which did not contain cDNA and a ‘negative reverse transcription’ control were 
included with every PCR run.     PCR reactions were run on a thermal cycler (Sensoquest 
labcycler, Gottingen, Germany), with cycling conditions of: 95°C for 5 minutes followed by 
35 cycles of 95°C for 30 seconds, annealing for 30 seconds and extension at 42°C for 40 
seconds.  Finally, elongation at 72°C for 10 minutes. Details of primer sequences and 
annealing temperatures can be found in appendix 2, section 10.2.1. 
 
Mastermix component Company Volume per 
reaction 
Ultrapure RNase/DNase free 
water 
Milli-Q with BioPak, Merck 
Millipore, Billerica, MA, 
USA 




NO447s, NEB, Ipswich, 
MA, USA 
0.5 µl 
10 x buffer 2200330, 5 Prime, Hilden, 
Germany 
2.5 µl 
Hotmaster Taq DNA 
polymerase 








2.5.3 Gel electrophoresis of PCR product 
Two percent agarose gels were cast by combining agarose (BP1356-500, Fisher Scientific, 
Loughborough, UK) with TAE buffer. The gel mixture was heated in the microwave until 
boiling and then cooled before the addition of ethidium bromide (1.5-3.5 µl according to size 
of gel).  The gel was poured into the casting tray containing a comb and allowed to set.  Once 
set the horizontal electrophoresis tank was filled with TAE buffer to cover the surface of the 
gel.  Two lanes were loaded with 6 µl of 100 bp DNA ladder (N3231S, NEB, Ipswich, MA, 
USA). Samples were mixed with 3 µl of 6 x gel loading dye (N3231S, NEB, Ipswich, MA, 
USA) and then loaded at a volume of 25 µl per well.  The electrophoresis tank was connected 
to the power pack (170-3846, Bio-Rad, Richmond, CA, USA) and run at 110-120 V for 30-
40 minutes until bands were adequately separated. 
2.5.4 Imaging of PCR product 
Gels were imaged using a Universal Hood 11, UV imager (BioRad, Richmond, CA, USA) 
and Quantity One® software.  
2.6 Reverse-transcription real-time polymerase chain reaction (RT-
qPCR) 
2.6.1 Reverse transcription 
Reverse transcription was undertaken using the Applied Biosystems® high capacity RNA 
to cDNA™ kit (4387406, Applied Biosystems, Foster City, CA, USA) according to the 
manufacturer’s instructions. Positive (with enzyme) and negative (without enzyme) reverse 
transcription reactions were mixed on ice with up to 1 µg of RNA being added to each 20 µl 
total reaction mix.  Tubes were vortexed and underwent a brief centrifuge before being 
placed in the thermal cycler (Sensoquest labcycler, Gottingen, Germany).  Incubations were 
performed at 37°C for 60 minutes and the reaction was stopped by heating to 95°C for 5 
minutes. 
2.6.2 Spectrophotometer analysis 
Estimation of the quantity and quality of DNA was made using the Nanodrop 
spectrophotometer (ND-1000, Thermoscientific, Waltham, MA, USA). 
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2.6.3 Real-time polymerase chain reaction 
Forward and reverse primers (MWG Eurofins, Germany) were dissolved in ultrapure 
RNase/DNase free water (Milli-Q with BioPak, Merck Millipore, Billerica, MA, USA) to a 
stock concentration of 100 µM and stored at -20°C.  Forward and reverse primers were then 
mixed and diluted with ultrapure RNase/DNase free water to create either a 10 µM or 5 µM 
(depending on primer optimisation) working solution prior to each PCR run.  Within the UV 
PCR hood (UVP, Fisher Scientific, Loughborough, UK) PCR mastermix was prepared on 
ice consisting of SYBR green jumpstart TAQ readymix (S9194, Sigma-Aldrich, St-Louis, 
MO, USA), forward and reverse primer mix and ultrapure RNase/DNase free water (Table 
2.2). Mastermix was loaded into each well of a 96 well PCR plate (72.1981.202, Sarstedt, 
Numbrecht, Germany) at a volume of 9 µl. Subsequently 2 µl of diluted cDNA (1/45 dilution 
for rat kidney and 1/29 dilution for rat renal pelvis) was added to each well, a plate sealer 
applied (95.1994, Sarstedt, Numbrecht, Germany) and the plate centrifuged in a plate spinner 
(PerfectSpin P, Peqlab, Leicestershire, UK) to eliminate air bubbles. A negative ‘no 
template’ control which did not contain cDNA and a ‘negative reverse transcription’ control 
were included with every PCR run.      
Mastermix component 
Company Volume per 
reaction 
SYBR Green TAQ Readymix 
S9194, Sigma-Aldrich, St-
Louis, MO, USA 
5.5 µl 
Forward and reverse primer mix MWG Eurofins, Germany 2.23 µl 
Ultrapure RNase/DNase free water 
Milli-Q with BioPak, 




Table 2.2 - Mastermix components of a single qPCR reaction 
 
Real time PCR reactions were run using the Step One Plus Real-time PCR system 
comparative CT method with cycling conditions of: 95°C for 10 minutes followed by 45 
cycles of annealing and extension (95°C for 15 seconds, 60°C for 1 minute) then 95°C for 
15 seconds and hold. Melt curves were generated for every reaction and the data analysed 
using StepOne Software v2.3. Details of primer sequences and working concentrations can 
be found in appendix 2, section 10.2.1. 
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2.7 Extraction of Protein  
2.7.1 Extraction of protein from whole cells 
A working solution of Triton X-100 containing protease and phosphatase inhibitors (P8340, 
p5726, P0044, Sigma-Aldrich, St-Louis, MO, USA) was made up immediately prior to use.  
Cells grown under sterile conditions within T75 cm2 flasks were washed with ice cold PBS 
three times and incubated in ice-cold Triton X-100 lysis buffer (500 µl per T75 cm2) on ice 
for 5 minutes.  Cells were collected from the flask using a cell scraper (08-100-242, 
Fisherbrand™ Cell scraper, Fisher Scientific, Loughborough, UK) and transferred with the 
lysis buffer into a 1.5 ml eppendorf and placed on ice for 15 minutes.  Eppendorfs were 
centrifuged at 13500 rpm (5415R Microcentrifuge, Eppendorf, Hamburg, Germany) at 4°C 
for 5 minutes.  The supernatant was aliquoted in fresh 1.5 ml eppendorfs, snap frozen in 
liquid nitrogen and stored at -80°C.   
2.7.2 Extraction of protein from whole tissue 
Whole human tissue samples were obtained with consent and appropriate ethical approval 
(see section 6.2). Whole rat tissues were obtained under the regulations of an appropriate 
animal licence. Samples were immediately washed in ice-cold PBS five times, snap-frozen 
and stored at minus 80°C for later protein extraction.    Previously frozen samples were 
retrieved, weighed and ground to a powder under liquid nitrogen in a pre-cooled pestle and 
mortar (Z247464, Z247502, Sigma-Aldrich, St-Louis, MO, USA).  Tissues were 
homogenised on ice using a hand-held homogeniser (11522443, Fisher Scientific, 
Loughborough, UK) for 10 minutes in ice-cold radioimmunoprecipitation assay (RIPA) 
buffer (SC-24948, Santa Cruz, Dallas, Texas, USA) containing supplied protease inhibitor, 
sodium orthovanadate and PMSF at 10 µl/ml of RIPA buffer.  One millilitre of RIPA buffer 
was used per 333 mg of tissue. This method of homogenisation was modified later in the 
research when processing the latter half of the samples obtained from the rat model (October 
2016 onwards). Previously frozen samples were retrieved, weighed, transferred quickly from 
liquid nitrogen into ice-cold radioimmunoprecipitation assay (RIPA) buffer (1 ml RIPA/333 
mg tissue) containing supplied protease inhibitor, sodium orthovanadate and PMSF at 10 
µl/ml of RIPA buffer (SC-24948, Santa Cruz, Dallas, Texas, USA).  Tissues were 
homogenised on ice using an Ultra-Turrax homogenizer (TP18/10, Janke and Kunkel, IKA 
Works, Staufen, Germany). 
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Following both homogenisation methods tissue lysates were transferred to 1.5 ml eppendorfs 
and agitated for 2 hours at 4°C and then centrifuged at 13500 rpm at 4°C for 10 minutes 
(5415R Microcentrifuge, Eppendorf, Hamburg, Germany).  The supernatant was aliquoted 
into fresh 1.5 ml eppendorfs, snap frozen in liquid nitrogen and stored at -80°C.   
2.7.3 Extraction of protein from whole tissue ≤30 mg  
Tissue ≤30 mg applies to rat renal pelvis and ureter samples.  This protein extraction was 
performed as an extension of the RNA extraction procedure using an RNeasy Mini Kit 
(74104, Qiagen, Austin, Texas, USA). Briefly, previously frozen samples were retrieved, 
transferred quickly from liquid nitrogen into 600 µl buffer RLT (1 µl β-mercaptoethanol/100 
µl buffer RLT) and homogenised using an Ultra-Turrax homogeniser (TP18/10, Janke and 
Kunkel, IKA Works, Staufen, Germany). The lysate was centrifuged at 16000 x g for 3 
minutes and the supernatant retrieved into a fresh RNase/DNase free Eppendorf whereupon 
600 µl of 70% ethanol was added and mixed by pipetting. Up to 700 µl of sample was added 
to an RNeasy Mini spin column placed in a 2 ml collection tube. The sample was centrifuged 
for 15 seconds at 14000 x g (1-14, Sigma-Aldrich, St-Louis, MO, USA) and the flow through 
transferred to a fresh 1.5 ml Eppendorf. Four volumes of ice-cold acetone were added to the 
flow-through and the mixture incubated at on ice for 30 minutes. The sample was centrifuged 
at 13500 rpm at 4°C for 10 minutes (5415R Microcentrifuge, Eppendorf, Hamburg, 
Germany). The supernatant was discarded and the pellet air dried for 5 minutes. The pellet 
was washed with 100 µl of ice cold ethanol and then air dried for 3 minutes before 
resuspension in 100 µl of RIPA buffer (SC-24948, Santa Cruz, Dallas, Texas, USA) 
containing supplied protease inhibitor, sodium orthovanadate and PMSF at 10 µl/ml of RIPA 
buffer. The tissue lysate was agitated for 2 hours at 4°C and then centrifuged at 13500 rpm 
at 4°C for 5 minutes (5415R Microcentrifuge, Eppendorf, Hamburg, Germany) to pellet 
insoluble material. The supernatant was transferred into a fresh 1.5 ml Eppendorf on ice and 
used for BCA assay. 
2.8 Bincinchoninic Acid (BCA) protein assay 
The Bincinchoninic Acid protein assay was performed using the Pierce™ BCA protein assay 
kit (23227, Rockford, IL, USA).  Bovine serum albumin (BSA, A9647, Sigma-Aldrich, St-
Louis, MO, USA) was serially diluted in ultrapure water to create protein standards (1440 
µg/ml to 11.25 µg/ml) which were added in duplicate (25 µl/well) to a 96 well flat-bottomed 
microplate (655180, Cellstar®, Greiner bio-one, Stonehouse, UK).  Protein lysate samples 
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were diluted 1:25 and 1:50 with ultrapure water and loaded in duplicate to the microplate 
with a final volume of 25 µl/well.  Working reagents A and B were mixed in a 50:1 ratio, 
200 µl added to each well and then incubated at room temperature for 30 minutes.  The plate 
was read at 570 nM using the Opsys MR™ microplate reader (Dynex Technologies, 
Chantilly, VA, USA).   Revelation Quicklink Software Version 4.25 was used to generate a 
standard curve and determine the protein concentration of each sample.  
2.9 Deglycosylation of proteins 
N-Deglycosylation of proteins was undertaken using a PNGase F Kit according to the 
manufacturers’ instructions (P0705, NEB, Ipswich, MA, USA). Briefly, 40 µg of protein 
lysate was combined, on ice, with 1 µl of 10x glycoprotein denaturing buffer and ultrapure 
water to make a total reaction volume of 10 µl.  Samples were heated to denature the 
glycoprotein in the thermal cycler (Sensoquest labcycler, Gottingen, Germany) at 100°C for 
10 minutes. Subsequently, 2 µl of PNGase F, 2 µl of 10% NP-40, 2 µl of 10x G7 reaction 
buffer and ultrapure water were added to make a 20 µl total reaction volume. The reaction 
was incubated in the thermal cycler at 37°C for 1 hour.  Samples then proceeded to sample 
preparation for western blotting. 
2.10 Concentration and fractionation of human urinary proteins 
2.10.1 Ultrafiltration 
Fresh human urine samples (15 ml) were placed on ice and 187.5 µl of protease inhibitor 
added (P2714, Sigma-Aldrich, St-Louis, MO, USA).  Samples were centrifuged at 3000 rcf 
for 15 minutes at 4°C to remove cellular debris (Sorvall® Legend RT, Thermoscientific, 
Waltham, MA, USA).  The supernatant was collected into an Amicon® Ultra-15 10K 
centrifugal filter device (UFC901008, Merck Millipore, Billerica, MA, USA) and 
centrifuged at 3000 rcf at 4°C for approximately 40 minutes until the volume of concentrate 
reached 400 µl.  The concentrate was aspirated, placed into an eppendorf and an equal 
volume of 2 x sample buffer (working solution) was added. Samples were vortexed to mix, 
heated to 95°C for 5 minutes (unless otherwise stated) and then used for western blotting.    
71 
 
2.10.2 Ultrafiltration and chemical precipitation of exosomes 
Fresh human urine samples (15 ml) were placed on ice and 187.5 µl of protease inhibitor 
added (P2714, Sigma-Aldrich, St-Louis, MO, USA).  Samples were centrifuged at 3000 rcf 
for 15 minutes at 4°C to remove cellular debris (Sorvall® Legend RT, Thermoscientific, 
Waltham, MA, USA).  The supernatant was collected into an Amicon® Ultra-15 10K 
centrifugal filter device (UFC901008, Merck Millipore, Billerica, MA, USA) and 
centrifuged at 3000 rcf at 4°C for approximately 40 minutes until the volume of concentrate 
reached 500 µl. The concentrate was aspirated, placed into an eppendorf and an equal 
volume of ExoQuick-TC™ exosome precipitation solution added. The samples were inverted 
to mix and placed at 4°C overnight.  Subsequently samples were centrifuged at 1500 rcf at 
room temperature for 30 minutes to pellet the precipitated exosome fraction.  The 
supernatant was aspirated and discarded, and the pellet centrifuged again at 1500 rcf for 5 
minutes at room temperature.  All traces of fluid were aspirated and discarded taking care 
not to disturb the exosome pellet. The pellet was resuspended in 200 µl of RIPA buffer (SC-
24948, Santa Cruz, Dallas, Texas, USA) containing the supplied protease inhibitor, sodium 
orthovanadate and PMSF at 10 µl/ml of RIPA buffer.  Tubes were vortexed for 15 seconds 
to ensure complete resuspension and then placed at room temp for 5 minutes to allow 
complete lysis of exosomes.  200 µl of sample buffer (working solution) was added, the 
sample vortexed to mix and then heated at 95°C for 5 minutes (unless otherwise stated).  
Samples were then used for western blotting.  
2.10.3 Urine lyophilisation 
Fresh human urine samples (5 ml) were centrifuged at 3000 x g for 15 minutes at 4°C to 
remove cellular debris (Sorvall® Legend RT, Thermoscientific, Waltham, MA, USA).  The 
supernatant was collected into a 15 ml centrifuge tubes (188271, Cellstar®, Greiner Bio-One, 
Gloucestershire, UK) snap frozen and placed in -80°C freezer prior to lyophilisation. Frozen 
samples were retrieved, the centrifuge tube cap removed and the tube re-sealed with 
Parafilm® (P7793, Sigma-Aldrich, St-Louis, MO, USA). The Parafilm® seal was pierced 
multiple times with a 21-gauge needle and the samples transferred to the Benchtop Pro 
(VirTis SP Scientific, Suffolk, UK) for 16 hours to undergo lyophilisation. Following 
lyophilisation samples were stored at 4°C. 
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2.11  Western Blotting – Chemiluminescent and fluorescent 
All incubations were carried out at room temperature unless otherwise stated.  Details of 
primary and secondary antibody concentrations used can be found in the relevant chapters. 
2.11.1 Apparatus 
Mini PROTEAN equipment was used for gel electrophoresis (Bio-Rad, Richmond, CA, 
USA).  Glass plates for gel preparation were washed with distilled water, cleaned with 70% 
ethanol and assembled on a casting stand.  
2.11.2 Preparation of the acrylamide gel 
Polyacrylamide gels were prepared by casting 4% stacking gels and 12.5% resolving gels to 
detect proteins of approximately 25-40 kDa.  Gels were prepared according to the recipe 
detailed in appendix 1 (section 10.1.2) with ammonium persulphate and TEMED being 
added last to achieve gel polymerisation. The resolving gel was poured first, between the 
glass plates, to 1 cm below the anticipated position of the bottom of the comb. Filter paper 
was used to remove any air bubbles within the top of the gel.  Once set, the top of the gel 
was washed with distilled water, the water removed with filter paper, and the stacking gel 
poured to reach the top of the glass plate. A 10 or 15 lane comb was then inserted, and the 
gel allowed to set. 
2.11.3 Sample preparation and loading 
Protein lysates were retrieved from -80°C storage and defrosted on ice.  Protein 
concentration of the samples was determined by prior BCA assay (23227, Pierce Rockford, 
Illinois, USA).  
For chemiluminescent western blotting, samples were diluted to a final concentration of 200 
µg in 20 µl using ultrapure water. When performing the fluorescent technique, samples were 
diluted to a final concentration of 150 µg in 20 µl using ultrapure water. One microliter of 
Cy5 dye (diluted 1:10 with ultrapure water) was added to each sample in order to 
fluorescently label all protein. The sample was mixed and incubated at room temperature for 
30 minutes.  
Unless indicated otherwise for both chemiluminescent and fluorescent techniques, samples 
were then mixed 1:1 with 2 x sample buffer (working solution).  Samples were then heated 
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at 95°C for 5 minutes (unless otherwise stated) in a hotblock (Accublock™, Labnet 
International, New Jersey, USA) followed by a short spin in the centrifuge (5415R 
Microcentrifuge, Eppendorf, Hamburg, Germany).  The glass plates containing the 
polyacrylamide gels were loaded in the electrophoresis tank and the tank filled with 1 x 
running buffer.  The combs were removed from the gels and sample loaded into the wells 
using a Gilson pipette (Pipetman®, Gilson, Wisconsin, USA) to achieve the appropriate total 
amount of protein concentration. Additionally, two lanes were loaded for each gel with either 
3 µl BLUeye prestained protein ladder (S6-0024, Geneflow Ltd, Fradley, UK) for the 
chemiluminescent technique, or 3 µl of Amersham™ ECL™ Plex Fluorescent Marker 
(10320125, GE Healthcare, Buckinghamshire, UK) for the fluorescent technique. 
2.11.4 Gel electrophoresis 
Following sample loading the electrophoresis tank was connected to the power pack (170-
3846, Bio-Rad, Richmond, CA, USA) and the gel run at 150 V for approximately 70 minutes 
until the samples had reached the bottom of the gel. 
2.11.5 Protein transfer 
When performing the chemiluminescent technique the gel was removed from the glass plates 
and the stack cut off. The PVDF membrane (88518, Perbioscience, Northumberland, UK) 
was pre-wet in methanol.  
For fluorescent western blotting, the gel was removed from the glass plates and both the 
stack and the bromophenol blue front cut off. The gel was soaked in cold transfer buffer for 
10 minutes. The PVDF hybond 0.2 µm low fluorescence membrane (10600060, 
Amersham™, GE Healthcare, Buckinghamshire, UK) was wet in methanol for 20 seconds 
then in ultrapure water for 20 seconds and then in cold transfer buffer for 5 minutes.   
Subsequently for both techniques the transfer cassette was assembled under 1 x transfer 
buffer on the black side as follows: sponge, filter paper, gel, PVDF, filter paper, sponge.  A 
roller was used to ensure no air bubbles were trapped between the layers and the cassette 
closed and placed in the transfer tank.  The tank was filled with 1 x transfer buffer and an 
ice pack added. The tank was connected to the power pack (170-3846, Bio-Rad, Richmond, 
CA, USA) and transfer was performed at 250 mA for 1 hour. 
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2.11.6 Blocking of membrane 
After completion of transfer, membranes were removed from the transfer cassette and placed 
in a square petri dish (foil covered for fluorescence) containing 10 ml of blocking solution.  
Blocking solutions used were either 5% skimmed milk (Tesco, Cheshunt, UK) in TBS-T or 
3% BSA (A9647, Sigma-Aldrich, St-Louis, MO, USA) in TBS-T according to the primary 
antibody to be used.  Blocking was carried out for at least 1 hour at room temperature with 
shaking. 
2.11.7 Antibody incubation 
The blocking solution was removed and 10 ml of primary antibody made up in either 3% 
BSA/TBS-T or 1% BSA/TBS-T was added (see individual chapters for dilutions and 
appendix 2, section 10.2.2 for specific antibody details).  The membrane was incubated with 
primary antibody overnight (protected from light for fluorescence) at 4°C with shaking.  
Following incubation, the membrane was rinsed twice in TBS-T followed by 5 TBS-T 
washes, each for 5 minutes with shaking.   
Subsequently, for chemiluminescent western blotting, 10 ml of horseradish peroxidase 
(HRP) conjugated secondary antibody made up in either 3% BSA/TBS-T or 1% BSA/TBS-
T was added to the membrane. When undertaking the fluorescent technique, 10 ml of Cy3 
conjugated anti-mouse secondary fluorescent antibody (PA43009V, GE Healthcare, 
Buckinghamshire, UK) diluted to 1:2500 in 3% BSA/TBS-T was added to the membrane 
(see relevant chapters for antibody dilutions and appendix 2, section 10.2.2 for specific 
antibody details).   
The membrane was then incubated in secondary antibody specific for the primary antibody 
host for 1 hour at room temperature (protected from light for fluorescence) with shaking. 
Following incubation, the secondary antibody was removed, and the membrane rinsed twice 
in TBS-T followed by 5 TBS-T washes, each for 5 minutes with shaking. 
2.11.8 Chemiluminescence imaging 
Clarity™ Western ECL substrate (170-5061, Bio-Rad, Richmond, CA, USA) was used to 
detect antibody bound proteins. Luminol/enhancer reagent was mixed with an equal volume 
of peroxide solution and then applied to the membrane for 1-5 minutes.  The membrane was 
then imaged using the ChemiDoc-It Imaging System (UVP Bioimaging Systems, Upland, 
CA, USA) and VisionWorks™ LS software.  Images were obtained every 30 seconds for 10 
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minutes. Later western blots including all from the final male neonatal rat PUUO model 
were imaged using an Amersham™ Imager 600 (GE Healthcare, Buckinghamshire, UK). 
Analysis of western blots was conducted using ImageJ software. 
2.11.9 Fluorescence imaging 
The membrane was rinsed 3 times with TBS without tween and imaged using an 
Amersham™ Imager 600 (GE Healthcare, Buckinghamshire, UK). Analysis of western blots 
was conducted using ImageJ software. 
2.11.10 Membrane stripping and re-probing following western blotting 
Dry membranes were wet in methanol, added to stripping buffer (Appendix 1, section 10.1)  
ensuring the membrane was completely covered, and incubated for 20 minutes in a water 
bath at 55°C.  Membranes were washed three times over 1 hour at 20 minute intervals in 
TBS-T at room temperature with shaking.  Membranes were then blocked as in section 
2.11.6 and immunostaining continued as previously described. 
2.12 Sample processing for immunohistochemistry and 
histopathological staining 
2.12.1 Sample fixation 
Whole tissue samples were obtained with consent and appropriate ethical approval.  Samples 
were immediately washed in ice-cold PBS five times, prepared to ensure sample thickness 
of 2-3mm and then fixed in 10% neutral buffered formalin (ratio of fixative volume to 
sample weight 20:1) for 24 hours at 4°C. Samples were transferred into 70% ethanol (for a 
maximum of 2 days) while awaiting dehydration and paraffin embedding.  Dehydration and 
paraffin embedding of fixed samples was performed by University of Bristol research staff 
within the histology department, level 7, Bristol Royal Infirmary until June 2015. 
Subsequently, paraffin embedding of fixed samples was performed by University of Bristol 
histopathology staff within the Bristol Medical School histopathology laboratory.  
2.12.2 Section cutting 
Blocks were positioned face down on a cooling block for 10 minutes. Using a microtome 
the block was trimmed in by cutting 10 µm sections.  Subsequently 4 µm sections were cut 
and then floated on a water bath at 37°C.  Sections were then floated onto clean Superfrost® 
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plus slides (4951plus4, Thermoscientific, Waltham, MA, USA) and placed in a rack to allow 
water to drain.  Slides were placed in a 37°C oven for 24 hours. From May 2016 onwards, 
histopathology sections were cut by University of Bristol histopathology staff within the 
Bristol Medical School histopathology laboratory. 
2.13 Immunohistochemistry 
2.13.1 Deparaffinisation/hydration 
Slides were incubated in 3 washes of Histo-Clear (HS-200, National diagnostics, Hessle, 
UK) for 5 minutes each, then 2 washes in 100% ethanol for 10 minutes each, and finally 2 
washes in 95% ethanol for 10 minutes each.  Sections were then washed twice in ultrapure 
water for 5 minutes each. 
2.13.2 Antigen unmasking 
Slides were placed in 10 mM sodium citrate buffer pH6 and brought to the boil using a 700 
Watt microwave.  Slides were then maintained at sub-boiling temperature for 10 minutes.  
Slides were left to cool for 30 minutes and then washed twice in TBS-T for 5 minutes each. 
2.13.3 Blocking 
Sections were incubated in 80-100 µl of 1.5% blocking serum in TBS-T for 1 hour at room 
temperature in a humidified chamber. The blocking serum used was specific to the antibody 
combination being applied and derived from the same species in which the secondary 
antibody was raised (see chapters 3 and 5 for details of blocking serum used). 
2.13.4 Antibody incubation  
Blocking serum was drained from the slides and sections incubated with 80-100 µl of 
primary antibody made up in blocking serum overnight at 4°C in a humidified chamber (see 
chapters 3 and 5 for antibody dilutions and appendix 2, section 10.2.2 for specific antibody 
details).  Following primary antibody incubation slides were washed 3 times in TBS-T for 5 
minutes each. Sections were then incubated in 0.5% hydrogen peroxide in distilled water for 
10 minutes at room temperature in a dark humidified chamber.  Slides were washed 3 times 
in TBS-T for 5 minutes each.  Sections were incubated in secondary HRP conjugated 
antibody 1-2 drops to each section for 30 minutes at room temperature in a humidified 
chamber.  Secondary antibodies used are polymerised reporter antibody staining systems 
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specific for the primary antibody host, namely SignalStain® boost IHC detection reagent 
HRP anti-rabbit (Cell signalling, Danvers, MA, USA) and ImmPRESS HRP anti-goat 
polymer detection system (MP7405, Vector Laboratories, Burlingame, CA, USA) 
2.13.5 Staining 
Slides were washed 3 times in TBS-T for 5 minutes each.  DAB chromogen 50x concentrate 
(SC-24982, Santa Cruz, Dallas, Texas, USA) was diluted 1:50 with 0.1 M Tris HCl/0.015 
% H2O2. Each section was incubated with 80-100 µl of DAB chromogen/peroxidase 
substrate for 5 minutes.   
Immunohistochemistry performed later in the research, for AQP3 only, utilised a different 
DAB chromogen (Signalstain® DAB chromogen kit, #8059, Cell signalling, Danvers, MA, 
USA) following a change of primary antibody (detailed in Chapter 5 section 5.2.2).  The 
DAB substrate was made up as per the manufacturer’s instructions and 80-100 μl added to 
each section for 5 minutes.  
Following using either DAB substrate, sections were washed in ultrapure water for 5 
minutes.  Counter staining in Gill’s #3 Haematoxylin solution (GHS316, Sigma-Aldrich, St-
Louis, MO, USA) for 10 seconds was performed followed by washing with several changes 
of distilled water. 
2.13.6 Dehydration and mounting 
Slides were incubated in 95% ethanol for 10 seconds twice, then 100% ethanol for 10 
seconds twice and finally Histo-Clear (HS-200, National diagnostics, Hessle, UK) for 10 
seconds thrice.  Excess Histo-Clear was wiped from slides and 1-2 drops of DPX mountant 
(44581, Sigma-Aldrich, St-Louis, MO, USA) immediately added to sections and covered 
with a glass coverslip (1233-3138, Fisher Scientific, Loughborough, UK).  
2.14 Masson’s Trichrome Stain 
2.14.1 Deparaffinisation/hydration 
Slides were incubated in 3 washes of Histo-Clear (HS-200, National diagnostics, Hessle, 
UK) for 5 minutes each, then 2 washes in 100% ethanol for 10 minutes each, and finally 2 
washes in 95% ethanol for 10 minutes each.  Sections were then washed twice in ultrapure 




Slides were placed in pre-heated Bouin’s solution (HT10132-1L, Sigma-Aldrich, St-Louis, 
MO, USA) and maintained at 56°C in a water bath for 15 minutes. The slides were 
subsequently cooled and washed in running in tap water to eradicate the yellow colouration 
from the sections. Sections were then incubated with working Weigert’s Iron Haematoxylin 
solution (RRSP72-D and RRSP73-E, Atom Scientific, Manchetser, UK), made up of equal 
volumes of Solution A and B, for 10 minutes at room temperature.  This was followed by a 
wash in running tap water for 10 mins then an ultrapure water rinse.  The remainder of the 
staining was accomplished using a Masson’s Trichrome Stain Kit used at room temperature 
(HT15-1KT, Sigma-Aldrich, St-Louis, MO, USA). Briefly, sections were incubated in 
Biebrich Scarlet-Acid Fucshin for 10 minutes followed by a rinse in ultrapure water and then 
immersion in working Phosphotungstic/Phosphomolybdic Acid Solution for 15 minutes. 
Slides were transferred into Aniline Blue Solution for 10 minutes and then 1% Acetic Acid 
for 2 minutes. Finally, sections were washed in ultrapure water. 
2.14.3 Dehydration and mounting 
Slides were incubated in 95% ethanol for 10 seconds twice, then 100% ethanol for 10 
seconds twice and finally Histo-Clear (HS-200, National diagnostics, Hessle, UK) for 10 
seconds thrice.  Excess Histo-Clear was wiped from slides and 1-2 drops of DPX mountant 
(44581, Sigma-Aldrich, St-Louis, MO, USA) immediately added to sections and covered 
with a glass coverslip (1233-3138, Fisher Scientific, Loughborough, UK).  
2.15 Periodic Acid Schiff Stain 
2.15.1 Deparaffinisation/hydration 
Slides were incubated in 3 washes of Histo-Clear (HS-200, National diagnostics, Hessle, 
UK) for 5 minutes each, then 2 washes in 100% ethanol for 10 minutes each, and finally 2 
washes in 95% ethanol for 10 minutes each.  Sections were then washed twice in ultrapure 
water for 5 minutes each. 
2.15.2 Staining 
Staining was performed at room temperature using a Periodic Acid Schiff Kit as per the 
manufacturer’s instructions (395B-1KT, Sigma-Aldrich, St-Louis, MO, USA). Briefly, 
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sections were incubated in Periodic Acid Solution for 5 minutes then rinsed in several 
changes of ultrapure water.  Sections were then incubated in Schiff reagent for 15 minutes 
followed by a rinse in running distilled water. Sections were counterstained in Gill’s #3 
Haematoxylin solution (GHS316, Sigma-Aldrich, St-Louis, MO, USA) and then rinsed in 
running distilled water for 5 minutes. 
2.15.3 Dehydration and mounting 
Slides were incubated in 95% ethanol for 10 seconds twice, then 100% ethanol for 10 
seconds twice and finally Histo-Clear (HS-200, National diagnostics, Hessle, UK) for 10 
seconds thrice.  Excess Histo-Clear was wiped from slides and 1-2 drops of DPX mountant 
(44581, Sigma-Aldrich, St-Louis, MO, USA) immediately added to sections and covered 
with a glass coverslip (1233-3138, Fisher Scientific, Loughborough, UK).  
2.16 Microscopy 
2.16.1 Light microscopy 
Imaging of immunohistochemistry sections was performed using a Leica DM IRB 
microscope and Leica IM50 (V1.20) software. Analysis of staining was performed using 
Image J software. 
2.16.1.1 Counting of glomeruli 
The number of glomeruli per field of view was established using axial kidney sections 
stained with Masson’s trichrome. Glomeruli were counted from at least seven independent 
20 x magnification images of an axial kidney section and the mean value calculated for each 
animal.  
2.16.1.2 Quantification of renal fibrosis 
Axial kidney sections stained with Masson’s trichrome were used to undertake relative 
quantification of interstitial collagen deposition. Images were taken at 20 x magnification 
and at least 7 independent fields of view for each of the cortex and medulla were used for 
assessment of fibrosis. Using image J software a grid (50 μm2 each square) was 
superimposed over each field of view and the number of points at which the blue stained 
collagenous fibrotic tissue intersected the grid were counted. The mean number from all 
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fields of view was then calculated for each animal and expressed as a percentage of the total 
number of grid points.   
2.16.1.3 Grading of renal pelvis AQP3 staining 
Grading of renal pelvis AQP3 staining in PUUO rats versus controls was undertaken blinded 
by 2 people, Professor Richard Coward and Miss Fern Barrington, Bristol Renal, University 
of Bristol. Multiple pictures were taken of the renal pelvis in paraffin embedded rat tissue 
using IHC. Then 6 images were randomly selected and scored for each condition. The 
relative intensity (score 0→5) and localisation were assessed. I then compared the “partially 
obstructed kidney” to its contralateral “non-obstructed” control and sham kidneys.  
2.16.2 Fluorescent microscopy  
Imaging of immunoflurescence sections was performed using a Leica DMI 6000B 
microscope. 
2.17 Urine sample collection, processing and storage 
2.17.1 Rodent urine 
Urine samples were collected in accordance with the project and personal licences issued by 
the Home Office.  Spot urine samples were collected at two weeks of age by allowing the 
pup to pass urine onto a sheet of clingfilm. Spot urine samples were obtained at 3 weeks of 
age by placing the pup into a cage containing hydrophobic sand (LABS-1, Datesand, 
Mancheser, UK).  At 4 weeks of age rats were placed in a metabolic cage for up to 5 hours 
and urine was collected into ice-cold collection tubes cooled by surrounding ice-packs. 
Regardless of the method of collection, urine samples were transferred into 1.5 ml 
eppendorfs, placed on ice and transported immediately to the laboratory. Samples were 
centrifuged at 3000 rcf for 15 minutes at 4°C to remove cellular debris (Sorvall® Legend RT, 
Thermoscientific, Waltham, MA, USA) and the supernatant aliquoted into new 1.5 ml 
eppendorfs. Aliquots were snap-frozen in liquid nitrogen and stored at -80°C for later 
analysis. 
2.17.2 Human urine 
Urine samples were obtained with consent and appropriate ethical approval. Fresh urine 
samples obtained from either the bladder (voided pre-operatively and/or by urinary catheter 
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intra-operatively) and the renal pelvis (aspirated intra-operatively) were collected into a 50 
ml centrifuge tubes (227270, Cellstar®, Greiner Bio-One, Gloucestershire, UK) and placed 
immediately into ice.  Samples were transferred immediately to the laboratory and were 
centrifuged at 3000 rcf for 15 minutes at 4°C to remove cellular debris (Sorvall® Legend RT, 
Thermoscientific, Waltham, MA, USA). The supernatant was aliquoted into new 1.5 ml 
eppendorfs and 15 ml centrifuge tubes (188271, Cellstar®, Greiner Bio-One, 
Gloucestershire, UK) depending on the total volume obtained. Samples were snap-frozen in 
liquid nitrogen and stored at -80°C for later analysis. 
2.18 Urinary creatinine assay 
Creatinine stock solution (100 µg/ml) (C3613, Sigma-Aldrich, St-Louis, MO, USA) was 
serially diluted in ultrapure water to create creatinine standards (100 µg/ml to 0.78 µg/ml) 
which were added in duplicate (25 µl/well) to a 96 well flat-bottomed microplate (655180, 
Cellstar®, Greiner bio-one, Stonehouse, UK).  Urine samples were diluted 1:10 and 1:20 
with ultrapure water and loaded in duplicate to the microplate with a final volume of 25 
µl/well.  Working reagents A (37 mM picric acid) and B (0.3 M NaOH) were mixed in a 1:1 
ratio, 50 µl added to each well and then incubated at room temperature for 6 minutes.  The 
plate was read at 490 nm using the Opsys MR™ microplate reader (Dynex Technologies, 
Chantilly, VA, USA).   Revelation Quicklink Software Version 4.25 was used to generate a 
standard curve and determine the creatinine concentration of each sample. 
2.19 Urinary creatinine measurement 
All urinary creatinines analysed from the final male neonatal rat PUUO model were 
processed as a single batch by Diagnostic Laboratories, Langford Veterinary Services, 
School of Veterinary Sciences, University of Bristol using a Konelab Prime 60i fully 
automated clinical chemistry analyser.  
2.20 Urinary aquaporin 1 ELISA 
2.20.1 Antigen coating of plate 
Recombinant AQP1 protein was diluted in 0.1% SDS in PBS to achieve a stock solution of 
400 ng/ml.  This stock solution was then serially diluted in 0.1% SDS in PBS to create AQP1 
standards (400 ng/ml to 3.125 ng/ml) which were added in duplicate or triplicate to a 96 well 
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flat bottomed high protein binding capacity plate (Nunc MaxiSorp®, 44-2404-21, Nalge 
Nunc International, NY, USA) at a volume of 50 µl per well. Frozen urine samples were 
defrosted, vortexed well and diluted with an equal volume of 0.2 % SDS in PBS.  A further 
2 to 3 2-fold serial dilutions were performed using 0.1% in PBS as diluent.  All urine 
dilutions were then added in duplicate or triplicate to the 96 well plate at a volume of 50 µl 
per well. Blank wells were included on each plate in duplicate and triplicate and contained 
only 0.1% SDS in PBS. A plate sealer was applied, and the plate incubated at 4°C overnight 
(16 hours). 
2.20.2 Blocking of plate 
The plate was retrieved from incubation at 4°C and allowed to acclimatise to room 
temperature for 90 minutes. The antigen solution was removed and 3 washes of each well 
with 300 µl of PBS-T performed. Each well was incubated with 300 µl of 3% BSA (A9647, 
Sigma-Aldrich, St-Louis, MO, USA) in PBS blocking solution for 1 hour at room 
temperature.  
2.20.3 Antibody incubation 
The blocking solution was removed and 50 µl of anti-AQP1 antibody diluted to 1:60 in 3% 
BSA/PBS was added to each well. The plate was sealed and incubated for 2 hours at 37°C 
with agitation (70-80 rpm)(Orbital Incubator S150, Stuart Scientific, Staffordshire, UK). The 
antibody was removed, and 4 washes of each well was performed with 300 µl PBS-T. Fifty 
microlitres of HRP conjugated anti-rabbit antibody diluted 1:5000 in 3% BSA (A9647, 
Sigma-Aldrich, St-Louis, MO, USA) in PBS was added to each well.  The plate was sealed 
and incubated for 1 hour at 37°C with agitation (70-80 rpm)(Orbital Incubator S150, Stuart 
Scientific, Staffordshire, UK). 
2.20.4 Substrate incubation 
The antibody solution was removed, and 5 washes of each well was performed with 300 µl 
of PBS-T. Tetramethylbenzidine (TMB) was added at a volume of 100 µl per well and the 
plate incubated in the dark for 15 minutes. One hundred microliters of 0.18 M H2SO4 was 
added to each well to stop the reaction. 
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2.20.5 Plate reading 
The plate was read at 450 nm using the Bio-Rad iMark™ microplate reader (Bio-Rad, CA, 
USA).   Microplate manager 6 software was used to generate a standard curve and determine 
the AQP1 concentration of each sample using 4 parameter logistic regression. 
2.21 Statistical analysis 
Microsoft Excel Software (Microsoft Corporation, WA, USA) was used to collate raw data 
from western blotting densitometry, qPCR CT values and microplate reader optical density 
values. GraphPad Prism 5 (GraphPad Software Inc, CA, USA) was used to produce 
descriptive statistics, generate graphical representations of the data and to undertake specific 
statistical analyses. For parametric data a two-tailed t-test was used to compare 2 groups 
while a one-way ANOVA was used for multiple group comparisons with a Tukey post-test 
correction. Repeated measures of multiple groups were analysed using a two-way ANOVA 
with Bonferroni post-test correction. Correlation of results was assessed using an XY scatter 






In order to successfully meet the aims and objectives of this research it was necessary to 
establish and optimise a number of molecular biological techniques.  
The first major aim was to measure the distribution and quantity of AQPs in the kidney and 
lower urinary tract in rodent and human models of neonatal PUJO and compare this with 
non-obstructed kidneys.  At the mRNA level this was achieved by endpoint RT-PCR 
(reverse transcription-polymerase chain reaction) to determine the presence or absence of 
individual AQP isoforms (AQP0-12), followed up by real-time RT-PCR (qRT-PCR) to 
determine comparative expression between obstructed and non-obstructed systems.   
At the protein level western blotting and immunohistochemistry was utilised to determine 
AQP isoform quantity and distribution respectively in obstructed versus non-obstructed 
systems.   
 Although a number of AQP isoforms (1-8, 11 in kidney and 1-4, 7, 9 in lower urinary tract) 
are expressed by the human and rodent renal tract, efforts were concentrated on optimising 
techniques to analyse the effect of urinary tract obstruction on the protein expression of 
AQPs 1-4.  The rationale was twofold: 
1. Within the nephron AQPs 1-4 are the major isoforms responsible for water re-
absorption. AQP1 is localised to the apical and basolateral membranes of the 
proximal tubular cells and is responsible for near iso-osmolar water re-absorption 
whereby the vast majority of the filtered fluid is re-absorbed.  AQP1 is also found in 
the thin descending limb of the loop of Henle and the vasa recta and is involved in 
generating medullary interstitial hypertonicity thus enabling the production of 
concentrated urine.  AQP2 shuttles between cytoplasmic vesicles and the apical 
membrane of the collecting duct cells and is responsible for vasopressin regulated 
water re-absorption from the collecting duct.  AQPs 3 and 4 are sited on the 
basolateral membrane of collecting duct cells with AQP3 tending to be situated in 
the proximal collecting duct whereas AQP4 is sited more distally in the inner 
Chapter 3. Establishing and optimising molecular biological        
techniques to analyse aquaporin expression 
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medulla.  Thus AQPs 2, 3 and 4 work in concert to allow transepithelial movement 
of water [255].  The vital role of renal AQPs 1-4 is powerfully demonstrated by 
transgenic mice studies.  Mice with AQP1-4 deletions all show varying degrees of 
polyuria.  Conversely AQP5, 7, 8 and 11 knockout mice do not develop polyuria and 
do not show a renal phenotype other than increased urinary glycerol clearance in 
AQP7 null mice and polycystic kidneys in AQP11 null mice [255, 389].  Moreover, 
mutations in AQPs 1 and 2 are described in humans leading to an inability to 
concentrate urine in response to water deprivation and nephrogenic diabetes 
insipidus respectively [255].   
 
2. The lower urinary tract rat bladder and ureter expresses AQPs 1-3 at the protein level 
with AQP1 localising to the vascular endothelium while AQPs 2 and 3 are present in 
the urothelium [249]. Although AQP2 has not been demonstrated in human 
urothelium, AQPs 3, 4, 7 and 9 are expressed by these cells [369]. Rodent and human 
studies suggest urothelial expression of AQPs 2, 3 and 9 can be regulated by 
hydration status or surrounding osmolality [249, 369].  
Ultimately, AQPs 1-4 are the most studied of the renally expressed AQPs giving solid 
scientific groundwork on which to base this research. However analysis of the mRNA 
expression of the other AQPs, 0 and 5-12, in renal and lower urinary tract tissue will be 
undertaken to establish specifically which of the 13 isoforms are expressed by these tissues 
enabling later analysis of whether they are regulated by PUJO.   
The second major aim of the research was to establish the urinary AQP profile in high 
pressure (damaging) and low pressure (non-damaging) PUJO in rodents and humans. AQPs 
1 and 2 are both excreted within exosomes in the urine therefore giving the opportunity for 
urine AQP and tissue AQP results to be correlated in obstructed versus non-obstructed 
systems [365, 386]. Additionally, reduced urinary excretion of both AQP isoforms has been 
noted post-operatively in children undergoing pyeloplasty highlighting their relevance to this 
study. Efforts were therefore concentrated on establishing techniques to identify and 
quantify AQPs 1 and 2 in the urine.   
Presented below are the techniques that were established during the research project. 
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3.2 Reverse transcription polymerase chain reaction (RT-PCR) 
The end point RT-PCR technique was undertaken as per the methods detailed in Chapter 2. 
The technique was performed using primer sequences as described by Rubenwolf et al. [259] 
(see appendix 2, section 10.2.1 for primer sequences and annealing temperatures).  
PCR using human genomic DNA (11691112001, Roche, Sussex, UK) (Figure 3.1) in place 
of cDNA was initially performed as positive control to confirm the suitability of the primers.  
As illustrated, a single band of the correct size was achieved for each primer pair.  
 
Figure 3.1 Endpoint PCR using human genomic DNA  
PCR was performed using human genomic DNA and the product run on a 2% agarose gel. Bands of the 
appropriate size for AQP isoforms 0-12 and b-actin were demonstrated. See appendix 2, section 10.2.1 for 
product sizes. 
 
Subsequently the same primers were used, under the same conditions, for cDNA obtained 
following reverse transcription of RNA isolated from human kidney, ureter and renal pelvis.  
Positive (with enzyme) and negative (without enzyme) reverse transcription (RT) reactions 
were performed on the RNA obtained from each tissue sample. The products from both RT 
positive and RT negative reactions were used when performing PCR with each set of AQP 
primers.  The presence of bands in some of the lanes containing RT negative samples 
indicated genomic DNA contamination of the RNA extraction. This was seen in both kidney 
and ureter RNA samples used for RT-PCR. The gel shown in Figure 3.2 illustrates this, as 
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RT negative samples show a band the same size as the genomic DNA controls seen in Figure 
3.1. Empty lanes left between loaded samples ensured contamination was not due to spill 
over.  
 
Figure 3.2 Genomic DNA contamination of human whole ureter RT-PCR 
RT-PCR including positive and negative reverse transcription (RT) reactions for each AQP1-4 isoform.  Bands 
are seen in negative RT reactions indicating genomic contamination. 
 
All reagents were changed, and new RNA samples extracted however this issue of genomic 
DNA contamination was only finally resolved by treating RNA samples with a DNAase 
(DNASE-50, PrimerDesign, Southampton, UK) prior to reverse transcription. 
A further issue that was encountered was the appearance of a hazy opacity present at about 
250 bp on a number of gels. This opacity didn’t have the appearance of a classic band 
representing PCR product (Figure 3.3). All reagents were changed sequentially, and repeat 
RT-PCR performed. Eventually the sample loading buffer was identified as the source of the 
problem (Figure 3.4). 
 
Figure 3.3 Ill-defined opacities present on all lanes of PCR gels 
Hazy opacities were noted at approximately 250 bp across all lanes of numerous PCR gels. This gel 
demonstrates RT-PCR product from human whole kidney using AQP3, 4, 5, 12 and b-actin primers. Reverse 





Figure 3.4 Loading buffer causes ill-defined opacities on PCR gels  
Loading buffer only was loaded to 3 wells of a 2% agarose gel and run as per the method section in Chapter 2. 
 
The sample loading buffer was substituted for the commercial gel loading dye which 
accompanies the DNA ladder and the hazy opacities resolved on subsequent gels.  
Once optimised this technique was used to assess AQP isoform expression by human kidney, 
renal pelvis and ureter (see Chapter 6). The same technique using newly designed primers 
against rat AQPs (see Section 3.3) was utilised to evaluate AQP isoform expression by rat 
kidney and renal pelvis (see Chapter 5). 
 
3.3 Reverse transcription real time polymerase chain reaction (RT-
qPCR) 
3.3.1 Primer design for rat aquaporin isoforms 
NCBI Primer-BLAST was used to design primers to detect rat AQPs 0-12. Briefly, the 
National Center for Biotechnology Information (NCBI) nucleotide database was used to 
search for the relevant aquaporin and the NCBI reference sequence obtained (Figure 3.5 A). 
The reference sequence was entered into NCBI/Primer-Blast (Figure 3.5 B) 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast) and the parameters for primer generation 
specified, aiming for a product size of 80-200 base pairs, a melting temperature of 60°C, a 
primer GC content of 40-60%, maximum self-complementarity of 4 and maximum 3’ self-
complementarity of 1. A report of potential primer pairs was then produced by the Primer-
BLAST tool (Figure 3.6). Where possible primers were designed to cross exon boundaries 




Figure 3.5 The NCBI database and Primer-BLAST are used to generate potential primer sequences for 
PCR 
The NCBI nucleotide database is used to retrieve the reference sequence for the particular aquaporin mRNA 
(A). The NCBI reference sequence is entered into the Primer-BLAST website (B) and subsequently the 
parameters for primer generation are entered into the Primer-BLAST tool which then generates potential primer 
pairs.  
 
The most suitable primer sequences generated by Primer-BLAST were then taken to the next 
step of primer design. CLC sequence viewer (version 6.8.2, CLC Bio, Qiagen, UK) was used 
to generate the cDNA product sequence for each primer pair (Figure 3.7) and the product 
sequence was input into mFold web server to assess likely folding of the cDNA product 
[390]. This software is a prediction tool which enables the user to determine whether the 
cDNA product is likely to form secondary structures during the PCR cycle (based on the 
products melting temperature), and if so their location within the PCR product (Figure 3.8). 
The presence of secondary structures within the region of the primer binding sites precludes 
the use of the primers and a new set of primers should be designed. 
Forward and reverse primers designed by this method were obtained from Eurofins (MWG 
Eurofins, Germany) and then validated for RT-qPCR using rat kidney cDNA.  
 





Figure 3.7 CLC sequence viewer generates the cDNA product sequence for a primer pair 
CLC sequence viewer enables the nucleotide sequence of the PCR product to be identified, seen here 




Figure 3.8 Mfold 
The mfold web server generates a prediction of secondary structure formation and their potential sites within 
the PCR product. This PCR product demonstrates secondary structure formation (arrow) however this structure 




3.3.2 Primer validation 
The Ct (threshold cycle) values generated during real-time PCR are inversely proportional 
to the DNA copy number in the original sample. In order to obtain accurate, reproducible 
results the reaction needs to be optimised so that the amplification process proceeds with the 
same efficiency regardless of the initial starting amount of template.  For each set of primers 
this was assessed in four ways by: 
• Generating a standard curve of serial dilutions of template and calculating the R2 
value. For a well optimised reaction a linear standard curve should be generated with 
an R2>0.980. 
• Calculating the amplification efficiency of the primers using the slope of the standard 
curve. Amplification efficiency should be roughly 90-105%. 
• Generating a single peak on the melt curve across template dilutions. 
• Demonstrating reproducibility between repeat reactions. 
Failure to meet these standards led to further optimisation of the reaction parameters or 
redesign of the primers. Primer pairs were also tested by endpoint PCR to confirm the 
presence of a single product of the correct size (See Chapter 5). The final primer sequences 
used for RT-qPCR of rat tissue are detailed in appendix 2 (section 10.2.1.2).  
3.3.2.1 Rat aquaporin 1-3 primers 
Primer pairs for APQs 1-3 were tested using a 1/5 serial dilution of rat kidney cDNA. The 
RT-qPCR technique was undertaken as per the methods detailed in Chapter 2. The standard 
curves generated, and amplification efficiencies calculated were acceptable for all three 
primer pairs while melt curves demonstrated a single peak (Figure 3.9, Figure 3.10, Figure 
3.11). These primer pairs were therefore used in sample analysis for the neonatal unilateral 




Figure 3.9 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP1 primers 
Standard curve generated for AQP1 primers using a 1/5 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9998 and amplification efficiency of 91.72% (A). Melt curves for rat kidney cDNA amplified with 
AQP1 primers (B).   
 
 
Figure 3.10 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP2 primers 
Standard curve generated for AQP2 primers using a 1/5 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9982 and amplification efficiency of 94.79% (A). Melt curves for rat kidney cDNA amplified with 





Figure 3.11 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP3 primers 
Standard curve generated for AQP3 primers using a 1/5 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9982 and amplification efficiency of 93.24% (A). Melt curves for rat kidney cDNA amplified with 
AQP3 primers (B).   
 
 
3.3.2.2 Rat aquaporin 4 primers 
The initial set of designed AQP4 primers didn’t cross exon boundaries and when used for 
endpoint PCR demonstrated signal in the RT negative samples despite treating samples with 
DNase. The band in the RT negative sample was sequenced (MWG Eurofins, Germany) and 
confirmed to be AQP4. Two new primers pairs were therefore designed to identify the four 
known AQP4 transcripts. One primer pair identified transcripts 1 and 2 and the other 
transcripts 3 and 4. Initial optimisation for RT-qPCR using a 1/5 serial dilution of rat kidney 
cDNA generated melt curves with large secondary peaks corresponding to primer dimers 
beyond a dilution of 1 in 125 for the transcript 3/4 primers and a dilution of 1 in 625 for the 
transcript 1/2 primers.  The amount of primers in the reaction for both primer pairs was 
therefore reduced by 50% and the qPCR repeated (Figure 3.12 and Figure 3.13). Although 
the melt curves were improved by this modification the amplification efficiencies remained 
unacceptably high for both sets of primers. This could be due to co-amplification of non-
specific products or the presence of inhibitors. These primers were therefore discarded. 
Following a literature search new primer sequences identifying all 4 AQP4 transcripts were 
obtained from a paper published by Nicaise et al. [391] and these were tested using a 1/5 
serial dilution of rat kidney cDNA. Initially the melt curves showed secondary peaks due to 
primer dimer formation at most dilutions which was improved by reducing the amount of 
primers in the reaction by 50% (Figure 3.14).  This primer pair was thus used in sample 




Figure 3.12 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP4 
transcript 1 and 2 primers 
Standard curve generated for AQP4 transcript 1 and 2 primers using a 1/5 serial dilution of rat kidney cDNA 
demonstrating an R2 = 0.9947 and amplification efficiency of 129% (A). Melt curves for rat kidney cDNA 




Figure 3.13 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP4 
transcript 3 and 4 primers 
Standard curve generated for AQP4 transcript 3 and 4 primers using a 1/5 serial dilution of rat kidney cDNA 
demonstrating an R2 = 0.9995 and amplification efficiency of 197% (A). Melt curves for rat kidney cDNA 







Figure 3.14 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP4 primers  
Standard curve generated for new AQP4 primers using a 1/5 serial dilution of rat kidney cDNA demonstrating 
an R2 = 0.9938 and amplification efficiency of 91.14% (A). Melt curves for rat kidney cDNA amplified with 
new AQP4 primers (B). Primers taken from Nicaise et al. paper [391] 
 
 
3.3.2.3 Rat aquaporin 5 primers 
The first AQP5 primer pair when tested over a 1/5 serial dilution of rat kidney cDNA failed 
to show a rise in Ct value across the different dilutions. New AQP5 primers were therefore 
designed and real-time PCR repeated again using a 1/5 serial dilution of rat kidney cDNA. 
Unfortunately, only the first 2 cDNA dilutions had acceptable melt curves, the remainder 
had moderate to large secondary peaks rendering it impossible to draw a standard curve.  It 
is likely that the amount of AQP5 cDNA is generally low in rat kidney therefore the next 
step will be to reduce the amount of AQP5 primers in each reaction or alternatively use 
cDNA from a tissue rich in AQP5 to optimise the PCR reaction. Due to time constraints 
further optimisation of the AQP5 primers was not performed and therefore AQP5 primers 
were not available when analysing tissue obtained from the neonatal rat unilateral ureteric 
obstruction model during this research project. 
3.3.2.4 Rat aquaporin 6 and 7 primers 
Initial optimisation of AQP6 and 7 primers using a 1/5 serial dilution of rat kidney cDNA 
for qPCR generated acceptable standard curves and amplification efficiencies, however, in 
both cases they were only valid up to a template dilution of 1 in 3125. Beyond this dilution 
the melt curves had large secondary peaks corresponding to primer dimers. The amount of 
primers in the reaction for both AQP6 and 7 primers was therefore reduced by 50% and the 
reactions performed using a 1/10 serial dilution of rat kidney cDNA. The standard curves 
generated, and amplification efficiencies calculated were acceptable, while the melt curves 
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demonstrated a single peak (Figure 3.15 and Figure 3.16). These primer pairs were therefore 
used in sample analysis for the neonatal rat unilateral ureteric obstruction model. 
 
Figure 3.15 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP6 primers 
Standard curve generated for AQP6 primers using a 1/10 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9986 and amplification efficiency of 102% (A). Melt curves for rat kidney cDNA amplified with AQP6 
primers (B).   
 
 
Figure 3.16 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP7 primers 
Standard curve generated for AQP7 primers using a 1/10 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9993 and amplification efficiency of 105.95% (A). Melt curves for rat kidney cDNA amplified with 
AQP7 primers (B).   
 
 
3.3.2.5 Rat aquaporin 8 and 9 primers 
Initial optimisation of AQP8 and 9 primers using a 1/5 serial dilution of rat kidney cDNA 
for qPCR demonstrated generally higher Ct values than other primer pairs alongside large 
secondary peaks on the melt curves at low template dilutions suggesting native expression 
of these AQP isoforms may be low. Reduction of the amount of primer in each reaction did 
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not significantly improve the situation therefore a 1/5 serial dilution of a positive control 
tissue (liver) was used to confirm validity of the primers.  The standard curves generated, 
and amplification efficiencies calculated were acceptable. Additionally, the melt curves 
demonstrated a single peak (Figure 3.17 and Figure 3.18). These primer pairs were thus used 
in sample analysis for the neonatal rat unilateral ureteric obstruction model. 
 
Figure 3.17 Standard curve and melt curves for real-time PCR of rat liver cDNA using AQP8 primers 
Standard curve generated for AQP8 primers using a 1/5 serial dilution of rat liver cDNA demonstrating an R2 
= 0.998 and amplification efficiency of 108.33% (A). Melt curves for rat liver cDNA amplified with AQP8 
primers (B).   
 
 
Figure 3.18 Standard curve and melt curves for real-time PCR of rat liver cDNA using AQP9 primers 
Standard curve generated for AQP9 primers using a 1/5 serial dilution of rat liver cDNA demonstrating an R2 
= 0.9997 and amplification efficiency of 99.97% (A). Melt curves for rat liver cDNA amplified with AQP9 
primers (B).   
 
 
3.3.2.6 Aquaporin 11 
AQP11 primers were tested for qPCR using a 1/10 serial dilution of rat kidney cDNA. These 
primers generated melt curves with a single peak, a standard curve with an R2 = 0.9986 and 
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an amplification efficiency of 102%. (Figure 3.19). This primer pair was therefore used in 
sample analysis for the neonatal rat unilateral ureteric obstruction model. 
 
Figure 3.19 Standard curve and melt curves for real-time PCR of rat kidney cDNA using AQP11 
primers 
Standard curve generated for AQP11 primers using a 1/10 serial dilution of rat kidney cDNA 
demonstrating an R2 = 0.9986 and amplification efficiency of 102% (A). Melt curves for rat kidney 
cDNA amplified with AQP11 primers (B).   
 
 
3.3.2.7 Endogenous controls 
Having appropriate endogenous controls (reference genes) is a commonly used method to 
normalise RT-qPCR data, thus controlling for experimental error.  Suitable reference genes 
should be stably expressed across the disease conditions being investigated. However; there 
are many examples where classical reference genes are regulated in certain tissues/disease 
processes [392]. With this in mind the aim was to identify at least two suitable sets of primers 
for reference genes, ideally targeting different cellular processes.  
Primers for rat β-actin were assessed for qPCR using a 1/5 serial dilution of rat kidney 
cDNA. The standard curve had an R2 = 0.9984 and the amplification efficiency of the 
primers was 106%. The melt curves showed a single peak across template dilutions (Figure 
3.20). This primer pair was therefore used in sample analysis for the neonatal rat unilateral 




Figure 3.20 Standard curve and melt curves for real-time PCR of rat kidney cDNA using β-actin primers 
Standard curve generated for β-actin primers using a 1/5 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9984 and amplification efficiency of 106.1% (A). Melt curves for rat kidney cDNA amplified with β-
actin primers (B).   
 
 
Ring finger protein 1 (RING 1 – binds DNA/transcriptional repressor) primers were 
designed and tested using rat kidney cDNA at a 1/5 dilution and a standard curve generated. 
Although the standard curve was generally acceptable it was only valid up to a template 
dilution of 1/625 as beyond that dilution there were secondary peaks on the melt curve 
corresponding to primer dimers. Additionally, the amplification efficiency was 116%. 
Reducing the amount of primers in the reaction did not improve the standard curve or 
amplification efficiency (Figure 3.21) and so a new set of primers was designed.  
Unfortunately, the new set of primers were worse and therefore not used.  
Primers were also designed for mitogen activated protein kinase 14 (MAPK 14) however 
these suffered a similar fate to the RING 1 primers showing secondary peaks and high 
amplification efficiency despite modification of the amount of primers used in each reaction 





Figure 3.21 Standard curve and melt curves for real-time PCR of rat kidney cDNA using RING 1 
primers 
Standard curve generated for RING 1 primers using a 1/5 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9974 and amplification efficiency of 116% (A). Melt curves for rat kidney cDNA at 1/3125 dilution 
amplified with RING 1 primers demonstrating a secondary peak at a lower melting temperature than the 
intended product (B).   
 
 
Cui et al. assessed 16 commonly used endogenous control genes in a mouse model of cystic 
kidney disease and identified GAPDH and PGK 1 to show low variability of expression 
[393]. Primers for GAPDH generated by another group within our laboratory were assessed 
and although a standard curve with R2 = 0.9945 was generated the amplification efficiency 
was only 72% and therefore these primers were not suitable (Figure 3.22). 
 
Figure 3.22 Standard curve and melt curves for real-time PCR of rat kidney cDNA using GAPDH 
primers 
Standard curve generated for GAPDH primers using a 1/5 serial dilution of rat kidney cDNA demonstrating 
an R2 = 0.9945 and amplification efficiency of 72% (A). Melt curves for rat kidney cDNA amplified with 




Primers were therefore designed for PGK 1. These primers demonstrated nice melt curves 
with single peaks across the template dilutions, a standard curve with R2 = 0.9997 and an 
amplification efficiency of 99% (Figure 3.23). This primer pair was therefore used in sample 
analysis for the neonatal rat unilateral ureteric obstruction model. 
 
Figure 3.23 Standard curve and melt curves for real-time PCR of rat kidney cDNA using PGK 1 primers 
Standard curve generated for PGK 1 primers using a 1/10 serial dilution of rat kidney cDNA demonstrating an 
R2 = 0.9997 and amplification efficiency of 99.1% (A). Melt curves for rat kidney cDNA amplified with PGK 
1 primers (B).   
 
3.4 Western blotting 
3.4.1 Aquaporin 1 
3.4.1.1 Western blotting for aquaporin 1 in an immortalised proximal tubular 
cell line 
Protein lysate obtained from conditionally immortalised human proximal tubular cells 
(ciPTEC) with SV-40 thermosensitive construct was first used to optimize the AQP1 
antibody.  Initial western blots performed as per the methods section in chapter 2 did not 
reveal a band at the predicted molecular weight (approx. 29kDa) for AQP1 (data not shown). 
A time course of protein extractions from ciPTEC’s (clone 1) at day 0 (before 
thermoswitching) and days 2, 4, 6, 8 and 10 after thermoswitching to 37°C demonstrated 
continuing expression of SV-40 for 10 days beyond thermoswitching. This suggests that the 
SV-40 temperature sensitive construct was not switching off appropriately leaving the cells 
in a proliferative rather than differentiated state. The detection of an appropriate band at 25 
kDa in human kidney lysate (positive control) and lack of this band in podocytes (negative 
control) supported the use of this antibody to detect AQP1 and demonstrated that this clone 
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of ciPTEc’s does not express AQP1 at the protein level, likely due to their inability to switch 
to the differentiated state (Figure 3.24) 
 
Figure 3.24 AQP1 is not expressed by conditionally immortalised proximal tubular cells 
Western blot demonstrating that AQP1 is not expressed by this particular clone of conditionally immortalised 
human proximal tubular cells (ciPTEC). Positive and negative controls are for AQP1 expression.  Lysate was 
extracted from cells over a range of days after thermoswitching to 37°C (day 0, 2, 4, 6, 8, 10 where day 0 = 
cells at 33°C). The cells continue to express SV-40 at 10 days post-thermoswitching to 37°C which may explain 
the lack of AQP1 expression. The non-glycosylated and glycosylated forms of AQP1 are expressed at 25 kDa 
and 40 kDa respectively by human kidney whole tissue lysate.   As expected SV-40 is not expressed by human 
kidney but is expressed by ciPTEC and conditionally immortalised human podocytes. Block- 3 % BSA/TBS-
T, Anti-AQP 1 1:1000 dilution, anti-SV-40 antibody 1:1000 dilution, β-actin 1:10,000 dilution.   
  
These findings were confirmed by immunofluorescence of a time line of immortalised 
proximal tubular cells with SV-40 thermosensitive construct (ciPTEC clone 1) seeded on 
coverslips in a 6 well plate.  At days 0, 6 and 11 post-thermoswitching SV-40 did not switch 
off in this clone of cells. Although some minor punctuate staining could be seen when day 
11 cells were incubated with anti-AQP1 antibody this was achieved at the expense of high 
background in the images and is not conclusive of AQP1 expression by this particular clone 




Figure 3.25 SV-40 does not switch off in conditionally immortalised proximal tubular cells 
Immunofluoresence demonstrating continuing expression of SV-40 (Alexa Fluor 488 – green) by conditionally 
immortalised proximal tubular cells (ciPTEC) at 11 days after thermoswitching incubation to 37°C.  AQP1 
expression was assessed in cells 11 days after thermoswitching.  Imaging shows some punctate staining of cells 
but is not conclusive for AQP1 expression (Alexa Fluor 568 – red). Nuclei are stained blue by DAPI.  Negative 
controls were produced by omitting the primary antibody and incubating with the appropriate fluorescent 
conjugated secondary antibody. Anti-AQP1 antibody 1:250 dilution, anti-SV40 1:200 dilution. 
 
The option of using a different clone of conditionally immortalised proximal tubular cells to 
ascertain whether they were thermoswitching appropriately was considered. However as this 
research aim was to assess AQP expression in human and rat tissue, work using cultured 
cells was halted and experiments progressed to characterising AQP expression in whole 
tissue.   
3.4.1.2 Western blotting for aquaporin 1 expression in human and rat tissue 
Western blots were performed to determine optimum protein loading concentration using 
human tissue. The protein concentrations of whole human kidney, ureter and renal pelvis 
lysates were determined by BCA protein assay. Western blotting was then performed loading 
25, 50, 75 and 100 μg protein per lane. The membranes were subsequently stripped and re-
probed with anti-B-actin. A representative blot is shown in Figure 3.26. Protein loading of 
75 µg per lane was selected as optimum, striking a balance between sufficient for aquaporin 




Figure 3.26 Western blot to determine optimum protein loading 
Western blot showing human renal pelvis lysate loaded at different protein concentrations and probed for 
AQP1.  The blot was stripped and re-probed for b-actin as loading control. Block- 3 % BSA/TBS-T, Anti-
AQP1 1:1000 dilution, β-actin 1:10,000 dilution. 
 
Membrane proteins such as AQPs can often be difficult to extract and the use of a 
urea/thiourea lysis buffer can improve their solubilisation [394].  Additionally, boiling 
samples following the addition of sample buffer can cause aggregation of membrane 
proteins. In order to optimise the results of western blotting for AQP1, different sample 
buffers and different incubation temperatures after addition of sample buffer were trialled. 
Furthermore, the use of a urea/thiourea tissue lysis buffer was compared to protein extraction 
using traditional RIPA buffer. 
Protein was extracted from whole human kidney using urea/thiourea tissue lysis buffer in 
the same manner as described in methods except following homogenisation of the tissue in 
the urea/thiourea lysis buffer, the lysate was left to stand at room temperature for 30 minutes.   
A BCA protein assay was performed to determine protein concentration of the RIPA buffer 
lysates and samples were loaded at 75 µg per lane.  It was not possible to perform a protein 
assay on the samples extracted in urea/thiourea buffer and so these lysates were loaded at 
the same volume as those extracted in RIPA buffer.  Prior to loading, urea/thiourea and RIPA 
kidney lysates were mixed with either a 2% SDS sample buffer, a 4% SDS sample buffer or 
a 7 M urea/SDS sample buffer.  Additionally, for each of these lysis buffer/sample buffer 
variables the samples were incubated at assorted temperatures, increasing the length of 
incubation as the temperature decreased.  
The results of western blotting for AQP1 (Figure 3.27 and Figure 3.28) demonstrated there 
is no added benefit to using urea/thiourea tissue lysis buffer for protein extraction or using a 
sample buffer other than 4% SDS when preparing samples.  Moreover, bands for AQP1 were 
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detected across the range of incubation temperatures used. Temperatures between 50-95°C 
produced the best resolution and there did not seem to be any benefit of a lower over a higher 
incubation temperature.  Future experiments were therefore performed using RIPA buffer 
for tissue protein extraction alongside 4% SDS sample buffer with incubation at 95 °C for 5 
minutes prior to sample loading.   
 
Figure 3.27 Western blots demonstrating AQP1 in human kidney lysate extracted with RIPA   
buffer  
Human kidney protein lysate was mixed with different samples buffers (either 2% SDS, 4% SDS or 7 
M urea/SDS and then incubated at different temperatures, increasing the length of incubation as the 





Figure 3.28 Western blot demonstrating AQP1 in human kidney lysate extracted using urea/thiourea 
buffer 
The lysate was mixed with different samples buffers (either 2% SDS, 4% SDS or 7 M urea/SDS) and then 
incubated at different temperatures, increasing the length of incubation as the temperature decreased. Samples 
loaded at 75 µg protein per lane. 
 
Using the optimised protocol, a western blot confirmed AQP1 expression by rat kidney, 
bladder and heart in addition to human urinary tract samples from two individuals.   The 
membrane was stripped and re-probed for β-actin as loading control.  Myocardium does not 
express β-actin, consequently, a 42kDa band for β-actin was not detected in the lane loaded 





Figure 3.29 Western blot demonstrating AQP1 expression in human and rat urinary tract tissues 
Western blot demonstrating the presence of AQP1 in rat kidney, bladder and heart.  AQP1 is also present in 2 
different human kidney cortex and medulla, renal pelvis and ureter samples. Positive control – rat heart. Rat 




3.4.2 Aquaporin 2  
Initial western blots to detect AQP2 in human kidney cortex and medulla lysate extracted 
with RIPA buffer demonstrated multiple bands for each sample. AQP2 would be expected 
to be detected at a molecular weight of approximately 29 kDa. It was not possible from these 
blots to differentiate AQP2, either non-glycosylated or glycosylated, from non-specific 
bands. Varying the antibody dilution and the pre-loading incubation temperature did not 
change the outcome of the blot (Figure 3.30). 
The blot was thus repeated using rabbit anti-AQP2 (Santa Cruz) at 1:500 dilution made up 
in 1% BSA, changing the block to 5% skimmed milk in TBS-T.  Both human and rat samples 
were loaded to ensure detection was not species specific.  Although the block reduced the 






Figure 3.30 Western blot of human kidney for AQP2 generates multiple bands 
Western blot demonstrating the effect of different dilutions (1:500 and 1:200) of the Santa Cruz (sc-28629) 
anti-AQP2 antibody and the effect of incubations at different temperatures prior to sample loading on the ability 
to detect AQP2 in human kidney cortex and medulla lysate.  3% BSA/TBS-T block was used. Multiple bands 
were demonstrated for all human kidney samples. The molecular weight of the most dominant bands has been 
marked.   
 
A new antibody, kindly donated by J Bedford, New Zealand, (raised in rabbits against a 
synthetic peptide made from the 15C terminus of human AQP 2 [aa 257-271: 
VELHSPQSLPRGTKA]) was used as per instructions from the donating laboratory.  Protein 
lysates were mixed with 4% SDS sample buffer then incubated at 95°C for 5 minutes. The 
blot was blocked in 5% skimmed milk in TBS-T and all antibodies were diluted in 1% BSA 
in TBS-T. The rabbit anti-AQP2 antibody was used at 1:2500 dilution. Human kidney, renal 
pelvis and ureter protein lysates were loaded and produced bands predominantly at 42 kDa 
(Figure 3.32). This band could represent a dimer although this is unlikely as it is not twice 
the size of the AQP2 monomer.  To determine whether this band represented glycosylated 
AQP2 human samples were deglycosylated as per the protocol in the methods section and 
the blot repeated.  This demonstrated no bands at 29 kDa in either the glycosylated or 
deglycosylated samples.  A strong band in all samples was seen at 42 kDa (Figure 3.33).  A 
control blot using AQP1 and rat kidney demonstrated that the deglycosylation protocol was 
successful therefore the 42 kDa band seen on the AQP2 blots does not represent glycosylated 




Figure 3.31 Western blotting of human kidney for AQP2 generates multiple bands with 5% milk block 
Western blot performed using 5% skimmed milk block and Santa Cruz anti-AQP2 antibody (sc-28629) at 1:500 
dilution.  Blocking of multiple bands was improved compared to 3% BSA block however a dominant band at 
approximately 29 kDa was not demonstrated in either human or rat samples.  
 
 
Figure 3.32 Western blot of human kidney with a new AQP2 antibody 
Western blot using 5% milk block and the anti-AQP2 antibody donated by the New Zealand group at 1:2500 
dilution.  Human kidney cortex and medulla, renal pelvis and ureter samples showed a major band at 42 kDa 





Figure 3.33 Western blot of deglycosylated and non-deglycosylated human kidney samples for AQP2  
Western blot using 5% skimmed milk block and the anti-AQP2 antibody donated by the New Zealand group 
at 1:2500 dilution.  Cortex and medulla samples from two human donors have been deglycosylated (DG) and 
run alongside the non-deglycosylated samples.  The 42 kDa band remains at the same intensity in the 
deglycosylated samples.  Deglycosylation of the samples does not produce a band at 29 kDa suggesting that 
the 42 kDa band does not represent glycosylated AQP2. DG – deglycosylated. 
 
Figure 3.34 Western blot of deglycosylated and non-deglycosylated rat kidney for AQP1 expression 
Deglycosylation of whole rat kidney results in loss of the 35 kDa glycosylated band on western blot compared 
to the non-deglycosylated (native) sample. DG – deglycosylated. 
 
Two alternative anti-AQP2 antibodies (Merck Milllipore and Abcam) were also trialled but 
did not show any bands in the anticipated location for human kidney samples (data not 
shown).    
In order to conclusively prove whether any of these antibodies could detect AQP2, a western 
blot using AQP2 overexpression lysate (LY424696, Origene, Rockville, MD, USA), 
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transiently expressed by HEK293T cells and tagged with FLAG was performed.  This was 
incubated with all four available anti-AQP2 antibodies and demonstrated the Santa Cruz (sc-
28629), and the donated antibody from New Zealand, identified AQP2 by detecting a single 
band at the correct molecular weight of 30 kDA.  A band at the same molecular weight was 
identified when the same overexpression lysate was probed with anti-FLAG antibody. As 
expected no significant bands were identified in lanes loaded with empty vector.  The 
remaining two anti-AQP2 antibodies (AB3066, Merck Millipore and ab15081, Abcam) did 
not identify a band for the AQP2 overexpression lysate (Fig 27).   
 
 
Figure 3.35 Detection of AQP2 on western blotting using AQP2 overexpression lysate 
Western blot where FLAG tagged AQP2 overexpression (O/E) lysate and empty vector control lysate have 
been probed with 4 different anti-AQP2 antibodies.  Santa Cruz 1:500, New Zealand 1:2500, Merck Millipore 
1:500, Abcam 1:500). Only two of the antibodies correctly recognize AQP2.  The anti-FLAG antibody 
confirms the correct position of the band. 
 
As there was not sufficient of the anti-AQP2 antibody donated by the New Zealand group 
left for further work the Santa Cruz anti-AQP2 antibody was optimised by assessing different 
tissue lysis buffers and sample buffers to ensure sample extraction methods had not 
compromised results.  During this process human and rat renal tract samples were run 
alongside the AQP2 overexpression lysate. 
Protein lysates were extracted using either RIPA or urea/thiourea tissue lysis buffer and 
incubated with sample buffer containing either 2% SDS, 4% SDS or 7 M urea/SDS at 
varying temperatures. Human protein lysates extracted with urea/thiourea tissue lysis buffer 
did not exhibit a band at 31 kDa corresponding to the band detected for the overexpression 
lysate. Conversely AQP2 was detected in both human and rat protein lysates extracted with 
RIPA buffer. There was no added benefit of using a sample buffer other than 4% SDS when 
preparing samples (Figure 3.36).   Identical blots were performed simultaneously using the 
Santa Cruz antibody at 1:250 and 1:500 dilutions. The results for the 2 antibody dilutions 
112 
 
were comparable and therefore the 1:500 antibody dilution was selected for use in future 
western blotting.   
 
Figure 3.36 Western blot demonstrating AQP2 expression in human and rat kidney protein lysates 
extracted with different buffers 
Human kidney cortex protein lysates were extracted using either RIPA or urea buffer and then mixed with 
different samples buffers (either 2% SDS, 4% SDS or 7 M urea/SDS) and then incubated at either 95°C for 5 
minutes or 37°C for 30 minutes. Samples loaded at 75 µg protein per lane. Standard protein extraction and 
sample buffer procedures were utilized for rat kidney. The AQP 2 overexpression lysate and vector control 
were prepared as per the manufacturer’s instructions. 5% milk block was used and an AQP2 dilution of 1:500. 
 
Using the optimised protocol and an appropriate negative control (rat eye) AQP2 expression 
was confirmed in human urinary tract tissue (kidney, renal pelvis and ureter), rat kidney and 
spleen (Figure 3.37). AQP2 was also demonstrated in human urine concentrated and 
fractionated by ultrafiltration (See section 3.6.1 for western blotting of urinary AQPs). 
Additionally, because the manufacturer supplied vector only control in Figure 3.36 showed 
a weaker positive band at 31 kDa standard human embryonic kidney (HEK 293) protein 




Figure 3.37 Western blot demonstrating AQP2 expression in human and rat tissues 
Western blot demonstrating AQP2 expression by human kidney cortex, renal pelvis and ureter and excretion 




3.4.3 Aquaporin 3  
Initial western blots to detect AQP3 in human kidney cortex and medulla lysate as per the 
methods section in chapter 2 demonstrated multiple bands for each sample.  The block was 
changed from 3% BSA to 5% skimmed milk and the anti-AQP3 antibody (Santa Cruz sc-
9885) was diluted in 1% BSA over a range of dilutions from 1:1000, 1:500, 1:250. 1:100.  
An AQP3 dilution of 1:100 was selected as giving the optimal band resolution and using rat 
spleen and heart as known positive and negative controls respectively the AQP3 band was 
documented at a molecular weight of 28 kDa (predicted 36 kDa) in human kidney, renal 
pelvis and ureter samples as well as rat kidney and bladder.  AQP3 was not detected in 
human urine treated by ultrafiltration (see section 3.6.1 for western blotting of urinary 
AQPs). The membrane was stripped and re-probed with anti-GAPDH.  AQP1 was used as 




Figure 3.38 Western blot demonstrating AQP3 expression by human and rat tissues 
Western blot demonstrating AQP3 expression by human kidney cortex and medulla, renal pelvis and ureter.  
Expression was also seen in rat kidney and bladder.  AQP3 was not detected in human urine. Loading controls 
were GAPDH for tissue and AQP1 for urine. Positive control – rat spleen, negative control rat heart. 
 
3.4.4 Aquaporin 4  
Initial western blots to detect AQP4 in human kidney cortex and medulla lysate as per the 
methods section in chapter 2 demonstrated multiple bands for each sample.  The block was 
changed from 3% BSA to 5% skimmed milk and the anti-AQP4 antibody (Santa Cruz sc-
9888) was diluted in 1% BSA in dilutions of 1:1000, 1:500.  An AQP4 dilution of 1:500 
gave better band resolution, and using rat brain and spleen as known positive and negative 
controls respectively, the AQP4 band was documented at a molecular weight of 34 kDa 
(predicted 34kDa) in human kidney cortex and medulla samples as well as rat kidney and 
bladder (Figure 3.39). AQP4 was not detected in human renal pelvis and ureter, however it 
has been detected on RT-PCR (Chapter 6).  The membrane was stripped and reprobed with 
anti-GAPDH.  
 
Figure 3.39 Western blot demonstrating AQP4 expression by human and rat tissues 
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Western blot demonstrating AQP4 expression by human kidney cortex and medulla, and rat kidney, bladder, 
brain and heart.  AQP4 was not detected in human renal pelvis and ureter. GAPDH was used as loading control. 
Positive control – Rat brain and heart, negative control rat spleen. 
 
 
3.5 Immunohistochemistry for aquaporins in formalin fixed paraffin 
embedded human tissue 
3.5.1 Aquaporin 1  
When first optimising human kidney immunohistochemistry for AQP1 the rabbit IgG 
control sections demonstrated non-specific tubular DAB staining despite blocking with 
increasing concentrations of normal goat serum with or without 1% BSA (Figure 3.40). 
Subsequently immunohistochemistry using either no primary antibody or no primary and no 
secondary antibody followed by an HRP conjugated avidin biotin complex (ABC) system 
was performed. Again, non-specific tubular staining throughout the renal cortex and medulla 
was noted (Figure 3.41). This indicted either endogenous peroxidase or endogenous biotin 
activity. 
 Human kidney sections were tested for endogenous peroxidase activity by incubating in a 
range of concentrations of hydrogen peroxide (0.5%, 1% and 3% diluted in ultrapure water) 
as well as ultrapure water (control) for 10 minutes at room temperature followed by 
incubation with DAB substrate.  Light microscopy imaging did not show DAB staining of 
any of the sections (Figure 3.42) indicating endogenous peroxidase activity was not the cause 
of the tubular staining seen on negative control slides. The lowest concentration of hydrogen 





Figure 3.40 Immunohistochemistry demonstrating tubular staining of IgG control human kidney 
sections 
Human kidney sections were incubated with rabbit IgG instead of primary antibody. Imaging demonstrated 
non-specific tubular DAB staining despite blocking sections with increasing concentrations of normal goat 





Figure 3.41 DAB staining of human kidney in the absence of primary and secondary antibodies  
Immunohistochemistry of human kidney sections involving the use of either no primary antibody or no primary 
and no secondary antibodies was performed. Sections were incubated with antibody diluent in place of 
antibodies. An HRP conjugated avidin biotin complex system was used to amplify signal using DAB substrate. 
Non-specific tubular DAB binding in all sections suggests either endogenous biotin or peroxidase activity. 
 
The experiments in Figure 3.40 and Figure 3.41 had used a Santa Cruz ABC (avidin biotin 
complex) secondary antibody system.  In the absence of significant endogenous peroxidase 
activity, it was likely the non-specific staining was due to endogenous biotin activity as renal 
tissue is known to have high biotin content [395].  The potential options to resolve this issue 
were either to include an avidin/biotin blocking step or to use a different secondary antibody.  
A polymerised reporter antibody staining system (SignalStain® boost IHC detection reagent 
HRP anti-rabbit, Cell signalling, Danvers, MA, USA) resolved the problem and enabled the 
detection of AQP1 with low background. The rabbit anti-AQP1 antibody (Santa Cruz, sc-
20810) was used at 1:250 dilution.  Rabbit IgG (used at the same concentration as primary 
antibody) and no primary antibody controls were included. 1.5% goat serum in TBS-T was 




Figure 3.42 Human kidney sections do not demonstrate endogenous peroxidase activity 
Human kidney sections were incubated with increasing concentrations of hydrogen peroxide diluted in 
ultrapure water or ultrapure water as control. Sections were then incubated in DAB substrate. None of the 
sections including the controls showed any DAB staining indicating minimal endogenous peroxidase activity. 
Scale bar = 50 μm.  
 
 
Figure 3.43 Immunohistochemistry demonstrating AQP1 expression by human kidney, renal pelvis and 
ureter 
Immunohistochemistry using anti-AQP1 at a dilution of 1:250 and rabbit IgG at a corresponding concentration.  
Sections labelled no primary antibody were incubated with 1.5% goat serum.  AQP1 expression is 
demonstrated in the apical and basolateral membranes of the proximal tubules within the kidney cortex, while 
AQP1 expression in the loop of Henle and vasa recta but not within collecting ducts is seen in the kidney 
medulla. AQP1 is also detected in the vasculature of the lamina propria of the renal pelvis and ureter. Scale bar 
= 50 μm. 
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AQP1 was detected in the apical and basolateral membranes of the proximal tubules, the 
loop of Henle and vasa recta of human kidney, however it was not present in the kidney 
collecting ducts.  AQP1 was also present in the vasculature of human renal pelvis and ureter 
but was not detectable in urothelium.  (Figure 3.43). 
 
3.5.2 Aquaporin 2 
The same protocol was employed for detection of AQP2 using rabbit anti-AQP2 (Santa 
Cruz, sc-28629) as was used for AQP1.  Primary antibody dilutions of 1:100 and 1:250 were 
assessed.  At 1:100 dilution the corresponding concentration of rabbit IgG control gave too 
much non-specific staining (data not shown) whereas the 1:250 anti-AQP2 and 
corresponding rabbit IgG control concentration demonstrated luminal staining of the 
collecting ducts without any non-specific staining.  The 1:250 antibody dilution was selected 
for future experiments.  Immunohistochemistry of human ureter and renal pelvis for AQP2 
did not show any staining suggesting AQP2 is not expressed by urothelium (Figure 3.44). 
 
Figure 3.44 Immunohistochemistry demonstrating AQP2 expression by human kidney and not by 
human renal pelvis and ureter 
Immunohistochemistry using anti-AQP2 at a dilution of 1:250 and rabbit IgG at a corresponding concentration.  
Sections labelled no primary antibody were incubated with 1.5% goat serum.  Images show AQP2 is present 
in the luminal membranes of the collecting duct.  AQP2 is not detected in human renal pelvis and ureter. Scale 




3.5.3 Aquaporin 3 
AQP3 within human kidney, renal pelvis and ureter was detected using goat anti-AQP3 
(Santa Cruz, sc-9885), 1.5% horse serum in TBS-T for blocking and a polymerised reporter 
antibody staining system ImmPRESS HRP anti-goat polymer detection system (MP7405, 
Vector Laboratories, Burlingame, CA, USA). Primary antibody dilutions of 1:50 and 1:200 
were assessed based on reports from other groups using the same antibody [259]. At 1:50 
dilution both primary antibody and the corresponding concentration of goat IgG control gave 
too much non-specific staining (data not shown). At a primary antibody dilution of 1:200, 
anti-AQP3 demonstrated appropriate staining of the basolateral membrane of the human 
kidney collecting ducts and also staining of the human renal pelvis and ureteric urothelium, 




Figure 3.45 Immunohistochemistry demonstrating AQP3 expression by human kidney, renal pelvis and 
ureter 
Immunohistochemistry using anti-AQP3 at a dilution of 1:200 and goat IgG at a corresponding concentration.  
Sections labelled no primary antibody were incubated with 1.5% horse serum.  Images show AQP3 is expressed 
in the basolateral membranes of the kidney collecting ducts as well as in the urothelium of human renal pelvis 




3.5.4 Aquaporin 4 
Immunohistochemistry for AQP4 was performed using a goat anti-AQP4 antibody (Santa 
Cruz, sc-9888) using the same protocol as when staining for AQP3.  AQP4 antibody 
dilutions of 1:50 and 1:200 were used alongside negative controls of goat IgG at a 
corresponding concentration and no primary antibody.  The anti- AQP4 antibody staining 
was non-specific, being cytoplasmic rather than predominantly basolateral membrane, and 
staining all tubules within the renal medulla rather than the collecting ducts (data not shown).  
The achieved staining pattern was not consistent with the known location of AQP4 [396] 
and therefore further studies were performed using different blocking steps to eliminate non-
specific binding at the same, and reduced, anti-AQP4 antibody concentrations (Figure 3.46). 
 
Figure 3.46 Immunohistochemistry for AQP4 in human kidney medulla using a Santa Cruz anti-AQP4 
antibody 
Immunohistochemistry of human kidney medulla sections using anti-AQP4 (Santa Cruz) at 1:200 and 1:500 
dilutions.  Sections were blocked with either 2.5% horse serum or 2.5% horse serum with 3% BSA. Non-
specific tubular DAB binding in all sections questions the specificity of the antibody. Regardless of the 
antibody concentration or the blocking step used both the collecting ducts (arrow) and other tubular structures 
(arrowhead) such as the loops of Henle are stained. Additionally, the collecting duct staining is predominantly 
cytoplasmic rather than at the basolateral membrane as shown by others. Scale bar = 50 μm. 
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A new rabbit anti-AQP 4 antibody was sourced from Alomone (249-323, Jerusalem, Israel) 
and immunohistochemistry using human kidney sections performed using an antibody 
dilution of 1:500 based on the manufacturers recommendations. Sections were blocked with 
either 1.5% or 5% goat serum and the SignalStain® boost secondary HRP anti-rabbit 
antibody was used. Again, non-specific tubular binding was noted throughout the section. 
Although an increased concentration of blocking serum attenuated the non-specific binding 
the remaining DAB staining was not localized to the collecting duct basolateral membrane 
as previously reported [187].  
 
Figure 3.47 Immunohistochemistry for AQP4 in human kidney medulla using an Alomone anti-AQP4 
antibody 
Immunohistochemistry of human kidney medulla sections using anti-AQP4 (Alomone) at 1:500 dilution and 
rabbit IgG at a corresponding concentration. Sections labelled no primary antibody were incubated with 
antibody diluent only. Sections were blocked with either 1.5% or 5% goat serum. Sections stained with anti-
AQP4 antibody demonstrated non-specific tubular binding with both the collecting ducts (arrow) and other 
tubular structures (arrowhead) such as the loops of Henle being stained. Although the DAB staining was 
attenuated by using a higher concentration of blocking serum, the remaining staining was again not localized 
correctly to the collecting duct. Scale bar = 50 μm.   
 
The sequence of slides seen in Figure 3.47 was repeated using Tris–EDTA (pH 9) antigen 
retrieval buffer instead of citrate (pH 6) buffer however the results were unchanged (data not 
shown) and no further attempts were made to optimise this antibody. 
Due to time constraints accurate detection of AQP4 by immunohistochemistry on human or 
rat, kidney, renal pelvis or ureter, was not possible during this research project. I would have 
liked to have performed this to confirm whether AQP4 is expressed by the urothelium of the 
ureter and renal pelvis and specifically by the umbrella cells of the urothelium which contact 
the urinary lumen. Optimising this technique to detect AQP4 by immunohistochemistry will 
be a priority for future work related to this thesis. 
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Results for the detection and localisation of AQPs 1-3 in rat kidney, renal pelvis and ureter 
tissue are presented in Chapter 5. 
 
3.6 Detecting urinary aquaporins 
3.6.1 Demonstrating urinary aquaporin 1 by western blotting 
The initial attempt to identify AQP 1 in human urine involved ultrafiltration of the urine 
(Amicon® Ultra-15 10K centrifugal filter device) to generate urine concentrate followed by 
chemical precipitation of exosomes. This was performed as described in the methods section 
except the urine concentrate: ExoQuick-TC ratio was 5:1 (rather than 1:1 in the final 
protocol). After incubation with the ExoQuick-TC it was noted that a visible exosome pellet 
had not formed and on western blotting AQP1 could not be identified in the exosome 
fraction.  Running of the aspirated supernatant which is normally discarded did however 
produce some murky bands suggesting there was simply not enough ExoQuick-TC to 
precipitate the exosomes. Subsequently, the ratio of urine concentrate:ExoQuick-TC was 
increased to 1:1, which enabled AQP1 detection with a major band at 25 kDa corresponding 
to the non-glycosylated band of the human kidney lysate positive control (Figure 3.48).  As 
a comparison, urine concentrate generated by ultrafiltration only from the same initial urine 
sample, along with urine concentrate mixed with RIPA buffer in a ratio of 2.5:1, were also 
run on western blot and probed for AQP1.  Figure 3.48 demonstrates that AQP1 can be 
detected in the urine using all three extraction techniques; ultrafiltration, ultrafiltration + 
RIPA buffer, and ultrafiltration + ExoQuick-TC.  Ultrafiltration and ultrafiltration + 
ExoQuick- TC generated the best results.  There was no benefit to adding RIPA buffer to 
the urine concentrate and if anything it made detection worse.  Ultrafiltration alone 
(producing urine concentrate) gives bands that are much better defined than those with 
ultrafiltration + Exo-Quick-TC, and using ultrafiltration alone does not seem to reduce the 
detection of AQP1. Samples of the urine filtered through the Amicon membrane and the 
supernatant from the Exo-Quick-TC sample were run on western blot and AQP1 was not 
detected (results not shown).  This suggests that all of these extraction techniques are 
isolating the majority of available urinary AQP1. 
Although the method of chemical precipitation of exosomes is designed to isolate exosomes 
for downstream applications, the field of work on exosomes is expanding rapidly and this 
method is probably an oversimplification and does not produce a purely exosomal fraction.  
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However for the purpose of the research the aim was to find a robust, reproducible, 
economically viable method of isolating aquaporins from the urine for further analysis 
initially by western blotting.  With this in mind the method of ultrafiltration was used to 
concentrate and fractionate urine for ongoing aquaporin analysis with the proviso that it did 
not reflect a truly exosomal population. 
Using this method of urine ultrafiltration to isolate AQPs, western blotting has confirmed in 
addition to AQP1 the presence of AQP2 and the absence of AQP3 in human urine (Figure 
3.37 and Figure 3.38, pages 113-114).  
 
Figure 3.48 Comparison of different methods of AQP1 isolation from urine 
Western blots demonstrating the presence of AQP1 in human urine using three different extraction techniques; 
ultrafiltration + chemical precipitation with ExoQuick-TC, ultrafiltration alone and ultrafiltration + addition of 
RIPA buffer.   The samples were loaded at three different volumes and the urinary creatinine equivalent (µmol) 
of each sample has been indicated. 
 
 
3.6.2 Urinary aquaporin 1 ELISA 
Looking forward, the application of this research would be a clinical test which would need 
to be reproducible, produce quantitative results and be cost effective.  A urinary AQP ELISA 
has the potential to meet these objectives and given the prohibitive costs of buying a 
commercial ELISA, an indirect ELISA using colorimetric substrate was designed in house 
using a method reported by Umenishi et al. [397]. Although both AQP1 and AQP2 are 
detected in the urine, for reasons which are reviewed in the discussion (section 3.7), a urinary 
AQP1 ELISA was developed rather than an AQP2 ELISA. 
Initially the ELISA was conducted as per the methods section in chapter 2 except using anti-
AQP1 antibody at a 1 in 30 dilution, 0.01% SDS/PBS as standard and sample diluent and 2, 
2’-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) (ABTS liquid substrate system, 
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A3219, Sigma-Aldrich, St-Louis, MO, USA) as substrate. A 2-fold serial dilution of the 
AQP1 standards returned a reasonable standard curve with an R2 = 0.987 however the overall 
level of signal in the standards could be improved (Figure 3.49).  
 
Figure 3.49 Urinary AQP1 ELISA standard curve 
The standard curve demonstrates a serial dilution of AQP1 standards from 1.5625-200 ng/ml. Analysis 
performed by 4 parameter logistic regression. R2 = 0.987. Anti- AQP1 antibody was used at 1:30 dilution and 
standard/sample diluent was 0.01% SDS in PBS. ABTS substrate was applied for 30 minutes in the dark 
followed by 1% SDS stop solution.  
A 2-fold serial dilution of a single human urine sample was analysed alongside these 
standards and returned an optical density equivalent to the blank wells for all dilutions 
signifying that the assay was not detecting the AQP1 in the sample. Additionally, the mean 
optical density of the blank wells was too high at 0.369 indicating significant background 
signal.  
Factors potentially responsible for the high optical density in the blank wells include:  
• Bovine serum albumin (BSA) grade   
• Insufficient washing of wells  
• Primary or secondary antibody binding 
An ELISA to establish the cause of high background was undertaken which involved: 
• Blank wells – 0.01% SDS/PBS, primary antibody and secondary antibody 
• Control wells – primary and secondary antibodies used but without initial 
addition of 0.01% SDS/PBS 
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• Secondary antibody only – as above except without addition of primary antibody 
Additionally, each of the above was performed with 2 different types of BSA as well as 
trialling 5% tween 20 in PBS for block and antibody diluent instead of BSA. Special 
attention was paid to adequate washing of the wells. Table 3.1 demonstrates the results of 
this ELISA where the optical density for all wells is perfectly acceptable suggesting that the 
washing step could have been responsible for the increased signal in the blank wells on the 
first ELISA run.  
 
Well Block/antibody diluent Optical 
density  1  
Optical 
density  2  
Mean optical 
density  
Blank 3% BSA (A9647, 
Sigma) 
0.093 0.093 0.093 
Control  3% BSA (A9647, 
Sigma) 
0.080 0.078 0.079 
Secondary 
antibody  
3% BSA (A9647, 
Sigma) 
0.071 0.073 0.072 
Blank  3% BSA (A7030, 
Sigma) 
0.091 0.088 0.0895 
Control 3% BSA (A7030, 
Sigma) 
0.075 0.075 0.075 
Secondary 
antibody  
3% BSA (A7030, 
Sigma) 
0.072 0.072 0.072 
Blank  5% tween 20 0.094 0.091 0.0925 
Control  5% tween 20 0.079 0.080 0.0795 
Secondary 
antibody  
5% tween 20 0.074 0.075 0.0745 
 
Table 3.1 AQP1 ELISA investigating high background in blank wells 
Anti-AQP1 antibody used at 1 in 30 dilution. ABTS substrate was applied for 30 minutes in the dark followed 
by 1% SDS stop solution. Blank wells – 0.01% SDS/PBS, primary antibody and secondary antibody. Control 
wells – primary (anti-AQP1) and secondary (anti-rabbit) antibodies used but without initial addition of 0.01% 
SDS/PBS. Secondary antibody only – secondary antibody used but without 0.01% SDS/PBS and primary (anti-
AQP 1) antibody.  For each permutation 3 different types of blocking step were used – 3% BSA (A9647) in 




The AQP1 ELISA was repeated using a 2-fold serial dilution of a single human urine sample 
run alongside AQP1 standards used to generate a standard curve. The blank was much 
improved at (0.092), however the signal obtained from the standards was significantly less 
than that achieved with the previous ELISA (Figure 3.50). The ELISA was able to detect 
AQP1 in the diluted urine sample however the optical density even in the undiluted sample 
was very low and at the bottom of the standard curve (Table 3.2).  Attention was turned to 




Figure 3.50 Urinary AQP1 ELISA standard curve associated with Table 3.2 
The standard curve demonstrates a serial dilution of AQP1 standards from 1.5625-200 ng/ml and reveals that 
the optical densities obtained for the individual AQP1 concentrations are much lower than on the previous 
ELISA assay. Analysis performed by 4 parameter logistic regression. R2 = 0.976. Anti- AQP1 antibody was 
used at 1:30 dilution and standard/sample diluent was 0.01% SDS in PBS. ABTS substrate was applied for 30 






















Urine dilution Optical 
density  1  
Optical 






1 0.02 0.007 0.014 6.884 
1:2 0.034 0.034 0.034 14.615 
1:4 0.023 0.032 0.032 13.866 
1:8 0.034 0.022 0.028 12.357 
1:16 0.021 0.019 0.02 9.474 
1:32 0.011 0.009 0.01 5.431 
1:64 0.016 0.002 0.009 4.789 
1:128 0.006 -0.004 0.001 0.959 
 
Table 3.2 Urinary AQP1 ELISA for serial dilutions of a single human urine sample 
Serial dilution of a single human urine sample was undertaken with 0.01% SDS in PBS from undiluted sample 
to 1 in 128 dilution. Although AQP1 was detected in the urine samples the optical density was very low placing 
the results at the bottom end of the standard curve.  
 
 
3.6.2.1 Lyophilisation and concentration of urine samples 
In order to try and improve detection of AQP1 in the urine samples a single human urine 
sample was split and used in three ways on the same ELISA plate: 
• Concentrated urine - Urine sample (15 ml) concentrated and fractionated in an 
Amicon® Ultra-15 10K centrifugal filter device (UFC901008, Merck Millipore, 
Billerica, MA, USA) to a volume of 500 μl followed by 2-fold serial dilutions using 
0.01% SDS/PBS as diluent 
• Lyophilised urine - lyophilisation of the urine sample (15 ml) and reconstitution to a 
volume of 600 μl with 0.01% SDS/PBS  






Figure 3.51 Urinary AQP1 ELISA standard curve associated with Table 3.3 
The standard curve demonstrates a serial dilution of AQP1 standards from 12.5-400 ng/ml however the optical 
densities are very low. Analysis performed by 4 parameter logistic regression reveals an R2 = 0.996. Anti- 
AQP1 antibody was used at 1:30 dilution and standard/sample diluent was 0.01% SDS in PBS. ABTS substrate 
was applied for 30 minutes in the dark followed by 1% SDS stop solution.  
 
 
Urine sample (dilution) Optical 
density  1 
Optical 
density  2 
Mean optical 
density 
Urine (1) 0.082 0.08 0.082 
Urine (1:2) 0.108 0.108 0.108 
Urine (1:4) 0.114 0.114 0.114 
Urine (1:8) 0.095 0.104 0.1 
Urine (1:16) 0.067 0.07 0.069 
Urine (1:32) 0.052 0.044 0.048 
Urine (1:64) 0.028 0.023 0.026 
Concentrated Urine (1) 0.178 0.136 0.158 
Concentrated  Urine 
(1:2) 
0.134 0.164 0.149 
Concentrated Urine (1:4) 0.11 0.101 0.106 
Concentrated Urine (1:8) 0.093 0.092 0.092 
Concentrated Urine 
(1:16) 





0.062 0.063 0.063 
Concentrated Urine 
(1:64) 
0.055 0.036 0.045 
Lyophilised Urine (1) 0.099 0.092 0.096 
Lyophilised Urine (1:2) 0.155 0.182 0.168 
Lyophilised Urine (1:4) 0.153 0.194 0.173 
Lyophilised Urine (1:8) 0.153 0.158 0.156 
Lyophilised Urine (1:16) 0.217 0.2 0.208 
Lyophilised Urine (1:32) 0.161 0.176 0.168 
Lyophilised Urine (1:64) 0.142 0.143 0.142 
 
Table 3.3 AQP1 ELISA of concentrated/fractionated or lyophilised urine  
A single human urine sample was split into 3 aliquots which were processed differently to produce: 
concentrated/fractionated urine, lyophilized urine and urine. All 3 aliquots were serially diluted by a factor of 
2 with 0.01% SDS in PBS from undiluted sample to 1 in 64 dilution. Lyophilisation and 
concentration/fractionation of the urine did not significantly improve the detection of AQP1.  
 
 
Unfortunately, the standards didn’t work very well reaching a maximum optical density of 
0.15 nm for the largest concentration of 400 ng/ml.  This may have been due to freeze-thaw 
effect (see 3.6.2.2) as the aliquot of standard used had been thawed before.  Moreover, 
concentration/fractionation and lyophilisation of the urine samples didn’t considerably 
improve the detection of urinary AQP1 compared to control urine. The next avenue was to 
explore different substrates used for peroxidase-based enzyme immunoassays to try and 
improve assay sensitivity.  
 
3.6.2.2 Freeze-thaw effect on recombinant aquaporin 1 protein standard and 
effect of different colorimetric based substrates 
A further ELISA was performed comparing TMB substrate which has higher sensitivity for 
HRP detection than ABTS.  Additionally, for both substrates, a new aliquot of AQP1 

















6.25 0.034 0.001 0.13 0.01 
12.5 0.07 0.004 0.258 0.014 
25 0.138 -0.005 0.548 0.004 
50 0.287 -0.001 1.07 0.009 
100 0.567 0.002 2.23 0.026 
200 1.065 0.015 >4 0.071 
400 1.557 0.043 >4 0.156 
 
Table 3.4 Recombinant AQP1 protein standard is rendered unusable by freeze-thawing 
A 2-fold serial dilution of AQP1 standards from 6.25-400 ng/ml was undertaken for both a new aliquot of 
protein standard alongside an aliquot which had undergone freeze-thaw. Anti-AQP1 antibody was used at 1:30 
dilution and standard/sample diluent was 0.01% SDS in PBS. ABTS substrate was applied for 30 minutes in 
the dark followed by 1% SDS stop solution. TMB was applied for 15 minutes in the dark followed by 0.18 M 
H2SO4 stop solution. These readings demonstrate that TMB has a much greater sensitivity than ABTS and 
freeze thaw of the AQP1 standard degrades the protein. ABTS substrate mean blank optical density 0.095. 
TMB substrate mean blank optical density 0.189.  OD = optical density. 
 
Table 3.4 demonstrates that following a single freeze-thaw cycle the AQP1 protein standard 
is no longer detected by the ELISA, suggesting that freeze-thawing affects the stability of 
the protein quickly degrading the recombinant AQP1 protein standard. Additionally, this 
data confirms that TMB is a more sensitive substrate enabling lower protein concentrations 
to be discerned. During this experiment this was at the expense of higher background signal 
with the mean blank optical density for ABTS being 0.095 compared to 0.189 for TMB 
substrate. Furthermore, AQP1 detection in the ABTS group using new standard was clearly 
improved compared to previous ELISAs. This is likely due to a protocol modification made 
for this ELISA run whereby the ELISA plate was removed from incubation at 4°C and 
allowed to equilibrate to room temperature for 90 minutes before the ELISA was continued.  
3.6.2.3 Effect of different colorimetric based substrates on urine AQP 1 
detection 
Using the newly modified protocol and comparing ABTS and TMB substrates directly on a 
single 96 well plate a single urine sample was split and used in four ways: 
ABTS Substrate TMB Substrate 
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• Concentrated urine - Urine sample (15 ml) was concentrated and fractionated in an 
Amicon® Ultra-15 10K centrifugal filter device (UFC901008, Merck Millipore, 
Billerica, MA, USA) to a volume of 500 μl followed by 2-fold serial dilutions using 
0.01% SDS/PBS as diluent 
• Urine - 2-fold serial dilutions of the native urine sample using 0.01% SDS/PBS as 
diluent  
• Urine RIPA – urine was diluted with an equal volume of RIPA buffer containing 
protease inhibitor and was not diluted any further 
• Urine 0.1% SDS - urine was diluted with an equal volume of 0.2% SDS/PBS to create 
final concentration of 0.1% SDS. 
Nice AQP1 standard curves were generated for both substrates. TMB substrate showed 
greater sensitivity, albeit with a greater blank well optical density reading of (0.2575 for 
TMB versus 0.1135 for ABTS) which would need to be rectified before application to 
samples from the human or rat models (Figure 3.52 and Figure 3.53). Generally speaking 
both substrates demonstrated roughly the same amount of AQP1 protein in the sample 
however the sensitivity of the assay to lower amounts of protein in more diluted samples was 
better with TMB. Consequently, TMB would be a better substrate to use when analysing 
samples from the human and rat models as it was expected AQP1 excretion would be 
reduced in the obstructed model. Interestingly concentration/fractionation of the urine 
sample with the centrifugal filter worsened the detection of AQP1 in urine as did the addition 
of RIPA buffer to the native urine sample. Increasing the amount of SDS in the urine sample, 
however, augmented AQP1 detection by over 2-fold when analysed with both TMB 




Figure 3.52 Urinary AQP1 ELISA standards using ABTS substrate associated with Table 3.5 
The standard curve demonstrates a serial dilution of AQP1 standards from 6.25-400 ng/ml Analysis performed 
by 4 parameter logistic regression reveals an R2 = 0.998. Anti- AQP1 antibody was used at 1:30 dilution and 
standard/sample diluent was 0.01% SDS in PBS. ABTS substrate mean blank optical density = 0.1135.  
 
Figure 3.53 Urinary AQP1 ELISA standards using TMB substrate associated with Table 3.5 
The standard curve demonstrates a serial dilution of AQP1 standards from 6.25-400 ng/ml Analysis performed 
by 4 parameter logistic regression reveals an R2 = 0.999. Anti- AQP1 antibody was used at 1:30 dilution and 






























Urine (1) 0.185 39.616 0.692 40.063 
Urine (1:2) 0.138 26.316 0.57 32.282 
Urine (1:4) 0.111 18.675 0.448 24.638 
Urine (1:8) 0.07 6.931 0.268 13.202 
Urine (1:16) 0.041 - 0.191 8.271 
Urine (1:32) 0.021 - 0.102 2.422 
Urine (1:64) 0.007 - 0.052 - 
Concentrated urine (1) 0.055 2.687 0.222 10.197 
Concentrated urine (1:2) 0.064 5.375 0.247 11.862 
Concentrated urine (1:4) 0.048 0.847 0.198 8.724 
Concentrated urine (1:8) 0.039 - 0.162 6.367 
Concentrated urine 
(1:16) 0.032 - 0.14 5.032 
Concentrated urine 
(1:32) 0.031 - 0.121 3.718 
Concentrated urine 
(1:64) 0.029 - 0.128 4.18 
Urine RIPA (1:2) -0.037 - -0.136 - 
Urine 0.1 % SDS (1:2) 0.304 - 1.366 - 
 
Table 3.5 Human urine AQP1 ELISA comparing ABTS and TMB substrates and concentrated versus 
native urine 
A single human urine sample was split into 4 aliquots which were processed differently to produce: 
concentrated/fractionated urine, urine, urine 0.1% SDS, urine RIPA. Aliquots were serially diluted by a factor 
of 2 with 0.01% SDS in PBS from undiluted sample to 1 in 64 dilution except sample ‘urine 0.1% SDS’ which 
was diluted with an equal volume of  0.2% SDS/PBS and ‘urine RIPA’ which was diluted with an equal volume 
of RIPA buffer containing protease inhibitor. Anti- AQP1 antibody was used at a 1:30 dilution. ‘Concentrated 
urine’ - urine concentrated and fractionated in a centrifugal filter device. ‘Urine’ – native urine sample. TMB 
shows a higher sensitivity for HRP than ABTS for both AQP1 standards and urine samples.  Concentration of 
the urine samples or the addition of RIPA buffer worsened APQ1 detection. Increasing the SDS concentration 
in the sample diluent improved AQP1 protein detection. OD = optical density. 
 
 
ABTS Substrate TMB Substrate 
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3.6.2.4 Addition of detergent to urine samples analysed using TMB substrate 
The AQP1 ELISA was repeated using TMB substrate alongside an increased SDS 
concentration in the sample/standard diluent of 0.1%. The enhanced concentration of SDS 
augmented the signal obtained from the standards significantly necessitating exclusion of 
the two top standards of 100 and 200 ng/ml from the standard curve as the optical densities 
were >4 (Figure 3.54). Fortuitously the sensitivity of AQP1 detection was increased even 
more so in the urine samples (Table 3.6). Consequently, urine sample optical densities were 
placed in the middle third of the standard curve increasing the accuracy of the calculated 
AQP1 concentration. It was noted that the initial urine dilutions for each sample 
paradoxically revealed increasing optical densities. This phenomenon has been noted by 
others [397] and is likely due to additional substances in the urine such as Tamm-Horsfall 
protein (THP) interfering with the assay. This indicates that for ongoing experiments serial 
dilutions would be required for each urine sample. The urine dilution at which the optical 
density first decreased would be used to calculate the urine AQP1 concentration.  
The mean blank well optical density remained a little high at 0.1455 which was addressed 
by the experiments presented in section 3.6.2.5.  
 
Figure 3.54 Urinary AQP1 ELISA using 0.1% SDS/PBS standard and sample diluent 
The standard curve demonstrates a serial dilution of AQP1 standards from 3.125-50 ng/ml Analysis performed 
by 4 parameter logistic regression reveals an R2 = 0.998. Anti- AQP1 antibody was used at 1:30 dilution and 









1 0.67 0.69 0.68 10.305 
1:2 1.114 1.152 1.132 18.068 
1:4 1.314 1.3 1.308 21.275 
1:8 0.828 0.836 0.832 12.835 
1:16 0.684 0.714 0.699 10.618 
1:32 0.472 0.478 0.476 6.956 
1:64 0.28 0.274 0.277 3.698 
 
Table 3.6 AQP1 ELISA using TMB substrate and 0.1% SDS/PBS as standard/sample diluent 
Serial dilution of a single human urine sample was undertaken with 0.1% SDS in PBS from undiluted sample 
to 1 in 64 dilution. The addition of 0.1% SDS in PBS significantly improved the detection of AQP1 in the urine 
bringing the optical density values closer to the centre of the standard curve. Increasing optical density values 
of the initial urine dilutions likely represents inhibitors within the urine sample which are diluted down at 
higher urine dilutions. OD = optical density. 
 
3.6.2.5 Optimisation of ELISA blank wells using TMB substrate 
TMB is known to have high sensitivity for HRP which can lead to increased background in 
blank wells. Factors potentially responsible for this phenomenon include:  
• Bovine serum albumin (BSA) grade   
• Increased concentration of SDS 
• Primary or secondary antibody binding 
An ELISA to establish the cause of high background was undertaken which involved: 
• Blank wells – 0.1% SDS/PBS, primary antibody and secondary antibody 
• Control wells – primary and secondary antibodies used but without initial addition 
of 0.1% SDS/PBS 
• Secondary antibody only – as above except without addition of primary antibody 
Additionally, each of the above was performed with 2 different types of BSA as well as 
testing 5% tween 20 in PBS for block and antibody diluent instead of BSA.  
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Table 3.7 demonstrates that the background is worse with 5% tween while it was slightly 
improved with the BSA A7030 compared to BSA A9647. There was little difference 
between the two types of BSA. Moreover, there is little difference in optical density values 
between blank and control wells indicating that the 0.1% SDS/PBS sample diluent is not 
responsible. A significant decrease in signal from the control to the secondary antibody wells 
suggests the primary antibody concentration could be the culprit and therefore the ELISA 
was repeated using decreasing concentrations of anti-AQP1 antibody on blank wells 
(incubated with 0.1% SDS/PBS diluent at 4°C only before addition of primary and secondary 
antibodies). The mean optical density decreased with decreasing anti-AQP1 antibody 
concentration and a primary antibody dilution of 1:60 was selected for use in further ELISA 
assays as this dilution demonstrated acceptable background signal (Table 3.8). 
Well Block/antibody diluent Optical 
density  1  
Optical 
density  2  
Mean optical 
density  
Blank 3% BSA (A9647, 
Sigma) 
0.134 0.161 0.1475 
Control  3% BSA (A9647, 
Sigma) 
0.124 0.179 0.1515 
Secondary 
antibody  
3% BSA (A9647, 
Sigma) 
0.044 0.046 0.045 
Blank  3% BSA (A7030, 
Sigma) 
0.108 0.116 0.112 
Control 3% BSA (A7030, 
Sigma) 
0.098 0.098 0.098 
Secondary 
antibody  
3% BSA (A7030, 
Sigma) 
0.040 0.038 0.039 
Blank  5% tween 20 0.381 0.411 0.396 
Control  5% tween 20 0.276 0.410 0.343 
Secondary 
antibody  
5% tween 20 0.048 0.049 0.0485 
 
Table 3.7 AQP1 ELISA to investigate factors responsible for high background in blank wells using 
TMB substrate 
Anti-AQP1 antibody used at 1 in 30 dilution with TMB substrate. Blank wells – 0.1% SDS/PBS, primary 
antibody and secondary antibody. Control wells – primary (anti-AQP1) and secondary (anti-rabbit) antibodies 
used but without initial addition of 0.1% SDS/PBS. Secondary antibody only – secondary antibody used but 
without 0.1% SDS/PBS and primary (anti-AQP1) antibody.  For each permutation 3 different types of blocking 
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step were used – 3% BSA (A9647) in PBS, 3% BSA (A7030) in PBS and 5% tween 20 in PBS. This data 




Optical density 1 Optical density 2 Mean optical 
density 
1 in 30 0.110 0.119 0.1145 
1 in 40 0.102 0.110 0.106 
1 in 50 0.101 0.099 0.1 
1 in 60 0.088 0.089 0.0885 
1 in 100 0.075 0.076 0.0755 
1in 200 0.058 0.060 0.059 
1 in 400 0.049 0.055 0.052 
1 in 1000 0.041 0.044 0.0425 
 
Table 3.8 AQP1 ELISA to determine the optimum anti-AQP1 antibody dilution  
An increasing dilution of anti-AQP1 antibody (1 in 30 – 1 in 1000) was applied to blank wells containing 0.1% 
SDS/PBS. Secondary antibody and TMB substrate were applied as per the usual protocol. A primary antibody 
dilution of 1 in 60 was selected for future use as this dilution demonstrated an acceptable level of background 
signal.  
 
Using anti-AQP1 at 1 in 60 dilution, two new human urine samples and one rat urine sample, 
the AQP1 ELISA was repeated with each sample being performed in triplicate. Triplicate 
repeats of AQP1 standards show good reproducibility with low intra assay variability 
(percentage co-efficient variation of the optical density ranging 1.833 – 7.566) and an 




Figure 3.55 Urinary AQP1 ELISA standard curve using anti- AQP1 at 1 in 60 dilution associated with 
Table 3.9 and Table 3.10 
The standard curve demonstrates a serial dilution of AQP1 standards from 0.39-50 ng/ml. Analysis performed 
by 4 parameter logistic regression reveals an R2 = 0.997. Anti- AQP1 antibody was used at 1:60 dilution and 



















0.78 0.068 0.07 0.072 0.07 0.002 2.871 
1.56 0.147 0.131 0.128 0.135 0.01 7.566 
3.125 0.276 0.272 0.262 0.27 0.007 2.674 
6.25 0.544 0.529 0.507 0.526 0.019 3.536 
12.5 1.101 1.147 1.139 1.129 0.025 2.177 
25 1.694 1.74 1.758 1.73 0.033 1.907 
50 2.830 2.875 2.938 2.88 0.054 1.883 
 
Table 3.9 Optical densities of AQP1 standards using anti-AQP1 at 1 in 60 dilution 
A 2-fold serial dilution of recombinant AQP1 protein standards was performed from 50 ng/ml to 0.78 ng/ml in 
0.1% SDS/PBS. Protein standards were performed in triplicate. Individual, and mean optical densities 
measured at 450 nm are presented for each AQP1 protein concentration alongside the standard deviation and 
percentage coefficient variation. Anti-AQP1 antibody was used at 1 in 60 dilution alongside TMB substrate. 
 
This ELISA demonstrated that AQP1 can be detected in rat urine as well as human urine. 
Similar to the AQP1 standards, good reproducibility with low intra-assay variation was 
140 
 
shown between sample triplicates (percentage coefficient variation of optical densities 
ranging 2.55 – 7.82). Using the standard curve generated by 4 parameter logistic regression 
the urine AQP1 concentration was calculated. This value was then corrected by the factor of 
the sample dilution. The AQP1 concentration was calculated for the urine dilution that first 
generated a decrease in optical density in order to account for the presence of inhibitors in 
the more concentrated dilutions (Table 3.10).  
Subsequently this modified AQP1 ELISA protocol was used for analysis of rat neonatal 
unilateral ureteric obstruction model samples, adjusting the AQP1 result to urine creatinine 




























A (1:2) 0.871 0.833 0.793 0.832 4.69   
Human 
A (1:4) 0.924 0.834 0.889 0.882 5.14   
Human 
A (1:8) 0.482 0.453 0.462 0.465 3.19 4.994 39.952 
Human 
B (1:2) 1.528 1.408 1.375 1.437 5.60   
Human 
B (1:4) 1.329 1.202 1.177 1.236 6.59 15.541 62.164 
Human 
B (1:8) 0.549 0.47 0.504 0.507 7.82   
Rat (1:2) 0.827 0.791 0.792 0.803 2.55   
Rat (1:4) 0.344 0.356 0.333 0.344 3.34 3.64 14.56 
 
Table 3.10 The AQP1 ELISA detects both human and rat urinary AQP1 
Two-fold serial dilutions of 2 human urine samples and a single rat urine sample were performed using 0.1% 
SDS/PBS. Samples were analysed in triplicate. Individual, and mean optical densities measured at 450 nm are 
presented for each sample alongside the percentage coefficient variation, calculated AQP1 concentration and 
the AQP1 concentration corrected for the dilution. The urine dilution at which the optical density first decreased 







Endpoint RT-PCR is a useful method to demonstrate the presence or absence of mRNA for 
a particular gene within cells or tissues [398]. Using this technique contamination of the 
human kidney samples with genomic DNA was detected and rectified by implementing a 
DNase step in the RNA extraction protocol. As a result of these experiments the endpoint 
PCR technique was optimised for future use in both the human and rat studies.   
Although semi-quantitative analysis of end-point PCR has been reported in the literature 
[187] this technique is imprecise having low sensitivity to detect changes in yield. By 
definition, the amount of product is measured at the end of the reaction when the starting 
and final amount of template do not necessarily have a direct correlation [399]. Real time 
PCR provides accurate quantitation of the starting amount of cDNA in a sample as it 
measures the accumulation of template in real time during the exponential phase of the PCR 
reaction [398, 399]. Real time (quantitative) PCR would be the optimum method to compare 
AQP expression between obstructed and non-obstructed urinary tracts in the human and rat 
models. Primers suitable for real time PCR were designed and validated [400] using standard 
techniques to detect rat AQP isoforms 1-4, and 6-11 as well as the reference genes, β-actin 
and PKG 1. Primers were also designed and tested to detect rat AQP5 however they were 
unsuitable for real time PCR and thus not used in sample analysis. Primers to detect rat AQPs 
0 and 12 were also designed but were not validated for real time PCR as endpoint PCR 
demonstrated these isoforms were not expressed by rat urinary tract (Chapter 5). 
Unfortunately, due to time constraints primers suitable for real time PCR which detect 
human AQPs were not developed. 
The technique of western blotting has been optimised, via testing a number of well described 
protocol modifications, to detect and quantify AQPs 1-4 in both human and rat tissue. AQP1 
was detected at the protein level in human kidney, renal pelvis and ureter, as well as rat 
kidney and bladder by western blotting. The protein was identified by a 25 kDa non-
glycosylated band, and a 35-40 kDa glycosylated band. The glycosylated band arises due to 
N-glycosylation of AQP1, which was confirmed by deglycosylation studies. Interestingly 
western blotting of human kidney revealed a glycosylated band of higher molecular weight 
(40 kDa) than that of human ureter, human renal pelvis and rat kidney (35 kDa). This could 
be due to differential glycosylation between distinct tissue types or potentially could be 
related to the protein extraction technique. The glycosylated band was reported between 35-
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50 kDa in human and rat kidneys by Frokiaers group [187, 189], however, samples from the 
two species were not assessed simultaneously. 
AQP2 detection by western blotting proved much more difficult to establish and following 
trials of a number of antibodies ultimately required the use of FLAG tagged AQP2 
overexpression lysate as a positive control to identify the correct band at 31 kDa. 
Subsequently AQP2 was detected in human kidney, renal pelvis and ureter, and rat kidney. 
Following optimisation of the blocking agent used and the primary antibody concentration 
AQP3 was detected by western blotting in human kidney, renal pelvis and ureter, and rat 
kidney and bladder while AQP4 expression was noted in human and rat kidney and rat 
bladder. Failure to detect AQP4 in human renal pelvis and ureter on western blotting may 
reflect lack of expression at the protein level in these tissues.  Alternatively, it has been 
reported that AQP4 is specifically expressed by the urothelium of the lower urinary tract 
[259]. Low expression levels within urothelium, combined with urothelium forming a 
relatively small percentage of the tissue lysed within a ureter or renal pelvis specimen, could 
also explain the absence of expression. 
Following optimisation of antibody dilutions and the introduction of a polymerised 
secondary reporter antibody to combat issues with endogenous biotin content, 
immunohistochemistry of human kidney was undertaken. This revealed AQP1 expression in 
the apical and basolateral membranes of the proximal tubules, the loop of Henle and vasa 
recta. AQP2 and AQP3 were localised to the apical and basolateral cell membranes of the 
renal collecting duct respectively. These expression patterns were consistent with previous 
reports in human and rodent tissue [187, 255]. Within the renal pelvis and ureter AQP1 was 
localized to the vasculature of the lamina propria but was not detectable in urothelium, while 
AQP3 was highly expressed by the urothelial cells.  Although AQP1 expression has 
previously been reported in the vascular endothelial cells of rat ureter and bladder, its 
expression pattern has not been documented before in human ureter or renal pelvis [249]. 
Contrary to the western blotting results, immunohistochemistry of human ureter and renal 
pelvis failed to demonstrate AQP2 in any area of the tissue. RT-PCR of human renal pelvis 
and ureter (Chapter 6), however, confirms AQP2 expression at the mRNA level thus 
supporting the western blotting results. Conflicting reports regarding AQP2 expression are 
noted in the literature with rat ureter and bladder urothelium demonstrating AQP2 expression 
by immunohistochemistry [249] whereas human ureter and bladder urothelium did not 
demonstrate AQP2 mRNA expression [259]. Given that both RT-PCR and western blotting 
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of whole ureter and renal pelvis demonstrated AQP2 expression it is likely that the error lies 
with the immunohistochemistry. Potential causes of lack of staining include:  
• Sample fixation with 10% neutral buffered formalin. This crosslinking fixative is 
good at preserving cell structure however crosslinking, particularly if the sample is 
over-fixed, can interfere with antibody-epitope binding.  
• Ineffective antigen retrieval. The antigen retrieval solution used needs to be tailored 
to the protein.  
• Antibody specificity for the native protein. During western blotting proteins are 
reduced and denatured while during immunohistochemistry proteins remain in their 
native form where they may also be obscured by fixative related crosslinking.  
• Protein not expressed by human renal pelvis and ureter. 
Future work will involve analysis of more human samples paying attention to sample 
fixation and antigen retrieval techniques which should definitively resolve this issue.  
Unfortunately, an antibody which reliably detected AQP4 was not found and therefore AQP4 
expression by urinary tract tissues was not assessed during this research. Future studies will 
involve establishing a reliable AQP4 immunohistochemistry method to apply to samples 
from both the human and rat models.  
A major aim of this research was to establish the urinary AQP profile in high pressure 
(damaging) and low pressure (non-damaging) PUJO in rodents and humans. The clinical 
application being the development of urinary AQP quantification as a novel operative 
biomarker. Techniques were therefore developed to firstly identify and then quantify AQPs 
in the urine.   AQPs are excreted within exosomes into the urine, and although a number of 
methods reportedly isolate urinary exosomes, many of these do not provide a purely 
exosomal population.  Ultracentrifugation particularly when followed by a double cushion 
sucrose/D2O centrifugation step returns the purest exosomal protein fraction. This technique, 
however, is time consuming, processes few samples simultaneously, and would be 
inefficient for use in the clinical setting [376].   
With an initial aim to simply identify urinary AQPs, western blotting of urine concentrate 
generated by ultrafiltration was undertaken. This confirmed the presence of AQP1 and 2 and 
the absence of AQP3 in human urine. These findings are consistent with previous reports 
[365, 372, 386]. 
144 
 
Ultimately the aim of this research would be to develop a clinical test, which would need to 
be efficient, reproducible, quantitative and cost effective. Umenishi et al. compared 3 
techniques to quantify urinary AQP2 levels; radioimmunoassay, quantitative 
immunoblotting and an in-house designed AQP2 ELISA, and showed significant correlation 
between the results from all 3 techniques [397]. Based on the method described by these 
authors an AQP1 ELISA was developed as this technique meets the aforementioned 
attributes and avoids the radiation exposure associated with radioimmunoassay.  
An AQP1 in preference to an AQP2 ELISA was developed for a number of reasons. Firstly, 
because urinary AQP1 excretion is not known to be significantly regulated whereas urinary 
AQP2 excretion is mediated by vasopressin [372]. Results of an AQP1 ELISA are therefore 
less likely to be affected by hydration status of the individual. Secondly, adult and neonatal 
murine UUO models have revealed that the proximal tubule is the most severely affected 
portion of the nephron demonstrating apoptosis, autophagy and atubular glomeruli formation 
[98]. AQP1 is expressed in the proximal tubule and thus may act as an early marker of this 
damage. Finally results from western blotting suggest the anti-AQP1 antibody has better 
specificity than the anti-AQP2 antibody.  
During the process of developing the ELISA a number of modifications were made to the 
original protocol in order to improve detection of urinary AQP1 protein and are summarised 
below:  
• Steps to reduce background signal in blank wells. 
o Thorough washing of wells 
o Assessment of the BSA used for blocking. Some BSA grades can be 
problematic if certain molecules remain following purification. Both BSA 
grades used in these experiments were produced by heat shock fractionation, 
however A7030 was also protease, fatty acid and globulin free.  
• Recombinant AQP1 protein should be stored in single use aliquots thus avoiding 
freeze-thaw effects which degrade the protein. 
• Enabling the plate to equilibrate with room temperature for 90 minutes after 
overnight incubation at 4 °C improved the signal obtained from both the AQP1 
standards and the urine samples. 
• TMB colorimetric substrate augmented the signal obtained from both AQP1 
standards and urine samples when compared to ABTS. The increased sensitivity of 
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TMB was at the expense of increased background signal which required further 
investigation.  
• Increasing the dilution of anti-AQP1 antibody from 1 in 30 to 1 in 60 reduced the 
background signal to an acceptable level in blank wells when using TMB substrate. 
• Increasing the amount of SDS from 0.01% to 0.1% in the standard and sample diluent 
improved the signal obtained from the AQP1 standards and even more so the urinary 
AQP1 protein. This brought the urine AQP1 results up into the middle third of the 
standard curve theoretically increasing accuracy. 
In summary, methods have been optimised to detect and quantify AQP expression at the 
mRNA level by Polymerase Chain Reaction and at the protein level by Western Blotting. 
Furthermore, techniques have been established to determine cellular location of AQPs by 
immunohistochemistry and quantify urinary AQP1 excretion by ELISA. These techniques 
were utilised to analyse samples obtained from the neonatal rat unilateral ureteric obstruction 






Adult and neonatal rodent models of unilateral ureteric obstruction (UUO) are well 
established and have been used by many groups to investigate the pathogenesis of 
obstructive nephropathy. Although adult and neonatal UUO models show a broadly similar 
pathological progression in terms of inflammatory, apoptotic and fibrotic processes, the 
response of the neonatal kidney reveals clear differences such as impeded renal maturation 
and growth as well as early nephron loss [90, 91, 94, 96-101]. These disparities in response 
to UUO arise because rodent nephrogenesis continues for the first week postnatally and renal 
maturation for the subsequent week. Fortuitously, this signifies that at birth and 1 week of 
age rodent renal development is equivalent to humans at the second trimester gestation and 
birth respectively [87]. Thus, surgery performed in the rodent neonatal period can simulate 
human in utero obstruction and is more informative in the setting of congenital PUJO. 
A comprehensive review comparing existing neonatal animal models with human PUJO 
suggests they are a legitimate approach for investigating the mechanism of obstructive 
nephropathy [88]. Nevertheless, the majority of children undergoing pyeloplasty have fewer 
renal histological abnormalities than their animal counterparts with complete UUO [86]. 
Models of variable partial unilateral ureteric obstruction (PUUO) show renal pelvic 
dilatation [91] and raised renal pelvic pressure [401] but less severe histological changes 
[91] than complete UUO and likely provide a better approximation to human disease. 
An animal model of partial UUO was undertaken during this research to complement the 
clinical study of human PUJO for a number of reasons:  
1. Animal models can be manipulated to produce different severities of obstruction  
2. Sacrificing rat pups at variable time points allows changes in aquaporin 
expression/distribution to be monitored over time, particularly enabling assessment 
of whether aquaporin down-regulation predates histopathological changes of 
nephropathy 
3. Control tissues are easily available 
4. Renal tissue was accessible which was not available for the human PUJO study  




5. Once established the model can be extended to AQP mutant mice to further develop 
the research. Despite their smaller size compared to rats this should be technically 
possible. Thornhill et al. have previously successfully undertaken PUUO in 2 day 
old neonatal mice in order to investigate the pathogenesis of obstructive nephropathy 
[94] 
A number of methods have been utilised to create partial unilateral ureteric obstruction in 
different species of animal. Chevalier et al. described the creation of chronic partial ureteric 
obstruction in the guinea pig by placing a 2mm sterilized piece of polyethylene tubing 
around the distal third of the ureter which was left in situ for up to 8 weeks [402]. More 
commonly, a method first described in 1962 by Ulm and Miller as a technique to create 
reversible hydronephrosis in dogs, has been utilised [403]. This technique to create partial 
UUO has since been applied to neonatal and adult rodents and involves embedding the upper 
section of the ureter in a groove created in the psoas muscle [120, 364, 401]. Increasing the 
amount of ureter embedded in the psoas muscle increases the severity of obstruction as 
demonstrated in the acute setting by proportionately raised baseline renal pelvis pressure 
[401].  
More recently Thornhill et al. described an alternative method to create variable partial 
ureteric obstruction in the neonatal rat. This method involved placing a wire template of 
known diameter (0.25 – 0.9mm) alongside the PUJ, tying a ligature of non-absorbable suture 
around both ureter and wire and then removing the wire. Histology demonstrated the suture 
did not lead to significant inflammatory reaction within the ureter. Decreasing wire diameter 
resulted in increasing severity of obstruction with an increasing renal pelvis diameter 
proportional to the degree of obstruction at 14 days post PUUO. This method was reported 
to generate reproducible, variable degrees of obstruction which could be precisely regulated, 
thus enabling the possibility of serial measurements [91].  On the basis of these reported 
results combined with the procedure being the least invasive this technique was selected for 
use in this research study. Due to the technical challenges of establishing a technique new to 
the laboratory and performing PUUO surgery on neonatal animals, rats rather than mice were 




4.2.1 Training and licensing for animal studies 
Following successful completion of the Home Office Training in Animal Scientific 
Procedures Course and procurement of a personal animal licence (Ref: I57BOBE74) (Figure 
4.1) procedures were performed under the Project Licence of Professor Richard Coward 
(Licence number: 30/2787, part F, protocol number 6). 
 
Figure 4.1 Certificates of training and licensing in animal procedures 
 
4.2.2 Surgical access and feasibility studies for the PUUO procedure 
The first consideration when establishing the PUUO procedure was optimal surgical access 




Figure 4.2 Size of a p2 rat pup 
P2 Han-Wistar rat pups are approximately 5-6 cm in length from nose to base of tail, weighing on average 7g 
(range 5.5g – 8.9g). 
Potential options were a midline laparotomy or a flank incision. A midline laparotomy would 
provide good access but involves opening the peritoneal cavity alongside bowel handling 
and mobilisation. This incision may cause a degree of post-operative ileus impairing the 
pups ability to feed post-operatively. Additionally, a midline incision would be larger and 
more painful potentially further hindering post-operative recovery. Although this incision 
would be required in order to perform the Ulm and Miller method of PUUO [401, 403] 
whereby the ureter is buried in the psoas muscle, it would not be necessary to perform 
Thornhill’s method of PUUO using a wire template [91].  
Flank incisions also provide excellent access to the kidney/ureter, while being smaller and 
less painful than a midline laparotomy. Additionally, they avoid the general exposure of 
intra-abdominal organs. This incision was selected as most appropriate, especially as the 
technique to be used was that described by Thornhill et al. involving the use of a wire 
template, which incidentally this group had performed via a flank incision [91].   
In human neonates the liver is incredibly friable and easily damaged during surgical 
procedures. Extrapolating this to the neonatal rat pups it was decided to perform the 
procedure on the left kidney in order to avoid the liver on the right side of the abdomen. 
Having determined that a flank incision would be most appropriate, the positioning of the 
pup, the exact placement of the incision and the steps of the procedure were established using 
wild-type Han-Wistar p3 and p4 pups that had already been culled by schedule 1 methods 
for another indication. All procedures were performed using 2.5 x standard loupes for 
magnification of the surgical field.   
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Right lateral positioning with a slight prone tilt was required for a left flank incision. A gauze 
roll was placed under the right flank to lift the kidney and proximal ureter towards the 
incision. Relevant anatomical features were marked including the costal margin, lateral 
border of the paraspinal muscles and the iliac crest.  Following a trial of various flank 
incisions (longitudinal, oblique, transverse subcostal) an oblique incision commencing just 
inferior to the costal margin at the lateral border of the paraspinal muscles continuing 
anteroinferiorly across the flank was selected as optimum (Figure 4.3). Care was made not 
to locate the incision too far cranially in order to avoid accidental pleurotomy.  
 
Figure 4.3 Left flank incision to access the left kidney and ureter 
P3 rat pup in right lateral position with a gauze roll positioned underneath the right loin. Pen markings illustrate 
anatomic features defined before siting the incision, namely the costal margin, lateral border of the paraspinal 
muscles and the iliac crest. The incision was commenced just inferior to the costal margin at the lateral border 
of the paraspinal muscles, continuing obliquely, anteroinferiorly across the flank.  
 
Subsequently the technique to mobilise the kidney, identify the proximal ureter and bluntly 
dissect around the PUJ/proximal ureter using 2 pairs of extra fine Graefe forceps (11152-10, 
Interfocus, Fine Science Tools, UK) was refined. Once mobilised an 8/0 ethilon suture (BV 
130-4, Ethicon, OH, USA) was passed underneath the proximal ureter. The suture was 
ligated around both the ureter and a 4-5 mm long wire template, and the wire template 
subsequently removed. The procedure was tested using both 0.3mm and 0.5mm stainless 
steel wire templates (FF215130/3 and FF215140/2 Goodfellow, Huntingdon, UK).  
Confirmation that a partial obstruction had been created using both wire templates was 
obtained by injecting blue dye (PBS containing bromophenol blue) into the renal pelvis 
whereby it was noted to flow past the suture and into the bladder (Figure 4.4).  Although 
Figure 4.4 demonstrates the kidney being grasped by the forceps and drawn out of the wound 
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this was for the purposes of illustration. It was noted during development of the technique 
that the kidney is very friable and easily injured. It should not be held at any time by forceps 
as this causes significant renal damage.   
4.2.3 Recoverable neonatal rat anaesthesia 
A number of methods of neonatal rodent anaesthesia have been employed in order to create 
ureteric obstruction models including: deep hypothermia [120], injectable intra-peritoneal 
agents (e.g. pentobarbital sodium) [137] and inhalant anaesthetics [91]. 
New born rats are poikilothermic with immature thermoregulatory capabilities. Unlike adult 
mammals they can tolerate prolonged periods of severe hypothermia without experiencing 
complications. Additionally, due to their small body size and high surface area to body 
weight ratio their core temperature may be cooled rapidly by surface cooling [404]. Cooling 
may be initiated by putting the pup in a cold room, immersing the pup in iced water or 
placing the pup on crushed ice [120, 404]. Measures to induce hypothermia generally result 
in anaesthesia lasting approximately 10 minutes although this can be extended by placing 
the pup on ice or a cold pack during the procedure [404]. Safe hypothermic anaesthesia has 
been demonstrated for 30–40 minutes [120, 405]. In addition to inducing analgesia, 





Figure 4.4 Stages of procedure to create left partial ureteric obstruction 
Following mobilisation of the kidney and ureter an 8/0 ethilon suture was passed underneath the proximal 
ureter (arrow - ureter) (A). The suture was tied around the ureter and a wire template (0.5mm) (B).  The wire 
template was removed leaving the suture (arrow) tied around the proximal ureter (C). A needle was inserted 
through the renal parenchyma into the renal pelvis. PBS containing bromophenol blue dye was injected into 
the renal pelvis (D). The dye flowed past the suture and down the ureter (arrow)(E). Dye reached the bladder 
(arrow) following injection into the renal pelvis confirming this was not a complete ureteric obstruction (F). 
Stages demonstrated using a p3 pup already culled by schedule 1 method for another indication.    
 
Although previously used for surgical anaesthesia intraperitoneal injectable anaesthetics 
(e.g. ketamine, pentobarbital and a combination of fentanyl-droperidol) should be avoided 
as the level of anaesthesia is difficult to regulate, they may be ineffective for short term 
anaesthesia and have been associated with excessive mortality (>50%) [405]. 
Alongside deep hypothermia, inhalant anaesthetics are safer and more effective than 
injectable anaesthetics [405]. Isoflurane, a halogenated ether, is a commonly used inhalant 
anaesthetic agent in both veterinary and human medicine. The advantage of inhalant 
anaesthetics is that their delivery can be easily adjusted throughout the procedure to maintain 
a level plane of anaesthesia and can be terminated at the end of the procedure enabling rapid 
recovery of the pup.  
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Having more personal experience using inhalant anaesthesia alongside performing both this 
procedure and recovery neonatal surgery for the first time in our unit, isoflurane was selected 
as the anaesthetic of choice. This would give more flexibility as the operative time and thus 
the duration of the anaesthetic was initially uncertain. Additionally, it would be easier to 
maintain a sterile field using isoflurane rather than crushed ice which would potentially melt 
and track around the operative site.  
When setting up the anaesthetic circuit it was noted that the normal rat co-axial mask (Size 
1, VetTech Solutions, Congleton, UK) for anaesthetic delivery and waste extraction was 
much too large for a neonatal rat pup. One option was to perform the surgery in an extraction 
hood where the isoflurane would be piped in from the anaesthetic circuit and delivered to 
the rat pups nose/mouth in a suitable sized tube. Waste anesthetic gases would then be 
scavenged by the extraction hood.  The second option was to try an extra small rodent mask 
usually used for mice (AN005F, VetTech Solutions, Congleton, UK). Although rat pups are 
about a third to half the size of an adult mouse a mouse co-axial nose cone used on the bench 
was tested and worked well enabling maintenance of anaesthesia without escape of waste 
anaesthetic gases.    
4.2.4 Creation of neonatal rat PUUO 
Following the establishment of the anaesthetic and surgical procedures pups underwent 
creation of left PUUO according to the protocol outlined below. 
A Han-Wistar pregnant dam was obtained from the University of Bristol H-floor colony and 
transferred to the animal facility at e16. The dam was housed singly with enrichment and 
appropriate bedding and nesting material. The dam was fed standard rodent diet (Eurodent 
diet 22 %, Labdiet, PMI nutrition, MO, USA), allowed free access to water and housed at 
21 °C, 50 % humidity in a 12 hour light:dark cycle. Pups underwent surgery between 24-48 
hours of age during the light phase. All procedures were carried out in accordance with the 
Animals (Scientific Procedures) Act 1986. 
4.2.4.1 Retrieval of pups from the cage for surgery 
The mother was removed from the cage, the pups counted and the male pups marked. Males 
were identified by having a longer anogenital distance than females. A single pup was moved 
into a transfer cage while the remaining pups were rubbed in the bedding to reduce the smell 
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of them being handled. The mother was returned to the cage and the retrieved pup was 
transferred to the surgery room and weighed prior to anaesthesia. 
4.2.4.2 General anaesthesia 
General anaesthesia was induced using a small induction chamber (AN010SR, VetTech 
Solutions, Congleton, UK) with a mixture of 3 % isoflurane (Merial, Essex, UK) and oxygen 
with the flow set at 1l/min. This would usually take approximately 3-4 minutes until surgical 
anaesthesia was reached, assessed by loss of the pedal reflex and lack of response to painful 
stimulus. 
When fully anaesthetised the pup was moved to the surgical area and its nose placed within 
the extra small rodent co-axial mask. The isoflurane/oxygen mix was delivered via the co-
axial system with an oxygen flow of 0.8 l/min and isoflurane concentration of 1.5-2%. 
4.2.4.3 Positioning and skin preparation 
The pup was positioned on a covered warming pad that was maintained on a low setting to 
generate an element of hypothermia which proved anaesthetic sparing and reduced intra-
operative bleeding. The pup was placed in the right lateral position, slightly tilted prone with 
a gauze roll under the right flank. It was ensured the pup’s nose was securely in the 
anaesthetic mask. Tape was placed over the front and hind paws to stabilise the pup. 
The costal margin, lateral border of the paraspinal muscles and the iliac crest were marked 
with permanent ink.  The skin of the surgical area was cleaned with 70% ethanol using a 
sterile cotton bud and allowed to dry. Ethanol rather than chlorhexidine or iodine skin 
preparation was used as ethanol doesn’t leave a residual smell which may be detected by the 
mother when the pup is returned to the litter. The pup was draped with transparent sterile 
drapes. 
4.2.4.4 Surgical procedure to create left partial ureteric obstruction 
The respiratory rate and depth, and animal colour were monitored throughout the procedure 
as indicators of the depth of anaesthesia. Sterile technique was used to perform the surgery 
and 2.5 x surgical loupes were used for magnification of the surgical field. Figure 4.5 
illustrates the key steps in the creation of neonatal rat PUUO. A left flank incision was made 
with number 15 blade (10015-00, Interfocus, Fine Science Tools, UK) and scissors were 
used to split and open the muscle layer from the medial end. The fascia overlying the kidney 
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was opened and the inferior pole of the kidney mobilized and tilted anteriorly until the 
posterior surface of the kidney was visible noting the vessels at the hilum and the ureter 
running inferiorly. The proximal ureter was identified and two pairs of Graefe forceps used 
to bluntly dissect around the PUJ/proximal ureter. The tips of the forceps were then passed 
posterior to the PUJ, one end of the 8/0 ethilon suture (BV 130-4, Ethicon, OH, USA) was 
grasped with the forceps and the forceps withdrawn to bring the suture posterior to the PUJ. 
A stainless steel wire template (size 0.3mm – 0.6mm diameter) was applied parallel to the 
proximal ureter and then a double throw of the suture was placed ensuring it was closed 
around the wire and ureter but not tightened and stretched. A further single throw was closed 
around the wire and ureter but again not tightened. The final throw of the knot was tightened 
to prevent future slipping or loosening. A single operator performed all PUUO procedures 
and paid attention to maintaining equal tension in the ligatures between animals. Following 
completion of the ligature the wire template was carefully removed, and the ureter was 
returned to its anatomical position. The muscle layer was closed with interrupted 6/0 vicryl 
sutures (J833G, Ethicon, OH, USA) and the skin with interrupted subcuticular 6/0 vicryl 
sutures (J833G, Ethicon, OH, USA). Initially the skin was closed with standard interrupted 
skin sutures with the knot tied on the skin surface. Unfortunately, the mother managed to 
remove those sutures in 1 pup in the first litter within 2 hours of surgery (see section 
4.2.5.4.1) therefore it was necessary to modify the closure and effectively bury the sutures. 
Although this results in a slightly crumpled looking wound initially (Figure 4.5F) the wound 
heals nicely (Figure 4.6) and there were no further episodes of wound dehiscence throughout 




Figure 4.5 Creation of PUUO under isoflurane general anaesthetic 
P2 rat pup in right lateral position with a gauze roll positioned underneath the right loin. The pup was laid on 
a covered warming pad with its nose within a co-axial mask delivering isoflurane anaesthetic (A). The inferior 
pole of the kidney was mobilised and the proximal ureter dissected out. The tips of the forceps were positioned 
posterior to the ureter ready to grasp the 8/0 ethilon suture (K – kidney, S – spleen) (B). An 8/0 suture (arrow) 
was passed posterior to the ureter (C). The suture was tied using a double throw followed by two single throws 
around the ureter and wire template (arrow) (D). Following removal of the wire template the ureter was returned 
to the abdomen and the muscle layer closed with 6/0 vicryl interrupted sutures (E). The skin was closed with 
interrupted subcuticular sutures using 6/0 vicryl (F). 
Following closure of the wound the area was washed with 70% ethanol and the isoflurane 




Figure 4.6 Healing left flank wound 
This figure demonstrates the healing left flank wound in a p8 rat pup (A) and a p15 rat pup (B). 
 
 
4.2.4.5  Sham surgery 
Sham surgery was performed in an identical manner to PUUO surgery except that following 
mobilisation of the kidney and dissection around the proximal ureter a ligature was not 
placed and the ureter was simply returned to the abdomen.   
4.2.5 Post-operative animal care 
4.2.5.1 Post-anaesthetic recovery 
Rat pups were recovered initially in 0.5 l/min of oxygen on the warming pad (at maximum 
temperature) for a few minutes and then transferred to incubator set at 33°C (nest 
temperature) [404] until they were warm, had recovered their righting reflex and were active.  
4.2.5.2 Return of the neonatal rat pup to the mother and litter 
When fully recovered from the anaesthetic the pup was placed in the transfer cage and taken 
back to the housing area of the animal facility. In order to successfully return the pup to the 
mother the pup must smell like their littermates and not of anything unusual. To achieve this 
the mother was removed from the cage. The gloved hands of the operator were rubbed in the 
bedding and sawdust of the cage and then the pup was rubbed in sawdust and bedding from 
the cage to transfer the smell. The pup was then placed amongst the other pups, leaving the 
operated pup underneath the others within the nest. If another pup was to be operated upon 
it would be removed at this point and then the mother would be returned to the cage. Post-
operatively the pups were monitored hourly using the Bristol Generic Animal Welfare 
Scoresheet for 4 hours and then daily thereafter. 
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4.2.5.3 Continuing animal husbandry and monitoring 
Post-operatively, the litter of pups was housed with the mother in a standard cage with 
enrichment in the same conditions as pre-operatively. The pups were weighed daily and 
assessed using the Bristol Generic Animal Welfare Scoresheet documenting their 
appearance, weight, clinical signs, natural behaviour and provoked behaviour for the first 
post-operative week and then weekly thereafter. The pups were ear-notched for 
identification at p8 and prior to this they were identified by permanent pen marking which 
was renewed on a daily basis. 
Spot urines were acquired from all pups at 2 and 3 weeks post-operatively. At 2 weeks these 
were obtained by placing the pup on a cage lid with clingfilm underneath. At 3 weeks urine 
was collected by placing the pup on hydrophobic sand. Urine samples were collected into an 
Eppendorf on ice from either the clingfilm or hydrophobic sand and then processed as per 
the methods section in Chapter 2. 
The pups were weaned at 3 weeks of age and the males and females separated into different 
cages and housed at 21°C, 50% humidity in a 12 hour light:dark cycle. Subsequently pups 
were fed a standard rodent diet including crushed food (Eurodent diet 22 %, Labdiet, PMI 
nutrition, MO, USA) and were allowed free access to water. Appropriate bedding materials 
and enrichment was provided.  
Four weeks post-operatively metabolic cages were used to collect urine from all operated 
rats. Rats were placed in the metabolic cages at 1700 hours and urine collected over a roughly 
4-5 hour period into the evening. This time point was chosen as, being nocturnal, the rats 
were more active and produced urine at a faster rate thus reducing the urine collection time. 
Ice packs were placed around the metabolic cage urine collection tube to keep the urine 
sample cooled.  At the end of the collection period the urine sample was transferred to 
eppendorfs on ice and processed as per the methods section in Chapter 2 (section 2.17.1). 
4.2.5.4 Effect of wire template diameter 
It was not initially known which wire template diameter would provide the desired amount 
of hydronephrosis for the study and therefore this was optimised over the first three litters 
of rat pups that underwent the PUUO procedure.  
159 
 
4.2.5.4.1 PUUO using a 0.3 mm wire template 
The first litter consisted of 6 pups, 5 female and 1 male. 5/6 pups underwent left PUUO with 
a 0.3 mm wire template (FF215130/3 Goodfellow, Huntingdon, UK). One female underwent 
left sham procedure. Post-operative complications included early wound dehiscence in a 
female pup with left PUUO requiring re-suturing of the wound and one female with PUUO 
was cannibalised by the mother within 1 hour of surgery. A further female pup who had 
undergone left PUUO died suddenly at 26 days. On inspection of the urinary tract the 8/0 
ethilon suture was still in place around the proximal ureter and there was no renal pelvis or 
renal dilatation. No cause of death was identified. The remaining pups (4) were culled at 31 
days of age by exposure to a rising concentration of CO2 gas. All 3 with left PUUO were 
found to have very dilated urine filled left kidneys with little discernible renal tissue. All had 
normal contralateral right kidneys (Figure 4.8). The sham pup had normal kidneys and 
ureters bilaterally (Table 4.1). Although there were generally small numbers in this first litter 
there did not seem to be an obvious detrimental effect of PUUO on somatic growth compared 
to the single sham rat (Figure 4.7). 
 
Figure 4.7 Weight of PUUO (0.3 mm wire) versus sham rats 
Weekly post-operative mean weight +/- SEM presented for rat pups who underwent left PUUO with a 0.3 mm 
wire, n=4 except for week 4 where  n=3. Weekly post-operative weights also presented for a single pup who 






Pup Sex Procedure Right kidney Left kidney  Complications 
1 F 
L PUUO 





(0.3 mm) Normal 







(0.3 mm) Normal 








(0.3 mm) Normal 
Very dilated, little 
renal tissue 
L-25mm, W – 18mm  
5 F 
L PUUO 
(0.3 mm) - - 
Died at 26 days – 
normal kidneys 
bilaterally suture 
intact proximal left 
ureter  
6 F L sham Normal Normal  
 
Table 4.1 Outcome of PUUO created with a 0.3 mm wire template  
Table of details of 6 pups who underwent either left PUUO using a 0.3 mm wire template or sham procedure. 





Figure 4.8 Outcome of left PUUO created using 0.3 mm wire template 
Images of the findings at 31 days of 2 rat pups (one female, one male) following creation of left PUUO using 
a 0.3 mm wire template at p2. The female pup had a very dilated urine filled left kidney with almost no residual 
renal tissue noted: in situ (A), alongside a ruler to demonstrate the size (B) and following retrieval compared 
to the contralateral normal kidney (C). The male pup also had an extremely dilated urine filled left kidney, the 
yellow circle indicates the position of the suture around the upper ureter (D). The ureter and renal pelvis were 
dilated (arrowhead) proximal to the suture (arrow) (E). Decompression of the kidney revealed no discernable 
renal tissue (F). R – right kidney, L – left kidney   
 
 
4.2.5.4.2 PUUO using a 0.6 mm wire template 
The second litter consisted of 12 pups, 7 male and 5 female. Six pups (3 male, 3 female) 
underwent left PUUO using a 0.6 mm wire template (FF215145/1, Goodfellow, Huntingdon, 
UK). Three pups (2 male, one female) underwent left sham procedure and the three final 
pups (2 male, one female) did not undergo either an anaesthetic or surgical procedure. One 
male PUUO pup was cannibalised by the mother at p5, the cause of which is unknown. Three 
PUUO rats (2 female, 1 male) were culled at age 37 days by terminal isoflurane anaesthesia 
(See section 4.2.6). The suture was intact around the proximal left ureter in all three rats 
however there was no evidence of dilatation of the ureter, renal pelvis or kidney. Three sham 
rats (2 male, 1 female) were also culled by terminal anaesthesia at age 37 days and 
demonstrated normal kidneys, renal pelvices and ureters bilaterally. In view of the fact that 
no dilatation had been observed in the 3 PUUO rats, the remaining 2 rats (1 female, 1 male) 
were observed up to an age of 100 days when they were culled by terminal isoflurane 
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anaesthesia. Despite the prolonged length of time the sutures had been in place the male rat 
had a completely normal left kidney and collecting system with no discernable dilatation. 
The female rat had mild prominence of the proximal ureter/renal pelvis only (Table 4.2 and 
Figure 4.10). Both contralateral kidneys were normal. One-way ANOVA confirmed no 
statistical difference between the renal pelvis and ureter dimensions of PUUO, sham and 
control rats age 37 days. Unpaired t-tests confirmed no statistical difference between the 
PUUO renal pelvis and ureter dimensions compared to contralateral system dimensions in 
rats aged 100 days (Figure 4.11). Compared to both sham rats and non-operated rats the 
PUUO procedure did not affect somatic growth over the first 5 weeks of life (Figure 4.9). 
 
 
Figure 4.9 Mean weight of left PUUO (0.6 mm wire) rats versus controls 
Weekly post-operative mean weights +/- SEM presented for rat pups who underwent left PUUO with a 0.6mm 
wire n=5, left sham procedure n=3 and non-operated rats n=3. No statistically significant difference between 







































(0.6 mm) 37 0.98 1.14 0.72 0.71 
3 F 
L PUUO 
(0.6 mm) 37 1.15 1.27 0.71 0.65 
4 M 
L PUUO 
(0.6 mm) 100 1.97 2.14 0.99 0.95 
5 F 
L PUUO 
(0.6 mm) 100 1.51 2.35 0.95 1.68 
6 F L sham 37 1.23 1.02 0.83 0.63 
7 M L sham 37 1.02 1.18 0.86 0.82 
8 M L sham 37 1 0.9 0.7 0.6 
9 M None 37 1.19 1.1 0.95 0.84 
10 M None 37 1.27 1.53 0.65 0.71 
11 F None 37 1.07 0.91 0.74 0.62 
 
Table 4.2 Outcome of PUUO created with a 0.6 mm wire template versus controls 
Table detailing the renal pelvis and ureter dimensions of 11 rat pups who underwent either left PUUO using a 
0.6 mm wire template, sham procedure or no procedure. Three PUUO rats were culled at 37 days and the 
remaining 2 were culled at 100 days. Using separate one-way ANOVAs for renal pelvis and ureter dimensions, 
no statistical difference was noted between PUUO, sham and non-operated animals. Using separate unpaired 
t-tests for renal pelvis and ureter measurements no significant difference was noted between PUUO and 





Figure 4.10 Outcome of left PUUO created with 0.6 mm wire template 
Images of the findings at 37 days and 100 days of 2 female rat pups following creation of left PUUO using a 
0.6 mm wire template at p2. The left kidney and collecting system was completely normal with no evidence of 
dilatation and the suture (arrow) in place around the proximal ureter at 37 days of age (A)(B). At 100 days 
following creation of PUUO one rat demonstrated prominence of the upper ureter and renal pelvis (arrowhead) 
proximal to the suture (arrow) (C). Left PUUO kidney with mild renal pelvis dilatation compared to the normal 





Figure 4.11 Renal pelvis and proximal ureter dimensions of PUUO (0.6 mm wire template) and control 
rats 
Comparison of the renal pelvis anteroposterior diameter (APD) at age 37 days between the left and contralateral 
systems for each intervention. One-way ANOVA demonstrates no significant difference between groups 
p=0.723 (A). Comparison of the proximal ureter diameter at age 37 days between the left and contralateral 
systems for each intervention. One-way ANOVA demonstrates no significant difference between groups 
p=0.7257 (B). Comparison of the renal pelvis APDs after left PUUO with the contralateral renal pelvis APDs 
at age 100 days. Unpaired t-test demonstrated no significant difference between groups p=0.1839 (C). 
Comparison of the proximal ureter diameters after left PUUO with the contralateral proximal ureter diameters 
at age 100 days. Unpaired t-test demonstrated no significant difference p=0.5762 (D). Mean +/- SEM presented 









4.2.5.4.3 PUUO using a 0.4 mm wire template 
Nine male pups from a third litter were studied, using a 0.4 mm wire template (FF215135/2, 
Goodfellow, Huntingdon, UK) to create PUUO in 7 of the pups. Two male pups remained 
non-operated. At 35 days of age all rats except one male PUUO rat (culled later at 86 days 
of age) were culled by terminal isoflurane anaesthesia (See section 4.2.6).  There were no 
complications of surgery and the rats demonstrated variable amounts of hydronephrosis 
ranging from mild to severe. This wire diameter was selected for ongoing studies involving 




Figure 4.12 Hydronephrotic rat kidneys created using a 0.4 mm wire template 
Mild hydronephrosis of the left kidney demonstrated by mild ureteric/renal pelvis dilatation above the suture 
(arrow). Pictured above are axial sections demonstrating preserved architecture of the left PUUO kidney in 
mild hydronephrosis compared to the contralateral kidney (A). Moderate hydronephrosis of the left kidney 
revealed by significant dilatation of the ureter/renal pelvis above the suture (arrow). Pictured above are axial 
sections demonstrating atrophy (medulla>cortex) of the left PUUO kidney in moderate hydronephrosis 
compared to the contralateral kidney (B). Severe hydronephrosis of the left kidney demonstrated by significant 
dilatation of the ureter/renal pelvis above the suture (arrow) and considerable dilatation of the kidney (C) 
Severe hydronephrosis resulted in substantial atrophy of the renal tissue as noted when the kidney was 
decompressed (D). All images are from rats culled at 35 days and result from PUUO performed using a 0.4 




4.2.6 End of study protocol 
4.2.6.1 Schedule 1 methods and retrieval of tissues 
The humane killing of the rats was conducted in accordance with UK Home Office 
legislation (Schedule 1). The first litter of rats were culled by exposure to a rising 
concentration of CO2 gas at 31 days of age. All subsequent litters were culled by terminal 
anaesthesia using isoflurane. This method would be necessary in later experiments when 
establishing an intra-renal pelvis pressure measurement technique.  
From litter 3 onwards all rats were culled at 35 days of age. The rats were weighed and then 
anaesthesia was induced using a large induction chamber (AN010ASR, VetTech Solutions 
Ltd, Congleton, UK) and exposure to a mixture of 3% isoflurane (Merial, Essex, UK) and 
oxygen with the flow set at 1 l/min. This would usually take approximately 4-5 minutes until 
surgical anaesthesia was reached assessed by loss of the pedal reflex and lack of response to 
painful stimulus. 
When fully anaesthetised the rat was moved to the surgical area, laid supine with its nose 
placed within a co-axial mask (Size 1, Vet Tech Solutions Ltd, Essex, UK). The 
isoflurane/oxygen mix was delivered via the co-axial system with an oxygen flow of 0.8 
l/min and isoflurane concentration of 2 - 2.5%. A midline laparotomy was performed which 
was extended laterally in both directions from the inferior aspect of the midline incision to 
enable good exposure of both kidneys and ureters. Measurements of the proximal ureter 
diameter, the renal pelvis anteroposterior diameter (APD) and, in cases of severe 
hydronephrosis, the kidney length and width were taken using digital calipers. At this point 
the intra-renal pelvis pressure was also measured in litters 4-6 (see 4.2.6.3). Subsequently 
0.9% saline was injected into the renal pelvis to confirm the presence of partial rather than 
complete ureteric obstruction. This was injected through the pressure measuring equipment 
in litters 4-6 and via a 27-gauge needle inserted through the kidney into the renal pelvis in 
litter 3. A small number of additional female rats (from litters 4-6) with PUUO created using 
a 0.4 mm wire template, had PBS containing bromophenol blue dye injected into the renal 
pelvis to visually confirm patency of the proximal ureter (Figure 4.14). Dye was not used in 
the male rats whose tissues would be processed for AQP analysis due to concerns this may 
interfere with the results. Bilateral nephroureterectomy was subsequently performed and the 




Figure 4.13 Rat positioning and incision site for intra-renal pelvis pressure measurement and tissue 
retrieval 
The rat was laid supine on a warming pad with its nose placed within the co-axial mask. Tape was applied to 
all paws to secure the position. A midline laparotomy was performed and extended laterally in both directions 
from the inferior aspect of the midline incision (marked by dotted line).  
 
 
Figure 4.14 Injection of dye to confirm ureteric patency  
A needle was inserted through the renal parenchyma into the renal pelvis of a 35-day old female pup with 
moderate hydronephrosis following PUUO using a 0.4 mm wire template at p2. PBS containing bromophenol 
blue dye was injected into the renal pelvis (red arrowhead). The dye flowed past the suture (red arrow) and 
down the ureter (black arrow). Dye reached the bladder (black arrowhead) following injection into the renal 
pelvis confirming this was not a complete ureteric obstruction. K – kidney. 
 
4.2.6.2 Preparation of samples 
Both kidneys, renal pelvices and ureters were dissected out and the kidneys individually 
weighed. The tissues were immediately washed 5 times in ice-cold PBS and then prepared 
as per Figure 4.15. For each kidney and its collecting system a total of 4 kidney samples 
were snap frozen in liquid nitrogen and stored at -80 °C for RNA and protein analysis while 
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1 renal pelvis sample and 1 ureter sample were snap frozen in liquid nitrogen and stored at 
minus 80 °C for RNA analysis. Additionally, the middle axial section of the kidney including 
the proximal renal pelvis as well as the middle section of ureter were placed in 10% neutral 
buffered formalin at 4°C for 24 hours before paraffin embedding.  
 
Figure 4.15 Rat model sample preparation for storage and formalin fixation 
The kidney was cut into 5 sections as marked. The sample for IHC was immediately placed into 10% neutral 
buffered formalin at 4°C. The samples for subsequent protein and RNA extraction were snap frozen in liquid 
nitrogen and stored at -80 °C. The renal pelvis/ureter was cut into 3 sections as marked. The section of renal 
pelvis above the suture obstruction and the lower section of the ureter were snap frozen in liquid nitrogen and 
stored at -80°C for later RNA extraction. The middle section was placed into 10 % neutral buffered formalin 
at 4 °C. The site of the suture obstruction is marked in blue. 
 
 
4.2.6.3 Pressure measurement within the obstructed renal pelvis 
Following establishment of the surgical technique, including the specific wire diameter 
necessary to create the desired amount of hydronephrosis, efforts were turned to developing 
a method to measure the intra-renal pelvis pressure. Measurement of intra-renal pelvis 
pressure was conducted on all PUUO (0.4 mm wire template) and sham rats from litters 4-6 
during terminal anaesthesia. 
The equipment including a NeuroLog system amplifier (Digitimer, Hertfordshire, UK), a 
CED Micro 1401-3 data acquisition unit (Cambridge Electronic Design Limited, Cambridge, 
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UK) and Spike 2 software v7.10 (Cambridge Electronic Design Limited, Cambridge, UK) 
for data acquisition and analysis were kindly loaned for use by Dr A O’Carroll, University 
of Bristol. This was connected to a Digitimer fluid-filled disposable physiological pressure 
transducer (NL108T2, Digitimer, Hertfordshire, UK) which was placed at the level of the 
rats’ kidney during calibration and pressure measurements (Figure 4.16). The technique 
developed was based on that used by Dr O’Carroll’s group to measure arterial blood pressure 
via the femoral artery.  
During initial tests of the procedure, the lumen of the pressure transducer was filled with 
0.9% saline and connected via a 25G needle to Micro-Renathane® (MRE-025, Braintree 
Scientific, MA, USA) tubing which was then flushed through with 0.9% saline (Figure 4.16). 
The system was calibrated using a sphygmomanometer to pressures of 20 mmHg and 5 
mmHg. These figures were chosen on the basis of previously published results and thus the 
expected pressures to be recorded. Wen et al. demonstrated baseline mean intra-renal pelvis 
pressures to be 4, 9 and 17 cmH2O for young rats with non-obstructed kidneys, acute mild 
ureteric obstruction and acute severe ureteric obstruction respectively [401]. Similar baseline 
pressures in non-obstructed and partially obstructed systems have been recorded in other 
mammals including dogs, pigs and humans [46, 112-114]. 
To introduce the Micro-Renathane® tubing into the renal pelvis, the needle from a 16G 
cannula (393209, Becton Dickinson, Swindon, UK) was inserted through the renal capsule 
on the anterior surface of the kidney at the intersection of the sagittal and axial planes through 
the centre of the kidney. The needle was then advanced through the kidney parenchyma in a 
postero-medial direction into the renal pelvis (Figure 4.18 and Figure 4.17). The Micro-
Renathane® tubing was fed through the needle and continuous intra-renal pelvis pressure 
measurements recorded on the computer using Spike 2 software.  
The problems noted with this set up were twofold: 
1. The large size of the needle. Although this was the smallest gauge of needle that 
would accept the micro-renathane tubing it was huge compared to the size of the 
kidney. This made it difficult to guide the needle into the correct location without 
obliterating most of the structures. 
2. Increased pressure within the kidney forced small amounts of urine up the needle 




The solution was to use a smaller needle, inserted into the renal pelvis, to measure the 
pressure directly without threading Micro-Renathane® tubing through it. The next issue was 
how to connect the needle to the pressure transducer as this would require some intermediate 
tubing. This was solved by using a 27G butterfly needle which has integral tubing and a 
screw connector (387412, Becton Dickinson, Swindon, UK) which fits perfectly onto the 3-
way tap of the pressure transducer. The modified set-up is shown in Figure 4.19 and Figure 
4.20 and was flushed through with 0.9% saline and calibrated in the same way using a 
sphygmomanometer to pressures of 20 mmHg and 5 mmHg. The transducer was placed at 
the level of the kidney and prior to measurement of renal pelvis pressure the bladder was 
emptied by aspirating urine using a 25G needle. 
The 27G needle was inserted into the renal pelvis in the same manner as previously described 
(Figure 4.18), proving much easier to direct into the correct position (Figure 4.21) and was 
associated with minimal urine leakage. Continuous intra-renal pressure measurements were 
recorded on the laptop in mmHg using Spike 2 software. Baseline pressures were measured 
in both kidneys of sham and PUUO rats from litters 4-6 using this modified intra-renal pelvis 
pressure measuring set-up. Results were excluded from rats with leakage around the needle. 
 
Figure 4.16 Equipment set-up to measure intra-renal pelvis pressure 
The Digitimer fluid-filled physiological pressure transducer was attached to a 25G needle. One end of the 
Micro-Renathane tubing (0.025” OD) was applied over the 25G needle and the other end inserted through the 
needle from a 16G cannula. Signals from the pressure transducer were amplified, collated and analysed using 






Figure 4.17 Intra-renal pelvis pressure measurement using a 16G cannula and microrenathane tubing 
The Digitimer fluid-filled physiological pressure transducer was attached to a 25G needle. One end of the 
Micro-Renathane tubing (0.025” OD) was applied over the 25G needle and the other end inserted inside the 
needle from a 16G cannula. The transducer, 25G needle and Micro-Renathane tubing are all flushed through 
with 0.9% saline (A). The needle from a 16G cannula was inserted through the renal parenchyma as described 
in Figure 4.18 and the Micro-Renathane tubing advanced through the cannula enabling the tip of the tubing to 




Figure 4.18 Cartoon demonstrating needle insertion technique to measure intra renal pelvis pressure 
The needle was inserted through the renal capsule on the anterior surface of the kidney at the point which marks 
the intersection of the sagittal and axial planes through the centre of the kidney (A). The needle was directed 
through the kidney parenchyma in a posteromedial direction into the renal pelvis. C – renal cortex, M- renal 







Figure 4.19 Modified equipment set-up to measure intra-renal pelvis  
The digitimer fluid-filled physiological pressure transducer was attached directly to a 27G buttefly needle. 
Signals from the pressure transducer were amplified, collated and analysed using a NeuroLog system amplifier, 
a CED micro 3 data acquisition unit and a laptop employing Spike 2 software.  
 
Figure 4.20 Digitimer pressure transducer with attached 27G butterfly needle 
The integral tubing from the 27G butterfly needle (arrowhead) is attached directly to the digitimer fluid filled 





Figure 4.21 Intra renal pelvis pressure measurement with 27G butterfly needle 
The 27G butterfly needle was inserted through the renal parenchyma as described in Figure 4.18 and was used 
to measure the pressure directly. 
4.3 Discussion 
This chapter has described how a neonatal rat partial unilateral ureteric obstruction model 
was developed based on a procedure described by Thornhill et al. in 2005.  Initial work 
tested the feasibility of performing the procedure in neonatal rat pups and determined 
optimum surgical access for the procedure considering not only the field of vision and access 
to structures, but also post-operative recovery for the pup.  A left oblique flank incision was 
determined to be optimum and procedures performed on p3/4 culled pups revealed that 
Thornhill’s technique was achievable and did not result in complete obstruction of the ureter. 
This procedure was taken forward and applied to p2 pups under isoflurane anaesthesia who 
were subsequently recovered and returned to the litter.  Thornhill’s paper reported that 
decreasing wire diameter resulted in increasing severity of hydronephrosis and rising renal 
pelvis diameter proportional to the degree of obstruction at 14 days post PUUO.  Wire 
templates of 0.35 mm were reported to create moderate PUUO, while 0.3 mm and 0.25 mm 
templates resulted in severe PUUO. Interestingly, this group noted that the renal pelvis 
became maximally dilated by 28 days post PUUO with no significant difference between the 
3 sizes of wire template at this point. Wire templates of 0.6 mm were reported to create mild 
obstruction such that ureteric dilatation was not detected until 42 days post-operatively [91].  
Based on this evidence PUUO was created in the first litter using a 0.3 mm wire template. 
Rats were culled at 1 month to ensure maximal dilatation of the ureter and renal pelvis was 
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achieved in order to test the adequacy of the template diameter chosen. At 31 days all 3 rats 
with left PUUO had severe hydronephrosis with extremely dilated urine filled left kidneys 
and severe renal atrophy such that there was little renal tissue apparent. All had normal 
contralateral right kidneys. This degree of hydronephrosis was too severe for the purposes 
of the study as some renal tissue was required for analysis. Additionally, this degree of 
hydronephrosis was greater than that reported by Thornhill et al. This could potentially be 
due to differences in tolerance between the wire templates used as they were sourced from 
different manufacturers.  
A second litter therefore underwent PUUO using a 0.6 mm wire template. At 37 days of age 
these rats did not show any evidence of hydronephrosis with no significant difference noted 
between the ureteric and renal pelvis diameters of PUUO and sham rats. This remained the 
case at 100 days of age and therefore a further litter was operated on using a 0.4 mm wire 
template. This litter of 6 operated males demonstrated variable hydronephrosis at 35 days of 
age. Two rats demonstrated mild hydronephrosis, 1 moderate hydronephrosis and 3 severe 
hydronephrosis compared to normal contralateral kidneys. These results are obviously very 
different from those presented by Thornhill et al. who reported reproducible degrees of 
obstruction with specific wire diameters [91]. There are a number of reasons why this model 
may have achieved variable hydronephrosis while using a constant wire template diameter 
and these include: 
• Natural variation in ureter size as compared to a fixed wire template size thus 
constricting the ureter by different proportions 
• Individual renal/urothelial factors which modulate the response of the kidney and its 
collecting system to a fixed degree of obstruction. The degree of dilatation may be 
affected by the compliance of the ureter and renal pelvis as well as other potentially 
compensatory mechanisms to reduce pressure within the kidney such as reduced 
urine production and increased urine re-absorption by the venous and lymphatic 
systems [88, 117, 121]. Furthermore, the individual ability of a kidney to reduce 
pressure may predict renal insult progression and necessity for surgery in human 
PUJO. This research will start to investigate the role of kidney and urothelial 
aquaporin expression in such a renoprotective pressure reduction mechanism  
• Technical issues with the procedure such as differing tension when tying the ligature 
around the ureter and wire template, or post-operative adhesions kinking the ureter. 
These problems had been anticipated and to minimise these the procedure was 
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performed by a single operator taking care in the method used to tie the ligature with 
equal tension for all operations. Attention was paid to ensuring the ureter was 
returned to the anatomical position within the abdomen to reduce the risk of kinking. 
Additionally, manoeuvres were undertaken involving injecting either bromophenol 
blue dye or 0.9% saline into the renal pelvis at completion of the study to ensure that 
a complete obstruction had not been created  
Despite the fact that this method did not reproduce exactly what had been reported, the 
decision was made to continue the neonatal rat PUUO model using a 0.4 mm wire template 
as this was generating precisely what was required, differing severities of hydronephrosis 
which could be used to assess aquaporin expression and excretion. 
Post-operative complications were noted affecting pups from the first 2 litters, however, 
there were no complications affecting the final 4 litters suggesting there was technical 
improvement as the research progressed.  
One pup suffered a post-operative wound dehiscence related to the mother removing the skin 
sutures shortly after the procedure. This issue was rectified by amending the method of skin 
closure and burying the absorbable sutures. Subsequently there were no wound 
complications. The placement of surgical skin clips was considered as an alternative, 
however, these would need to be removed a few days post-operatively causing further 
distress to the pups. Vicryl sutures are absorbable and therefore do not require removal.  
Two pups were cannibalised by the mother. A female pup who had undergone creation of 
PUUO using a 0.3 mm wire template was eaten by the mother shortly after surgery. It is 
unknown whether this pup had died as a complication of the surgery or whether it was 
maternal infanticide due to interference with the litter. Skin glue had been trialled for wound 
closure on this pup which may have rendered the pup with an unusual smell noticed by the 
mother. Skin glue was not used again for any future pups. A male pup from litter 2 who had 
undergone PUUO with a 0.6 mm wire template was also eaten by the mother at p5 for reasons 
which are unknown. There was no indication that this pup was unwell, and it had been 
gaining weight at a comparable rate to its littermates. 
A female pup from litter 1 who had undergone left PUUO with a 0.3 mm wire template died 
suddenly at 26 days of age. A post-mortem performed by Dr J Roe, named veterinary 
surgeon, did not identify any evidence of chronic ill health or a cause of death. 
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At the end of the study protocol bilateral nephrouretectomy was performed and the rats were 
culled by terminal isoflurane anaesthesia. Additionally, litters 4-6 underwent basal intra-
renal pelvis pressure measurement while still under surgical anaesthesia. This procedure 
utilized a fluid-filled pressure transducer and was based on a technique used by Dr 
O’Carrolls group, University of Bristol to measure arterial blood pressure via the femoral 
artery. This method was modified to enable simultaneous puncture of the kidney and renal 
pelvis pressure measurement with the same equipment, namely, a 27G butterfly needle 
which could be conveniently connected to the pressure transducer using the integral tubing 
and screw connector. The needle was inserted through the kidney parenchyma into the renal 
pelvis rather than into the pelvis directly to reduce the incidence of leakage around the needle 
which would compromise the results. This technique was utilised to measure intra-renal 
pelvis pressure in litters 4-6 and the results are presented in Chapter 5.  
Basal intra-renal pelvis pressure measurement during the current study indicated the pressure 
the obstructed kidney was exposed to under physiological conditions in each rat. The 
relationship between intra-renal pelvis pressure and AQP expression and excretion was then 
analysed. It is acknowledged, however, that basal pressure measurement at a single time 
point within the obstructed kidney is affected by variables such as the velocity of urine flow, 
compliance of the system, the degree of obstruction and intra-abdominal pressure [406]. 
Although variation in intra-abdominal pressure was not a concern in the current study as 
measurements were made with abdomen open, the variable rate of urine inflow into the renal 
pelvis between individuals would modify intra-renal pelvis pressure. Urine production is 
influenced by GFR and tubular reabsorption of water and solutes, both of which are reduced 
in PUUO [91, 185]. To overcome this issue, fluid inflow can be standardised between 
individuals using a dynamic perfusion-pressure test (Whitaker technique). Using a single 
cannula, intra-renal pelvis pressure is measured while fluid is infused into the renal pelvis at 
a standard fast flow rate [406]. For future studies, further development of the intra-renal 
pelvis pressure measurement technique to include fluid perfusion will enable measurement 
of both basal and dynamic perfusion-pressure.  
In summary, based on methods described by other groups, techniques were established to 
perform neonatal rat recoverable anaesthesia, to create neonatal rat partial UUO, and to 
measure intra-renal pelvis pressure in normal and hydronephrotic kidneys in young rats. 
These techniques were applied to further litters of rat pups in order to meet the aims and 





Various AQP isoforms are expressed by rat kidney and urothelium and are excreted into the 
urine within exosomes. Dysregulation of renal AQP expression has been demonstrated in 
both adult and neonatal models of obstructive hydronephrosis and is associated with defects 
of tubular solute and water handling [185]. Little is known regarding the effects of 
obstruction on urothelial AQP expression.  
Following 24 hours of adult rat complete UUO, downregulation of AQPs 1, 2, 3, 4 and 
phosphorylated AQP2 expression is noted at the protein level and is associated with 
increased free water clearance [184, 186]. AQP2 mRNA expression is also downregulated 
indicating these changes may be transcriptionally regulated [186]. Concomitant 
downregulation of AQPs 1 and 2 in the contralateral kidney of this UUO model suggests 
both intrarenal and systemic factors are involved in AQP dysregulation [184, 186].  
Similarly, 24 hours of complete bilateral ureteric obstruction (BUO) in adult rats is 
associated with reduced renal AQP1, 2 and 3 protein expression, polyuria and diminished 
urinary concentrating ability [188, 189]. AQP2 and 3 expression remains reduced at 14 days 
following release of BUO but normalises by 30 days. Conversely AQP1 expression remains 
downregulated at 30 days following release of BUO at which time rats continue to exhibit 
significant polyuria and a urinary concentrating defect in response to thirst [189].   
Although informative, these models do not mimic the situation in congenital PUJO, which 
is better appraised by neonatal rat models involving chronic partial UUO. These models 
suggest the response to obstruction in PUJO may be more complicated than indicated by 
adult acute UUO models, being age and/or time dependent. An initial increase in AQP1, 2 
and 3 protein expression in the obstructed kidney at 7 weeks post PUUO is followed by a 
reduction in expression of AQP1 and 2 expression and a normalisation of AQP3 expression 
compared to sham at 14 weeks post PUUO. The early increase in AQP expression points to 
possible compensatory mechanisms while the subsequent downregulation likely represents 
tubular dysfunction related to chronic obstruction. Interestingly, the amount of 
phosphorylated AQP2 (pS256-AQP 2) at both time points is reduced compared to both the 
Chapter 5. Aquaporin expression and urinary excretion in a       
neonatal rat partial unilateral ureteric obstruction model 
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contralateral and sham kidneys implying AQP2 translocation to the apical membrane is 
diminished despite variations in the total expression of AQP2 protein [364]. Furthermore 
AQP2 protein expression remains downregulated at 24 weeks post-PUUO compared to the 
contralateral non-obstructed kidney which corresponds to a significant reduction in the GFR 
and solute free water reabsorption by the obstructed kidney at 12 and 24 weeks post PUUO 
[185].   
AQP1, 2 and 3 proteins are also expressed by rat bladder and ureter. AQPs 2 and 3 are 
expressed by urothelial cells while AQP1 is located to the vascular endothelial cells of the 
blood vessels [249, 367, 368]. Regulation of urothelial AQPs has been noted with AQP2 and 
3 expression being significantly upregulated by dehydration and downregulated by lack of 
oestrogen in ovariectomised female rats [249, 250]. There are very few studies that have 
investigated urothelial AQP expression in response to urinary tract obstruction. Partial 
bladder outlet obstruction in rats results in a significant upregulation of AQP1 expression in 
the capillaries, arterioles and venules of bladder tissue [367], while AQP2 and 3 expression 
is increased in the bladder urothelial cells [368]. It is postulated that this heightened AQP 
expression may contribute to the bladder dysfunction that characterises partial bladder outlet 
obstruction. There are no studies assessing AQP expression in the ureter or renal pelvis in 
response to urinary tract obstruction. 
AQPs 1 and 2 are detected in rat urine in amounts that generally correspond to the level of 
renal expression [372, 381, 383]. Conversely AQP3 is not detected in urine [372]. Urinary 
exosomal AQP excretion likely occurs via a selective apical pathway whereby factors which 
change apical cell membrane AQP expression lead to altered excretion. Acetazolamide 
treatment of rats leads to upregulation of proximal tubular apical cell membrane AQP1 
expression and is associated with increased urinary AQP1 excretion [382]. Similarly, in the 
basal state approximately 3-4% of total kidney AQP2 is excreted in the urine on a daily basis 
[372, 383], however, excretion is regulated by vasopressin and in states of significant 
vasopressin flux AQP2 excretion mirrors apical cell membrane expression (also vasopressin 
mediated) rather than total kidney abundance [371, 384, 385].  
As a proxy of renal AQP expression, urinary AQP measurement has many research and 
potentially clinical applications, particularly given the non-invasive nature of the test. 
Reduced urinary excretion of AQPs 1 and 2 by the obstructed kidney has been demonstrated 
in the post-operative period following pyeloplasty for human PUJO [365, 386], however 
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there are no pre-operative studies in either humans or rodents to identify whether AQPs 
would be a useful biomarker of the severity of disease and the necessity of surgery for PUJO.  
This chapter presents all data obtained after implementation of the neonatal PUUO model 
and delineates urinary tract AQP expression and urinary excretion in this model. 
 
5.2 Methods 
5.2.1 Study protocol 
Male Han-Wistar p2 pups (24-48 hours of age) weighing 5.4g – 8.9g underwent creation of 
left PUUO (n=13) using a 0.4 mm wire template or left sham procedure (n=6) as outlined in 
Chapter 4. Sham and PUUO animals were derived from five litters of rats (denoted litters 2-
6). Seven non-operated female rats from litter 5 underwent bilateral intra-renal pelvis 
pressure measurement under terminal anaesthesia at 35 days of age to establish normal intra-
renal pelvis pressure. No tissue or urine samples were collected from these female animals.  
A significant difference in urinary AQP1/creatinine excretion between males (mean +/- SEM 
0.35 +/- 0.01 μg/mg) and females (mean +/- SEM 0.17 +/- 0.017 μg/mg) on an initial test of 
the urinary AQP1 ELISA necessitated the use of only male animals for the study (Figure 
5.1). The urine used in this ELISA was obtained from rats who had undergone either left 
PUUO using a 0.6 mm wire template or sham procedure and none of the rats had 
hydronephrosis (discussed in Chapter 4). As expected, no significant difference was noted 





Figure 5.1 Urine AQP1 in male versus female rats 
Vertical scatter plot demonstrating urine AQP1 levels normalised to creatinine for male (1 x sham, 1 x left 
PUUO 0.6 mm wire) compared to female (1 x sham, 2 x left PUUO 0.6mm wire) rats. *p=0.0045 compared to 
females. Individual data points and mean +/- SEM presented. 
 
Following the PUUO or sham procedure pups were housed with their mother and the rest of 
the litter in standard conditions until three weeks of age when they were weaned and 
separated into male and female groups. Rats were weighed on a weekly basis and a spot 
urine sample was obtained at 2 and 3 weeks of age. These samples were stored at -80 °C but 
thus far have not been analysed due to their small volume which is unsuitable for the AQP1 
ELISA. A larger urine sample was obtained at 4 weeks of age by placing the rat in a 
metabolic cage for up to 5 hours. These samples were used to determine AQP1/creatinine 
excretion during the study.    
At 5 weeks (35 days) of age all rats except one underwent terminal anaesthesia, measurement 
of intra-renal pelvis pressure (litters 4-6 only) and retrieval of kidney, renal pelvis and 
ureteric tissues (PUUO n= 12, sham n=6). Kidney and renal pelvis samples were processed 
for later mRNA and protein analysis. Individual wet kidney weights were recorded in 
accordance with previous data supporting their good approximation to dry weights and renal 
growth in rats [93, 129]. Where possible paired left renal pelvis and bladder urine specimens 
were also obtained although these have not been analysed during this study due to time 
constraints. A timeline of the neonatal rat partial unilateral ureteric obstruction model is 
presented in Figure 5.2. One PUUO rat was followed up to 86 days and then underwent 
terminal anaesthesia, intra-renal pelvis pressure measurement and tissue collection. The 
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renal tissue was used for protein expression analysis by western blotting only. This was to 
gain a preliminary insight of how a longer period of PUUO might impact on the urinary tract 
and thus direct future studies. 
 
Figure 5.2 Timeline of neonatal rat partial unilateral ureteric obstruction model 
 
5.2.2 Immunohistochemistry 
Immunohistochemistry for AQP3 expression by whole renal pelvis obtained from 35-day 
old PUUO and sham rats was performed as a mass batch to reduce the risk of technical error 
between biological replicates. Unfortunately, the initial round of staining was unsuccessful 
as confirmed by lack of expected staining in the positive control sections. Due to time 
constraints, investigation into this problem was continued by a colleague within the renal 
group (Miss Fern Barrington). The primary antibody, which was from a new batch, was 
identified as being the likely cause. A new AQP3 antibody was sourced from an alternative 
manufacturer, the antibody dilution optimised, and the method performed as described in the 
methods section (Chapter 2, section 2.13). The immunohistochemistry and imaging for 
AQP3 using the new antibody was undertaken as a mass batch by Miss Fern Barrington. 
Blinded grading of AQP3 staining of all sections from PUUO and sham rats was undertaken 
by Professor Richard Coward and Miss Fern Barrington as detailed in the methods section 
(Chapter 2, section 2.16.1.3).  
5.2.3 Statistics 
Data is presented as mean +/- SEM. Any data group containing only one animal was not 
included in statistical analyses. Statistical analysis of real time RT-PCR results was 
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undertaken on the ΔCt values and the relative fold change calculated for graphical 
representation. Comparison of two groups was performed using an unpaired two tailed t-test 
while multiple groups (>2) comparisons were assessed using a one-way analysis of variance 
(ANOVA) with Tukey post-test correction. Repeated measures of multiple groups were 
analysed using a two-way ANOVA with Bonferroni post-test correction. Correlation of 
results was assessed using an XY scatter plot and Pearsons correlation test. P<0.05 was 
accepted as statistical significance.  
 
5.3 Results 
5.3.1 Body weight is reduced in PUUO rats compared to sham rats  
Rat body weight was consistent between PUUO rats and sham rats from the time of surgery 
until 4 weeks of age. At 5 weeks of age, however, rats who had undergone left PUUO had a 
significantly reduced body weight compared to those treated by sham procedure (Figure 5.3). 
 
Figure 5.3 Mean weight of PUUO rats versus sham rats 
Bar graph demonstrating weekly post-operative mean weights +/- SEM presented for all rats who underwent 
PUUO versus sham procedure.  Left PUUO n=13, left sham procedure n=6. PUUO rats were significantly 
lighter than sham rats at 5 weeks of age. *p<0.05 compared to sham  
 
5.3.2 Stratification of PUUO rats according to severity of hydronephrosis  
All rats in this study had undergone PUUO using a fixed wire template size of 0.4 mm. It 
was known however from preliminary studies that this would generate variable degrees of 
hydronephrosis. Bilateral renal pelvis APD and proximal ureter diameters were therefore 
measured at the time of terminal anaesthesia in all animals prior to intra-renal pelvis pressure 
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measurement and tissue retrieval. The renal pelvis measurements alongside the degree of 
preservation of the renal parenchyma were then used to stratify rats arbitrarily into groups 
denoting the severity of hydronephrosis.  Rats with a left renal pelvis APD ≥ 1.8 mm were 
designated to have mild hydronephrosis. Those with a left APD ≥ 3 mm, with or without 
mild to moderate parenchymal thinning, were assigned to the moderate hydronephrosis 
group. Rats with a left renal pelvis APD ≥ 3 mm and substantial parenchymal thinning were 
classified as severely hydronephrotic. The stratification of the PUUO rats into groups is 
presented in Table 5.1.   
The bar graphs in Figure 5.4 show the mean renal pelvis APDs and proximal ureter diameters 
for sham rats and each severity of hydronephrosis alongside corresponding values for the 
normal contralateral kidneys. The mean renal pelvis APD and proximal ureter diameter were 
significantly larger in the severely hydronephrotic kidneys (renal pelvis 6.36mm +/- 0.56, 
ureter 2.3mm +/- 0.24) compared to sham (renal pelvis 1.2 +/- 0.09, ureter 0.76 +/- 0.04), 
mildly (renal pelvis 2.21 +/- 0.20, ureter 1.18 +/- 0.04) and moderately (renal pelvis 3.99 +/- 
0.52, ureter 1.78 +/- 0.13) hydronephrotic kidneys. Similarly, the mean renal pelvis APD 
and proximal ureter diameter were significantly increased in the moderately hydronephrotic 
kidneys compared to sham and mild hydronephrosis but significantly smaller compared to 
severe hydronephrosis. Although the mean renal pelvis APD and proximal ureter diameter 
for the mildly hydronephrotic group were not statistically different to those of sham animals 
these kidneys were visibly different at the time of terminal anesthesia and the measurements 
show a trend towards significance which would almost certainly be achieved with larger 
































1 Mild 1.91 1.13 1.13 0.64 None 
2 Mild 2.6 1.49 1.16 0.76 None 
3 Mild 2.12 1.25 1.25 0.82 None 
4 Moderate 5.98 1.04 1.69 0.66 Mild 
5 Moderate 3.7 1.4 1.83 1.06 None 
6 Moderate 3.98 1.22 1.71 0.89 None 
7 Moderate 3.3 1.4 1.43 0.77 Mild 
8 Moderate 3 1.39 2.22 0.82 None 
9 Severe 6.55 1.01 2.14 0.61 Substantial 
10 Severe 6.91 1.17 2.05 0.7 Substantial 
11 Severe 7.23 1.33 2 0.86 Substantial 
12 Severe 4.73 1.12 3.01 0.81 Substantial 
13 Sham 1.18 1.02 0.82 0.86 None 
14 Sham 0.9 1 0.6 0.7 None 
15 Sham 1.4 1.46 0.81 0.82 None 
16 Sham 1.03 1.31 0.73 0.82 None 
17 Sham 1.33 1.44 0.84 1 None 
18 Sham 1.43 1.2 0.77 0.78 None 
 
Table 5.1 Outcome of PUUO created with a 0.4 mm wire template versus sham rats 
Table detailing the renal pelvis and ureter dimensions at 35 days of age for 18 rat pups who underwent either 
left PUUO using a 0.4 mm wire template or sham procedure. The presence of parenchymal thinning is also 
noted. PUUO rats are stratified into three groups according to the severity of hydronephrosis. 




Figure 5.4 Renal pelvis and proximal ureter dimensions of PUUO and sham rats 
Bar graph comparing renal pelvis APD (mean +/- SEM) between PUUO rats with varying degrees of 
hydronephrosis and sham rats (A). Bar graph comparing proximal ureter diameter (mean +/- SEM) between 
PUUO with varying degrees of hydronephrosis and sham rats. *p<0.05 compared to sham, mild and severe 
hydronephrosis. #p<0.05 compared to sham, mild and moderate hydronephrosis. Sham n=6, mild 
hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4. Black bars - left 
obstructed/sham kidney, white bars – right contralateral kidney. 
 
5.3.3 The individual wet weight of the obstructed kidney is unchanged 
compared to the sham kidney 
Following retrieval of the renal tract tissues under terminal anaesthesia at 35 days of age the 
kidneys were dissected from the renal pelvis and ureter and separately weighed. No 
significant difference in mean wet kidney weight was revealed between each degree of 
hydronephrosis when compared to each other, sham, contralateral sham and contralateral 









Group Mean kidney weight (g) +/- SEM 
Sham  0.65 +/- 0.03 
Contralateral sham 0.71 +/- 0.04 
Mild hydronephrosis 0.56 +/- 0.03 
Contralateral mild hydronephrosis 0.59 +/- 0.02 
Moderate hydronephrosis 0.63 +/- 0.03 
Contralateral moderate hydronephrosis 0.68 +/- 0.03 
Severe hydronephrosis 0.64 +/- 0.08 
Contralateral severe hydronephrosis 0.73 +/- 0.05 
 
Table 5.2 Mean kidney weights of left PUUO rats  








Figure 5.5 Mean kidney weights of left PUUO rats compared to controls 
Bar graph demonstrating mean wet kidney weights +/- SEM at 35 days of age for all rats who underwent left 
PUUO versus sham procedure and are stratified according to the severity of hydronephrosis. Sham n=6, mild 
hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4. No significant difference was 




5.3.4 Intra-renal pelvis pressure is increased in moderate hydronephrosis 
Intra-renal pelvis pressure measurements at 35 days of age were only undertaken on PUUO 
and sham rats from litters 4-6 as the technique had not been fully developed when earlier 
litters reached the end of the protocol. Seven additional age-matched female non-operated 
rats from litter 5 also underwent intra-renal pelvis pressure measurement to determine 
normal renal pressure using this method.  Eight intra-renal pelvis pressure readings were 
excluded from the study (2 contralateral moderate hydronephrosis, 1 contralateral severe 
hydronephrosis, 1 contralateral sham and 4 female non-operated kidneys) due to either 
failure to site the needle in the renal pelvis or because of urine leakage around the needle.  
Figure 5.6 shows representative intra-renal pelvis pressure traces obtained for 
hydronephrotic, sham and contralateral kidneys. The traces demonstrate increased pressure, 
to varying degrees, following insertion of the pressure measuring needle into the renal pelvis. 
When results for all kidneys were analysed the intra-renal pelvis pressure was observed to 
be significantly elevated in moderately hydronephrotic kidneys (8.299 mmHg +/- 2.920) 
compared to sham (0.5011 mmHg +/- 0.1494), contralateral sham and PUUO (1.511 +/- 
0.2871) and non-operated (1.518 mmHg +/- 0.1801) kidneys.  The mild and severely 
hydronephrotic kidney groups contained only a single kidney each and therefore were 
excluded from statistical analysis. The pressure measured in the mildly hydronephrotic 
kidney (0.4 mmHg) fell within the range of sham, contralateral and non-operated kidneys 
whereas the severely hydronephrotic kidney pressure was slightly above their range at 2.973 
mmHg. Substantial variability of the pressure measurements in the moderately 





Figure 5.6 Intra-renal pelvis pressure traces for hydronephrotic, sham and contralateral kidneys 
Representative pressure traces generated by Spike 2 software for a moderately hydronephrotic kidney (A), a 
sham kidney (B) and a contralateral sham kidney (C). Arrow indicates time at which the pressure measuring 





Figure 5.7 Intra-renal pelvis pressure measurements of PUUO rats compared to sham and non-
operated rats 
Vertical scatter plot demonstrating the intra-renal pelvis pressure measurements (mean +/- SEM) of the left 
PUUO kidney with mild (n=1), moderate (n=4) and severe (n=1) hydronephrosis compared to left sham (n=4) 
and contralateral sham /PUUO kidneys (n=6). Right and left kidney intra-renal pelvis pressure measurements 
from non-operated female rats (n=10) are also included. *p<0.05 compared to sham, contralateral sham/PUUO 
and non-operated rats.  
The individual intra-renal pelvis pressure measurements for each degree of hydronephrosis 
are presented in Table 5.3 alongside the corresponding renal pelvis APD and proximal ureter 
diameters. Consistent with the large variability in intra-renal pelvis pressures noted in the 
moderately hydronephrotic group, the scatter plot shown in Figure 5.8 using the data from 
Table 5.3 demonstrates that for all degrees of hydronephrosis there is no correlation between 
the renal pelvis APD and the intra-renal pelvis pressure (R2 = 0.01898, Pearsons correlation 


























3 Mild 2.12 1.25 None 0.4 
5 Moderate 3.7 1.83 None 16.38 
6 Moderate 3.98 1.71 None 2.42 
7 Moderate 3.3 1.43 Mild 7.12 
8 Moderate 3 2.22 None 7.27 
12 Severe 4.73 3.01 Substantial 2.97 
 
Table 5.3 Renal pelvis APD and intra-renal pelvis pressure in PUUO rats 
The left renal pelvis and proximal ureter dimensions are presented alongside the intra-renal pelvis pressure 
measurements for PUUO rats with mild, moderate and severe hydronephrosis.  
 
 
Figure 5.8 Scatter plot demonstrating renal pelvis APD and intra-renal pelvis pressure in PUUO rats 
Scatter plot of renal pelvis APD versus intra-renal pelvis pressure for PUUO rats with mild, moderate and 












5.3.5 Reduced numbers of glomeruli and increased renal fibrosis are noted 
in severe hydronephrosis 
Severely hydronephrotic kidneys in PUUO rats at 35 days of age demonstrated a reduction 
in the number of glomeruli to 39% of sham kidneys.  Mild and moderately hydronephrotic 
kidneys, as well as kidneys contralateral to PUUO, did not show any abnormality in 
glomerular number (Figure 5.9).   
 
Figure 5.9 Mean number of glomeruli per field of view for PUUO and sham kidney sections 
Bar graph demonstrating mean number of glomeruli +/- SEM at 35 days of age for all rats who underwent 
PUUO versus sham procedure.  Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe 
hydronephrosis n=4. *p<0.05 compared to left sham and left mild hydronephrosis, #p<0.05 compared to left 
severe hydronephrosis 
 
Figure 5.10 shows representative images following Masson’s trichrome staining of the renal 
cortex, outer medulla and inner medulla of sham and PUUO kidneys at 35 days of age. 
Severely hydronephrotic PUUO kidneys demonstrated a significant increase in interstitial 
collagen deposition compared to sham and contralateral kidneys. There was no evidence of 
increased fibrosis affecting the mild or moderately hydronephrotic PUUO kidneys (Figure 
5.11).    
Additionally, severely hydronephrotic PUUO kidneys show other parenchymal architectural 
abnormalities compared to mildly and moderately hydronephrotic kidneys including tubular 
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dilatation and abnormal glomeruli with ill-defined Bowmans capsules and shrunken 
capillary loops (Figure 5.12).    
 
Figure 5.10 Masson’s Trichrome of PUUO versus sham rat kidneys  
Representative images of left kidney sections from PUUO rats with mild, moderate and severe hydronephrosis 
alongside left kidney sections from sham rats. Images from the renal cortex, outer and inner medulla are 
presented. Masson’s trichrome renders the cytoplasm red and areas of collagen/fibrosis blue. Nuclei are stained 




Figure 5.11 Relative interstitial fibrosis affecting PUUO compared to sham rats 
Bar graph presenting mean deposition of interstitial collagen +/- SEM at age 35 days for all rats who underwent 
PUUO versus sham procedure. Left PUUO n=12, left sham procedure n=6. *p<0.05 compared to all other 
groups. Hydro – hydronephrosis. 
 
 
Figure 5.12 Renal histological abnormalities noted in severe hydronephrosis  
An image of rat renal cortex in the presence of severe hydronephrosis following PUUO. Masson’s Trichrome 
staining renders the cytoplasm red, collagen/fibrosis blue and the nuclei black. The glomeruli are abnormal 
with an ill-defined Bowmans capsule and shrunken capillary loops (arrowheads). The tubules are abnormally 




5.3.6 Renal aquaporin mRNA expression is reduced in severe 
hydronephrosis 
Endpoint RT-PCR was performed to determine which AQPs are expressed at the mRNA 
level by normal rat kidney. Figure 5.13 shows that whole rat kidney expresses mRNA 
transcripts for AQPs 1, 2, 3, 4, 5, 6, 7, 8, 9 and 11. AQPs 0 and 12 are not expressed at the 
mRNA level. A double band for AQP8 was initially noted (Figure 5.13B) and therefore these 
primers were discarded. Following redesign of the primers AQP8 mRNA expression in the 
rat kidney was confirmed (Figure 5.13C). It was not possible to conclude whether AQP4 
was expressed at the mRNA level in the rat kidney from this endpoint PCR as on two 
occasions a band was noted in the AQP4 RT negative sample indicating sample 
contamination with genomic DNA (Figure 5.13A and B). The band in the RT negative lane 
was confirmed as AQP4 by sequencing (as discussed in Chapter 3, section 3.3.2.2). New 
primers were obtained from a paper by Nicaise et al. [391] and subsequent real-time PCR 
confirmed AQP4 is expressed at the mRNA level by rat kidney (Figure 5.14).  
Initial real time RT-PCR of whole kidney from PUUO rats compared to sham demonstrated 
that β-actin is not regulated in this PUUO model at the mRNA level and therefore was 
suitable to be used as a reference gene to normalize results (Figure 5.14F). Subsequent real 
time RT-PCR studies were conducted to assess renal mRNA expression of AQPs 1-4 and 6 
at 35 days of age by rats from the PUUO model. Across all AQP isoforms assessed there 
was no difference in renal mRNA expression in mild or moderate hydronephrosis compared 
to sham or contralateral kidneys. It was established that AQP1 and 2 mRNA expression was 
significantly downregulated in severely hydronephrotic kidneys compared to sham (0.7 fold 
and 0.8 fold reduction respectively), mild and moderate hydronephrosis, and all contralateral 
kidney groups (Figure 5.14A and B).   
No significant difference was noted in AQP3 mRNA expression between any degree of 
hydronephrosis and sham kidneys (Figure 5.14C). 
AQP4 mRNA expression was significantly downregulated in severe hydronephrosis 
compared to the contralateral intact kidneys from rats with mild and moderate 
hydronephrosis. However AQP4 expression in severe hydronephrosis was 0.5 fold lower, 
but not statistically significantly different to sham kidneys. This finding could be due to the 





Figure 5.13 Endpoint PCR demonstrating the AQP isoforms expressed by rat whole kidney 
RT-PCR was performed using mRNA extracted from whole normal rat kidney and the product run on 2% 
agarose gels. Bands of the appropriate size for AQP isoforms 1, 2, 3, 5, 6, 7, 9 and 11 and β-actin were noted 
indicating they are expressed at the mRNA level by whole rat kidney. See appendix 2 (section 10.2.1) for 
product sizes. A band in the AQP4 RT negative sample on 2 occasions indicated sample contamination with 
genomic DNA. The AQP8 primers revealed a double band and therefore were discarded (A and B). RT-PCR 
was performed using whole rat eye as a positive control for the AQP0 primers. RT-PCR using whole rat kidney 
and new AQP8 primers confirmed AQP 8 is expressed by rat kidney (C).  PCR was performed using rat kidney 






Figure 5.14 Renal AQP isoform mRNA expression by PUUO rats compared to sham rats 
Relative fold change of AQP isoform expression normalized to β-actin in whole rat kidney is presented for 
PUUO rats compared to sham rats at 35 days of age. Coloured bars = left sham/obstructed kidney, white bars 
= contralateral kidney. Mean +/- SEM presented. AQP1 mRNA expression *p<0.05 compared to all other 
199 
 
groups (A). AQP2 mRNA expression *p<0.05 compared to all other groups (B). AQP3 mRNA expression 
demonstrated no significant differences between groups (C). AQP4 mRNA expression *p<0.05 compared to 
contralateral mild and contralateral moderate hydro groups (D). AQP6 mRNA expression *p<0.05 compared 
to all other groups except contralateral severe hydro (E). β-actin mRNA expression demonstrated no significant 
differences between groups (F). Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe 
hydronephrosis n=4. 
 
AQP6 mRNA expression was significantly downregulated in severe hydronephrosis 
compared to sham (0.6 fold reduction), mild and moderate hydronephrosis. Expression was 
not significantly different between the severely hydronephrotic kidney and its corresponding 
contralateral. However AQP6 mRNA expression was significantly reduced compared to all 
other contralateral kidney groups (Figure 5.14E).  
In severe hydronephrosis across all AQP isoforms the intact contralateral kidney did not 
show any upregulation of AQP expression suggesting there was no attempt to compensate 
for the obstructed kidney. 
   
5.3.7 Renal aquaporin and housekeeping gene protein expression 
5.3.7.1 Β-actin protein expression is regulated in PUUO rats 
Initial western blotting using cy5 labelled protein lysate demonstrated that β-actin 
expression, when normalised to total protein loading, was significantly downregulated in the 
left obstructed kidney from PUUO rats (mean OD +/- SEM: 14280 +/- 1275) compared to 
non-operated rats (19710 +/- 1203), however expression was not significantly different to 
sham rats (16170 +/- 416.7) (Figure 5.15 A and C). Although a reduction in expression of 
GAPDH by the left obstructed kidney in PUUO (12300 +/- 1643) compared to non-operated 
rats (15990 +/- 52.14) was noted, this was not statistically significant. Again, there was no 
significant difference in expression between PUUO and sham rats (13960 +/- 72.32), which 
is the main comparator used in the PUUO study (Figure 5.15 B and D). GAPDH was 






Figure 5.15 Regulation of reference proteins in PUUO 
Western blots using fluorescently labelled antibodies and fluorescently labelled left total kidney protein from 
PUUO, sham and non-operated rats at 35 days of age.  β-actin (42 kDa) and total protein (A). GAPDH (37 
kDa) and total protein (B). Bar graph demonstrating β-actin (A) and GAPDH (B) expression normalised to 
total protein by whole rat left kidney in PUUO rats compared to sham and non-operated rats at 35 days of age. 
*p<0.05 compared to non-operated rats. PUUO n=7 (2 x mild, 2 x moderate, 3 x severe), sham n=2 and non-
operated n=4. L = ladder. 
 
 
5.3.7.2 AQP1 protein is expressed by the cortex and medulla of rat kidney 
Immunohistochemistry of whole rat kidney confirmed that AQP1 protein was expressed both 
by the renal cortex and medulla. Within the renal cortex AQP1 was expressed by the luminal 
and basolateral membranes of the proximal tubules (Figure 5.16A) while in the medulla it 




Figure 5.16 Immunohistochemistry demonstrating rat kidney AQP1 expression 
AQP1 expression is demonstrated in the apical and basolateral membranes of the proximal tubules (arrow) 
within the kidney cortex (A), while AQP1 expression in the loop of Henle (arrow) and vasa recta (arrowhead) 
but not within collecting ducts is seen in the kidney medulla (B). Negative controls (no primary antibody) 
demonstrated an absence of staining (C, D).  Scale bar = 25 μm. 
 
 
5.3.7.3 Renal AQP1 protein expression is unchanged in obstructive 
hydronephrosis compared to sham  
Western blotting and subsequent densitometry was utilised to semi-quantitatively analyse 
changes in AQP1 expression resulting from neonatal rat PUUO. Kidney protein lysate from 
litters 2-3 and 4-6 was extracted and assessed by western blot in two separate batches which 
unfortunately seemed to generate disparate results. This may have been due to the protein 
extraction methods employed which will be addressed in the discussion. Consequently, for 
AQP1 and all other AQP isoforms, the results for each batch processed are presented 
individually and then combined. 
Analysis of left (obstructed) and right (contralateral) whole kidney protein lysate from 
PUUO and sham rats from litters 2 and 3 at 35 days of age was undertaken. Inspection of 
the western blots revealed very clearly that both non-glycosylated and glycosylated AQP1 
were downregulated in severe hydronephrosis compared to both the contralateral kidney and 
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sham kidneys. This observation was borne out by subsequent semi-quantitative analysis 
using densitometry whereby expression of non-glycosylated and glycosylated AQP1 were 
statistically significantly reduced in severe hydronephrosis (non-glycosylated mean OD +/- 
SEM; 8132 +/- 1200, glycosylated; 9119 +/- 1971) compared to sham (non-glycosylated; 
19490 +/- 773.1, glycosylated; 30020 +/- 1537). Interestingly this analysis also showed 
glycosylated AQP1 expression was significantly upregulated in mild hydronephrosis (42730 
+/- 1206) compared to sham kidneys. Due to the small numbers involved moderate 
hydronephrosis could not be assessed statistically although inspection of the blot suggested 
a tendency toward downregulation compared to sham (Figure 5.17).   
Assessment of the western blots of left (obstructed) and right (contralateral) kidney protein 
lysate at 35 days of age from litters 4-6 revealed a very different picture compared to litters 
2 and 3. Non-glycosylated and particularly glycosylated AQP1 appeared downregulated in 
the contralateral kidney compared to the obstructed kidney across all degrees of 
hydronephrosis. Obstructed kidneys displaying moderate and severe hydronephrosis did not 
show any significant difference in non-glycosylated and glycosylated AQP1 expression 
compared to sham kidneys while in mild hydronephrosis, akin to litters 2 and 3, protein 
expression showed a shift towards upregulation (Figure 5.18 A). Similar trends were noted 
on densitometry of these blots however due to the small numbers involved statistical analysis 
was not possible for the majority of the groups (n=1 for both mild and severe 
hydronephrosis). Statistical analysis was performed to compare the obstructed and 
contralateral kidneys of the sham and moderate hydronephrosis groups and did not reveal a 







Figure 5.17 AQP1 protein expression by rat kidney in PUUO rats compared to sham rats from litters 2 
and 3 
Western blots demonstrating non-glycosylated and glycosylated AQP1 expression by whole kidney from 
PUUO and sham rats at 35 days of age from litter 2 and 3. Mild, moderate and severe indicates degree of 
hydronephrosis noted in PUUO rats. Obs – left/obstructed kidney, Con – contralateral kidney. GAPDH – 
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loading control. Old – whole kidneys, obstructed and contralateral, from PUUO rat at 86 days of age (A). Bar 
graphs demonstrating non-glycosylated and glycosylated AQP1 protein expression (optical density expressed 
as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from litters 2 and 3. Coloured bars 
– left sham/obstructed kidney, white bars – contralateral kidney *p<0.05 compared to sham and mild 
hydronephrosis (B) *p<0.05 compared to sham, mild hydronephrosis, contralateral sham and contralateral 
severe hydronephrosis. #p<0.05 compared to sham, contralateral sham, contralateral mild hydronephrosis and 
contralateral severe hydronephrosis (C). Sham n=2, mild hydronephrosis n= 2, moderate hydronephrosis n=1, 
severe hydronephrosis n=3, old PUUO rat n=1 (not included in graph/data analysis).  
 
A further western blot was performed using selected protein lysates from litter 2-3 and 4-6 
to determine whether the obstructed and contralateral samples had been inadvertently loaded 
incorrectly. Additionally, a fresh aliquot of one pair of obstructed and contralateral lysates 
from litters 4-6 was used to determine whether samples may have been mixed up at the point 
of the addition of sample buffer.   Lysates run on this blot demonstrated the same pattern of 
expression as on their original blots suggesting the differing results were not due to incorrect 
loading or differences between the western blotting procedure among the two batches 
(Figure 5.19).  
When all the densitometry results were combined no significant difference was noted in non-
glycosylated AQP1 expression between obstructed kidneys of any degree of hydronephrosis 
compared to sham kidneys or contralateral kidneys (Figure 5.20 A).  Glycosylated AQP1 
expression was not significantly different in severe hydronephrosis (10340 +/- 1853) 
compared to sham kidneys (16460 +/- 4367), but was significantly downregulated compared 
to mild hydronephrosis (25130 +/- 7627). Glycosylated AQP1 expression in mild 
hydronephrosis, in turn, was significantly upregulated compared to contralateral sham 
kidneys (12546 +/- 3968) and contralateral moderate hydronephrosis (8505 +/-2831) but 
again was not significantly different to sham (Figure 5.20 B). 
As a consequence of the differences noted between the results from the two batches of 
protein lysates, the western blotting densitometry results from litters 2-3 and litters 4-6 for 







Figure 5.18 AQP1 protein expression by rat kidney in PUUO rats compared to sham rats from litters 4-
6 
Western blot demonstrating non-glycosylated and glycosylated AQP1 expression by whole kidney from PUUO 
and sham rats at 35 days of age from litters 4-6. Mild, moderate and severe indicates degree of hydronephrosis 
noted in PUUO rats. Obs – left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control (A). 
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Bar graphs demonstrating non-glycosylated and glycosylated AQP1 protein expression (optical density 
expressed as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from litters 4-6. 
Coloured bars – left sham/obstructed kidney, white bars – contralateral kidney. No significant differences were 




Figure 5.19 Repeat western blot of selected rat kidney lysates for AQP1 expression 
Repeat western blot detecting APQ1 using selected whole kidney protein lysates from PUUO and sham rats 
from litters 2-6. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control. NA – new aliquot. Rats 3, 11 
and 12 were from litters 4-6 and rat 5 from litters 2-3.  
 
Figure 5.20 Glycosylated and non-glycosylated AQP1 expression in PUUO rats compared to sham 
Bar graphs demonstrating non-glycosylated and glycosylated AQP1 protein expression (optical density 
expressed as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from litters 2-6 
combined at 35 days of age. Coloured bars – left sham/obstructed kidney, white bars – contralateral kidney. 
No significant differences were noted between groups (A). *p<0.05 compared to mild hydronephrosis, #p<0.05 
compared to contralateral sham and contralateral moderate hydronephrosis (B).  Sham n=6, mild 
hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4 (A and B). 
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5.3.7.4 AQP2 protein is expressed by the cortex and medulla of rat kidney 
Immunohistochemistry of whole rat kidney demonstrated that AQP2 is expressed at the 
protein level by the luminal membrane of the cortical and medullary collecting ducts, with a 
predominantly medullary location (Figure 5.21).  
 
Figure 5.21 Immunohistochemistry demonstrating AQP2 expression by rat kidney 
AQP2 expression is demonstrated in the luminal membranes of the cortical collecting ducts (arrow) (A) and 
the medullary collecting ducts (arrowhead) (B). Negative controls (no primary antibody) demonstrated an 




5.3.7.5 Renal AQP2 protein expression is unchanged in obstructive 
hydronephrosis compared to sham 
The effect of neonatal rat PUUO on renal AQP2 expression was assessed semi-quantitatively 
following western blotting for the protein. Visual review of western blots using left 
(obstructed) and right (contralateral) whole kidney protein lysate from PUUO and sham rats 
from litters 2 and 3 at 35 days of age suggested a possible downregulation of AQP2 
expression in moderately hydronephrotic kidneys and an upregulation of AQP2 expression 
in severely hydronephrotic kidneys (Figure 5.22 A). On densitometry a marked reduction in 
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expression was noted in moderate hydronephrosis (OD 3667) compared to sham kidneys 
(Mean OD +/- SEM; 7370 +/- 110) as well as mild (8093 +/- 411.6) and severe (8231 +/- 
576.3) hydronephrosis. This difference was not analysed statistically, however, due to there 
being only a single animal in the moderate hydronephrosis group. No statistically significant 
differences in AQP2 expression were demonstrated between any of the other groups (Figure 
5.22 B). 
Inspection of western blots using whole kidney protein lysate from PUUO and sham rats 
from litters 4-6 at 35 days of age revealed fairly consistent expression across the samples 
(Figure 5.23 A). These observations corresponded with the densitometry results which 
demonstrated no significant differences between the obstructed and contralateral kidneys of 
the sham and moderate hydronephrosis groups. Again, the mild and severe hydronephrosis 
groups were not included in the statistical analysis due to small number size (Figure 5.23 B). 
Amalgamation of the densitometry results from litters 2-3 and litter 4-6 demonstrated no 
significant differences in AQP2 expression across the degrees of hydronephrosis compared 
to sham kidneys. A significant increase in APQ2 expression was noted in severe 
hydronephrosis (mean OD +/- SEM; 8068 +/- 439.6) compared to moderate hydronephrosis 
(4697 +/- 312), contralateral sham kidneys (5153 +/- 439.4), contralateral mild 
hydronephrosis (4283 +/- 572.9) and contralateral moderate hydronephrosis (4680 +/- 465.2) 






Figure 5.22 AQP2 protein expression by rat kidney in PUUO rats compared to sham rats from litters 2 
and 3 
Western blots demonstrating AQP2 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 2 and 3. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control. Old – whole kidneys, obstructed 
and contralateral, from PUUO rat at 86 days of age (A). Bar graph demonstrating AQP2 protein expression 
(optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from 
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litters 2 and 3. Coloured bars – left sham/obstructed kidney, white bars – contralateral kidney. No significant 
differences were noted between groups (B). Sham n=2, mild hydronephrosis n= 2, moderate hydronephrosis 





Figure 5.23 AQP2 protein expression by rat kidney in PUUO rats compared to sham rats litters 4-6 
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Western blot demonstrating AQP2 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 4-6. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control (A). Bar graph demonstrating 
AQP2 protein expression (optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO 
compared to sham rats from litters 4-6. Coloured bars – left sham/obstructed kidney, white bars – contralateral 
kidney. No significant differences were noted between groups (B). Sham n=4, Mild hydronephrosis n=1, 




Figure 5.24 AQP2 expression in PUUO rats compared to sham rats 
Bar graph demonstrating AQP2 protein expression (optical density expressed as mean +/- SEM) normalised to 
GAPDH for PUUO compared to sham rats from litters 2-6 combined at 35 days of age. Coloured bars – left 
sham/obstructed kidney, white bars – contralateral kidney. *p<0.05 compared to moderate hydronephrosis, 
contralateral sham, contralateral mild and contralateral moderate hydronephrosis. Sham n=6, mild 




5.3.7.6 AQP3 protein is expressed by the cortex and medulla of rat kidney 
Immunohistochemistry demonstrated that AQP3 is expressed by the basolateral membranes 




Figure 5.25 Immunohistochemistry demonstrating AQP3 expression by rat kidney 
AQP3 is expressed in the basolateral membranes of the cortical collecting ducts (arrow) (A) and the medullary 
collecting ducts (arrowhead) (B). Negative controls (no primary antibody) demonstrated an absence of staining 




5.3.7.7 Renal AQP3 protein expression is unchanged in obstructive 
hydronephrosis compared to sham 
Densitometry of western blots for AQP3 in whole rat kidney was used to semi-quantitatively 
assess the effect of neonatal PUUO on AQP3 protein expression. Evaluation of western blots 
using left (obstructed) and right (contralateral) whole kidney protein lysate from PUUO and 
sham rats from litters 2 and 3 at 35 days of age revealed a significant increase in AQP3 
expression in severe hydronephrosis (mean OD +/- SEM; 10890 +/- 805.2) compared to 
sham kidneys (7280 +/- 90.78) as well as mild hydronephrosis (6045 +/- 581.3), contralateral 
sham (6923 +/- 286.9), and contralateral severe hydronephrosis (7771 +/- 773.3). No 







Figure 5.26 AQP3 expression by rat kidney in PUUO rats compared to sham rats litters 2 and 3 
Western blots demonstrating AQP3 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 2 and 3. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control. Old – whole kidneys, obstructed 
and contralateral, from PUUO rat at 86 days of age (A). Bar graph demonstrating AQP3 protein expression 
(optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from 
litters 2 and 3. Coloured bars – left sham/obstructed kidney, white bars – contralateral kidney. *p<0.05 
compared to sham, contralateral sham, mild hydronephrosis and contralateral severe hydronephrosis (B). Sham 
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n=2, mild hydronephrosis n= 2, moderate hydronephrosis n=1, severe hydronephrosis n=3, old PUUO rat n=1 
(not included in graph/data analysis). 
 
Conversely when renal AQP3 protein expression by litter 4-6 was assessed, the visual 
appearance on the blots was of reduced expression in severe obstruction compared to both 
sham and contralateral kidney (Figure 5.27 A) which was also noted on densitometry (Figure 
5.27 B). Statistical tests however could not be applied to assess this difference as there was 
only one animal in the severely hydronephrotic group. No statistically significant differences 
were noted between the moderately hydronephrotic kidneys and sham kidneys. 
Combined results from litters 2-3 and litters 4-6 reveal no significant differences in renal 
AQP3 expression at 35 days of age between obstructed kidneys of all degrees of 









   
 
 
Figure 5.27 AQP3 protein expression by rat kidney in PUUO rats compared to sham rats litters 4-6 
Western blot demonstrating AQP3 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 4-6. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control (A). Bar graph demonstrating 
AQP3 protein expression (optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO 
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compared to sham rats from litters 4-6. Coloured bars – left sham/obstructed kidney, white bars – contralateral 
kidney. No significant differences were noted between groups (B). Sham n=4, Mild hydronephrosis n=1, 
moderate hydronephrosis n=4, severe hydronephrosis n=1. 
 
 
Figure 5.28 AQP3 expression in PUUO rats compared to sham rats 
Bar graph demonstrating AQP3 protein expression (optical density expressed as mean +/- SEM) normalised to 
GAPDH for PUUO compared to sham rats from litters 2-6 combined at 35 days of age. Coloured bars – left 
sham/obstructed kidney, white bars – contralateral kidney. No significant differences were noted between 
groups. Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4. 
 
 
5.3.7.8 Renal AQP4 protein expression is reduced in severe hydronephrosis 
compared to sham 
Tissue obtained from the PUUO model was not assessed by immunohistochemistry for 
AQP4 expression due to the lack of a suitable antibody (discussed in Chapter 3, section 
3.5.4). Assessment of AQP4 protein expression and analysis of regulation in response to 
PUUO was therefore undertaken wholly by western blotting. Inspection of western blots 
using left (obstructed) and right (contralateral) whole kidney protein lysate from PUUO and 
sham rats from litters 2 and 3 at 35 days of age revealed substantially reduced AQP4 
expression in severe hydronephrosis (Figure 5.29 A). This observation was confirmed by 
densitometry, which showed a significant downregulation of expression in severe 
hydronephrosis (mean OD +/- SEM; 4146 +/- 1696) compared to sham (15530 +/- 1167) 





Figure 5.29 AQP4 expression by rat kidney in PUUO rats compared to sham rats litters 2 and 3 
Western blots demonstrating AQP4 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 2 and 3. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control. Old – whole kidneys, obstructed 
and contralateral, from PUUO rat at 86 days of age (A). Bar graph demonstrating AQP4 protein expression 
(optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO compared to sham rats from 
litters 2 and 3. Coloured bars – left sham/obstructed kidney, white bars – contralateral kidney. *p<0.05 
compared to sham, contralateral sham, mild hydronephrosis, contralateral mild and contralateral severe 
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hydronephrosis (B). Sham n=2, mild hydronephrosis n= 2, moderate hydronephrosis n=1, severe 
hydronephrosis n=3, old PUUO rat n=1 (not included in graph/data analysis). 
 
Consistent with expression patterns in litters 2-3, AQP4 expression in litters 4-6 at 35 days 
of age appeared reduced in the severely hydronephrotic kidney compared to sham and 
contralateral. Additionally, AQP4 expression in mild hydronephrosis appeared reduced 
although the contralateral kidney was affected to the same extent suggesting this may be due 
to animal related factors rather than the procedure itself (Figure 5.30A). Again, statistical 
analysis of the densitometry from these two groups (mild and severe hydronephrosis) was 
not possible due to the small numbers. No significant differences in AQP4 expression were 
noted in moderate hydronephrosis compared to sham (Figure 5.30).  
Combined densitometry results from litter 2-3 and 4-6 confirmed a significant reduction in 
AQP4 expression in severe hydronephrosis (mean OD +/- SEM; 5976 +/- 2188) compared 









Figure 5.30 AQP4 protein expression by rat kidney in PUUO rats compared to sham rats litters 4-6 
Western blot demonstrating AQP4 expression by whole kidney from PUUO and sham rats at 35 days of age 
from litters 4-6. Mild, moderate and severe indicates degree of hydronephrosis noted in PUUO rats. Obs – 
left/obstructed kidney, Con – contralateral kidney. GAPDH – loading control (A). Bar graph demonstrating 
AQP4 protein expression (optical density expressed as mean +/- SEM) normalised to GAPDH for PUUO 
compared to sham rats from litters 4-6. Coloured bars – left sham/obstructed kidney, white bars – contralateral 
kidney. No significant differences were noted between groups (B). Sham n=4, Mild hydronephrosis n=1, 





Figure 5.31 AQP4 expression in PUUO rats compared to sham rats 
Bar graph demonstrating AQP4 protein expression (optical density expressed as mean +/- SEM) normalised to 
GAPDH for PUUO compared to sham rats from litters 2-6 combined at 35 days of age. Coloured bars – left 
sham/obstructed kidney, white bars – contralateral kidney. *p<0.05 compared to sham and contralateral sham. 
Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4. 
 
 
5.3.8 Renal pelvis aquaporin mRNA expression is reduced in moderate and 
severe hydronephrosis 
Endpoint PCR was performed to determine AQP isoform expression by rat renal pelvis and 
direct future real-time PCR. Figure 5.32 reveals that AQPs 1, 3, 4, 7, 9 and 11 are expressed 
at the mRNA level by normal rat renal pelvis.  AQP5 mRNA expression was not tested as 





Figure 5.32 Endpoint PCR demonstrating the AQP isoforms expressed by rat renal pelvis 
RT-PCR was performed using mRNA extracted from whole normal rat renal pelvis and the product run on 2% 
agarose gels. Bands of the appropriate size for AQP isoforms 1, 3, 4, 7, 9 and 11 and reference genes PGK-1, 
36B4 and HPRT were noted indicating they are expressed at the mRNA level by whole rat renal pelvis. The 
400 bp band in the lanes for AQP 11, PGK1, 36B4 and HPRT is a reference band from the sample loading 
buffer. See appendix 2 (section 10.2.1) for product sizes. 
 
Initial real-time RT-PCR demonstrated a significant reduction in β-actin expression in severe 
hydronephrosis compared to sham kidneys. Further PCR was therefore performed to assess 
expression of β-actin mRNA compared to 2 other reference genes (PGK1 and 36B4). This 
was undertaken using the 3 samples that had shown the lowest β-actin expression from the 
severe hydronephrosis group and the 3 samples from the sham group with the highest levels 
of expression. The relative expression of β-actin in severe hydronephrosis compared to sham 
(0.832) was shown to be similar to that of PGK1 and 36B4 (0.867 and 0.856 respectively) 
confirming that the differences in reference gene expression were likely due to variations in 
cDNA loading rather than regulation of β-actin expression in PUUO (Figure 5.33).  
Subsequently, relative quantification of the various AQP isoforms expressed by renal pelvis 
was undertaken in PUUO rats compared to sham rats at 35 days of age. Results were 





Figure 5.33 Reference genes for normalisation of rat renal pelvis mRNA expression data 
Relative β-actin mRNA expression in whole rat renal pelvis for PUUO rats normalised to sham at 35 days of 
age. Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4. Coloured 
bars = left sham/obstructed kidney, white bars = contralateral kidney. *p<0.05 compared to left sham. (A). 
Relative reference gene (β-actin, PGK1, 36B4) mRNA expression for left sham rat renal pelvis (coloured bars) 
compared to left severe hydronephrosis (white bars). The relative expression of β-actin, PGK1 and 36B4 in the 
severely hydronephrotic renal pelvis is 0.832, 0.867, and 0.856 respectively compared to the corresponding 
sham renal pelvis at 35 days of age. N=3 in each group (B).  Mean +/- SEM presented for all data. 
 
AQP1 mRNA expression in the renal pelvis was significantly reduced in moderate and 
severe hydronephrosis compared to sham renal pelvis (relative expression 0.63 and 0.48 
respectively). AQP1 mRNA expression in severe hydronephrosis was also significantly 
downregulated compared to all contralateral groups (Figure 5.34 A).  
Analogous to AQP1 expression, AQP3 mRNA expression was significantly decreased in 
moderate and severe hydronephrosis compared to sham renal pelvices (relative expression 
0.48 and 0.34 respectively). Expression in severe hydronephrosis was also significantly 
reduced compared to the contralateral renal pelvis in rats with mild and severe 
hydronephrosis (Figure 5.34 B).  
Analysis of AQP4 mRNA expression by rat renal pelvis demonstrated a tendency towards 
reduction in severe hydronephrosis versus sham (ΔCt 95% CI -0.6868 – 4.180) and moderate 
hydronephrosis versus sham (ΔCt 95% CI -0.8339 – 4.180) (Figure 5.34 C), however 
statistical significance was not achieved. This is potentially due to the number of 
observations not having sufficient power to detect a difference 
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Similar to AQP4, AQP7 mRNA expression showed a large degree of variability such that 
no significant differences in expression were observed between obstructive hydronephrosis, 
sham and contralateral renal pelvices (Figure 5.34 D). AQP9 mRNA expression within the 
renal pelvis was unchanged in obstructive hydronephrosis compared to sham and 
contralateral renal pelvices (Figure 5.34 E). It must be noted that, due to generally lower 
levels of expression of AQP7 and 9 mRNA in rat renal pelvis, some results were excluded 
due to poor melt curves or very high Ct values (Figure 5.34 legend). 
AQP11 mRNA expression was significantly downregulated in severe hydronephrosis 
compared to sham renal pelvices (relative expression 0.27). Expression in severe 
hydronephrosis was also significantly reduced compared to all other groups except mild 
hydronephrosis and the contralateral renal pelvis from rats with moderate hydronephrosis 
(Figure 5.34F).  
Furthermore, it was established that in moderate and severe hydronephrosis the intact 
contralateral renal pelvis did not show upregulation of AQP expression. This suggests there 
was no attempt by the contralateral renal pelvis to compensate for the downregulation in 





Figure 5.34 Renal pelvis AQP isoform mRNA expression by PUUO rats compared to sham rats 
Relative fold change of AQP isoform expression normalised to β-actin in whole rat renal pelvis is presented 
for PUUO rats compared to sham rats at 35 days of age. Coloured bars = left sham/obstructed kidney, white 
bars = contralateral kidney. Mean +/- SEM presented. AQP1 mRNA expression *p<0.05 compared to sham 
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and all contralateral groups, #p<0.05 compared to sham (A). AQP3 mRNA expression *p<0.05 compared to 
sham, contralateral mild and contralateral severe hydronephrosis, #p<0.05 compared to sham (B). AQP 
isoforms 4, 7 and 9 mRNA expression demonstrated no significant differences between groups (C, D and E). 
AQP11 mRNA expression *p<0.05 compared to all groups except mild hydronephrosis and contralateral 
moderate hydronephrosis (F). Sham n=6, mild hydronephrosis n=3, moderate hydronephrosis n=5, severe 
hydronephrosis n=4 except for AQP7 where sham n=2 and contralateral moderate hydronephrosis n=4 and 
AQP9 where sham n=4, mild hydronephrosis n=2, contralateral mild n=2, contralateral moderate n=2. 
 
 
5.3.9 Renal pelvis aquaporin protein expression 
Confirmation of the presence and distribution of AQP isoform protein expression by rat renal 
pelvis was sought by two methods; western blotting and immunohistochemistry.  
Immunohistochemistry of normal rat renal pelvis demonstrated that AQP1 was expressed by 
the vasculature within the lamina propria of the renal pelvis but was not expressed by the 
transitional epithelium (urothelium) of the renal pelvis. AQP2 was not expressed by any 
layer of the renal pelvis. AQP3 was abundantly expressed by the urothelium only of the renal 
pelvis (Figure 5.35).  
Due to the small size of the rodent renal pelvis only a single sample was obtained from each 
obstructed and contralateral kidney per animal to be used for both RNA and protein work. 
This sample was snap frozen with the primary goal of extracting RNA, which was performed 
using the Qiagen RNeasy mini-kit. Using a supplementary protocol provided by Qiagen, 
protein extraction from the RNeasy column flow-through (which is usually discarded) was 
attempted on two occasions. Unfortunately, minimal protein extraction was achieved which 
was not sufficient to complete a western blot. No further attempts were made to extract 
protein from the renal pelvis samples. 
Immunohistochemistry of samples was therefore utilised to assess the impact of neonatal 
PUUO on both the quantity and distribution of AQP 3 expression by the rat renal pelvis. 
This AQP was selected due to its urothelial expression pattern as demonstrated by 
immunohistochemistry and the proven transcriptional regulation of expression as shown by 
qPCR in response to PUUO. Additionally, studies in human urothelial cell culture have 
demonstrated AQP3 to be the major urothelial AQP demonstrating altered regulation in 
response to changes in osmolality. Accordingly, non-specific AQP blockade with mercurials 
reduces osmotic water and urea flux across these cells [369] making AQP3 a potential 




Figure 5.35 Renal pelvis aquaporin 1, 2 and 3 protein expression  
Immunohistochemistry of AQP isoform protein expression by rat renal pelvis. Negative controls (no primary 
antibody) are included for each primary antibody presented (B, D, F). AQP1 is expressed by the renal pelvis 
vasculature present within the lamina propria (arrow) however it is not expressed by the renal pelvis urothelium 
(arrowhead (A). AQP2 is not expressed by either the urothelium (arrowhead), vasculature or muscle of the 
renal pelvis (B). AQP3 is expressed by the renal pelvis urothelium (arrowhead) but not the vasculature or 
muscle (C). Scale bar = 25 μm.      
 
Immunohistochemistry of PUUO, sham and contralateral whole renal pelvis sections 
obtained from 35-day old rats was performed by Miss Fern Barrington. Blinded evaluation 
of staining was undertaken by both Miss Fern Barrington and Professor Richard Coward. 
Evaluation of sections demonstrated no urothelial or tubular staining in negative control 
sections treated with rabbit IgG. Sections treated with anti-AQP3 antibody demonstrated 
227 
 
DAB staining of the urothelium for all sections analysed. As expected tubular staining was 
also noted in sections containing renal medulla/cortical tissue. In all sections, whether 
operated or contralateral side, and regardless of sham or PUUO procedure, staining involved 
the plasma membrane and the cytoplasm through all layers of the urothelium from the basal 
to the umbrella cells. The severity of hydronephrosis did not affect the distribution of 
staining through the urothelium compared to sham or contralateral kidneys (Figure 5.36). 
The thickness of the urothelium did vary somewhat between animals with several (6 out of 
36) renal pelvis samples showing slightly thickened urothelium compared to the other 
samples. These samples, however, were not confined to animals which had undergone a 
particular procedure and included; 1 x severe hydronephrosis, 1 x mild hydronephrosis, 2 x 
contralateral sham, 1 x contralateral severe, 1 x sham renal pelvis.  
Evaluation of the intensity of urothelial staining between samples demonstrated no 
significant difference between all degrees of hydronephrosis, sham and contralateral renal 






Figure 5.36 Rat renal pelvis AQP3 staining in obstructed, sham and contralateral systems  
Representative immunohistochemistry of rat renal pelvis is presented for PUUO rats compared to sham rats at 
35 days of age. AQP3 is expressed by all layers of the urothelium within rat renal pelvis in both the operated 
and contralateral kidneys regardless of the degree of hydronephrosis. The urothelial cell membrane shows 
predominant expression however cytoplasmic expression is also noted. No discernable differences in the 
amount or distribution of expression were noted between PUUO and sham rats. Sham (A, B), mild 
hydronephrosis (C, D) moderate hydronephrosis (E, F) and severe hydronephrosis (G, H). Left – 
obstructed/sham renal pelvis, Right – contralateral renal pelvis. Arrow – urothelium, CD – collecting duct, G-






Figure 5.37 Intensity of urothelial AQP3 staining in PUUO compared to sham rats 
Relative intensity of urothelial AQP3 expression on immunohistochemistry in PUUO compared to sham rats 
at 35 days of age. Intensity of staining was scored from 0-5 (0 = no expression, 5 = most intense expression). 
No significant differences were noted between obstructed, sham and contralateral renal pelvices. Coloured bars 
= left sham/obstructed kidney, white bars = contralateral kidney. Mean +/- SEM presented. Sham n=6, mild 
hydronephrosis n=3, moderate hydronephrosis n=5, severe hydronephrosis n=4.   
 
 
5.3.10 Urinary AQP1 excretion is unchanged in hydronephrosis 
Bladder urine obtained by placing the rats in a metabolic cage at 29 days of age was analysed 
by AQP1 ELISA. Initial runs of the ELISA demonstrated that the optical densities achieved 
for the standard curve were much lower than when the ELISA was optimised. As a new 
batch of AQP1 antibody was being used, a test ELISA was performed trialling this batch of 
antibody with a new one. Each antibody was used at the original and double concentration. 
This ELISA revealed that both batches of antibody achieved similar, lower optical densities 
for a given concentration of AQP1 standard than was achieved when optimising the ELISA 
previously. Increasing the concentration of the antibody did not improve the sensitivity of 
the assay but did increase background signal. It is likely that this reduction in sensitivity was 
due to diminished activity of the new batches of antibody. Despite the reduced sensitivity of 
the assay, the optical densities of the standards were still doubling nicely as the AQP1 
concentration increased (Table 5.4). Additionally, upon using this assay to assess urine 
AQP1 excretion in rat samples, all results fell satisfactorily within the optical density range 
of the standard curve. This assay, using the AQP1 antibody at the original 1 in 60 dilution, 






AQP1 A  
1 in 60    
(Mean  OD) 
AQP1 A  
1 in 30  
(Mean OD) 
AQP1 B  
1 in 60  
(Mean OD) 
AQP1 B  
1 in 30 
(Mean OD) 
Blank 0.107 0.152 0.092 0.098 
3.125 0.0285 0.013 0.0305 0.038 
6.25 0.064 0.0605 0.049 0.068 
12.5 0.1115 0.125 0.099 0.1285 
25 0.226 0.2625 0.229 0.243 
50 0.4425 0.488 0.3885 0.4365 
100 0.827 0.9535 0.6745 0.799 
200 1.4605 1.6175 1.299 1.4695 
 
Table 5.4 AQP1 ELISA testing different batches of anti-AQP1 antibody and antibody dilutions  
Two different batches of AQP1 antibody (A and B) were each used at 1 in 60 and 1 in 30 dilutions and applied 
to two-fold serial dilutions of recombinant AQP1 protein standards from 3.125 ng/ml to 200 ng/ml in 0.1% 
SDS/PBS. The protein standards were performed in duplicate and the mean optical densities measured at 450 
nm are presented for each AQP1 protein concentration. OD – optical density. 
Figure 5.38 and Table 5.5 show a representative standard curve obtained when processing 
urine samples from the rat PUUO model.   
 
Figure 5.38 Urinary AQP1 ELISA standard curve associated with Table 5.5  
A representative AQP1 standard curve generated when analyzing urine samples from the rat PUUO model. A 
serial dilution of AQP1 standards from 12.5-400 ng/ml is demonstrated. Analysis performed by 4 parameter 
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logistic regression reveals an R2 = 0.999. Anti-AQP1 antibody was used at 1:60 dilution and standard/sample 



















12.5 0.071 0.078 0.079 0.076 0.004 5.735 
25 0.162 0.164 0.17 0.165 0.004 2.518 
50 0.345 0.352 0.356 0.351 0.006 1.586 
100 0.703 0.72 0.712 0.712 0.009 1.195 
200 1.316 1.316 1.291 1.308 0.014 1.104 
400 2.381 2.466 2.515 2.515 0.068 2.763 
 
Table 5.5 Optical densities of AQP1 standards  
Representative values obtained when performing a two-fold serial dilution of recombinant AQP1 protein 
standards in order to analyse samples from the rat PUUO model. Protein standards were performed in triplicate. 
Individual, and mean optical densities measured at 450 nm are presented for each AQP1 protein concentration 
alongside the standard deviation and percentage coefficient variation. Anti-AQP1 antibody was used at 1 in 60 
dilution. 
 
When analysing the urine samples from 29 day old PUUO and sham rats, the PUUO group 
was stratified based on the degree of hydronephrosis detected at the end of the protocol at 
35 days of age. The ELISA demonstrated that regardless of whether the animal had a sham 
or PUUO procedure there was large individual variability in urinary AQP1 excretion. 
Urinary AQP1 excretion was also revealed to be not significantly different between PUUO 




Figure 5.39 Urinary AQP1 measurements normalized to creatinine in PUUO and sham rats  
Bar graph demonstrating the urinary AQP1 levels normalised to creatinine in PUUO rats with mild (n=3), 
moderate (n=5) or severe (n=4) hydronephrosis compared to sham (n=6) rats. No significant differences were 
noted between groups.  
 
5.4 Discussion 
Although no difference in growth was noted between rats up to 4 weeks of age, body weight 
was significantly reduced in PUUO compared to sham rats at 5 weeks of age. This finding 
is similar to that of Thornhill et al. who reported growth impairment proportional to the 
severity of obstruction in PUUO rats from 3-4 weeks of age whereby at 4 weeks of age, body 
weight in the most severely obstructed group was significantly reduced compared to sham. 
It is not clear why rats with unilateral PUUO show growth impairment, however, as 
highlighted by Thornhill et al., it is unlikely this growth restriction is due to a reduction in 
GFR. Neonatal PUUO models show unchanged creatinine clearance (measured from bladder 
urine) compared to sham rats at both 7 and 14 weeks of age [364], while GFR is maintained 
in the normal contralateral kidney 28 days after PUUO [91]. Thornhill et al. suggest that 
reduced body weight may be related to renal acid-base disturbance which when combined 
with an immature compensatory response in PUUO causes renal tubular acidosis which is 
known to affect somatic growth [91].  Certainly, UUO for 24 hours in adult rats leads to a 
significant reduction in the protein expression of many major acid-base transporters along 
the nephron including NHE3, NBC1, NBCn1, NKCC2 and pendrin. Following an acid load, 
impaired renal H+ excretion and HCO3




- in UUO rats compared to sham [407]. Similarly, in neonatal PUUO, altered 
expression of renal acid-base transporters is demonstrated and this occurs in an age/time 
dependent manner. NHE3, NBC1, pendrin and Na+-K+-ATPase are significantly upregulated 
in both the obstructed and contralateral kidney compared to sham at 7 weeks following 
obstruction. At 14 weeks following PUUO, NBC1, NBCn1 and Na+-K+-ATPase expression 
are significantly downregulated in the obstructed kidney compared to sham and are 
associated with impaired acid excretion and metabolic acidosis following an acid load [408]. 
Others have also shown NKCC2 expression to be significantly reduced 12 and 24 weeks 
after creation of neonatal PUUO [185]. In accordance with these observations, a study of 50 
infants with either unilateral or bilateral hydronephrosis demonstrated 46% of children (39% 
and 61 % respectively) had evidence of renal tubular acidosis [409]. 
Individual kidney weight was unchanged between all degrees of partially obstructed, 
contralateral and sham kidneys at 5 weeks of age which is similar to observations made by 
Wang et al. at 7 weeks following neonatal PUUO. Interestingly this group reported 
decreased weight of the obstructed kidney compared to the contralateral but not the sham 
kidney at 14 weeks post PUUO [364], which may have been noted in this study had the 
protocol been continued for longer. Others have demonstrated reduced weight of the 
obstructed kidney at an earlier time point of 28 days post neonatal PUUO, the severity of 
which correlated non-linearly with the degree of obstruction. A key threshold of 70% 
luminal reduction was identified which resulted in substantial inhibition of renal growth [91], 
suggesting the degree of obstruction during this study may not have reached this critical 
point. Koff et al. suggested that the presence of contralateral hypertrophy in children with 
PUJO might aid the diagnosis of obstruction in hydronephrosis and thus the selection of 
patients for pyeloplasty [410].  Although contralateral renal hypertrophy has been noted at 
28 days following complete neonatal UUO it was not detected at 5 weeks of age in this 
current study of partial obstruction and has not been reported by other groups using neonatal 
PUUO models until at least week 14. From this time point onwards, using MRI studies, 
contralateral hypertrophy was noted in the presence of severe but not mild obstruction and 
this persisted until the end of the study at 24 weeks [91, 364, 411]. The onset of contralateral 
hypertrophy, however, was significantly delayed beyond the commencement of functional 
deterioration in the obstructed kidney [411] thus casting doubt on the predictive value of this 
measurement in children.  
Intra-renal pelvis pressures in mild and severe hydronephrosis were similar and slightly 
elevated respectively compared to sham, contralateral and non-operated kidneys. 
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Unfortunately, the mild and severe hydronephrosis groups contained only 1 animal each, 
thus precluding statistical analysis and the ability to draw meaningful conclusions. The lack 
of increased intra-renal pressure within the severely hydronephrotic kidney, however, 
suggests decompensation may have occurred with deterioration of the architecture, function 
and urine output of the kidney. Intra-renal pelvis pressure was significantly increased in 
moderate hydronephrosis compared to sham, contralateral and non-operated kidneys and is 
consistent with other reports of acute and chronic PUUO causing a rise in the mean basal 
intra-renal pelvis pressure [112, 401]. Pigs and dogs have baseline renal pelvis pressures of 
up to 4.12+/-0.94 cmH2O which increases in the partially obstructed pig to 16.4+/-3.83 
cmH2O [112]. Similarly, in the supine anaesthetised human adult, mean renal pelvis pressure 
is 5.2+/-1.3 cmH2O [46] which rises to 10.7 cmH2O [113] and 8.9 mmHg (approx. 12.1 
cmH2O) in high pressure chronic urinary retention and idiopathic hydronephrosis 
respectively [114]. Substantial variability in the intra-renal pelvis pressure measurements for 
the moderate hydronephrosis group was noted.This suggests  that with greater numbers 
assessed, this group may naturally split into kidneys with raised pressure and those with 
pressure equivalent to sham. Conversely, it is possible that pressure is a continuous variable 
in this group.  Neonatal rat studies have demonstrated that functional and histological 
changes occur acutely after PUUO and may stabilise and not progress significantly in the 
longer term [412, 413]. This equilibrium may be related to compensatory mechanisms within 
the kidney to reduce damaging pressure rises [121] such as reduced RBF/GFR, renal pelvis 
dilatation, urine drainage by the venous/lymphatic systems [88, 117, 121] as well as other, 
as yet undefined, mechanisms. For future work this raises the question of whether, in the 
absence of substantial parenchymal loss, hydronephrotic animals should be stratified by 
intra-renal pelvis pressure rather than renal pelvis APD, thus furthering investigation of the 
renal mechanisms employed to relieve pressure and resist functional damage. Ultimately, 
more animals need to be assessed to draw firm conclusions from this aspect of the research. 
In this current study significant renal parenchymal abnormalities were only noted in the 
severely hydronephrotic kidneys whereby the number of glomeruli per field of view was 
significantly reduced and the degree of interstitial fibrosis was significantly increased 
compared to mild and moderate hydronephrosis, sham and contralateral kidneys.  The 
number of glomeruli per field of view was slightly reduced in the moderately hydronephrotic 
kidneys however this difference was not significant. PUUO did not have any effect on the 
number of glomeruli or interstitial fibrosis formation in the contralateral kidney. This is 
similar to the findings of Thornhill et al. who demonstrated increased interstitial fibrosis in 
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severely hydronephrotic kidneys at 14 days following neonatal rat PUUO alongside a 
reduction in the number of glomeruli in higher grade obstruction at 28 days but not 14 days 
post-PUUO. The loss of glomeruli after the period of nephrogenesis indicates predominantly 
a disappearance of previously formed but immature glomeruli. The process by which this 
occurs is not completely understood but involves phenotypic transformation of glomerular 
cells to a less differentiated state [87, 91].   
In this current study, the finding of increased intra-renal pelvis pressure in moderate 
hydronephrosis alongside a lack of significant architectural abnormalities will be incredibly 
informative as any detected modifications of renal protein expression are likely due to altered 
regulation rather than simply structural damage and nephron loss.   
Consistent with previous studies of mammalian renal AQP mRNA and protein expression 
[241, 296, 299], this study demonstrated that whole rat kidney expresses mRNA transcripts 
for AQPs 1-8 and 11. Contrary to previous studies that demonstrated an absence of AQP9 
in rat kidney using northern blot analysis [286], this study demonstrated the presence of 
AQP9 mRNA using RT-PCR in rat kidney. At 5 weeks of age mRNA expression of AQPs 
1, 2 and 6 was significantly downregulated in severe hydronephrosis. AQP3 mRNA 
expression was unchanged in the obstructed kidney compared to sham kidneys. Although 
AQP4 mRNA expression showed a tendency towards reduced expression in severe 
hydronephrosis compared to sham kidneys a significant difference was not detected. This 
was potentially due to substantial variability in the results. Increasing the number of animals 
assessed to increase the power of the study would be necessary toinvestigate this further. 
Upregulation of AQP expression in the contralateral kidney was not noted for any of the 
AQP isoforms suggesting there was no attempt to compensate for the reduction of AQPs in 
the obstructed kidney.  
This is the first study to assess renal mRNA expression of a range of AQP isoforms in a 
neonatal PUUO model. AQP2 mRNA expression has previously been shown to be 
significantly downregulated 24 hours after complete UUO in adult rats [186]. Furthermore, 
in a study of children undergoing pyeloplasty for congenital PUJO, mRNA expression of 
AQPs 1-4 was shown to be significantly reduced in both grade 3 and 4 hydronephrosis (SFU 
grading) compared to normal kidneys [187]. Contrary to the results from the childhood 
PUJO research, this current study demonstrated that dysregulation of mRNA expression did 
not affect all AQP isoforms assessed (AQP 1-4 and 6). AQPs 1 and 2 function predominantly 
as water channels and are expressed on the apical and basolateral membranes of the proximal 
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tubular cells and the apical membrane of the collecting duct cells respectively [241].  AQPs 
3 and 4 also function predominantly as water channels, however, they are located on the 
basolateral membrane of the collecting duct [241] where they are potentially not directly 
exposed to the increased intratubular pressure associated with PUJO. Further discussion of 
possible regulatory factors in PUJO is undertaken later in the chapter. AQP6 is an anion 
channel which has low permeability for water at physiological pH and is thought to be 
involved in acid-base balance. It is located on the membrane of intracellular vesicles within 
type A intercalated cells of the collecting duct [330, 332, 335]. Downregulation of this AQP 
within the obstructed kidney would be consistent with observations of renal tubular acidosis 
in neonatal PUUO models [408] and childhood PUJO [409], and additionally may contribute 
to the impairment of growth noted in this study.  
Immunohistochemistry of whole rat kidney demonstrated that AQPs 1-3 were expressed by 
the cortex and medulla of rat kidney in a pattern consistent with previous reports of both 
rodent and human expression. AQP1 was expressed by the apical and basolateral membranes 
of the proximal tubules as well as the loop of Henle and vasa recta. AQPs 2 and 3 were 
expressed by the apical and basolateral membranes of the renal collecting ducts [187, 255].  
Subsequent assessment of the effect of neonatal rat PUUO on the quantity of AQP protein 
expression was undertaken using semi-quantative analysis of western blotting. When 
assessing renal AQP protein expression by western blotting, GAPDH rather than β-actin was 
used as reference protein for two reasons. Firstly, in the current study GAPDH was not 
regulated in PUUO kidneys when compared to sham or non-operated kidneys whereas β-
actin protein expression was significantly downregulated in PUUO compared to non-
operated kidneys. This could be explained by their differing cellular roles; GAPDH is an 
enzyme involved in glycolysis amongst other functions [414] whereas β-actin is a highly-
conserved cytoskeletal protein which could be affected by the histological changes detected 
in obstructive hydronephrosis [415]. Secondly, rat heart, which expresses GAPDH but not 
β-actin, was used as positive control for selected western blotting experiments.  
Protein lysates for litters 2-3 and litters 4-6 were extracted and analysed for AQP expression 
by western blotting in 2 separate batches. This may have contributed to the significant 
differences noted particularly between AQP1 and 3 expression in PUUO and sham kidneys 
across the 2 experiments. Visual inspection of the AQP1 blots seemed to demonstrate 
opposite results such that in litters 2-3, downregulation of AQP expression was noted in the 
PUUO kidney whereas in litters 4-6 downregulation seemed to occur in the contralateral 
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kidneys. Inspection of AQP3 Western Blots demonstrated the reverse phenomenon with 
increased expression in the severely hydronephrotic kidneys of litters 2-3 and reduced 
expression in litters 4-6. Separate semi-quantitative densitometric analysis of the two batches 
was furthered hampered by the resultant small numbers in each group, precluding statistical 
analysis for certain degrees of hydronephrosis. The results were therefore presented 
separately for each batch of experiments and then combined for all experiments. 
In order to ensure the differences between litters 2-3 and 4-6 were not due to inaccurate 
loading of samples or differences in the running of the western blot, re-runs of certain 
samples from both batches was undertaken in a single experiment and analysed for AQP1 
expression. The results were consistent with the original experiments suggesting the 
variation in the results were potentially due to either:  
• Different methods used to homogenise tissue between the 2 experiments. Tissue 
homogenisation in litters 2-3 was carried out by hand using a pestle and mortar to 
grind the tissue under liquid nitrogen to a powder, which was subsequently 
homogenised using a glass hand homogeniser on ice. In litters 4-6, due to the time-
consuming nature of hand homogenisation, an electric Ultra-Turrax homogeniser 
was used to homogenise the samples on ice. Disparity between the results was 
particularly noted in severely hydronephrotic kidneys which had been demonstrated 
by Massons trichrome staining to have significantly increased interstitial fibrosis. 
Conical glass hand homogenisation, employs grinding to tear and rip tissue to release 
proteins and can be ineffective at disrupting fibrous/membranous tissue. Rotor-stator 
homogenisors such as the Ultra-Turrax work by shearing and are effective at 
disrupting a wide variety of sample types including those which are particularly 
fibrous [416]. Increased amounts of fibrosis in the severely hydronephrotic kidneys 
may thus have rendered the tissue more difficult to breakdown by hand 
homogenisation, reducing the amounts of protein of interest isolated in the first batch 
processed. Conversely, although roto-stators are more time efficient and disrupt 
fibrous tissue more easily, they produce larger particles than are achieved with a hand 
glass homogeniser. The glass homogeniser produces exceptionally small particle 
sizes thus potentially enabling them to release more protein than the roto-stators 
[416]. When isolating AQPs from kidney tissue some groups have used motor driven 
Potter-Elvehjem homogenisers [185, 364] which disrupt tissue by either grinding or 
shearing according to the kind of pestle employed, while others have homogenised 
the tissue first  by an unspecified method followed by sonication [417]. Ultimately a 
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two-step process employing different mechanisms of tissue/cellular disruption is 
generally best to achieve optimum protein recovery. Cryogrinding™ followed by 
sonication is particularly effective at liberating proteins from tissue [416] and could 
be investigated for use in future experiments. To determine the effect of the method 
of mechanical tissue lysis on the results obtained in this study, however, both 
techniques of sample homogenisation need to be repeated in the future using the same 
samples.  
• Surgery carried out at a different time. Operations on litters 2-3 and litters 4-6 were 
separated by a few months due to a period of leave from the laboratory. Genetic drift 
in the animals may have therefore affected the results.   
• Changes in AQP expression related to the natural progression of the insult in PUUO. 
AQP expression is time/age dependent in neonatal rat PUUO [364]. Such changes in 
AQP expression (from increased to decreased expression) may have been occurring 
around the time of sacrifice of the animals although previously this had been shown 
to occur slightly later (>7 weeks of age) using Munich-Wistar rats. The current study 
used Han-Wistar rats which may account for this difference.  
• Natural variation in protein expression which could be addressed by performing 
PUUO on a greater number of animals.  
Analysis of litters 2-3 demonstrated that both glycosylated and non-glycosylated AQP1 
protein expression was significantly downregulated in severe hydronephrosis compared to 
sham kidneys while glycosylated AQP1 was significantly upregulated in mild 
hydronephrosis compared to sham kidneys. No significant differences in AQP2 expression 
were detected between groups while AQP3 expression was significantly upregulated in 
severe hydronephrosis compared to sham kidneys. Conversely AQP4 was significantly 
downregulated in severe hydronephrosis compared to sham. Statistical tests were not applied 
to the moderate hydronephrosis group as this contained only one animal. Analysis of litters 
4-6 demonstrated no significant differences in both glycosylated AQP1, non-glycosylated 
AQP1, AQP2, AQP3 and AQP4 expression compared to sham kidneys. Statistical tests were 
not applied to the mild and severe hydronephrosis groups as they each contained only one 
animal. Visual inspection of the blots alongside the densitometry results suggested both 
AQP3 and 4 expression was decreased in severe hydronephrosis.  
Combination of the results for all 5 litters revealed that at 5 weeks of age renal protein 
expression of non-glycosylated AQP1 was unchanged in the obstructed kidney. 
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Glycosylated AQP1 was significantly upregulated in mild hydronephrosis compared to 
contralateral sham kidneys but not sham kidneys. This suggests a tendency towards 
upregulation in mild hydronephrosis, analysis of increased numbers of animals would enable 
a difference compared to the sham kidneys to be detected or refuted. Any upregulation of 
AQP1 in mild hydronephrosis would be occurring via post-transcriptional/post-translational 
regulation as no differences in AQP1 mRNA expression in mild hydronephrosis were 
detected. Increased expression in mild hydronephrosis may represent a compensatory 
mechanism to offset damaging intra-tubular pressure rises.  
In moderate and severe hydronephrosis glycosylated AQP1 expression was unchanged 
compared to sham kidneys. This data conflicts with the mRNA results which demonstrated 
AQP1 downregulation in severe hydronephrosis. A reduction in mRNA expression 
potentially heralds subsequent protein downregulation which may have been detected had a 
later study endpoint been used.  
Angiotensin II acting via the AT1 receptor has been demonstrated to upregulate AQP1 
mRNA and protein expression in rat proximal tubular cells both in vitro and in vivo. 
Interestingly, the response is biphasic with dose dependent increases in expression at lower 
concentrations of angiotensin II but suppression of AQP1 mRNA expression at higher 
strengths. Thus, the activation of the renin angiotensin system which is known to occur in 
UUO, may contribute to the dysregulation of AQP1 seen following PUUO [308]. AQP1 
expression is not regulated directly by vasopressin [325] but is also upregulated by 
hypertonicity [308]. 
It is not clear why glycosylated AQP1 expression seemed more affected by PUUO than non-
glycosylated in this study. Glycosylation has not been identified as necessary for AQPs to 
be targeted to the plasma membrane and does not change the water permeability of AQP1 
[242, 243]. Wang et al. performed neonatal PUUO in Munich-Wistar rats by embedding the 
upper 2/3 of the ureter into the psoas muscle, a method which they had previously described 
as generating severe obstruction [401]. In contrast to the current study they demonstrated 
AQP1 (combined glycosylated and non-glycosylated) to be upregulated at 7 weeks of age in 
the obstructed kidney compared to sham, however, expression subsequently fell such that it 
was downregulated at 14 weeks of age [364]. Conversely, in a separate study using the same 
neonatal PUUO model, the same group demonstrated AQP1 expression to be unchanged at 
12 and 24 weeks of PUUO compared to non-obstructed kidneys [185]. These studies 
highlight the sometimes variable nature of AQP expression in PUUO, and indicate that 
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individual factors may be involved in the animal’s ability to maintain AQP expression in the 
presence of PUUO.  
Results for AQP2 expression in PUUO were more consistent between the two batches 
assessed, and when combined, confirmed that at 5 weeks of age AQP2 protein expression 
was unchanged in the obstructed kidney compared to sham kidneys. This was discordant 
with the mRNA results where AQP2 expression was significantly downregulated in severe 
hydronephrosis.  Wang et al. demonstrated renal AQP2 protein expression in neonatal 
PUUO to rise at 7 weeks of age followed by downregulation at 14 weeks of age which 
continued until at least 24 weeks of age [185, 364]. Interestingly, the same group 
demonstrated phosphorylated AQP2 (pS256-AQP 2) was downregulated at both 7 and 14 
weeks compared to sham suggesting that transport to the plasma membrane was impaired at 
both time points [364]. These studies only assessed protein expression, whereas the current 
study assessed both mRNA and protein expression. Again, downregulation of AQP2 mRNA 
in the current study likely precedes later protein downregulation, which may thus occur at 
an earlier time point than noted by Wang et al. Upregulation of AQP2 expression was not 
noted in the current model, however, if regulatory changes were occurring earlier than 
detected in other studies it is possible an initial upregulation was missed using an end point 
of 5 weeks of age.  
Under normal circumstances short and long term regulation of AQP2 expression is 
predominantly controlled by vasopressin acting via the G-protein coupled V2 receptor [241]. 
UUO leads to upregulation of the renin angiotensin system [118], but paradoxically a 
significant reduction in V2 receptor and cAMP expression which consequently reduces 
AQP2 expression and trafficking [180]. This phenomenon is probably related to the biphasic 
effects exerted by angiotensin II on tubular solute and fluid transport, stimulating movement 
under normal physiological conditions meanwhile inhibiting fluid/solute transport when 
angiotensin II levels are pathologically raised [418, 419].  
Adult UUO models have demonstrated that the increased COX-2 activity associated with 
obstructive nephropathy is vital to guard against tubular apoptosis and damage [128]. 
However, increased COX-2 and the resultant elevation of intra-renal prostaglandins is also 
involved in causing reduced mRNA and protein expression of renal AQPs 2 and 3 [127, 
352]. In the case of AQP2 regulation, increased prostaglandins may reduce expression by: 
• contributing to V2 receptor downregulation [420] 
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• inhibiting the formation of intracellular cAMP [421]  
• binding the EP3 receptor on the basolateral membrane of the collecting duct cell, 
activating Rho and leading to the polymerization of F-actin which obstructs APQ2 
translocation [354] 
Changes in environmental tonicity [356] as well as many other molecules such as ATP, 
dopamine [318], bradykinin [319], NO, ANP [320] and integrins [355] are also known to 
modulate AQP2 expression and trafficking via various mechanisms and may be involved, in 
ways not yet elucidated, in the context of PUUO.  Nuclear factor-κB (NFκB) is a 
transcriptional regulator activated by angiotensin II via AT1 and AT2 receptors [101, 158, 
422] which is involved in the upregulation of pro-inflammatory genes in UUO [101]. In vitro 
studies using immortalised collecting duct principal cells have demonstrated that NFκB 
activation decreases AQP2 mRNA and protein expression in a proportionate manner [423] 
suggesting a role for NFκB in the AQP2 downregulation noted in PUUO.  
Combined results from all 5 litters confirmed that AQP3 protein expression was also 
unchanged in the obstructed kidney of 5 week old PUUO rats compared to sham kidneys 
which reflected renal AQP3 mRNA expression. This in contrast to others who described an 
increase in AQP3 expression in PUUO rats at 7 weeks of age which normalised by 12 weeks 
of age and remained comparable to non-obstructed kidneys until 24 weeks [185, 364]. It is 
possible, that the initial rise and return to normal levels occurred earlier in the rats in the 
current study and was therefore missed by the 5-week time point. Others have demonstrated 
that AQP3 is regulated in the long-term but not in the short term by vasopressin, likely due 
to the absence of intracellular stores of the protein [323, 325, 360]. The lack of long term 
downregulation of AQP3 in this study, which is consistent with the results of others [185, 
364], suggests that the renin angiotensin system activation and V2 receptor depression 
known to occur in ureteric obstruction may not be the main regulators of AQP3 expression 
in PUUO.  In vitro work in non-renal cells has demonstrated AQP3 expression to be 
upregulated by hypertonicity, insulin and leptin [258, 322] although a role for these factors 
in obstruction has not been investigated. Additionally, AQP3 is known to be regulated by 
gating such that at physiological pH it is permeable to both water and glycerol, but at acidic 
pH its water permeability is diminished [363].  
Results for AQP4 protein expression were consistent between the two batches of 
experiments and at 5 weeks of age combined results from all 5 litters demonstrated that 
AQP4 protein expression was significantly downregulated in severe hydronephrosis 
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compared to sham kidneys. This was consistent with the tendency towards downregulation 
noted in renal AQP4 mRNA expression indicating that AQP4 may be transcriptionally 
regulated in PUUO. Renal AQP4 expression has not been studied in a neonatal PUUO model 
previously, however in adult rat UUO [184] as well as human congenital PUJO [187, 424], 
AQP4 is downregulated in the obstructed hydronephrotic kidney. There are conflicting 
reports regarding the regulation of AQP4 expression by vasopressin. Initially thought to be 
unaffected by vasopressin [325], more recent reports suggest there is differential regulation 
along the distal nephron in response to vasopressin. Additionally,  in vitro work using non-
renal cells demonstrates AQP4 is upregulated by hypertonicity [289]. 
All four AQP isoforms appear to be regulated by tonicity. Neonatal PUUO and adult UUO 
and BUO are all known to decrease renal expression of major tubular sodium transporters 
and increase urine fractional excretion of sodium [181, 182, 185]. Decreased tubular sodium 
reabsorption would be expected to reduce interstitial tonicity which in theory may lead to 
AQP downregulation. Certainly, extracellular hypotonicity causes AQP2 transcriptional 
downregulation [357, 358], as well as promoting internalisation of AQP2 from the 
membrane [359].  
Both at the mRNA and the protein level there was no altered expression noted in the 
contralateral kidneys to compensate for dysregulated AQP expression in the obstructed 
kidney. This concurs with functional studies where a reduction in both single kidney GFR 
and solute free water reabsorption was noted at 12 and 24 weeks post PUUO in the obstructed 
kidney, while no changes in these parameters compared to control were noted in the 
contralateral non-obstructed kidney [185]. Interestingly, contrary to the current study, other 
groups have demonstrated alterations in aquaporin expression in the contralateral kidneys 
following UUO, indicating potential systemic in addition to intrarenal regulatory factors. 
Wang et al. demonstrated AQP2 and 3 protein expression was upregulated in the 
contralateral kidney at 7 weeks of age following neonatal PUUO, which corresponded with 
increased expression of the same AQP isoforms in the obstructed kidney. At 14 weeks of 
age AQP1 protein expression was downregulated in both the obstructed and contralateral 
kidneys compared to sham kidneys [364]. Similarly, adult rodent complete UUO models 
have demonstrated downregulation of AQPs 1 and 2 [184, 186] in the contralateral kidney.  
Similar to recent research this study has shown that dysregulation of renal AQP expression 
in neonatal PUUO varies between AQP isoforms. However whereas other groups have 
shown a temporal change [364], this study highlights a change according to severity of 
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hydronephrosis. This is consistent with human studies of congenital PUJO where reduced 
AQP expression correlated with the severity of hydronephrosis [187] and the degree of 
functional impairment [424].  In the current study AQP mRNA (AQP 1-6) and protein (AQP 
1-4) expression for all isoforms assessed was maintained in moderate hydronephrosis in the 
presence of raised intra-renal pressure. Downregulation was only noted in the severely 
hydronephrotic group who also demonstrated abnormalities of renal structure in the absence 
of raised intra-renal pelvis pressure. The presence of differential regulation of the various 
isoforms in this group suggests downregulation may not purely reflect kidney damage but 
dysregulation in response to the insult of severe obstructive hydronephrosis.  
Endpoint PCR reveals that AQPs 1, 3, 4, 7, 9 and 11 are expressed at the mRNA level by 
normal whole rat renal pelvis.  AQP5 mRNA expression was not tested as the primers 
available were not suitable for subsequent real time PCR. These findings are consistent with 
those from studies of human ureter and bladder which demonstrated AQPs 3, 4, 7, 9, 11 but 
not AQPs 0, 1, 2, 5, 8 and 12 to be expressed by human urothelial cells [259]. AQP1 is not 
expressed by either human [259] or rat urothelium but has been reported to be expressed by 
the blood vessel vascular endothelium of the urinary tract [249] which was confirmed by 
immunohistochemistry of rat renal pelvis in this study.   Consistent with the results of human 
and rodent research, AQP3 expression was confirmed to be localised to the urothelium by 
immunohistochemistry in this study [249, 259].  Although previous studies have suggested 
AQP2 protein was expressed by rat urothelium [249] this was not confirmed in this study at 
either the RNA or protein level. Lack of AQP2 expression by rat urothelium is consistent 
however with results from human research [259].  Unfortunately, due to time constraints and 
the lack of suitable antibodies it was not possible to localise the expression of AQPs 4, 7, 9 
and 11 in the rat renal pelvis tissue, however, the expression patterns in human urothelium 
would suggest that AQPs 4, 7, 9 and 11 are also likely expressed by rat urothelium [259].  
Following identification of the isoforms expressed by normal rat renal pelvis, relative 
quantification of these AQPs in the PUUO model at 35 days of age was undertaken and 
results were normalised to β-actin. Although initial real-time RT-PCR suggested β-actin 
expression may be regulated in PUUO, further experiments using two additional reference 
genes involved in alternate cellular processes (PGK1 and acidic ribosomal 36B4) confirmed 
the discrepancy was due to cDNA loading. 
AQP1 and 3 mRNA expression in the renal pelvis was significantly reduced in moderate and 
severe hydronephrosis compared to sham renal pelvis, while AQP11 expression was 
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significantly downregulated in severe hydronephrosis only. AQP4 mRNA expression 
demonstrated a tendency towards reduction in moderate and severe hydronephrosis, 
however, no significant differences between groups was detected. Assessment of greater 
numbers of samples to increase the power of the study would be required to gain a definitive 
answer. Renal pelvis AQP7 and 9 mRNA expression was unchanged in obstructive 
hydronephrosis compared to sham and contralateral tissue. Additionally, both AQP isoforms 
demonstrated generally low levels of expression compared to the other AQPs. 
No changes in AQP expression by the contralateral renal pelvis were detected indicating 
there was no attempt to compensate for the obstructed renal pelvis. The AQP dysregulation 
in the obstructed renal pelvis is thus likely controlled by local rather than systemic factors.  
Immunohistochemistry demonstrated that the distribution/tissue localisation of AQP3 was 
unchanged in obstructed compared to sham and contralateral renal pelvices at 35 days of 
age. All layers of the urothelium expressed AQP3 in a plasma membrane and cytoplasmic 
distribution across all groups assessed. Additionally, evaluation of the relative intensity of 
urothelial staining did not demonstrate any statistically significant differences between 
PUUO and sham rats. It must be remembered, however, that intensity of staining may not 
be a reliable indicator of the amount of antigen.  DAB stain is not stoichiometric and does 
not follow the Beer Lambert Law, which describes the linear relationship between the 
concentration of an absorbing substance and absorbance [425].  
These findings of renal pelvis AQP dysregulation in PUUO have significance given that 
urothelium is no longer considered to be an impervious membrane with a simple function of 
urine storage. Studies are increasingly highlighting an active role for urothelium in 
regulating urine composition. In a human urothelial cell culture system hyperosmolality 
leads to upregulation of primarily AQP3 but also AQP9 expression, associated with 
increased transurothelial water and urea flux along an osmotic gradient. Accordingly, in this 
model, non-selective blockade of AQPs with mercurials results in decreased water and urea 
flux [369]. Regulation of urothelial AQP2 and AQP3 expression has also been documented 
in rats, being significantly decreased by hypoestrogenaemia [250] and increased by 
dehydration [249] and partial bladder outlet obstruction [368]. Interestingly, partial bladder 
outlet obstruction also leads to upregulation of AQP 1 within the vasculature of bladder 
tissue [367].   
The effect of urinary tract obstruction on the expression of AQPs by renal pelvis tissue has 
not before been analysed. This research demonstrated for the first time that AQPs expressed 
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by both the vascular endothelium (AQP1) and the urothelium (AQP3 and AQP11) are 
transcriptionally downregulated in the PUUO model at 35 days of age. This reduction in 
urothelial AQP3 and vascular endothelial AQP1 expression could seriously impair the ability 
of the renal pelvis to offset, by transurothelial transport and dissipation into the local 
capillaries, the increased fluid volume and intrarenal pressure in PUUO.  Similar to renal 
AQP expression the reduction in renal pelvis AQP expression was related to severity of 
obstruction. However in the renal pelvis both AQP1 and 3 mRNA expression were 
downregulated in moderate hydronephrosis in the presence of raised intra-renal pelvis 
pressure as well as in severe hydronephrosis.  
The use of a wire template in this PUUO model creates a fixed degree of obstruction. The 
manifestation of different severities of obstruction may indicate that, similar to human 
disease, factors specific to the individual determine whether the response is pathological or 
not. Accordingly, this data may suggest that the individual ability of the rat to maintain renal 
pelvis AQP expression following neonatal PUUO determines the severity of hydronephrosis 
developed. A failure to maintain renal pelvis AQP expression, with consequent reduced 
urothelial water re-absorptive capacity potentially compounds intratubular pressure rises 
eventually leading to severe hydronephrosis, renal damage and functional impairment. 
Furthermore, the degree of interstitial fibrosis is a good correlate of functional impairment 
[83]. Compromised function will ultimately reduce urine output and thus intra-renal pelvis 
pressure, as was noted in the severely hydronephrotic kidney in this study. Conversely, 
sustained AQP expression following PUUO may protect against continuing intra-tubular 
pressure rises thus manifesting in this study as mild hydronephrosis with preserved histology 
and normal intra-renal pelvis pressure.  
Factors other than hydrostatic pressure may also influence the direction of potential 
transurothelial water flow across AQPs. Partial and complete ureteric obstruction causes 
significantly increased urine fractional excretion of sodium, reduced solute free water 
reabsorption [185], reduced urinary urea excretion [183] and reduced urine osmolality [185] 
compared to sham animals. Despite these changes in solute and water excretion, in rats with 
free access to water, urine from the obstructed kidney remains hyperosmotic (approximately 
400 mOsmol/kgH2O) compared to plasma (approximately 295 mOsmol/kgH2O) [185] and 
contains substantially more urea (approximately 588 mmol/l vs 7.4 mmol/l in plasma) [183] 
but less sodium (approximately 78 μmol/ml vs 131 μmol/ml in plasma) [185]. When 
combined these factors may favour water movement across AQPs into the urine thus 
potentially counteracting the direction of flow due to raised hydrostatic pressure. Although 
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AQP 3 is regulated by gating, whereby its water permeability is reduced at acidic pH (pH ≤ 
6.1) [363], this will not affect water flux in the current study as the urine pH in neonatal 
PUUO and sham animals is approximately 8 [407].  
In order to further investigate a potential pressure reduction mechanism for AQPs, ongoing 
research will involve creating a neonatal mouse PUUO model using an AQP3 knockout 
mouse under the control of the uroplakin II promoter which is specific to urothelial cells. If, 
as predicted, these mice show a more severe phenotype than wild type mice, attempted 
rescue using an AQP3 overexpression mouse under the same promoter will be undertaken. 
Table 5.6 summarises the mRNA and protein expression of the various AQP isoforms by 
kidney and renal pelvis in PUUO compared to sham rats. Dysregulation of expression in 
both kidney and renal pelvis becomes more apparent as the degree of hydronephrosis 
progresses.  
 Mild Hydro Moderate Hydro Severe Hydro 
 Kidney RP Kidney RP Kidney RP 
AQP mRNA Protein mRNA mRNA Protein mRNA mRNA Protein mRNA 
1 ↔ ↔ ↔ ↔ ↔   ↔  
2 ↔ ↔ NE ↔ ↔ NE  ↔ NE 
3 ↔ ↔ ↔ ↔ ↔  ↔ ↔  
4 ↔ ↔ ↔ ↔ ↔ ↔ ↔  ↔ 
6 ↔  NE ↔  NE   NE 
7   ↔   ↔   ↔ 
9   ↔   ↔   ↔ 
11   ↔   ↔    
 
Table 5.6 Summary of AQP isoform expression following neonatal PUUO 
Table summarising AQP isoform mRNA and protein expression following neonatal rat PUUO compared to 
sham rats, stratified according to degree of hydronephrosis. Hydro - hydronephrosis, RP - renal pelvis, G - 
glycosylated, NG - non-glycosylated, NE - not expressed, ↔ - unchanged expression compared to sham,  - 
increased expression compared to sham,  - decreased expression compared to sham,            - AQP isoform 
not assessed. 
 
The major dilemma when managing children with PUJO is deciding which require surgery 
and which don’t. Current radiological imaging methods are not completely reliable to 
distinguish between these two groups [2, 26, 66]. The development of a non-invasive 
biomarker to aid surgical decision making would be very advantageous. Previous research 
has demonstrated that AQPs 1 and 2 but not AQP3 are excreted in urine [372, 381]. These 
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findings have been confirmed by western blotting in the current study.  AQPs 1 and 2 are 
generally excreted in proportion with the level of renal expression [372, 381, 383], however, 
AQP2 excretion may be influenced by vasopressin flux [371, 384, 385].  Although urinary 
AQP excretion has not been measured in rat models of PUUO, human studies of PUJO have 
demonstrated reduced urinary excretion of both AQP1 and AQP2 by the obstructed kidney 
following pyeloplasty surgery [365, 386]. There have been no studies assessing the 
suitability of AQP1 as a pre-operative biomarker of disease severity in the obstructed kidney 
in either humans or rodents.  
Given that the current study demonstrated reduced renal expression of AQP1 in severe 
hydronephrosis and reduced renal pelvis AQP1 expression in moderate and severe 
hydronephrosis it was anticipated that urinary AQP1 measurements would be reduced in the 
severely hydronephrotic PUUO rats compared to sham. Interestingly, however, urinary 
AQP1 excretion in this study was demonstrated by ELISA measurement to not be 
significantly different between PUUO rats across all degrees of hydronephrosis compared to 
sham rats. This contrasts with post-operative studies in humans where AQP1 excretion by 
the obstructed kidney was reduced compared to the normal contralateral kidney [386]. There 
are a number of potential reasons for the discrepancy in results: 
• Large variability in the results in the current research. Significant intra and 
interpatient variation is a common finding with many potential biomarkers. This is 
because biomarkers are often excreted in health as well as disease states, and their 
detection may be affected by patient factors such as age, weight, and the presence of 
urinary tract infection [212, 213].   
• Human studies used semi-quantitative methods (densitometry of western blotting) to 
assess urinary AQP1 excretion whereas this was a fully quantitative ELISA. 
• Human studies compared urine from the obstructed kidney to urine from the normal 
contralateral kidney. In this study bladder urine from PUUO rats compared to sham 
was used for AQP1 measurement as it is a better proxy for a future non-invasive pre-
operative biomarker test. Bladder urine however, is a composite of urine from both 
the obstructed and non-obstructed kidneys, thus any changes in excretion by the 
obstructed kidney will be tempered by the contralateral normal kidney. It is therefore 
possible that AQP1 excretion from the obstructed kidney is reduced in neonatal rat 
PUUO but was not detectable in this assay due to the mixing of urine in the bladder 
from both kidneys. 
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Ultimately this research demonstrated that in this rat neonatal PUUO model, urinary AQP1 
measurement does not predict the severity of hydronephrosis. These results therefore cast 
doubt on whether urinary AQP1 measurement will be useful as a biomarker of disease in the 
clinical setting. Further analysis of urine samples obtained from the human study will clarify 
whether this is also the case in children with PUJO. Conveniently, however, valuable urine 
samples have been obtained and stored from this robust model of neonatal rat PUUO and 
will be used alongside human urine samples in future proteomics studies. These will aim to 
identify urinary biomarker proteins for subsequent validation which show suitability in the 






Approximately 1 in 7 [5, 6, 24] neonates with antenatally detected hydronephrosis has pelvi-
ureteric junction obstruction (PUJO), making PUJO one of the commonest causes of 
congenital urinary tract obstruction with an incidence of 1 in 1000 – 1 in 2000 live births [6, 
24, 426]. Interestingly, males are affected approximately three times more frequently than 
females by this condition [24]. The reason for this difference is unknown. Intrinsic 
obstruction due to an adynamic stenotic segment at the PUJ is the most common aetiology 
(75% of cases) [24], where failure of peristalsis produces an incomplete, functional 
obstruction. 
The major challenge for clinicians is deciding which of these children, who are largely 
asymptomatic, require a pyeloplasty to relieve obstruction. This is because two thirds of 
children with PUJO do not sustain renal damage or need surgery, and their hydronephrosis 
spontaneously stabilises or improves [26, 62, 63]. 
Currently, serial ultrasound and invasive isotope studies are performed to guide surgical 
management [24]. However their ability to accurately detect obstruction, identify children 
at risk of functional deterioration and predict the need for surgery is questionable. 
Additionally, there remains debate regarding the parameters which indicate clinically 
significant obstruction [2, 26, 66, 87]. 
Usually pyeloplasties are performed for [56]: 
• differential renal function deterioration (differential function <40% or falls by >10% 
on serial MAG 3 renograms)  
• significant hydronephrosis with a renal pelvis anteroposterior diameter >3 cm on 
ultrasound scan  
• increasing hydronephrosis with a rising anteroposterior diameter on serial ultrasound 
scan 
• symptomatic children   




At present our understanding of the natural history of PUJO is inadequate. Available 
diagnostic tests cannot accurately discern whether children have PUJO that will resolve 
spontaneously or will persist causing functional impairment. Consequently, despite 
radiological monitoring, there is a risk of loss of function in the affected kidney while under 
observation [67].  
There is significant need for greater understanding of the mechanisms underlying the clinical 
evolution of PUJO, and for the development of an early biomarker to distinguish between 
damaging hydronephrosis requiring surgery and safe hydronephrosis which might resolve 
spontaneously.  
The underlying aetiology of PUJO is currently unknown, however, it is well-documented 
that there are underlying innervation [73] and myogenic abnormalities [72, 76] at the 
adynamic narrowed pelvi-ureteric junction. The resultant functional obstruction leads to 
increased pressure within the proximal urinary tract. In vivo research reveals pigs have 
baseline renal pelvis pressures of 4.12 +/-0.94 cmH2O which increases in partial PUJO to 
16.4 +/- 3.83 cmH2O [112]. Similarly, in humans mean renal pelvis pressure is 5.2+/- 1.3 
cmH2O [46] which rises to 10.7 cmH2O [113] and 8.9 mmHg (approx. 12.1 cmH2O) in high 
pressure chronic urinary retention and idiopathic hydronephrosis respectively [114]. 
Following the onset of obstruction various factors, often viewed as compensatory, may lead 
to a reduction in renal pelvis pressure including: tubular and renal pelvis dilatation, reduced 
urine production due to diminished RBF and GFR, and venous and lymphatic drainage of 
urine [88, 117, 121, 427, 428]. 
Direct transurothelial absorption of urine constituents has traditionally been thought to 
contribute little to the dissipation of urine volume in the obstructed kidney due to the inherent 
barrier function of the urothelium [427]. Urothelium lines the renal pelvis, ureters, bladder 
and proximal urethra and consists of an apical glycan layer plus three main cell layers [429]:  
• highly differentiated single layer of apical umbrella cells connected by tight junctions 
which demonstrates very high transepithelial resistance 
• several layers of intermediate cells  
• single basal cell layer  
Recently the urothelium has been recognised to have a potential role in water and solute 
homeostasis. Although it is well known that human urine composition changes from the 
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renal pelvis to the bladder [366], while bears reabsorb their daily urine output during 
hibernation [430], the possible underlying mechanisms are only just being described.  
Aquaporins have an established role in the transmembrane movement of water [237]. Their 
identification in mammalian urothelium [249, 259] alongside sodium [431], potassium [432] 
and urea transporters [433] provides evidence of potential routes for the urothelium to 
achieve transport functions.   
As discussed previously, AQP2 and 3 expression is upregulated in rat bladder urothelium by 
dehydration [249] and partial bladder outlet obstruction [368] and downregulated by hypo-
oestrogenaemia [250].  AQP regulation is not confined to those detected in urothelium, 
vascular expression of AQP1 within rat bladder is also increased following partial bladder 
outlet obstruction [367]. The data presented in Chapter 5 confirms the presence of AQPs 1, 
3, 4, 7, 9 and 11 in rat renal pelvis and supports the dysregulation of AQP expression in 
urinary tract pathology. Both AQP3 and AQP 1, which are expressed by the urothelium and 
suburothelial vascular-endothelial cells respectively, are significantly transcriptionally 
downregulated in the obstructed renal pelvis following neonatal rat PUUO.    
Human urothelial cell cultures express AQPs 3, 4, 7 and 9 at the protein level [259] and 
demonstrate regulation of predominantly AQP3, but also AQP9, expression in response to 
variations in osmolality.  In fact, in the presence of an osmotic gradient, the permeability of 
differentiated human urothelial cell constructs to water and urea significantly increases 
following hyperosmolar pre-conditioning compared to controls. Significantly, 
transurothelial permeability decreases following non-selective AQP blockade, corroborating 
a role for AQPs in transurothelial transport [369]. 
The childhood study of PUJO described in this chapter aims to build on the in vitro human 
urothelial cell work by Rubenwolf et al., and enhance the animal work reported in chapter 
5. A major aim being to investigate renal pelvis urothelial AQP expression as the mechanistic 
link explaining why some children with PUJO have ‘safe’ hydronephrosis and others 
‘damaging’ hydronephrosis. Additionally, these complementary rodent and human studies 
aim to investigate AQPs as a potential biomarker to aid early detection of those children with 
damaging hydronephrosis who require prompt surgery to protect kidney function.  
A biomarker is defined as “a characteristic that is objectively measured and evaluated as an 
indicator of normal biological processes, pathogenic processes or pharmacological responses 
to a therapeutic intervention” [434]. Many potential urinary biomarkers including cytokines, 
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growth factors, chemokines, tubular enzymes and tubular transport proteins have been 
investigated in children with PUJO. Although a number have shown promise, no single 
biomarker or collection of markers has been identified and implemented to guide selection 
of patients for surgery. The urine biomarkers previously assessed in human bladder urine 
samples are presented in Chapter 1,Table 1.6.Those biomarkers with conservatively 
managed hydronephrosis as comparator are most useful in terms of discerning which 
children require surgery in the clinical setting, however, many studies have used healthy 
children only as controls. A recent systematic review of urine and serum biomarkers in 380 
patients undergoing pyeloplasty for PUJO failed to draw any firm conclusions, citing a large 
range of occasionally opposing results and issues with study design [214].   
This finding is echoed by the predictive safety testing consortium (PTSC) who in 2006 
advised that good biomarkers should be: [435] 
• present in peripheral body tissue and/or fluid (e.g. blood, urine, saliva, breath or 
cerebro-spinal fluid) 
• easy to detect or quantify in assays that are both affordable and robust 
• their appearance must be associated as specifically as possible with damage of a 
particular tissue preferably in a quantifiable manner (in terms of drug toxicity testing) 
Despite meeting the above criteria many potential biomarkers from the literature have failed 
to achieve further development because studies are scientifically inadequate with 
underpowered or biased studies and/or inadequate description of methods, control groups 
and statistical analyses [435]. Other problems encountered in biomarker discovery are those 
of significant intra and inter patient variation, biomarker presence in both health and disease 
states with coinciding reference values, and variation with patient age and factors such as 
urinary tract infection and concurrent renal disorders [212, 213]. Consequently, finding a 
biomarker with high sensitivity, specificity and predictive value is difficult [116].  This study 
aims to provide robust scientific data to either confirm or refute AQP 1 as a potential 
biomarker of PUJO.   
Four AQPs are known to be excreted in human urine. AQPs 1 and 2 are both detected on 
western blotting of human urine [365, 386] and in rat studies their excretion generally 
reflects the level of renal expression [372, 381, 383]. The excretion of AQPs 5 and 7 has 
been demonstrated on proteomic studies only [387]. Urinary excretion of AQPs 1 [386] and 
AQP 2 [365] by the obstructed kidney is significantly reduced  (64% and 54% respectively) 
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compared to the normal contralateral kidney following pyeloplasty in childhood PUJO. This 
reduction in expression is noted for up to 4 days post-operatively and is associated with a 
marked polyuria and significant decrease in urine osmolality from the obstructed kidney 
which persists for at least 4 days post-operatively [365].  The potential of urinary AQPs as 
biomarkers to predict the need for surgery in PUJO has not previously been analysed. 
Consequently, there are no published studies investigating urinary AQP levels either pre-
operatively in children undergoing pyeloplasty or in those under monitoring for 
hydronephrosis. Moreover, normal AQP levels in children are unknown.  
This chapter outlines the design and implementation of a childhood study of PUJO and all 
preliminary results.  
The aims of this study are to: 
• Measure the distribution and quantity of aquaporins in the lower urinary tract in 
childhood PUJO 
• Establish the urinary aquaporin profile in damaging (operated) and safe (non-
operated) PUJO in children 
Additional data is presented in a separate section of this Chapter demonstrating normal 
human urinary tract AQP expression and urinary excretion using samples unrelated to the 
childhood study. 
 
6.2 Methods – childhood cross-sectional study of PUJ obstruction 
This single-site clinical cross-sectional study recruiting children with PUJO at Bristol 
Children’s Hospital commenced recruitment in November 2014 and is currently ongoing. 
Study commencement followed completion of the IRAS application (IRAS ID: 131160) and 
lengthy consultation with the South West - Central Bristol Research Ethics Committee 
(REC) and the local University Hospitals Bristol Research and Innovation department (R + 
D). Approval for the study to commence was given by the South West - Central Bristol 
Research Ethics Committee on the 2/9/14 (REC No: 14/SW/1027) and by UH Bristol 
Research and Innovation department on 29/9/14 (R + D number: CH/2014/4699). 
Permission has been given for the study to run until 31/7/20. The University of Bristol 
Research and Enterprise Development team has been significantly involved in the 
implementation of the study and the University of Bristol is the study sponsor. This study is 
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being conducted in accordance with the Research Governance Framework, Good Clinical 
Practice and NHS Trust policies and procedures.  
6.2.1 Study protocol 
This study involves the recruitment of three groups of children (aged 0-15 years inclusive) 
attending Bristol Children's Hospital as detailed below (Figure 6.2). See appendix 3 (Section 
10.3) for copies of the study protocol, patient information leaflets, consent forms, and GP 
letters. 
6.2.1.1 Group 1 – Children undergoing pyeloplasty for PUJ obstruction 
Group 1 consists of children undergoing an open or laparoscopic pyeloplasty as treatment 
for PUJO at the Bristol Children’s Hospital.  Potential participants are identified by the 
operating consultant surgeon and given appropriate child and parent information leaflets 
detailing the study. Consent for the study is then obtained by the chief investigator (member 
of the research team) on the day of surgery after the surgeon has explained the surgical 
procedure. The GP is informed by letter of the child’s participation in the study.   
Following enrolment to the study, on the day of hospital admission, the operative data 
collection form documenting the child’s demographic details, medical history and the results 
of pertinent radiological tests is completed.  Prior to surgery a urine specimen is collected 
where possible either into a specimen pot or from the nappy in the younger child.  
The pyeloplasty is performed under general anaesthetic either laparoscopically or as an open 
procedure in the usual manner based on the surgeon’s preference and the best interests of the 
child.   
During the pyeloplasty the following procedures are performed, and samples obtained:  
• A urine sample is taken from the bladder catheter at the start of the operation for 
urinary aquaporin measurement.   
• Intra-renal pelvis pressure is measured using a Rocket® spinal manometer (# R55990, 
Rocketmedical, Washington, England) connected to the needle from a 22G cannula 
(BD Venflon™ Pro, #393202, Becton Dickinson, Surrey, UK) (Figure 6.1) which is 
inserted into the renal pelvis through tissue that will be subsequently removed as part 
of the procedure.  
• An intra-renal pelvis urine sample is obtained for urinary aquaporin measurement. 
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• Samples of renal pelvis and ureter obtained from the narrowed pelvi-ureteric junction 
(removed as part of the pyeloplasty procedure) are obtained for aquaporin analysis.   
• The operative data collection form is completed by the operating surgeon at the end 
of the procedure detailing the procedure performed, the kidney pressure and the 
samples collected.                   
Post-operatively a urine sample is collected every 24 hours until the child is discharged from 
hospital (usually within 2-5 days).  Initially this is taken from the bladder catheter collection 
bag, however once the catheter is removed voided samples are collected either into a 
specimen pot or from the nappy. 
No changes to the routine post-operative radiological and clinic follow-up have been made 
for the study. The length of post-operative follow-up varies but is usually between 3 months 
and 2 years. When the child is discharged from clinic follow-up participation in the study 
concludes (Figure 6.2).  
The initial requirement for the study was that at each outpatient visit the child would provide 
a urine specimen for aquaporin measurement and a follow-up data collection form would be 
completed.  Unfortunately, it has proved exceptionally difficult to identify these patients 
when they return for follow-up, especially as many are reviewed in outreach outpatient 
clinics across the South-West of England.  Additionally, transport of urine samples on ice 
from these clinics for processing in Bristol would take many hours and would likely 
adversely affect the results of the study. Consequently, follow-up samples have not been 




Figure 6.1 Equipment used to measure intrarenal pelvis pressure in group 1 patients 
A Rocket® Spinal manometer connected to the needle from a 22G cannula (Venflon™) is inserted into the 
dilated renal pelvis while the child is under general anaesthetic prior to performing the pyeloplasty. When 
performing pressure measurement, the needle is inserted keeping both the needle and hub of the manometer at 
the level of the renal pelvis while the manometer is perpendicular to the renal pelvis.  
 
6.2.1.2 Group 2 – Children with hydronephrosis not requiring surgery 
Group 2 consists of children with hydronephrosis but no evidence of other causes of urinary 
tract obstruction.  These children are identified when they attend urology outpatient clinics. 
The family are provided with patient information leaflets on arrival in clinic and the 
consulting clinician obtains consent for inclusion in the study if the family are agreeable. 
Following enrolment into the study a urine sample is obtained and a data collection form 
completed at all clinic appointments until they are discharged from follow-up.  The expected 
length of follow-up and thus study participation for these children is up to 4 years. It is 
anticipated that some children from group 2 may move into group 1 if they have progression 
of hydronephrosis and require a pyeloplasty for PUJO (Figure 6.2).  
6.2.1.3 Group 3 – Children with normal kidneys 
Group 3 consists of children with no kidney tract abnormalities attending general surgical or 
urology outpatient clinic for consultation regarding unrelated problems. The family are 
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provided with patient information leaflets on arrival in clinic and the consulting clinician 
obtains consent for study inclusion if the family wish to take part. Following enrolment into 
the study a urine sample is obtained, and a data collection form completed.  This concludes 
the involvement of this group of children in the study (Figure 6.2). 
 
Figure 6.2 Summary of childhood cross-sectional study of pelvi-ureteric junction obstruction 
  
6.2.1.4 Inclusion criteria 
Inclusion criteria into the study include: 
Group 1 - Children placed on a planned waiting list for a laparoscopic or open pyeloplasty. 
Group 2 - Children with hydronephrosis but no evidence of other causes of urinary tract 
obstruction other than PUJO attending urology outpatient clinics 
Group 3 - Children with no kidney tract problems attending general surgery/urology 
outpatient clinics for an unrelated issue. 
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6.2.1.5 Exclusion criteria 
Exclusion criteria from the study include: 
Group 1 - Children with other causes of urinary tract obstruction in addition to PUJO. 
Group 2 - Children with differential function <40% on MAG 3 renogram of the 
hydronephrotic kidney. Children with other causes of urinary tract obstruction other than 
PUJO. 
Groups 1-3 - Children taking medicines which affect kidney function or act on the kidney. 
Children who have concurrent intrinsic kidney disease. 
6.2.1.6 Consent for study participation 
Informed consent from at least one parent/carer with parental responsibility is required for 
all groups of children recruited.  Consent is obtained for group 1 patients by the chief 
investigator. Consent for groups 2 and 3 patients is obtained by the treating NHS clinician. 
Older children may give assent (in addition to parental consent) to be included in the study. 
Due to the nature of the study, consent is obtained for the removal (consent under common 
law), storage (consent under Human Tissue Act), and use (consent under Human Tissue Act) 
of human tissue.  Consent is also gained for access to medical records. Families can choose 
whether they will give generic consent for the tissue and urine samples to be used for 
ongoing/future research projects or specific consent just for this study. Thus far all families 
have given generic consent. See appendix 3 (section 10.3.3) for copies of the consent forms 
used in the study.  
6.2.2 Ethical approval and study amendments  
In this study the initial IRAS application was followed by a meeting with the South West - 
Central Bristol Research Ethics Committee in July 2014. A provisional favourable opinion 
was given provided that certain modifications to the study protocol were made. The major 
issue was the inclusion in the original study protocol of a Tru-cut® biopsy from the 
obstructed kidney for aquaporin analysis during the pyeloplasty. Following discussion with 
the Research Ethics Committee this was removed from the study protocol and after some 
other minor adjustments the study was approved in November 2014. 
During the study any change to the protocol or study paperwork was subject to approval of 
an amendment which was submitted to the Research Ethics Committee and Research and 
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Innovation departments. Details of the requested amendments were submitted via the IRAS 
system and required authorisation by the study sponsor. Amended copies of the study 
protocol and/or study paperwork were also submitted complete with updated version 
numbers and dates. Depending upon the particular amendment, recruitment to the study 
sometimes needed to halt while approval was awaited.  Table 6.1 details all amendments 







6.11.14 Substantial REC Change of informed consent for 
group 1 patients to require only 1 
rather than both parental 
signatures. Approval to use 
urinary tract tissues not suitable 
for transplant (obtained as part of 
another ethically approved study) 
to develop molecular biological 
techniques for this study. 
Correction of mistakes on patient 
information leaflet and study 
protocol. 
Approved 
31.5.15 Substantial REC Appointment of Acting Chief 
Investigator during a period of 
maternity leave for the Chief 
Investigator 
Approved 
16.9.15 Substantial R+D Appointment of Acting Chief 
Investigator during a period of 
maternity leave for the chief 
Investigator 
Approved 
15.6.16 Minor  REC  
R+D 
Re-instate original Chief 




Table 6.1 Study amendments  
During the study 2 substantial and 1 minor amendments have been submitted to the Research Ethics Committee 




6.2.3 Study documentation 
The implementation of a new study requires the design and production of a significant 
amount of study specific and supporting documentation which is included in appendix 3 
(section 10.3). Documentation utilised within this study includes: 
• Study protocol which details all aspects of how the study is conducted  
• Specific patient information leaflets for adults, young people and children for each 
of the three groups  
• Specific consent forms for participation in the study including assent forms for older 
children for each of the three groups 
• Data collection forms for each of the three groups 
o Group 1 – operative case report forms and post-operative case report forms 
o Group 2 - recruitment case report forms and follow-up case report forms 
o Group 3 – case report forms 
• GP letter detailing inclusion in the study which is dispatched for each child recruited 
to group 1 
6.2.3.1 Investigator site file 
In accordance with the principles of ICH-GCP (International Conference on Harmonisation 
– Good Clinical Practice) certain essential documents must be established prior to onset of 
the study, maintained throughout the study and retained following the completion of the 
study. This is to ensure the conduct of the study and the quality of data produced can be 
easily evaluated. These documents are collectively held within an investigator site file (ISF) 
which is maintained by the principal investigator at the study site. The principal investigator 
for this study is Mr Mark Woodward, Consultant Paediatric Surgeon, Bristol Royal Hospital 
for Children.  Documentation contained within the investigator site file for this study 
includes: 
• Details of study personnel including up to date Curriculum Vitae’s and records of 
GCP training 
• Site staff log and delegation of study tasks 
• Subject screening and recruitment record enabling the calculation of recruitment 
rates 




• Record of retained urine and tissue samples and their storage location 
• Details of research safety reporting 
• Copies of current and previous versions of study specific documentation such as 
patient information leaflets, consent forms, GP letters, study protocol 
• Copies of the Research Ethics Committee and Research and Innovation Department 
approvals for commencement of the study 
• Record of amendments made and dates of approval by the Research Ethics 
Committee and the Research and Innovation Department 
Data is being collected and retained in accordance with the Data Protection Act 1998. 
6.2.3.2 EDGE clinical management system 
Local recruitment data is uploaded to the EDGE clinical management system to enable real 
time assessment of study progress. 
6.2.4 Sample collection  
6.2.4.1 Group 1 
Tissue and urine samples are obtained with consent and appropriate ethical approval on the 
day of surgery. The renal pelvis and ureter samples are dissected out from the narrowed 
pelviureteric junction resected at the time of pyeloplasty (Figure 6.3). The samples are placed 
into separate collection tubes in ice cold PBS, put immediately onto ice and transferred to 
the laboratory. The tissues are washed 5 times in ice-cold PBS. For each renal pelvis and 
ureter specimen at least 2 samples are snap frozen in liquid nitrogen and stored at -80 °C for 
RNA and protein analysis while 1 renal pelvis sample and 1 ureter sample are placed in 10% 




Figure 6.3 Human tissue sample preparation for storage and formalin fixation 
The narrowed pelvi-ureteric junction is resected (as marked by dotted line) by standard technique during the 
pyeloplasty (A). The resected specimen is further cut (as marked by dotted line) to generate two separate 
specimens for aquaporin analysis; The renal pelvis proximal to the narrowing and the ureter distal to the 
narrowing (B). The renal pelvis and ureter specimens are immediately cut into at least 3 samples. Two samples 
are snap frozen in liquid nitrogen and stored at -80°C for later RNA and protein extraction. At least one sample 
from each renal pelvis and ureter specimen is placed into 10% neutral buffered formalin at 4 °C. 
 
Fresh urine samples obtained from the bladder (voided pre-operatively and/or by urinary 
catheter intra-operatively) and the obstructed renal pelvis (aspirated intra-operatively) are 
collected into 50 ml centrifuge tubes and placed immediately onto ice and transferred to the 
laboratory. Chapter 2 (section 2.17.2) contains details of further processing procedures.  
6.2.4.2 Group 2 
A single urine sample from a patient recruited to group 2 was obtained intra-operatively by 
bladder catheter on the 20/9/16 and collected into a 50 ml centrifuge tube, placed 
immediately onto ice and transferred to the laboratory. This patient was due to have a 
pyeloplasty for suspected PUJO however at operation was noted to have a grossly 
hydronephrotic kidney with ectopic ureteric insertion and so underwent a nephrectomy. This 
patient had initially been recruited to group 1 but was transferred to group 2 following the 
operative findings. Further samples for this group however will be collected at routine 
outpatient clinics in the same manner as those for group 3 (see below).  
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6.2.4.3 Group 3 
Urine samples for children recruited to group 3 were obtained with consent and appropriate 
ethical approval at routine outpatient clinic appointments. Fresh voided urine samples were 
collected into 50 ml centrifuge tubes and placed immediately onto ice and transferred to the 
laboratory. Chapter 2 (section 2.17.2) contains details of further processing procedures.  
6.2.5 Outcome measures 
6.2.5.1 Primary outcome measure 
The primary outcome measure is the first bladder urine aquaporin level when recruited into 
the study. This may be collected intra-operatively for group 1 patients. Comparison of this 
first aquaporin level between children with PUJO requiring surgery (group 1) and children 
with non-obstructive hydronephrosis (group 2) will enable assessment of whether urine 
aquaporin levels are good biomarker to aid surgical decision making in PUJO.  
Additionally, assessment of the urine aquaporin levels in children with no kidney 
abnormality will enable us to determine whether age, gender or size has any impact on 
normal urine aquaporin levels. 
6.2.5.2 Secondary outcome measures 
• Tissue (renal pelvis and ureter) aquaporin levels 
• Intra-operative renal pelvis urine aquaporin levels 
• Kidney pressure (measured intra-operatively) 
• Pre-operative split kidney function (measured by MAG 3 renogram or DMSA) 
• Post-operative urine aquaporin levels in group 1 patients 
• Follow-up urine aquaporin levels in group 2 patients 
6.2.6 Study sample size 
The primary outcome will be analysed by comparing group 1 and group 2 urine aquaporin 
levels.  It is known that approximately 20 children per year undergo a pyeloplasty for PUJO 
at the Bristol Children's Hospital.  It is anticipated approximately 75% of these children will 
be recruited which equates to 30 children over 2 years.  Recruitment to group 2 will be faster 
as children suitable for inclusion are seen in greater numbers throughout the year.  Children 
will therefore be recruited in a 4:1 manner with 4 children in group 2 to every child in group 
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1.  This method of recruitment will increase the sample size and power of the study while 
keeping the number needed to recruit in group 1 achievable within an appropriate timescale.  
Current studies suggest a target difference of 30% between groups 1 and 2 is feasible.  It is 
currently unclear what degree of variability there is in the data.  If the target difference is 
hypothesized to be to 0.75 of the standard deviation of the data then with a 4:1 recruitment 
method, a significance of 5% and a power of 80% it is estimated the minimum number of 
children to be recruited is: 
• Group 1: 18 children 
• Group 2: 70 children  
Recruitment of children in group 3 (no kidney abnormality) is necessary to determine normal 
urine aquaporin levels across ages 0-15 years. For simplicity the aim is to recruit similar 
numbers to group 2.  
In view of the fact it is estimated up to 30 patients could be recruited over two years the 
target is to recruit 30 children to group 1 and 80 children to each of groups 2 and 3.  
6.2.7 Statistical analysis 
Data is presented as mean +/- SEM except for the graphical representation of renal pelvis 
pressure which is presented as the median value due to the non-parametric appearance of the 
data.  Any data group containing only a single result was not included in statistical analyses. 
Comparison of two groups was performed using an unpaired two tailed t-test. Correlation of 
results was assessed using an XY scatter plot and Pearson’s correlation test. P<0.05 was 
accepted as statistical significance.  
 
6.3 Methods - Western blotting and immunohistochemistry of human 
urinary tract samples unrelated to the childhood study 
All western blotting and immunohistochemistry results presented in this chapter were 
performed on tissue obtained from human kidneys with their associated renal pelvis and 
ureter which had been prepared for transplant but were later deemed clinically unsuitable. 
These kidneys were collected by our laboratory (Academic Renal Unit), with full consent 
for research, as part of another NHS REC approved study (Ref: 06/Q2002/101).     
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All urine samples used in western blotting results presented here were normal adult urine 
samples processed by ultrafiltration to concentrate the AQP 1 protein.  
RT-PCR, western blotting, immunohistochemistry and urine ultrafiltration techniques were 
all undertaken as described in the methods section of Chapter 2. 
 
6.4 Results - childhood cross-sectional study of PUJ obstruction 
6.4.1 Demographic data of study population 
To date, all families approached for recruitment into groups 1 and 2 have participated in the 
study giving a 100% recruitment rate. Study participation, of those approached, for group 3 
patients is currently slightly lower at 85%, where 11 out of 13 families agreed to take part. 
The reasons given for non-participation in potential group 3 recruits were, lack of time 
following the outpatient clinic appointment and the child not being toilet-trained.   
When comparing general recruitment for groups 1-3 a male predominance was noted across 
all groups but particularly so for group 3 children (Figure 6.4A). Group 1 contains a 
statistically significantly lower age group than group 3. The mean age of group 1 children at 
recruitment and surgery was 17.7 +/- 6.6 months compared to 7 years and 5 months +/- 16 




Figure 6.4 Demographic details of study population 
Bar chart comparing the gender distribution of children recruited to the 3 groups in the PUJO study. A male 
predominance in each group was demonstrated (A). Vertical scatter plot comparing the ages of children 
recruited to each group of the study population. *p = 0.0018 compared to group 3. Individual data points and 
mean +/- SEM are presented (B). 
 
 
6.4.2 Group 1 results 
To date 8 children have been recruited to group 1. The male to female ratio in this group was 
5:3 with a mean age at recruitment and surgery of 17.7 +/- 6.6 months (Figure 6.4). An 
antenatal diagnosis of hydronephrosis was made in 89% (7/8) of children, while 1 child 
presented at 7 months of age with pyelonephritis.  
Three-quarters of children had left sided PUJO which in 2 children was associated with a 
solitary left kidney.  One child had right sided PUJO while the remaining child presented 
with bilateral disease (Figure 6.5A).  
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Most children underwent surgery due to increasing hydronephrosis (4/8), while 3/8 children 
had a renal pelvis APD ≥30 mm. The remaining child underwent a pyeloplasty for reduced 
function on the affected side (Figure 6.5C). Overall left sided pyeloplasties were performed 
in three-quarters (6/8) of children and no child underwent bilateral pyeloplasty (Figure 
6.5D). All children underwent an open dismembered Anderson-Hynes pyeloplasty. 
Half of all children (4/8) experienced at least one urinary tract infection prior to surgery 
(Figure 6.5B), three-quarters of these children (3/4) were taking antibiotic prophylaxis at the 
time of surgery. Overall, at the time of surgery, half of children (4/8) were taking antibiotic 
prophylaxis.  
None of the children were taking any medication other than antibiotic prophylaxis, gavison 
and abidec vitamin supplements.  
The mean renal pelvis APD on the last pre-operative ultrasound scan was 30.2 +/- 2.9 mm 
(Figure 6.6A).  Pre-operative calyceal dilatation of the obstructed kidney was noted in 7/8 
children while cortical thinning was noted in 3/6 children. In 2 children the presence or 
absence of cortical thinning of the obstructed kidney was not documented (Figure 6.6B). The 
last pre-operative ultrasound scan was performed a mean of 3.3 months (+/- 1.1 months) 
prior to the surgery.  
Three-quarters of children (6/8) underwent MAG 3 renogram at a mean of 7.3 months (+/- 
2.1 months) prior to surgery. Five out of six children demonstrated retained split function in 
the obstructed kidney. In one child the split function on MAG 3 renogram was 30% in the 
obstructed kidney. In the remaining 2/8 children, 1 had a DMSA scan which demonstrated 
equal split function, and the other child underwent early pyeloplasty without pre-operative 
radioisotope renography due to substantial bilateral hydronephrosis.   All MAG 3 renograms 
demonstrated delayed drainage and obstructed systems with either type 2 or type 3b curves 
(Table 6.2).  
A pre-operative MCUG was performed in 5/8 children. This study was normal in 3 children 





Figure 6.5 Group 1 demographic details 
Pie charts demonstrating details regarding group 1 patients: The laterality of PUJO (A). The presence or 
absence of pre-operative urinary tract infections (B). The main radiological indication for surgery (C). The 
laterality of the open pyeloplasty performed (D). 
 
Intra-operative bladder and obstructed renal pelvis urine samples along with renal pelvis and 
ureteric tissue specimens were collected from all children. The renal pelvis pressure of the 
obstructed kidney was measured in all children and had a median value of 1 cmH2O and 




Figure 6.6 Pre-operative renal ultrasound scan features of children in group 1 
Vertical scatter plot demonstrating renal pelvis APD measurements of the obstructed kidney prior to 
pyeloplasty in children recruited to group 1 of the PUJO study. Individual data points and the mean +/- SEM 
are presented (A). Stacked bar chart presenting the number of children with calyceal dilatation and/or cortical 
thinning of the obstructed kidney prior to pyeloplasty in children recruited to group 1 of the PUJO study. In 2 
children the presence or absence of cortical thinning on the pre-operative renal ultrasound scan was unknown 








Figure 6.7 Intra-renal pelvis pressure measurements from group 1 children  
Vertical scatter plot illustrating the renal pelvis pressures measured in children undergoing pyeloplasty in group 
1 of the PUJO study. Individual data points and the median value are presented (A). Scatter plot of renal pelvis 
APD versus renal pelvis pressure of the obstructed kidney for children in group 1 with PUJO. No correlation 
was detected between renal pelvis APD and renal pelvis pressure R2 = 0.1176 (B). Scatter plot of the split 
function (MAG 3 renogram or DMSA) versus renal pelvis pressure of the obstructed kidney for children in 
group 1 with PUJO. No correlation was detected between the parameters R2 = 0.4056. Two results were omitted 
as the child had a solitary kidney with a split function value of 100% (C).  
 
No correlation was detected between the intra-operative renal pelvis pressure and either the 
pre-operative sonographic renal pelvis APD measurements (R2 = 0.1176, (Figure 6.7B) or 
the pre-operative split function on radioisotope renograms (R2 = 0.4056, Pearson’s 
correlation coefficient) (Figure 6.7C). Three children were excluded from the analysis of 
renal pelvis pressure versus split renal function: One child had not had pre-operative 
radionuclide imaging and 2 children had solitary kidneys rendering their split function at 
100% which would confound the results. Table 6.2 summarises the demographic details and 
results for group 1. 
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on MAG 3 
renogram 




1 M 10 Y Unilateral - SK Y 27 100 3b Normal Left 1 









4 F 10 Y Unilateral  N 21 54 2 Normal Left 4 
5 M 18 N Unilateral  Y 30 44 2  Left 6 
6 M 41 Y Unilateral  N 26 54 3b  Left 20 
7 F 4 Y Unilateral - SK N 42 100 3b  Left 0 
8 M 52 Y Unilateral  N 30 30 2 Normal Right 0 
 
Table 6.2 Demographic details of group 1 recruits 
Demographic details of the 8 children recruited pre-operatively to group 1 of the PUJO study. APD – anteroposterior diameter of renal pelvis, DMSA – 
dimercaptosuccinic acid, F – female, MAG 3 – mercapto acetyl tri glycine, M – male, MCUG – micturating cystourethrogram, N – no, PUJO – pelvi-ureteric junction 








6.4.3 Group 2 results 
A single child was recruited to group 2. A four- month old male infant with an antenatal 
diagnosis of hydronephrosis. He was recruited during his admission where he underwent a 
left nephrectomy for a grossly dilated poorly functioning kidney with an ectopic ureter. Split 
function of the hydronephrotic kidney was 11% on pre-operative DMSA renography. An 
intra-operative bladder catheter specimen at the commencement of surgery was obtained.    
6.4.4 Group 3 results 
Eleven patients were recruited while attending routine general surgery/urology outpatient 
clinics however only 9 were able to give a urine sample at the time of clinic attendance 
(Table 6.3). None of the children were taking any medication. The recruited children showed 
a male preponderance similar to group 1. Mean age at recruitment and provision of the urine 
sample was 7 years and 5 months +/- 16 months (Figure 6.4). 
ID Sex Age  Reason for clinic attendance 
1 M 2y 4m Undescended testis 
2 M 11y 4m Post-op hypospadias repair  
3 M 3y 8m Undescended testis 
4 M 14y 2m Buried penis correction and circumcision for BXO 
5 M 6y 9m Physiological phimosis 
6 M 6y 4m Post-op drainage of peri-anal abscess 
7 F 12y 10m Vaginal reflux 
8 F 11y 3m Bartholins cyst 
9 M 5y 11m Post-op meatotomy 
 
Table 6.3 Demographic details of group 3 recruits 
Demographic details of the 9 children recruited from outpatient clinic to group 3 of the PUJO study who 
provided a voided urine sample on the day of recruitment.  M – male, F – female. y – years, m – months. 
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6.5 Results - aquaporin expression and excretion by the normal human 
urinary tract 
Studies to develop laboratory techniques and ascertain general AQP isoform expression by 
the human urinary tract were undertaken on human kidney, renal pelvis and ureter tissue not 
suitable for transplant. This tissue was unrelated to samples obtained from the childhood 
study of PUJO which have not yet been analysed. Normal human adult urine samples were 
used to demonstrate typical urinary aquaporin excretion. The results are presented below. 
6.5.1 Aquaporin isoform mRNA expression in normal human kidney, renal 
pelvis and ureter  
Endpoint RT-PCR established that human kidney expresses AQPs 1-7 and 11 at the mRNA 
level (Figure 6.8) Sequencing of the AQP7 double bands (Eurofins MWG Operon, 
Germany) demonstrated that the lower 200bp band is AQP7 while the upper 400bp band 
represents an AQP7 pseudogene, consistent with reports from Rubenwolf et al. [259]. The 
detection of AQPs 1-6 in human kidney is consistent with the amalgamated results from 
other human studies (See Chapter 1, Table 1.8). Additionally, AQPs 7 and 11 are now known 
to be expressed by human kidney at the mRNA level. 
Subsequent analysis of whole human renal pelvis and ureter samples demonstrated that the 
renal pelvis expresses AQPs 1-7, 9 and 11 at the mRNA level but not AQPs 0 or 12.  Faint 
bands for AQPs 8 and 10 suggest these isoforms may also be expressed by human renal 
pelvis (Figure 6.9). Whole human ureter expresses AQPs 1-11 but not AQP 0 or AQP 12 
(Figure 6.10).   




Figure 6.8 AQP isoform mRNA expression by human kidney 
Endpoint RT-PCR was performed using mRNA extracted from whole normal human kidney and the product 
run on 2% agarose gels. Bands of the appropriate size for AQP isoforms 1, 2, 3, 4, 5, 6, 7 and 11 and β-actin 
were noted indicating they are expressed at the mRNA level by whole human kidney. See appendix 2 (section 
10.2.1.1) for product sizes.  Sequencing of the AQP7 bands confirmed that the lower band of the appropriate 
size is AQP7 and the upper band is a pseudogene as previously published. NTC – no template control. The 
hazy opacities at 250 bp on the second gel represent an artefact of loading buffer as explained in Chapter 3 





Figure 6.9 AQP isoform mRNA expression by human renal pelvis 
Endpoint RT-PCR was performed using mRNA extracted from whole normal human renal pelvis and the 
product run on 2% agarose gels. Bands of the appropriate size for AQP isoforms 1, 2, 3, 4, 5, 6, 7, 9 and 11 
and β-actin were expressed at the mRNA level by human whole renal pelvis. Faint bands for AQPs 8 and 10 
suggest these isoforms may also be expressed at low level by human renal pelvis. The upper band of the AQP7 
double band represents the AQP7 pseudogene while the lower band corresponds to AQP7. See appendix 2 
(section 10.2.1.1) for product sizes. 
 
 
Figure 6.10 AQP isoform mRNA expression by human ureter 
Endpoint RT-PCR was performed using mRNA extracted from whole normal human ureter and the product 
run on 2% agarose gels. Bands of the appropriate size for AQP isoforms 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 and 11 and 
β-actin were expressed at the mRNA level by human whole renal pelvis. The upper band of the AQP7 double 
band represents the AQP7 pseudogene the lower band corresponds to AQP7.  See appendix 2 (section 10.2.1.1) 




6.6 Aquaporin protein expression by human kidney, renal pelvis and 
ureter 
6.6.1 Aquaporin 1 
Glycosylated (35-40 kDa) and non-glycosylated (25 kDa) AQP1 is expressed by human 
kidney cortex and medulla as well as whole renal pelvis and ureter (Figure 6.11). 
Interestingly glycosylated AQP1 in human kidney produces a band of higher molecular 
weight (40 kDa) than that of human ureter and renal pelvis (35kDa) which is discussed 
below.  
Immunohistochemistry confirms AQP1 expression within the cortex and medulla of the 
human kidney. AQP1 is expressed by the apical and basolateral membranes of the proximal 
tubules and loops of Henle. It is also expressed by the endothelial cell membranes of the 
vasa rectae. (Figure 6.12A-D).  AQP1 is also detected in the vascular endothelial cell 
membranes of the renal pelvis (Figure 6.12E, F) and ureter (Figure 6.12G, H) lamina propria. 
 
Figure 6.11 AQP1 protein expression by human urinary tract tissue 
Western blot demonstrating that glycosylated and non-glycosylated AQP1 is expressed in both the kidney 
cortex and medulla as well as whole renal pelvis and ureter. Glycosylated AQP1 in the renal pelvis and ureter 




Figure 6.12 Immunohistochemistry demonstrating the distribution of AQP1 expression within human 
urinary tract tissue 
AQP1 expression is demonstrated in the apical (arrowhead) and basolateral (arrow) membranes of the proximal 
tubules within the kidney cortex (A, B). AQP1 expression in the loop of Henle and vasa recta but not within 
collecting ducts is seen in the kidney medulla (C, D). AQP1 is also detected in the vascular endothelial cells 
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(arrow) in the lamina propria of the renal pelvis (E, F) and ureter (G, H). CD – collecting duct, G – glomerulus, 
L – lumen, LH – Loop of Henle, PT- proximal tubule, UR – Urothelium, VR – vasa recta containing red blood 
cells. No primary antibody negative controls are presented for each section. Scale bar = 25 μm. 
 
 
6.6.2 Aquaporin 2 
AQP2 is expressed by human kidney, renal pelvis and ureter as demonstrated by western 
blotting showing a 31 kDa band for each of these samples (Figure 6.13). 
Immunohistochemistry confirms that both the kidney cortex and medulla express AQP2 in 
the apical membranes of the collecting ducts (Figure 6.14A-D). Contrary to the western 
blotting results immunohistochemistry of renal pelvis and ureter samples did not show any 
protein expression either in the urothelium or deeper layers (Figure 6.14E-H).   
 
Figure 6.13 AQP2 protein expression by human urinary tract tissue 
Western blot demonstrating AQP2 expression by human kidney cortex and whole renal pelvis and ureter.  
AQP2 expressed by HEK 293 cells is noted at the same molecular weight. Positive controls - rat spleen and rat 





Figure 6.14 Immunohistochemistry demonstrating the distribution of AQP2 protein expression within 
human urinary tract tissue 
AQP2 is expressed by the apical membranes (arrow) of the kidney cortical collecting ducts (A, B) and 
medullary collecting ducts (C, D). AQP2 was not detected in the urothelium of human renal pelvis and ureter. 
CD – collecting duct, G-glomerulus, L – lumen, UR – urothelium. No primary antibody negative controls are 
presented for each section. Scale bar = 25 μm. 
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6.6.3 Aquaporin 3 
AQP3 protein expression (28 kDa) by human kidney cortex and medulla as well as whole 
renal pelvis and ureter was demonstrated by detection of the appropriate 28 kDa band on 
western blotting (Figure 6.15). Subsequent immunohistochemistry confirmed that AQP3 
was expressed by the basolateral membranes of the cortical and medullary collecting ducts 
of the kidney (Figure 6.16A-D). AQP3 was abundantly expressed by the urothelium of the 
renal pelvis and ureter with predominantly cell membrane, but also cytoplasmic, expression 
thoughout all layers of the urothelium. Contrary to previous reports [249, 259] the apical 
membrane of the umbrella cells (best seen on the renal pelvis images) did appear to express 
AQP3 (Figure 6.16E-H).    
 
Figure 6.15 AQP3 protein expression by human urinary tract tissue 
Western blot demonstrating AQP3 expression by human kidney cortex and medulla, and whole renal pelvis 
and ureter.  AQP3 expression by rat kidney and bladder is noted at the same molecular weight.  AQP3 and 






Figure 6.16 Immunohistochemistry demonstrating the distribution of AQP3 protein expression within 
human urinary tract tissue 
AQP3 is expressed by the basolateral membranes (arrow) of the kidney cortical collecting ducts (A, B) and 
medullary collecting ducts (C, D). AQP3 is also abundantly expressed by all layers of the urothelium within 
human renal pelvis (E, F) and ureter (G, H). The urothelial cell membrane shows predominant expression 
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however cytoplasmic expression is also noted. CD – collecting duct, G-glomerulus, L – lumen, UR – 
urothelium. No primary antibody negative controls are presented for each section. Scale bar = 25 μm. 
 
6.6.4 Aquaporin 4 
Detection of an appropriate 34 kDa band on western blotting demonstrated that AQP4 was 
expressed at the protein level by human kidney cortex and medulla. AQP4 expression was 
not detected in whole human renal pelvis and ureter samples (Figure 6.17). As discussed in 
chapter 3, despite testing two different antibodies using different antigen retrieval techniques 
accurate detection of AQP4 by immunohistochemistry was not achieved within the time 
constraints of the project. Immunohistochemistry for AQP4 was therefore not performed on 
human samples.  
 
Figure 6.17 AQP4 protein expression by human urinary tract tissue 
Western blot demonstrating AQP4 expression by human kidney cortex and medulla. AQP4 was not detected 
in human renal pelvis and ureter. AQP4 expression by rat kidney and bladder is noted at the same molecular 




6.7 Aquaporin protein excretion in human urine 
Western blotting of adult human urine samples concentrated by ultrafiltration indicated that 




Figure 6.18 Non-glycosylated AQP1 excretion in human urine 
Western blot demonstrating the excretion of non-glycosylated AQP1 in two independent samples of human 
urine. Positive controls – rat bladder and rat kidney. B-actin was used as loading control for the tissue samples 
and as expected was not excreted in urine.  
 
 
Figure 6.19 AQP2 excretion in human urine 
Western blot demonstrating the excretion of AQP2 in human urine. Positive control – HEK 293 cell lysate, 
negative control – rat eye. B-actin was used as loading control for the control samples and as expected was not 






Figure 6.20 Western blot demonstrating lack of AQP3 excretion in human urine 
Western blot demonstrating that AQP3 is not excreted in human urine. AQP1 was used as loading control for 




The enthusiasm of children and families to be recruited into this study has been remarkable. 
A 100% recruitment rate following screening for groups 1 and 2 is excellent and 
demonstrates that families feel this study is worthwhile. A lower recruitment rate of 85% 
following screening for group 3 is not unexpected yet still very good. The reasons given for 
non-participation in group 3 (lack of time, child not toilet trained) were anticipated given the 
short time interval between screening and recruitment and the time pressures associated with 
families visiting the outpatient department.     
Generally, the study is running very well. The major difficulty identified so far has been the 
failure to obtain follow-up urine samples in outpatient clinic from any of the group 1 patients 
recruited.  In part this has been due to difficulties identifying these children when they return 
for follow-up, particularly as many are reviewed in outreach outpatient clinics with different 
sets of patient notes across the South-West of England.  Furthermore, transport of urine 
samples on ice from these distant clinics for processing in Bristol would take many hours 
and may adversely affect the results of the study. Although samples could be placed in liquid 
nitrogen for transport, ideally they need to be aliquoted first to avoid subsequent freeze- 
thawing. Aliquoting of samples wouldn’t be possible within the time constraints and 
facilities of an NHS clinic. The decision has therefore been made to concentrate on obtaining 
follow-up samples from children attending Bristol Children’s Hospital initially.  In terms of 
children reviewed within Bristol, difficulties have been encountered due to the changeover 
to a computerised notes system (Evolve). Originally the method to identify study participants 
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was the insertion of a sticker on the patient notes to remind the clinician to undertake study 
follow-up. With the introduction of computerised notes this system became obsolete. Steps 
are now being taken alongside the Evolve administrators to add study participation to the 
patient alerts on the computerised system. 
Thus far 8 children have been recruited to group 1, 1 child to group 2 and 11 children to 
group 3 (although only 9 provided urine samples).  There is still a distance to go in terms of 
meeting the sample size target however the study is still running and there is permission for 
recruitment to continue until 2020.   
Generally, the recruited population is as expected with a male predominance in group 1 of 
1.7:1. This ratio is slightly lower than the reported M:F ratio of 3:1 and is likely due to the 
currently small sample size. Interestingly there is also a male predominance in group 3 which 
is likely because most children have been recruited from urology clinics where there is a 
preponderance of male referrals due to the nature of the conditions managed. This can be 
easily rectified by recruiting from a wide range of general surgical clinics with a more 
balanced male to female ratio.  
Children recruited to group 3 were also noted to be significantly older than those recruited 
to group 1. Again, this can be easily rectified by ensuring clinics that have a younger patient 
base are included in patient recruitment.  
Children undergoing surgery had a mean age of 17.7 months. This is consistent with 
observations by Ulman et al. who suggests the first two years of life as being the most crucial 
to monitor children with hydronephrosis as this is the time period over when most 
pyeloplasties are performed [62].  
Consistent with current literature an antenatal diagnosis of hydronephrosis was made in 89% 
of children operated for PUJO, three-quarters of children had left sided PUJO and bilateral 
disease occurred in 12.5% of children [436]. Equally, the indications for surgery in group 1 
were all consistent with current usual practice [56].   
All children recruited to group 1 so far underwent an open dismembered Anderson-Hynes 
pyeloplasty. This was intentional, as currently a method to measure pressure within the 
kidney during a laparoscopic pyeloplasty has not been devised.  The ethical approval for the 
study includes laparoscopic pyeloplasty therefore there is potential for children undergoing 
this procedure to be included, as and when possible, at a later date.  
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Interestingly, 1 child experienced deterioration of function (30% split function on MAG 3 
renogram) in the obstructed kidney while half of all children experienced at least one urinary 
tract infection prior to being considered for surgery. These complications highlight the need 
for earlier identification of children requiring surgery for PUJO which may be achieved via 
the identification of new biomarkers. 
The median renal pelvis pressure of the obstructed kidney was within normal limits at 1 
cmH2O (range 0-20 cmH2O). Based on known normal [46] and pathological [113, 114] 
baseline renal pelvis pressures only 1 out of 8 children had a raised renal pelvis pressure (20 
cmH2O) at the time of surgery.   Similar to the results of the rat model presented in Chapter 
5, no correlation was detected between the pre-operative sonographic renal pelvis APD and 
the intra-operative renal pelvis pressure measurements. This indicates that the renal pelvis 
APD measurement is likely a poor predictor of the presence or absence of damaging raised 
intra renal pressure.  However; the current sample size is small and this will need to be 
confirmed when all results are available at the end of the study. Additionally, the time 
difference between the pre-operative ultrasound scan and the intra-operative pressure 
measurement (mean 3.3 +/- 1.1 months), as well as the impact of factors affecting urine 
output and thus renal pelvis pressure (length of pre-operative fasting and intra-operative 
hydration) must be considered. 
Likewise, no correlation was detected between the pre-operative split renal function 
(measured by MAG 3 or DMSA renogram) and the intra-operative renal pelvis pressure 
measurement. Again, these results were confounded by a small sample size particularly 
given that the results of three children were excluded from the analysis. Valid results will be 
obtained after the study when sufficient sample size has been achieved.    
This childhood study has been designed to try and address some of the issues encountered 
when assessing previous studies in the search for non-invasive urine biomarkers to aid 
diagnosis, management and prognosis of PUJO.   
Many previous studies have included only healthy controls as comparator for children 
undergoing pyeloplasty for PUJO (Chapter 1,  
Table 1.6). Although these studies can highlight whether the potential biomarker is changed 
compared to the normal population, it is not helpful in terms of distinguishing children who 
require surgery from those who can be safely managed conservatively. This study has 
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addressed this issue by including two control groups; those with conservatively managed 
hydronephrosis as well as children with no urological abnormality. 
Additionally, the previous studies which assessed AQP1 and 2 excretion in childhood PUJO 
both assessed post-operative urine from the obstructed kidney only, and used the normal 
kidney as comparator [386]. While this is incredibly useful data which highlights the 
reduction in urinary AQP excretion from the obstructed kidney following surgery, it does 
not indicate whether this reduction can be detected pre-operatively in bladder urine which 
inevitably is a mixture from both kidneys.  This study assesses pre-operative bladder urine 
samples which are the most suitable non-invasive biomarker.   
Finally, we currently do not know why the natural evolution of PUJO leads to two very 
different outcomes. This study aims to address the potential role of the urothelium and 
specifically AQPs in this conundrum. 
In general, the advantages of this human study include: 
• Normal childhood urinary aquaporin levels will be defined for the first time  
• Comparison between groups 1 and 2 will determine whether urinary aquaporin 
measurement is a useful non-invasive biomarker to differentiate between those 
children with ‘damaging’ hydronephrosis who require surgery and those with ‘safe’ 
hydronephrosis which might resolve spontaneously.  Inherent bias which is 
acknowledged with this method is that the children who need surgery have been 
selected by current clinical and radiological measures. It would, however, be very 
difficult to avoid this.  
• Follow-up urine AQP levels in group 2 will provide a prospective cohort of children 
enabling the assessment of the early predictive value of urinary aquaporin 
measurement.  This will be achieved by comparing those children whose 
hydronephrosis resolves or remains stable with those who progress to need an 
operation and move into group 1.   
• Post-operative urinary aquaporin levels in group 1 children will determine the effect 
of pyeloplasty on aquaporin excretion. 
• The assessment of renal pelvis (pre-obstruction) compared with ureteric (post-
obstruction) tissue will enable investigation of the effect of obstruction on human 
urothelial AQP expression.   
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• The availability of corresponding radiological imaging and intra-operative pressure 
monitoring will enable us to correlate changes in tissue and urine aquaporin levels 
with currently used markers of severity, function and pressure. 
Initial testing of kidney, renal pelvis and ureter samples not suitable for transplant enabled 
the establishment of techniques which will be used in future analysis of samples from the 
childhood study. Furthermore, these experiments were utilised to delineate normal urinary 
tract AQP isoform expression in humans as described below.  
Endpoint RT-PCR demonstrated that human kidney expressed mRNA transcripts for AQPs 
1-7 and 11. AQPs 0, 8, 9 and 12 were not detected. The expression of AQPs 1-6 has been 
documented previously by other studies, however, the detection of both AQP7 and 11 is a 
new finding. This is not unsurprising, however, given that these isoforms are detected in 
other mammals (See Chapter 1, Table 1.8). Despite AQP8 [281] and 9 (demonstrated in 
Chapter 5) expression being noted in rat kidney these AQP isoforms have not been detected 
by others in human kidney [282, 287], which is corroborated by these results. Interestingly, 
previous studies of AQP9 expression by various rat and human tissues concluded that the 
tissue distribution of this particular AQP is quite different between the two species. For 
example, human AQP9 is expressed in peripheral leucocytes and tissues where they accrue 
while rat AQP9 is not [287].  
In accordance with previous studies AQPs 1-4 were all expressed by human kidney as 
demonstrated by both western blotting and immunohistochemistry. The cellular location of 
AQPs 1-3 by immunohistochemistry was as expected. AQP1 was expressed by the apical 
and basolateral membranes of the proximal tubular cells and the loop of Henle, as well as 
the endothelial cell membranes of the vasa rectae. AQP2 was expressed by the apical 
membrane of the cortical and medullary collecting ducts while AQP3 was expressed by the 
basolateral membrane of the cortical and medullary collecting ducts [187, 255]. AQP4 
expression was not assessed by immunohistochemistry due to lack of a suitable antibody.    
Whole human renal pelvis expressed mRNA transcripts for AQPs 1-7, 9 and 11. Faint bands 
on endpoint PCR were also appreciated for AQPs 8 and 10. Interestingly whole human ureter 
expressed AQPs 1-11. Neither renal pelvis nor ureter expressed AQPs 0 or 12 at the mRNA 
level. Although the bands are faint for AQPs 8 and 10 in human renal pelvis it is likely they 
are expressed given that there is definite expression by human ureter.  
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Rubenwolf et al. demonstrated that AQPs 3, 4, 7, 9 are expressed at the mRNA and protein 
level by urothelium. AQP11 was confirmed to be expressed by the urothelium at the mRNA 
level only, due to lack of a suitable antibody for protein work [259]. Together with the results 
from this study this suggests that AQPs 1, 2, 5, 6, 8 and 10 are expressed by non-urothelial 
elements of the renal pelvis and ureter as discussed below. 
AQPs 1-3 were present at the protein level by western blotting in both whole renal pelvis 
and ureter while AQP4 was not detected in either tissue. AQP4 would be expected to be 
present given the results of the RT-PCR in this study and the finding by others of the 
presence of AQP4 in human urothelium at the mRNA and protein level [259]. Inability to 
detect it on western blotting may reflect generally low expression levels within the 
urothelium, which forms a relatively small percentage of the tissue lysed within a ureter or 
renal pelvis specimen. Further work will involve establishing a satisfactory protocol for 
assessing tissue AQP4 expression by immunohistochemistry to confirm cellular location of 
expression. 
Another interesting finding on western blotting was that glycosylated AQP1 had a higher 
molecular weight in human kidney (40 kDa) compared to both renal pelvis and ureter (35 
kDa). This likely represents differential glycosylation between distinct tissue types as a post-
translational modification. Frokiaers group reported the glycosylated AQP1 band at 35-50 
kDa in human kidneys [187], however, renal pelvis or ureter samples have not been assessed 
by this group or indeed by any other groups previously for comparison. 
Cellular localisation of the AQP isoforms by immunohistochemistry demonstrated that 
AQP1 was present in the vascular endothelial cells of the lamina propria of both renal pelvis 
and ureter but was not detectable in urothelium. Although AQP1 expression has previously 
been reported in the capillary endothelial cells of rat ureter and bladder [249], its location 
within human ureter and renal pelvis has not previously been documented.  
AQP3 was abundant throughout all layers of the renal pelvis and ureter urothelium. 
Expression was predominantly localised to the cell membrane, but cytoplasmic expression 
was also noted. This concurs with previous findings in human urothelium [259] but contrasts 
with observations by Spector et al. who noted that in rat urothelium AQP3 was confined to 
the cell membrane with no cytoplasmic expression [249]. Differing from previous findings 
in both human and rat tissues, however, is that AQP3 in this study appeared to be expressed 
equally by all layers of the urothelium and specifically was expressed by the apical cell 
290 
 
membrane of the umbrella cells of the urothelium. In human urothelium expression has 
previously been reported to be strongest in the basal layers and faint or not present in the 
superficial umbrella cell layer [259], while in rat tissue AQP3 was reported to be absent on 
the luminal surface of the umbrella cells [249].  This observation is important because it is 
the umbrella cells which contact the lumen of the urinary tract and thus the urine flowing 
through.  AQP4 could facilitate transurothelial water transport across the apical membrane 
as it is reportedly expressed throughout all layers of human urothelium. Although, the 
authors describe the expression pattern as cytoplasmic [259], as noted by Khandelwal, 
review of the published images suggests that both AQP4 as well as AQP7 are present along 
the umbrella cell apical membrane [429].  It is too early to say whether AQPs such as AQP 
3, 4 and 7 have a definitive role in mass water transport across the urothelium or whether 
their function is simply related to regulation of cell volume and tonicity in the face of 
fluctuating hypertonic and hypotonic urine content. The fact that AQPs 3 and 7 also transport 
small uncharged molecules such as urea in addition to water [238, 239, 288, 324] expands 
their potential role to the dissipation of urea and other solutes from the urothelium. Further 
studies using knockout urothelial cell lines and AQP knockout mice under control of the 
uroplakin II promoter will enable testing of these potential mechanisms.  
Contrary to the RT-PCR and western blotting results, immunohistochemistry of human 
ureter and renal pelvis failed to demonstrate AQP2 in any area of the tissue. Contradictory 
reports regarding urothelial AQP2 expression are noted in the literature. AQP2 mRNA 
expression by rat whole ureter and bladder has been demonstrated by RT-PCR, which was 
localised by immunohistochemistry to the urothelial cytoplasm and cell membranes 
(excluding the apical surface of the umbrella cells) [249]. By contrast, AQP2 mRNA 
expression is absent in human urothelium [259]. Together, the results of this study and those 
of Rubenwolf suggest that AQP2 is likely not expressed by urothelium but may be expressed 
by another layer which was not identified on immunohistochemistry. The potential reasons 
for absent AQP2 staining on immunohistochemistry were discussed in Chapter 3. 
Continuing analysis of many samples from the childhood study paying attention to sample 
fixation and antigen retrieval techniques should resolve this issue.  Additionally, ongoing 
work developing immunohistochemistry for AQPs 4 – 11 (suitable antibodies permitting) 
will help to clarify the tissue location of the other AQP isoforms present in human renal 
pelvis and ureter. 
Consistent with other research, western blotting of ultrafiltered normal human urine in this 
study confirmed that AQPs 1 and 2, but not APQ3 are excreted into the urine. It is postulated 
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this differing excretion pattern occurs because AQPs are shed by an apical pathway. AQPs 
1 and 2 are apically sited in the proximal tubules and collecting ducts respectively while 
AQP3 is located in the basolateral cell membrane of the collecting ducts [370-372].  
Analysis of the human tissue and urine samples collected throughout the study has not yet 
commenced as the intention is to perform this in large batches to reduce inter-experimental 
error. As is evident from the data presented above and in Chapter 5, the major techniques 
are all established ready for analysis to begin.  To complement this work primers suitable 
for real time quantitative PCR will also be developed to assess mRNA as well as protein 
expression by human renal pelvis and ureter in PUJO.  
Although translation across species does not always occur, it is acknowledged, given the 
results of the neonatal rat model, that human urinary AQP1 measurement may not prove a 
successful biomarker. Many samples, however, will have been appropriately stored from a 
robust cross-sectional study which will be utilised in further analysis including proteomic 
studies, to identify other potential biomarkers which may facilitate the diagnosis and 
management of children with hydronephrosis. 
Ultimately this study has the potential to improve the management of many children who are 
antenatally diagnosed with hydronephrosis, both nationally and globally.  Development of 
urine aquaporin measurement as a non-invasive biomarker aims to identify children early who 
require a pyeloplasty for damaging hydronephrosis, while sparing those with safe 
hydronephrosis. Early identification of those who require surgery will reduce the risk of 
progressive damage to the kidney and reduce the need for repeated radiological imaging some 
of which is invasive and involves radiation. Furthermore, establishing the mechanism of 
dysregulation of tissue and urinary aquaporin expression will enable the future development 







The main conclusions from each chapter in this thesis are summarised in Table 7.1 below.  
Chapter Findings/Outcome 
3 Primers designed and validated to detect rat AQP isoforms 1-4 and 6-11 by 
endpoint and real-time PCR 
Primers designed and validated to detect AQP isoforms 0, 5 and 12 by 
endpoint PCR 
Western blotting technique optimised to detect AQP isoforms 1-4 in rat and 
human tissue  
Immunohistochemistry technique optimised to detect AQP isoforms 1-3 in 
rat and human tissue 
AQP1 ELISA developed to detect and quantify urinary excretion of AQP1 
by rats and humans  
4 Development of a technique to create partial unilateral ureteric obstruction 
in neonatal rats under recoverable general anaesthetic 
Development of a technique to measure intra-renal pelvis pressure under 










All findings are from 5-week old rats who underwent neonatal PUUO 
or sham procedure:  
PUUO rats show reduced body weight compared to sham  
Individual kidney weight is unchanged between all degrees of partially 
obstructed, contralateral and sham kidneys  
Intra-renal pelvis pressure is significantly increased in moderate 
hydronephrosis compared to sham, contralateral and non-operated kidneys 
Severely hydronephrotic kidneys show a reduced number of glomeruli per 
field of view and increased interstitial fibrosis compared to mild and 
moderate hydronephrosis, sham and contralateral kidneys 
Whole normal rat kidney expresses mRNA transcripts for AQPs 1-9 and 11 
AQP1 is expressed by the apical and basolateral membranes of the proximal 
tubules as well as the loop of Henle and vasa recta of normal rat kidney. 
Chapter 7. Conclusions and future work 
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AQPs 2 and 3 are expressed by the apical and basolateral membranes of the 
renal collecting ducts in normal kidney. 
AQP1, 2 and 6 mRNA expression is downregulated in the severely 
hydronephrotic kidney compared to sham. AQP3 expression is unchanged 
in obstruction while AQP4 shows a tendency towards downregulation in 
severe hydronephrosis compared to sham 
Non-glycosylated and glycosylated AQP1, AQP2 and AQP3 protein 
expression is unchanged in the obstructed kidney compared to sham 
kidneys. AQP4 protein expression is downregulated in severe 
hydronephrosis compared to sham kidneys 
AQP expression at the mRNA and protein level by the contralateral kidney 
is unchanged in PUUO rats compared to sham 
Normal whole rat renal pelvis expresses mRNA transcripts for AQPs 1, 3, 
4, 7, 9 and 11 
AQP1 and 3 mRNA expression in the renal pelvis is reduced in moderate 
and severe hydronephrosis compared to sham, while AQP11 expression is 
significantly downregulated in severe hydronephrosis only. AQP4 mRNA 
expression shows a tendency towards reduction in moderate and severe 
hydronephrosis compared to sham 
AQP expression by the contralateral renal pelvis is unchanged in PUUO rats 
compared to sham 
The urothelial distribution of AQP3 is unchanged in obstructed compared 
to sham and contralateral renal pelvices  
Urinary AQP1 excretion is not significantly different between PUUO rats 




6 Design and implementation of clinical cross-sectional study of 
childhood PUJO has been achieved with the following preliminary 
findings: 
Children undergo open pyeloplasty for PUJO at a mean age of 17.7 months 
An antenatal diagnosis of hydronephrosis is made in approximately 90% of 
children operated for PUJO 
1 out of 8 children experienced deterioration in split kidney function prior 
to surgery 
The median renal pelvis pressure of the obstructed kidney is within normal 
limits in children undergoing open pyeloplasty 
No correlation between renal pelvis pressure and pre-operative renal pelvis 
APD and split function is noted 
Analysis of normal human tissue generated the following findings: 
Whole normal human kidney expresses mRNA transcripts for AQPs 1-7 
and 11 
Whole normal kidney expresses AQPs 1-4 at the protein level. AQP1 is 
expressed by the apical and basolateral membranes of the proximal tubules 
as well as the loop of Henle and vasa recta. AQPs 2 and 3 are expressed by 
the apical and basolateral membranes of the renal collecting ducts 
Whole human renal pelvis expresses mRNA transcripts for AQPs 1-7, 9 and 
11. Whole human ureter expresses mRNA transcripts for AQPs 1-11. 
AQPs 1 and 3 are expressed at the protein level by whole human renal pelvis 
and ureter. AQP1 is expressed by the vascular endothelial cells of the lamina 
propria while AQP3 is expressed by all layers of the urothelium 
AQPs 1 and 2, but not 3, are excreted in normal human urine   
 
 
Table 7.1 Table summarising the main findings of each chapter 
 
The over-riding aims of this research were to investigate kidney and urinary tract AQP 
expression in PUJO and correlate with measures of kidney function, severity of 
hydronephrosis, and intra-renal pelvis pressure. Furthermore, to assess urinary AQP 
excretion in ‘damaging’ and ‘safe’ PUJO to determine the potential of this measurement as 
a biomarker to aid surgical decision making in this condition. The approach employed was 
to develop a neonatal rat partial unilateral ureteric obstruction model and implement a 
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childhood cross-sectional study of PUJO. Molecular biology laboratory techniques were 
optimised to conduct sample analysis from each of these models.    
Neonatal partial unilateral ureteric obstruction models are well described and have been used 
to investigate the mechanism of obstructive nephropathy [115, 120, 401, 413, 437, 438]. 
Additionally, these same models have been used to demonstrate renal dysregulation of AQP, 
sodium channel and acid base transporter expression in obstructive hydronephrosis [185, 
364, 408, 439]. Several techniques have been described to create PUUO, however the model 
of variable PUUO described and validated most recently by Thornhill et al. [91] was 
employed in this study.  This model involves tying a ligature around both the pelvi-ureteric 
junction and a fixed diameter wire, followed by removal of the wire to create a defined 
amount of obstruction. Using this neonatal rat PUUO model the current study has built on 
previously published work to not only assess renal AQP isoform expression but also AQP 
expression by urothelium, the specialised lining of the urinary tract. Additionally, these 
findings have been correlated with the degree of hydronephrosis, renal architecture and the 
intra-renal pelvis pressure. 
Consistent with previous studies, the expression of selected renal AQP isoforms was 
dysregulated at both the mRNA and protein level in the obstructed kidney. This study also 
extends the known AQPs that are dysregulated to include AQP4. It is recognised that 
temporal variation of AQP expression occurs in the partially obstructed kidney [364]. This 
study, which was conducted at a single time point, highlights that changes in AQP expression 
are also influenced by the severity of hydronephrosis. These results are consistent with 
human studies of congenital PUJO where reduced AQP expression correlates with the 
severity of hydronephrosis and the degree of functional impairment.  Furthermore, this study 
enabled AQP dysregulation to be related to intra-renal pelvis pressure. In moderate 
hydronephrosis, in the presence of raised intra-renal pressure, AQP mRNA and protein 
expression for all isoforms assessed was maintained. By contrast, downregulation of AQP 
expression was noted only in severely hydronephrotic kidneys where abnormalities of renal 
structure in the absence of raised intra-renal pelvis pressure was noted.    
The variable degree of hydronephrosis noted in the rats in this study in response to a fixed 
degree of ureteric obstruction highlighted the possibility of individual renal and/or urothelial 
factors modulating the response of the kidney and its collecting system to obstruction. 
Following the identification of AQPs in human and rat urothelium, an active role for this 
specialised epithelium in modulating urine composition has been suggested [369].   
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Urothelial AQPs demonstrate regulation in response to environmental conditions [249, 369] 
and have been shown to facilitate transurothelial water and urea flux [369]. Until now the 
role of urothelial AQP expression within the obstructed renal pelvis in PUJO has not been 
investigated.  
The chief finding in this PUUO model was that AQPs expressed by both the vascular 
endothelium (AQP1) and the urothelium (AQP3 and AQP11) were transcriptionally 
downregulated in the obstructed renal pelvis at 35 days of age. Again, reduced AQP 
expression was related to obstruction severity, however, in the renal pelvis both AQP1 and 
3 mRNA expression were downregulated in moderate hydronephrosis in the presence of 
raised intra-renal pelvis pressure and normal kidney architecture as well as in severe 
hydronephrosis. Although AQP3 expression was downregulated in the renal pelvis, 
immunohistochemistry demonstrated urothelial expression of AQP3 was not completely 
abolished and its distribution within the renal pelvis was unaffected by obstruction.    
Reduced urothelial AQP3 and vascular endothelial AQP1 expression in PUUO may 
critically diminish the ability of the renal pelvis to compensate for increases in intra-renal 
pressure by transurothelial transport and dispersion of water and solutes into the local 
vasculature (Figure 7.1). Thus, the individual ability of the rat to maintain renal pelvis AQP 
expression following neonatal PUUO may determine the severity of hydronephrosis 
developed. Persistent AQP expression following PUUO may protect against intra-renal 
pressure rises, seen in this study as rats with mild hydronephrosis with normal renal histology 
and intra-renal pelvis pressure. Equally, failure to maintain renal pelvis AQP expression, 
with resultant diminished urothelial water re-absorptive capability, theoretically augments 
intratubular pressure rises potentially leading to severe hydronephrosis, renal damage and 
functional impairment. Additionally, as discussed in chapter 5, other factors such as urine 
solute concentrations and gating of channels may impact on the direction of water flow 
across AQPs. Ultimately, it is not possible to identify from this study whether urothelial 
AQP expression is a significant renoprotective factor in the obstructed kidney in PUUO.  
This question will be addressed by further work described in section 7.2.   
The other major aim of this study was to assess urinary AQP excretion in ‘safe’ and 
‘damaging’ PUJO. AQPs 1 and 2 are known to be excreted in the urine of rats and humans 
[365, 372, 381, 386]. This was confirmed by western blotting in this study and an ELISA 
was subsequently developed to assess urinary AQP1 excretion. Childhood studies have 
previously demonstrated a significant reduction in urinary AQP1 excretion from the 
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obstructed compared to the normal contralateral kidney immediately following pyeloplasty. 
Conversely, bladder urine specimens from 29 day old rats in this study did not show any 
difference in urinary AQP1 excretion between PUUO rats across all degrees of 
hydronephrosis compared to sham rats.  
Fundamentally, this result does not necessarily indicate that AQP1 excretion by the 
obstructed kidney is normal. It does, however, indicate that changes in excretion by the 
obstructed kidney may not be detectable in the bladder urine which reflects output from both 
kidneys. Additionally, the presence of obstruction in PUJO will physically restrict the 
passage of biomarkers to the bladder, further influencing AQP1 detection in voided urine.  , 
Ultimately, this result raises scepticism on the ability of urinary AQP1 measurement to be a 
useful non-invasive biomarker of disease when measured pre-operatively in children using 
bladder urine.  
In conjunction with the neonatal rat PUUO model a complementary childhood cross-
sectional study of PUJO was designed and implemented with full ethical approval.  
Recruitment has proceeded well, and the study is predicted to run until July 2020. Laboratory 
testing of normal human renal tract tissue and urine unrelated to the study, has confirmed 
the expected expression and excretion patterns of AQP isoforms. Large batch analysis of the 
PUJO study samples will be undertaken in the future.     
The human study will assess similar parameters to the rat model and confirm whether the 
animal data translates between species. Particularly, further analysis of urine samples 
obtained from the human study will clarify whether pre-operative bladder urine AQP1 
measurement has potential as a non-invasive biomarker to aid surgical decision making in 
PUJO. Opportunely, even if the human study rejects urinary AQP1 measurement as a 
suitable biomarker, valuable urine samples have been obtained and stored from both animal 
and human models which will be used in future proteomics studies (See section 7.2.2.4) 
In summary, despite not achieving the initial aim of identifying a novel biomarker, this 
research contributes significantly to current knowledge of disease mechanism in PUJO by 
revealing a potential role for urothelial AQPs. The following section highlights future work 





Figure 7.1 Theoretical path of transurothelial water movement  
This diagram highlights the potential pathway for water from urine within the renal pelvis lumen to travel 
across the layers of the urothelium and into suburothelial capillaries in the lamina propria via aquaporin 




7.2 Future work 
Future work to develop this research is required in several areas: 
7.2.1 Laboratory techniques 
7.2.1.1 Immunohistochemistry 
Unfortunately, an antibody which reliably detected AQP4 in human and rat tissues by 
immunohistochemistry was not discovered during this research and therefore AQP4 
expression by urinary tract tissues was not assessed. Future studies will involve establishing 
a reliable AQP4 immunohistochemistry method to apply to samples from both the human 
and rat models. This will be important to localise AQP4 expression within the urothelium, 




RT-PCR and western blotting of whole human ureter and renal pelvis demonstrated AQP2 
expression. Immunohistochemistry, however, did not reveal expression in any layer of these 
tissues. Human urothelium has previously been demonstrated to not express AQP2 mRNA 
transcripts [259] suggesting that AQP2 expression detected from whole tissues in this study 
is probably from a layer other than urothelium. It is unlikely therefore that AQP2 
significantly contributes to transurothelial transport. Future work to resolve this disparity 
between results will involve analysis of more human samples paying attention to sample 
fixation and antigen retrieval techniques which may affect detection of proteins by 
immunohistochemistry.   
7.2.1.2 Western blotting 
Chapter 5 discussed the differences in western blotting results achieved following protein 
extraction and analysis of the kidney samples for the 5 litters of rats in two separate batches. 
It was also noted that surgery on these litters of rats was separated in time by a few months.  
Potential causes of the differences in results between litters 2-3 and 4-6 are: 
• Different methods used to homogenise tissue between the 2 batches. 
• Surgery carried out at a different time. Genetic drift in the animals may have 
therefore affected the results. 
• Changes in AQP expression related to the natural progression of the insult in PUUO 
• Natural variation in protein expression which could be addressed by performing 
PUUO on a greater number of animals 
To determine the effect of the method of mechanical tissue lysis on the results obtained in 
this study, both techniques of sample homogenisation will be repeated using the same 
samples.  This will be important to establish prior to analysing any further samples from 
either the animal model or human study.  
7.2.2 Animal models 
7.2.2.1 Current neonatal rat PUUO model 
AQP4 mRNA expression within the renal pelvis demonstrated a tendency towards reduction 
in moderate and severe hydronephrosis compared to sham kidneys however significance was 
not achieved, potentially due to substantial variability in the results. Increasing the number 
of animals assessed, to increase the power of the study, will  help to confirm or refute 
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whether a real difference exists, This could be addressed when undertaking the knockout 
murine model as described below. 
In the later stages this study involved measuring the intra-renal pelvis pressure of PUUO and 
sham rats. Unfortunately, the numbers of animals involved was small and in some groups, 
such as those with mild and severe hydronephrosis, there was only one animal precluding 
meaningful analysis. Larger numbers will need to be assessed to draw firm conclusions from 
this aspect of the research. Additionally, the technique of intra-renal pelvis pressure 
measurement will be developed to enable measurement of both basal pressure and dynamic 
perfusion-pressure in order to control for variation in urine inflow into the renal pelvis. 
Again, these modifications could be achieved during completion of the knockout murine 
model.  
In this model the sham procedure was performed the same as PUUO surgery except that 
following kidney mobilisation and proximal ureteric dissection a ligature was not placed and 
the ureter was returned to the abdomen. In the future, to ensure that appropriate sham surgery 
is undertaken, the sham procedure will be performed in an identical manner to PUUO 
surgery including placement of the metal template and ligature. The ligature will then be 
removed before returning the ureter to the abdomen.  
 
7.2.2.2 Urothelium specific AQP3 knockout murine neonatal PUUO model 
AQP null mouse models, including AQP3 knockouts, have been used previously to 
demonstrate the renal role of AQPs [255]. Future work, building on the results of this study, 
will aim to target AQP3 knockout to urothelium enabling investigation of the specific role 
of urothelial AQP3 in the outcome of PUJO. Although transgenic models targeting gene 
expression to the urothelium are described, using promoters for genes such as K19 [440] and 
fatty acid-binding protein (FABP) [441], these models are not urothelium specific.  
Uroplakin II is expressed specifically by urothelial cells [442-444]. In rodents, contrary to 
humans, it expressed throughout all suprabasal layers of the urothelium [445, 446]. A murine 
uroplakin II Cre/loxP knockout system has been developed by Mo et al. whereby Cre 
expression was under the control of the uroplakin II promoter. This model demonstrated 
precise urothelial specificity enabling targeted gene deletion in urothelium by exclusive 
expression of Cre recombinase [445].   
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Additionally, a conditional floxed AQP3 knockout reporter mouse, strain C57BL/6NTac, is 
available commercially from Infrafrontier (EM:08279, Infrafrontier, Munich, Germany). 
In order to further investigate this mechanism, ongoing research will involve developing 
urothelium specific AQP3 knockout mice using the uroplakin II Cre/loxP approach and then 
undertaking neonatal PUUO on these knockouts versus litter-mate and wild-type controls. 
If, as anticipated, the transgenic mice demonstrate a more severe phenotype than controls, 
attempted rescue using an AQP3 overexpression mouse under the same promoter will be 
undertaken. 
7.2.2.3 Human study 
The current major focus for the human study is ongoing recruitment of patients to all groups 
but particularly to group 2 (children with hydronephrosis not undergoing surgery). 
Furthermore, attempts will be made to recruit from clinics whereby a more balanced 
male:female ratio and spread of ages is obtained. Analysis of the existing demographic data 
for study recruits demonstrated a significant difference in the mean age between groups 1 
(children undergoing pyeloplasty for PUJO) and 3 (children with normal kidneys).  
A chief area to improve during ongoing running of the study is identification of follow-up 
patients at Bristol children’s Hospital. Alongside the hospital ‘Evolve’ administrators, 
changes are being made to add study participation to the patient alerts on the computerised 
system. Moreover, investigative work will be needed to institute processes to gain follow-
up data and urine samples from children at peripheral outreach clinics. 
7.2.2.4 Urine proteomics 
Identifying a non-invasive urine biomarker which enables early identification of those 
children requiring surgery would greatly improve the current management of children with 
PUJO. Currently, there is little evidence from animal studies to aid this goal. While a number 
of different potential biomarkers have been tested in human studies, the control groups have 
not always been ideal, and no biomarkers which would be cost-effective for routine 
implementation in the hospital setting have been identified.   
Urine samples obtained from the human and rat studies will be fully interrogated using state 
of the art focused proteomic analysis in new facilities within the University of Bristol. 
Proteins in urine will be identified using an LTQ-Orbitrap Velos mass spectrometer, which 
combines the industry-leading Orbitrap mass analyser with the world's fastest and most 
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sensitive ion trap mass spectrometer. This system permits production of ultra-high resolution 
and precise mass data and enables the identification and quantitation of proteins, even those 
of low abundance, within complex mixtures in a single experiment. Firstly, this method will 
allow high quality assessment of urinary AQP excretion, complementing results from 
traditional protein analysis techniques.  Secondly, proteomics will provide an unbiased 
screen of other excreted proteins that may be involved in the pathogenesis of ‘damaging’ 
PUJO.  Identified proteins will then be further verified using a range of protein analysis 
techniques. 
 
7.3 Implications of this work 
During this research project an in vivo neonatal rat partial unilateral ureteric obstruction 
(PUUO) model and a complementary (fully ethically approved) human PUJO study have 
been implemented. This translational research project has utilised molecular biological 
techniques to begin investigating whether aquaporins, as key mediators of water-
reabsorption, protect the kidney against high-pressure damage in PUJO.  
Importantly, downregulation of urothelial and vascular endothelial AQP expression in the 
obstructed renal pelvis, which varies according to the severity of hydronephrosis, has been 
demonstrated in rat PUUO for the first time. This finding may begin to explain the 
mechanism behind ‘safe’ and ‘damaging’ hydronephrosis and certainly warrants further 
investigation which will be definitively achieved using transgenic mouse neonatal PUUO 
models.  
AQP3 expression, and more specifically its expression in urothelium, in response to 
therapeutic intervention has not previously been investigated. Renal AQP2 downregulation 
in UUO and BUO models is attenuated by both statins [203] and COX-2 inhibitors [127] 
respectively, suggesting AQP expression in general is amenable to exogenous manipulation.  
Furthermore, AQP3 is known to show long term but not short term renal upregulation by 
vasopressin in rats. In non-urinary tract cells, AQP3 is upregulated by insulin and leptin 
acting via the PI3K/Akt/mTOR pathways [258] as well as hypertonicity [322]. These 
pathways provide potential targets for manipulation in order to develop new therapeutic 
approaches for PUJO. 
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Development of a non-invasive biomarker which can predict the need for pyeloplasty in 
PUJO would protect children from unnecessary operations, while enabling early 
identification of those that require timely surgery to prevent long-term kidney damage. 
Future analysis of human urine samples collected from the childhood PUJ study will 
ultimately determine whether AQP1 is a useful biomarker to guide surgical decision-making 
in PUJO. Additionally, further proteomic analysis of rat and human urine will enable the 
examination of aquaporin isoform excretion alongside performing an unbiased urine protein 
screen.  
Our current understanding of the natural history of PUJO and our ability to distinguish which 
children require surgery is inadequate.  Improving our understanding of the mechanism of 
injury in PUJO will enable earlier diagnosis and better management of this important 
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10.1 Appendix 1 Solution and gel recipes, cell culture media 
10.1.1 Solution recipes 
Solution Constituents pH 
Phosphate buffered saline 
(PBS) 
8g Sodium chloride, 1.16g Sodium phosphate 
dibasic, 0.2g Potassium chloride, 0.2g 
Potassium phosphate monobasic, made up to 
1 litre with ultrapure water 
7.4 
Phosphate buffered saline with 
0.1% tween 20 (PBS-T) 
1000 ml of PBS, 1ml Tween 20 7.4 
10 x Tris buffered saline (TBS) 24.23g Tris base, 80.06g Sodium chloride, 
made up to 1 litre with ultrapure water 
7.5 
1 x Tris buffered saline with 
0.1% tween 20 (TBS-T) 
100ml of 10 x TBS, 899ml ultrapure water, 
1ml Tween 20 
7.5 
3M Tris-HCl 36.342g Tris base made up to 100ml final 
volume with ultrapure water. Adjust pH with 
concentrated HCl  
8.8 
0.5M Tris-HCl 6.057g Tris base made up to 100ml final 
volume with ultrapure water. Adjust pH with 
concentrated HCl 
6.8 
0.1M Tris-HCl 1.211g Tris base made up to 100ml final 
volume with ultrapure water. Adjust pH with 
concentrated HCl 
7.6 
30mM Tris-HCl 0.363g Tris base made up to 100ml final 
volume with ultrapure water. Adjust pH with 
concentrated HCl 
8.5 
10 x Running buffer  30.3g Tris base, 144g Glycine, 10g Sodium 
dodecyl sulfate, made up to 1 litre with 
ultrapure water 
N/A 
1 x Running buffer 100ml of 10 x Running buffer, 900ml 
ultrapure water 
N/A 
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10 x Transfer buffer 30g Tris base, 144g Glycine, made up to 1 
litre with ultrapure water 
N/A 
1 x Transfer buffer 100ml Methanol, 100ml 10 x Transfer buffer, 
800ml ultrapure water 
N/A 
2 x Sample buffer (Stock 
solution) 
3.4ml ultrapure water, 1ml 0.5M Tris-HCl 
pH6.8, 2ml Glycerol, 1.6ml 20% sodium 
dodecyl sulfate, sprinkle bromophenol blue.   
N/A 
2 x Sample buffer (Working 
solution) 
950µl 2 x Sample buffer stock solution, 50µl 
β-mercaptoethanol 
N/A 
2 x Sample buffer + 7M urea 2ml 20% Sodium dodecyl sulfate, 2ml 
Glycerol, 2.5ml 0.5M Tris-HCl pH 6.8, 4.2g 
Urea, 0.5ml β-mercaptoethanol, make up to 
10ml with ultrapure water 
N/A 
Stripping buffer 4ml 0.5Mtris-HCl pH6.8, 2g Sodium dodecyl 
sulfate, 700µl β-mercaptoethanol, make up to 
100ml with ultrapure water 
N/A 
Urea/thiourea tissue lysis 
buffer (Stock solution) 
4.2g Urea, 1.52g Thiourea, 0.4g CHAPS, 
10ml 30mM Tris-HCl (pH8.5) 
N/A 
Urea/thiourea tissue lysis 
buffer (Working Solution) 
Add 10µl protease inhibitor (#p8340, Sigma-
Aldrich, St-Louis, MO, USA), 10µl 
phosphatase inhibitor cocktail 2 (#p5726, 
Sigma-Aldrich) and 10µl phosphatase 
inhibitor cocktail 3 (#p0044, Sigma-Aldrich) 
to 1ml of Urea/thiourea tissue lysis buffer 
stock solution   
N/A 
Triton X-100 cell lysis buffer 
(Stock solution) 
3.03g Tris base, 0.186g EDTA, 0.19g EGTA, 
46.2g Sucrose, 1.05g Sodium fluoride, 1.12g 
Sodium pyrophosphate, 0.078g 
Benzamidine, make up to 495ml with 
ultrapure water, pH to 7.5 then add 5ml 
Triton X-100 
7.5 
Triton X-100 cell lysis buffer 
(Working solution) 
Add 10µl protease inhibitor (#p8340, Sigma-
Aldrich, St-Louis, MO, USA), 10µl 





Sigma-Aldrich) and 10µl phosphatase 
inhibitor cocktail 3 (#p0044, Sigma-Aldrich) 
to 1ml of Triton X-100 cell lysis buffer stock 
solution   
4% Paraformaldehyde Add 40g Paraformaldehyde powder to 800ml 
of PBS heated to 60°C. Add 1N Sodium 
hydroxide until solution clears. Make up to 1 
litre with ultrapure water, cool and filter. 
Adjust pH to 6.9 with HCl. Aliquot and store 
at -20°C. 
6.9 
10% Neutral buffered formalin 100ml of 37% formaldehyde, 4g Sodium 
phosphate monobasic, 6.5g Sodium 
phosphate dibasic (anhydrous), make up to 1 
litre with ultrapure water 
N/A 
10mM Sodium citrate buffer 2.94g Sodium citrate trisodium salt 
dihydrate, make up to 1 litre with ultrapure 
water 
6 
50 x TAE 242g Tris base, 100ml of 0.5M EDTA pH8, 
57.1ml of acetic acid, make up to 1 litre with 
ultrapure water  
N/A 
37mM Picric acid 32ml of 1.3% picric acid, 28ml ultrapure 
water 
N/A 
0.3M NAOH 30ml of 1M NaOH, 70ml of ultrapure water N/A 
0.5M EDTA 18.61g EDTA disodium salt dihydrate, make 
up to 100ml with ultrapure water, filter 
through a 0,5 micron filter 
8 
10.1.2 Western blotting gel recipe 
Constituent (per 2 gels) Stacking 4% Gel Resolving 12.5% Gel 
Ultrapure Water 5.65ml 7.9ml 
30% bis acrylamide 1.25ml 8.4ml 
0.5MTris-HCl pH6.8 2.5ml N/A 
3M Tris-HCl pH8.8 N/A 2.5ml 






TEMED 5µl 10µl 
 
10.1.3 Cell culture media 
Medium Constituents 
Modified RPMI 1640 culture media 500ml of RPMI 1640 with L-glutamine 
(#R8758, Sigma-Aldrich, St-Louis, MO, 
USA), 5ml Insulin-transferrin-selenium 
(41400-045, Gibco, Invitrogen, Paisley, 
Scotland, UK) 50ml Fetal bovine serum 
(10500-064, Gibco, Invitrogen, Paisley, 
Scotland, UK)  
Freeze media 10ml of Fetal bovine serum (10500-064, 
Gibco, Invitrogen, Paisley, Scotland, UK), 
8ml of modified RPMI 1540 culture 
medium, 2ml DMSO (#D8418, Sigma-




10.2 Appendix 2 Primer sequences and antibodies 
10.2.1 Primer sequences 
10.2.1.1 Human primer sequences 







AQP0 Forward TGTTCTGCAGGTGGCTATG 59.9 232 (232) 




AQP1 Forward TCATCAGCATCGGTTCTGC 58.4 297 (297) 
 Reverse CAAGCGAGTTCCCAGTCAG   
AQP2 Forward TAGCCTTCTCCAGGGCTGT 58.8 305 (305) 
 Reverse CGTGATCTCATGGAGCAGAG   
AQP3 Forward GTCACTCTGGGCATCCTCAT 59.8 157 (464) 
 Reverse CTATTCCAGCACCCAAGAAGG   
AQP4 Forward GCCCATCATAGGAGCTGTC 58.4 209 (209) 
 Reverse GGTCAACGTCAATCACATGC   
AQP5 Forward CCACCCTCATCTTCGTCTTC 59.9 212 (212) 
 Reverse GTAGAAGAAAGCCCGGAGC   
AQP6 Forward AGTCTTGGGGGAGAAAGGAA 58.4 196 (196) 
 Reverse AACCACACCCAAGGTCAGAG   
AQP7 Forward TGCCACCTACCTTCCTGATC 59.9 210 (420) 
 Reverse GACGGGTTGATGGCATATCC   
AQP8 Forward TGAGCCTGAATTTGGCAATG 60 226 (226) 
 Reverse CAGCGTGGCAATCACGAGC   
AQP9 Forward CTCAGTGTCATCATGTAGTG 59.7 336 (336) 
 Reverse GACTATCGTCAAGATGCCG   
AQP10 Forward GCACTGGGATGCTGATTGT 60 190 (190) 
 Reverse CCAGCCACGTAGGTGAAGAG   
AQP11 Forward GACGCTGACGCTCGTCTACT 59.7 279 (279) 
 Reverse TCTGTGATGACCGCTTTGAG   
AQP12 Forward GAACCTGTTCTACGGCCAGA 59.3 204 (204) 











10.2.1.2 Rat primer sequences 









AQP0 Forward GGGCACCTCTTTGGGATGTATT 60 177 - 
 Reverse ACTCTTGAGCCGTGGGAAGA    
AQP1 Forward TTGGCTTGTCTGTGGCTCTT 60 132 10 
 Reverse GTCCCACCCAGAAAATCCAGT    
AQP2 Forward GTGGGTTGCCATGTCTCCTT 60 145 10 
 Reverse CGTTGTTGTGGAGAGCATTGAC    
AQP3 Forward TTGAACCCTGCTGTGACCTT 60 145 10 
 Reverse AGGCCCAGATTGCATCATAGTA
G 
   
AQP4 Forward CCACTGGATATATTGGGTTGGA 60 83 5 
 Reverse CCACGTCAGGACAGAAGACAT
A 
   
AQP5 Forward TGCGCTGAACAACAACACAA 60 182 - 
 Reverse CGGTGAAGTAGATCCCCACAA    
AQP6 Forward AGTTGGTTCTCTGTGTCTTTGCT 60 200 5 
 Reverse CGGTCCTACCCAGAAGATCCA    
AQP7 Forward GCTTCGTGGATGAGGTATTTGT
G 
60 134 5 
 Reverse CACCCCAAGAACGCAAACAA    
AQP8 Forward GCTGTGATGGCTGGCTACT 60 163 10 
 Reverse AAGTGTCCACCGCTGATGTTC    
AQP9 Forward CTGCAACGGTCTTTGGCATT 60 130 10 
 Reverse CCTGGCGTGGATATGAATGGA    
AQP11 Forward GGCGTGATGATGCAGATGATT 60 195 10 
 Reverse CGCTTTGGATATGTCGGTGTTG    
AQP12 Forward TACCGGCAGAAAAGCAAATAC
C 
60 81 - 
 Reverse CTCCCCTTTGAGCATCTTGGT    
B-
Actin 




 Reverse CTGACCCATACCCACCATCAC    
Pgk1 Forward TTTGGACAAGCTGGACGTGA 60 107 10 
 Reverse CAGCAGCCTTGATCCTTTGG    
36b4 Forward TGCCCAGGGAAGACAGGGCGA 
 
60 185 10 
 Reverse GCGCATCATGGTGTTCTTG    
 
10.2.2 Antibodies 
10.2.2.1 Primary antibodies 
Antibody Host Catalogue number and supplier 
Anti-AQP1 Rabbit sc-20810, Santa Cruz, Dallas, Texas, USA 
Anti-AQP2 Rabbit sc-28629 Santa Cruz, Dallas, Texas, USA 
Anti-AQP2 Rabbit Gift from J Bedford, New Zealand 
Anti-AQP2 Rabbit AB3066, Merck Millipore, Billerica, MA, USA 
Anti-AQP2 Rabbit ab15081, Abcam, Cambridge, UK 
Anti-AQP3 Goat sc-9885, Santa Cruz, Dallas, Texas, USA 
Anti-AQP3 Rabbit ab125045, Abcam, Cambridge, UK 
Anti-AQP4 Goat sc-9888, Santa Cruz, Dallas, Texas, USA 
Anti-
FLAG® 
Mouse F1804, Sigma-Aldrich, St-Louis, MO, USA 
Anti-SV-40 Mouse GTX16879, Genetex, Irvine, CA, USA 
Anti-β-actin Mouse A5441, Sigma-Aldrich, St-Louis, MO, USA 
Anti-
GAPDH 
Mouse MAB374, Merck Millipore, Billerica, MA, USA 
 
10.2.2.2 Secondary antibodies 
Antibody Host Conjugation Supplier 
Anti-Goat Donkey HRP sc-2020Santa Cruz, Dallas, Texas, USA 
Anti-Rabbit Goat HRP A6667, Sigma-Aldrich, St-Louis, MO, 
USA 




Anti-Mouse Goat Alexa Fluor® 488 A-11001, Invitrogen, Paisley, Scotland, UK 
Anti-Rabbit Donkey Alexa Fluor® 568 A-10042, Invitrogen, Paisley, Scotland, UK 
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An investigation of whether renal and lower urinary tract aquaporin expression protects kidney 
function from the pressure effects of pelvi-ureteric junction (PUJ) obstruction in children.  
Furthermore, this study aims to develop urine aquaporin measurement as a novel, non-invasive, 
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AQP – Aquaporin 
GP – General Practitioner 
IHC - Immunohistochemistry 
MCUG – Micturating cystourethrogram 




NHS – National Health Service 
PACS – Picture Archiving and Communications System 
PUJ Obstruction – Pelvi-ureteric junction obstruction 
R & D – Research and Development Department 
REC – Research Ethics Committee 
RT-PCR – Reverse Transcription Polymerase Chain Reaction 
 
Definitions 
Antenatal – Before Birth 
Biomarker - A naturally occurring substance by which a particular pathological process or disease 
can be identified. 
Biopsy -  An examination of tissue removed from a living body to discover the presence, cause, or 
extent of a disease. 
Hydronephrosis – Dilatation and distension of the collecting system (renal pelvis and calyces) of 
the kidney. 
Isoforms – Protein isoforms are slightly different forms of the same protein.  
MAG 3 Renogram – A test which involves injecting a radioisotope dye into a vein which is 
subsequently excreted by the kidneys.  The kidneys are then scanned with a gamma camera to work 
out their function compared to each other and to estimate how well the kidneys drain. 
MCUG – A test where dye is inserted into the bladder via a catheter and x-ray images are taken as 
the bladder fills and then as the patient voids the dye. 
Nephron – Each of the functional units in the kidney, consisting of a glomerulus and its associated 
tubule, through which the glomerular filtrate passes before emerging as urine. 
Paediatric Urologist – A children’s surgeon who is concerned with the function and disorders of 
the urinary system. 
PUJ Obstruction – Obstruction to the flow of urine from the renal pelvis into the proximal ureter 
most commonly caused by narrowing of the junction between the renal pelvis and the proximal 
ureter. 
Pyeloplasty – Surgical reconstruction of the junction between the renal pelvis and the ureter to 
decompress the kidney and allow it to drain urine properly. 
Renal Pelvis – A funnel-like structure that connects the kidney to the ureter. 
Ultrasound Scan - A type of medical imaging that uses echoes of ultrasound pulses to delineate 
objects or areas of different density in the body. 
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Ureter – A tube that carries urine from the kidney to the bladder. 
Urinary tract – The organs of the body that produce, drain, store and discharge urine. These are the 
kidneys, renal pelvis, ureters, bladder and urethra.  
Urothelium – The urothelium is the epithelium that lines much of the urinary tract.  It is a layer of 
tissue that lines the renal pelvis, the ureters, the bladder, and parts of the urethra. 








Antenatal hydronephrosis is a major clinical issue for paediatric urologists (incidence of 1 in 200)1, 
which has become more problematic since antenatal scanning became routine. Of these children 
approximately 1 in 7 will have pelviureteric junction (PUJ) obstruction2, which causes a blockage to 
urine drainage from the kidney.  The major surgical issue is deciding which children require urgent 
surgery to relieve obstruction and limit kidney damage, and which do not. This is because some 
children with PUJ obstruction do not damage their kidneys, do not require surgery and ultimately 
grow out of the problem. We currently do not know how to distinguish effectively between those 
children with high pressure damaging obstruction and those with safe non-renal damaging PUJ 
obstruction3.  
Ultrasound scans and MAG 3 renograms are currently used to diagnose PUJ obstruction, however 
there is limited consensus on diagnostic thresholds, and ultimately these tests are unable to 
adequately predict which children will need surgery and which won’t.  Children are therefore 
'observed' and undergo repeated radiological investigations over the first few years of life in order to 
finally determine the need for intervention.  Kidney function becomes adversely affected during this 
period of observation in up to a quarter of children3.  Moreover, there are no good biomarkers 
currently available to aid diagnosis, assess severity of obstruction and direct treatment. 
Once diagnosed however, treatment of PUJ obstruction involves a well described operation called a 
pyeloplasty to remove the narrowed junction between the renal pelvis and ureter.  This procedure is 
successful in 95% -97% of cases.4  
It is known that urinary tract obstruction at any level causes raised intratubular hydrostatic pressure 
throughout the nephron.  A resultant cascade of signaling pathways leads to interstitial fibrosis, 
tubular atrophy and nephron loss.5  We propose that water channels called aquaporins are key 
mediators of water resorption from the renal tract in this situation, relieving kidney pressure and 
explaining the mechanism behind “safe” and “damaging” PUJ obstruction.  Furthermore we propose 
that urinary levels of aquaporins are good biomarkers for determining high and low pressure systems 
and could be useful in our surgical practice. 
Aquaporins are transmembrane proteins, normally expressed by the kidney and urothelium, which 
regulate urine volume by reabsorbing water.  There are 13 mammalian aquaporin isoforms, which 
have diverse expression patterns among different tissues.6 Certain aquaporin isoforms are also 
excreted within exosomes in urine.  Animal and human data suggests ureteric obstruction causes 
downregulation of renal aquaporin expression and urinary exosomal aquaporin excretion7,8,9. There 
is very limited evidence that severity of renal down-regulation correlates with the degree of 
hydronephrosis8 and renal impairment10.  The effect of urinary tract obstruction on urothelial 





The central hypothesis is thus: 
 
Aquaporins in the renal tract protect the kidney against high-pressure 
damage in PUJ obstruction. Detecting them in the urine and manipulating 
them in the kidney and lower urinary tract will result in the development 
of novel operative biomarkers and new therapeutic approaches for this 
condition. 
 
Through preliminary work (Fig.1) in the Academic Renal Unit all the necessary 
protein and molecular biology techniques for the identification of aquaporin isoforms at the mRNA 
and protein level within renal tract tissue have been established. (Fig.1a-d,f)  Exosomes have also 
been successfully extracted from urine and it has been demonstrated that exosomal aquaporin levels 
























Figure 1. Selection of Initial Results.(1a) Western blots of human kidney demonstrating AQP 1 and 4 protein expression.  (1b) 
Immunohistochemistry of human kidney cortex demonstrating AQP 1 staining of proximal tubules. (1c) RT-PCR of human kidney 
demonstrating AQP 1-8 and 11 expression at mRNA level. AQP 0,9,10,12 not expressed (data not shown) (1d) Immunofluorescence 
of proximal tubule cells in culture demonstrating the presence of AQP 1(1e) Western blot demonstrating AQP 1 protein detected in 





This study will build on the above preliminary work in order to:  
• Measure the distribution and quantity of aquaporins in the lower urinary tract and kidney in 
childhood PUJ obstruction  
o Comparing renal pelvis (pre-obstruction) with ureteric (post-obstruction) aquaporin 
expression will enable assessment of the effect of obstruction on human urothelium. 
• Establish the urinary aquaporin profile in high pressure (damaging) and low pressure (non-
damaging) PUJ obstruction in children 
o Normal childhood urinary exosomal aquaporin levels will also be defined for the 
first time  
• Determine whether urinary aquaporin measurement is a useful non-invasive biomarker 
directing the timing and necessity of corrective surgery for children with hydronephrosis and 
potential PUJ obstruction. 
o The availability of corresponding radiological imaging and intra-operative pressure 
monitoring will enable us to correlate changes in tissue and urine aquaporin levels 
with currently used markers of severity, function and pressure to determine the 
predictive value of urinary exosomal aquaporin measurement. 
• Establish the mechanism behind changes in tissue and urinary aquaporin expression, 
enabling the future development of therapeutic treatment aiming to either protect renal 
function or reduce symptoms.   
• Continuing work will involve further analysis of urine samples, including proteomic studies, 
to identify other potential biomarkers which may facilitate the diagnosis and management of 
children with hydronephrosis. 
 
Potential Study Benefits 
This project has the potential to improve the management of many children who are antenatally 
diagnosed with hydronephrosis, both nationally and globally.   
• Development of urine aquaporin measurement as a non-invasive biomarker aims to identify 
children early who require a pyeloplasty for ‘harmful’ hydronephrosis, while sparing those 
with harmless hydronephrosis.  
• Early identification of those with harmful hydronephrosis requiring a pyeloplasty will:  
o Reduce the risk of progressive damage to the kidney 
o Reduce the need for repeated radiological imaging some of which is invasive and 
involves radiation 
• Shedding light on the mechanism of aquaporin downregulation will help achieve new therapies 
to: 
o Reduce progression of the renal injury after surgical release of obstruction 
o Reduce symptoms, particularly in patients with significant dieresis 
• Other potential urine biomarkers for the diagnosis of PUJ obstruction may be revealed 
through further analysis including proteomic screening of urine samples. 
 
Study Feasibility 
There are many causes of urinary tract obstruction in childhood, however we have chosen to study 
PUJ obstruction for a number of reasons:   
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1. These are an easily identified group of children who attend outpatient clinic and are 
monitored regularly as part of their normal management.  By comparison with other causes of urinary 
tract obstruction PUJ obstruction is relatively common, therefore recruitment of enough children to 
make a meaningful study over a reasonable time frame will be possible.  All radiological 
investigations required for correlation of study results will already have been performed as per usual 
management for this group.  Additional radiological investigations will therefore not be required as 
part of the study.  Radiological reports will be easily accessible on the NHS PACS system enabling 
efficient data collection for the study.   
2. On the basis of radiological imaging results and/or the presence of symptoms such as pain 
or urine infections a proportion of children with hydronephrosis will require a pyeloplasty to correct 
PUJ obstruction.  This provides an opportunity to collect tissue and urine samples while the child is 
under general anaesthetic, when informed consent has been given.  The integral part of a pyeloplasty 
for correction of PUJ obstruction involves removing the narrowed section of renal pelvis/ureter 
causing the obstruction and then joining the remaining tube back together.  This section of removed 
renal pelvis/ureter is normally discarded.  Laboratory analysis of this tissue will not change the way 
the operation is performed or the outcome from surgery in any way.  Analysis of this tissue will, 
however, allow us to assess for the first time the effect of urinary tract obstruction on urothelial 
aquaporin expression. 
3. Finally, a major reason for investigating this group is the potential to improve current 
evaluation and management of children with hydronephrosis and improve our understanding of the 
mechanism of disease.     
Summary 
Our current understanding of the natural history of PUJ obstruction and our ability to distinguish 
which children require surgery is inadequate.  Improving our understanding of the mechanism of 
renal injury will enable earlier diagnosis and better management of this important condition through 




This study is non-commercial and will form part of an MD thesis. 
Research Objectives 
To determine whether urine aquaporin measurement can improve our ability to distinguish between 
children with 'damaging' PUJ obstruction who require urgent surgery to protect their kidney function, 
and those with 'safe' non-kidney damaging PUJ obstruction in whom surgery should be avoided. 
 
To investigate the mechanism by which kidneys are damaged in PUJ obstruction, and to define the 
role of aquaporins in protecting kidney function in this situation.  This will involve assessing urine 
and tissue aquaporin levels and determining whether changes in kidney function and /or pressure are 
associated with a significant change in aquaporin levels.   Knowledge in this area will pave the way 









This is a cross-sectional study involving the laboratory analysis of urine and tissue samples.  It will 
involve the recruitment of three groups of children attending Bristol Children's Hospital: 
   
Group 1 will consist of children undergoing an open or laparoscopic (keyhole) pyeloplasty at the 
Bristol Children’s Hospital.  Potential participants will be identified in outpatient clinic and given 
information leaflets detailing the study.  Consent for the study will then be obtained by the chief 
investigator (member of the research team) on the day of surgery after the surgeon has explained the 
surgical procedure.   
Following enrolment to the study, on the day of hospital admission, the doctors will complete the 
initial data collection form documenting the child’s demographic details, information about their 
medical history and the results of radiological tests.   
Prior to surgery the child will be asked to provide a urine specimen; this may be into a pot if the child 
is old enough or collected from the nappy in younger children.   
The pyeloplasty will be performed under general anaesthetic either laparoscopically (keyhole) or as 
an open (traditional) procedure. This decision will be based on the surgeons’ preference and the best 
interests of the child.  Participation in the study will not influence the way the procedure is performed.  
During the child’s operation samples will be obtained and procedures performed while they are under 
general anaesthetic.  These are:   
• All children undergoing a pyeloplasty normally have a bladder catheter inserted at the 
beginning of the procedure.  A urine sample will be taken from the bladder catheter for 
laboratory analysis for the levels of water channels.   
• A pressure reading will be taken from the obstructed kidney before the obstruction is 
relieved.  This involves inserting a small pressure probe through the piece of drainage tube 
tissue that will subsequently be removed as part of the operation.  Measuring the pressure in 
the kidney is an extra procedure for the child. 
• During pyeloplasty surgery urine is usually removed from the obstructed kidney to reduce 
the size of the renal pelvis and make surgery easier.  This urine is normally discarded 
however we will take a sample of this urine for laboratory analysis for the levels of water 
channels. 
• The narrow section of tube at the junction of the renal pelvis and ureter will be removed and 
then the tube will be joined back together.  Removing this narrowed piece of drainage tube 
is a normal part of the operation to correct PUJ obstruction and this piece of tissue is normally 
disposed of at the end of the operation.  The narrowed piece of renal pelvis/ureter will be 




• An operative data collection form will be completed by the operating surgeon at the end of 
the procedure detailing the procedure performed, the kidney pressure and the samples 
collected.                   
Post-operatively a urine sample will be collected every 24 hours until the child is discharged from 
hospital (usually within 2-5 days).  Initially this can be taken from the bladder catheter collection 
bag, however once the catheter is removed the child will be asked to pass urine into a pot or the 
sample will be collected from the nappy in younger children.   
Children will attend outpatient clinic post-operatively as part of their routine surgical follow-up.  No 
changes to the usual regime of radiological and clinic follow-up will be made for the study.  The only 
requirement of the study will be that at each visit the child provides a urine specimen for laboratory 
analysis.  The consulting doctor will be asked to complete a copy of the follow-up data collection 
form at each clinic visit.  The length of post-operative follow-up varies depending on the age of the 
child and their post-operative progress and usually is between 3 months and 2 years.  Participation 
in the study will terminate when the child is discharged from clinic follow-up.  
 
Group 2 will consist of children with hydronephrosis but no evidence of other causes of urinary tract 
obstruction.  These children will be identified when they attend general surgical or urology outpatient 
clinics. This group is necessary in order to find out if it is possible to differentiate between those 
children with ‘safe’ hydronephrosis and those with ‘damaging’ hydronephrosis. The child will be 
weighed and measured (if not already performed) and asked to provide a urine sample for analysis 
(either into a pot or collected from the nappy).  This group of children will be asked to provide a 
urine sample at every clinic attendance.  A data collection form will be completed at each clinic 
attendance. The expected length of follow-up and thus study participation in these children will be 
up to 4 years. Participation in the study will terminate when they are discharged from clinic follow-
up.  
 
Group 3 will consist of children with no kidney tract abnormalities attending general surgical or 
urology outpatient clinic for consultation regarding unrelated problems. This group is necessary in 
order to generate a table/graph of normal aquaporin excretion across varying ages and weights 
against which to compare group 1 patients.  The child will then be weighed and measured (if not 
already performed) and asked to provide a urine sample for analysis (either into a pot or collected 
from the nappy).  The consulting doctor will complete a data collection form.  This will conclude the 
involvement of this group of children in the study. 
 
Obtaining Kidneys Prepared for Transplantation 
Kidneys which have been prepared for transplant but are later deemed clinically unsuitable are 
collected by our laboratory (Academic Renal Unit), with full consent for research, as part of another 
NHS REC approved study (Ref: 06/Q2002/101).  In order to make full use of these organs which 
have been donated for research, the ureter and renal pelvis (which is often discarded as surplus tissue) 
will be used to develop and refine the laboratory techniques that will subsequently be employed for 










Children with PUJ obstruction are an easily identified group who attend outpatient clinic and are 
monitored regularly as part of their normal management.  By comparison with other causes of urinary 
tract obstruction PUJ obstruction is relatively common, therefore recruitment of enough children to 
make a meaningful study over a reasonable time frame will be possible.  All children within the 
South West region have their pyeloplasty surgery at the Bristol Children’s Hospital so this study will 
capture children from a large geographical area.  All children will be identified as potential 
participants in the outpatient clinic setting and will be invited to take part in the study.   
This is a single-centre study involving the Bristol Royal Hospital for Children where it is estimated 
there will be 20 pyeloplasties performed per year in children eligible for the study.  It is hoped that 




Group 1 - Children (aged 0-15 years) placed on a planned waiting list for a laparoscopic or open 
pyeloplasty. 
Group 2 - Children (aged 0-15 years) with hydronephrosis but no evidence of other causes of urinary 
tract obstruction attending general surgery/urology outpatient clinics 
Group 3 - Children (aged 0-15 years) with no kidney tract problems attending general 











Children with differential function <40% on MAG 3 renogram of the hydronephrotic kidney 
Children with other causes of urinary tract obstruction other than PUJ obstruction. 
 
Groups 1-3 
Children taking medicines which affect kidney function or act on the kidney.  





All patients will be identified when they attend the Bristol Children's Hospital outpatient clinics.  
There will not be any financial remuneration for participants. 
 
Group 1 (undergoing pyeloplasty) participants will be identified by their paediatric urologist during 
the same clinic visit as the decision is made to place them on the planned waiting list for a pyeloplasty 
operation.  The decision to perform an operation will be made by the operating surgeon, based solely 
on the usual diagnostic methods/criteria. Consideration of recruitment into the study will only 
possible once the decision to proceed with surgery has been made.  The paediatric urologist will then 
review their notes and radiology reports to ensure suitability for inclusion in the study.   
At the end of the consultation, following a discussion of the details of surgery, the urologist will give 
the family patient information leaflets (adult and child/young adult) detailing the study to take home 
and read.  Contact details for the chief investigator will be provided on the leaflet should the families 
have any questions.  The child’s details will be added to a patient database as a potential participant.   
The family will have the time from their outpatient clinic appointment until the child’s admission for 
surgery to decide whether they wish to consent to be included in the study.  This period of time will 
be variable but in the order of a few weeks.  
The family will next be met on the day of the child’s operation when they are admitted for surgical 
pre-assessment. After the surgeon (paediatric urologist) has explained the surgical procedure the 
chief investigator (member of the research team) will go through all aspects of the study with the 
parents and child.  This is to ensure the study is explained correctly, and also that there is no undue 
pressure for the family to consent.  If the family wish to be included in the study they will be able to 
provide written consent in the presence of the lead researcher at this point.    
Enrolment onto the patient database will be completed and the child will be assigned a numeric code.  
This numeric code will be used throughout the study to enable the child’s clinical data to be linked 





A coloured sticker will be applied to the front of the child’s notes to identify participation in the 
study. 
 
Group 2 and 3 participants will be identified during general surgery or urology outpatient clinics by 
their treating clinician.  All patients attending outpatient clinic will be considered a potential 
participant and the clinician will review their notes and radiology reports to ensure suitability for 
inclusion in the study.   
The families will be given adult and child patient information leaflets by the outpatient clinic nurse 
on arrival at the hospital.  At the end of the clinic appointment the clinician will explain the details 
of the study and go through a written consent form with them if they wish to take part.  This means 
families in these groups will have had about 30 minutes – 1 hour to decide whether they wish to be 
included in the study if they wish to be recruited and participate on the day.  Ultimately, however, 
families with children in groups 2 and 3 have an unlimited amount of time to make a decision and 
we would be happy to accommodate them at later date should they wish to take part.  
The patient database will then be completed by the clinician and the child assigned a numeric code. 
A coloured sticker will be applied to the front of the child’s notes to identify participation in the 
study, and the consulting doctor will complete a data collection form. 
For all groups of children a standard letter will be sent to their GP indicating they have been enrolled 
into a study.  In addition a copy of the signed consent form and patient information leaflets will be 
filed in the child’s notes and in the investigator site file.  A copy will also be given to the parents. 
 
Gaining Patient Consent 
Children in all groups will require consent from at least one parent/carer with parental responsibility.  
Consent will be obtained for group 1 patients by the chief investigator. Consent for groups 2 and 3 
patients will be obtained by the treating NHS clinician. A witness will not be required.  Due to the 
nature of the study, consent will be obtained for the removal (consent under common law), storage 
(consent under Human Tissue Act), and use (consent under Human Tissue Act) of human tissue.  
Consent will also be gained for access to medical records.  
We aim to gain generic consent for the tissue and urine samples which means they can be used for 
ongoing/future research projects and this will be explained to the families. 
This study will involve recruiting children who are under the age of 16 years.  Valid informed written 
consent will therefore be obtained from one adult (parent or carer) with parental responsibility in 
addition to obtaining assent from the child if they have sufficient understanding.   
If the child and family do not have adequate understanding of English due to linguistic or hearing 
issues then a qualified medical interpreter will be engaged to enable effective communication with 
the family.  Due to financial and logistical constraints it will not be possible to provide patient 
information leaflets and consent forms in languages other than English however an interpreter will 





All families who are identified as potential participants will be recorded on a patient database and 
their decision whether to participate in the study or not will also be recorded.  In this way we will be 
able to calculate the uptake rate for the study.  
Inability to obtain tissue or urine samples during the inpatient stay of group 1 will be documented on 
the appropriate data collection form. 
Failure to attend routine outpatient clinic follow-up will be documented on a data collection form 
and in the patient’s clinical notes (usual procedure).  On the data collection form it will be indicated 
whether a further appointment is planned and the form will be returned as usual for analysis. 
If two outpatient appointments are missed a telephone call will be made to the family to assess 
whether they wish to continue in the study or whether they would like to leave the study.  If the 
family cannot be contacted with a minimum of three telephone calls a letter will be sent to enquire 
of their well-being and their intentions regarding the study.  This will be in addition to the usual NHS 




A patient may be withdrawn from the study by the investigators if: 
• Continued participation in the study could be harmful to the patients’ health 
• After enrollment it is discovered that the patient does not meet the eligibility criteria 
• The patient needs a medicine or other medical treatment that is not allowed in the 
study 
• The patient was enrolled by error, e.g., due to misinterpretation of the eligibility 
criteria 
Additionally, the family/child may request to withdraw from the study if they no longer want to 
participate. In this case it would be documented in the patient notes and on a data collection form the 
reason why the family wanted to withdraw from the study (if they wish to disclose this) and the date 
of withdrawal. In this scenario all results gained so far would be used in the analysis but no further 
samples/data would be processed.  The child would not be replaced in the study.  Following 
withdrawal from the study the child will continue their usual outpatient follow-up with their treating 













Study sample size: 
Group 1: 30 patients 
Group 2: 80 patients 
Group 3: 80 patients 
Total: 190 patients 
 
Power of the study: 80% 
Level of significance: p<0.05 
 
The primary outcome will be analysed by comparing group 1 and group 2 urine aquaporin levels.  It 
is known that approximately 20 children per year undergo a pyeloplasty for PUJ obstruction at the 
Bristol Children's Hospital.  It is anticipated approximately 75% of these children will be recruited 
which equates to 30 children over 2 years.  Recruitment to group 2 will be much faster as children 
suitable for inclusion are seen in greater numbers throughout the year.  Children will therefore be 
recruited in a 4:1 manner with 4 children in group 2 to every child in group 1.  This method of 
recruitment will increase the sample size and power of the study while keeping the number needed 
to recruit in group 1 achievable within an appropriate timescale.  
 
Current studies suggest a target difference of 30% between groups 1 and 2 is feasible.  It is currently 
unclear what degree of variability there is in the data.  If the target difference is hypothesized to be 
to 0.75 of the standard deviation of the data then with a 4:1 recruitment method, a significance of 5% 
and a power of 80% it is estimated the minimum number of children to be recruited is: 
Group 1: 18 children 
Group 2: 70 children  
 
Recruitment is therefore planned over two years, predicting recruitment of approximately 30 patients 
to group 1 and 80 patients to group 2 will be achieved. 
Recruitment of children in group 3 (no kidney abnormality) is necessary to determine normal urine 
aquaporin levels across ages 0-15 years. For simplicity the aim is to recruit similar numbers to group 
2.  




There are no statistical criteria for termination of the study however a descriptive analysis of the data 
will be performed at 1 year.  It is understood that descriptive analysis of the resultant data may 
demonstrate the variability to be different to that hypothesized.  In this scenario the results obtained 
will form a pilot study from which the true variability can be ascertained and used to appropriately 





Primary Outcome Measure 
• First urine aquaporin level when recruited into the study 
In order to determine whether urine aquaporin levels are a good biomarker to aid surgical decision 
making the first urine aquaporin level will be of prime importance.  This will enable us to compare 
aquaporin levels between children with PUJ obstruction requiring surgery and children with 
hydronephrosis but no evidence of other causes of kidney obstruction.  In this way we will be able 
to demonstrate whether urine aquaporin levels can differentiate between those children with 
'damaging' PUJ obstruction and those with 'safe' non-kidney damaging PUJ obstruction.  
Additionally, assessment of the urine aquaporin levels in children with no kidney abnormality will 
enable us to determine whether age, gender or size has any impact on normal urine aquaporin levels. 
 
Secondary Outcome Measures 
• Tissue (renal pelvis and ureter) aquaporin levels 
• Intra-operative urine aquaporin levels 
• Kidney pressure (measured intra-operatively) 
• Pre-operative kidney function (measured by MAG 3 renogram) 
• Post-operative urine aquaporin levels in group 1 patients 
• Follow-up urine aquaporin levels in group 2 patients 
 
Tissue (renal pelvis and ureter) aquaporin levels and intra-operative urine aquaporin levels when 
combined with intra-operative kidney pressure measurement and results from tests of kidney function 
will enable us to determine whether significant changes in aquaporin levels are seen with increased 
pressure and reduced kidney function in PUJ obstruction. 
Post-operative urine aquaporin levels will enable us to determine whether pyeloplasty restores 
aquaporin levels to normal. 
Follow-up urine aquaporin levels in group 2 will provide a prospective cohort of children enabling 





comparing those children whose hydronephrosis resolves with those who progress to need an 




Source of data Time point for 
collection 
Who will collect 
data 
Reason for data 
collection 
Type of data 
Group 1-3 
Gender 
Baseline Treating Clinician Baseline Binary 




Treating Clinician Baseline 
comparison data 
Continuous 




































Group 3  
Weight 





Group 3  
Height 















Baseline  Treating Clinician Baseline 
comparison data 
Categorical 
Group 1  
Urine sample for 
biomarker 
estimation 
Baseline Sample collection 
- Treating 
Clinician/Nurse 
Lab analysis – 
Laura Jackson 
Main outcome Continuous 
Group 2  Baseline Sample collection 
- Treating 
Clinician/Nurse 
Main outcome Continuous 
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Urine sample for 
biomarker 
measurement 
Lab analysis – 
Laura Jackson 
Group 3  
Urine sample for 
biomarker 
measurement 
Baseline Sample collection 
- Treating 
Clinician/Nurse 
Lab analysis – 
Laura Jackson 
Main outcome Continuous 





During surgery Sample collection 
- Treating 
Clinician 










During surgery Sample collection 
- Treating 
Clinician 





Group 1  
Kidney pressure 
measurement 
During surgery Sample collection 
- Treating 
Clinician 





Group 1  
Renal pelvis and 
ureter tissue for 
aquaporin 
measurement 
During surgery Sample collection 
- Treating 
Clinician 





Group 1  
Urine samples for 
biomarker 
measurement 
Post-operative Sample collection 
- Treating 
Clinician/Nurse 





Group 1  
Urine samples for 
biomarker 
measurement 
Follow-up Sample collection 
- Treating 
Clinician/Nurse 







Group 2  
Urine samples for 
biomarker 
measurement 










Lab analysis – 
Laura Jackson 







Baseline Treating Clinician Explanatory 
variable 
Continuous 







Follow-up Treating Clinician Explanatory 
variable 
Continuous 







Baseline Treating Clinician Explanatory 
variable 
Descriptive 







Follow-up Treating Clinician Explanatory 
variable 
Descriptive 





kidney as reported 
by radiologist 
Baseline Treating Clinician Explanatory 
variable 
Continuous 





kidney as reported 
by radiologist 





Group 1 and 2  
MAG 3 type of 
curve as reported 
by radiologist 
Baseline Treating Clinician Explanatory 
variable 
Categorical 
Group 1 and 2  
MAG 3 type of 
curve as reported 
by radiologist 
Follow-up Treating Clinician Explanatory 
variable 
Categorical 





Baseline Treating Clinician Baseline 
comparison data 
Descriptive 





Follow-up Treating Clinician Explanatory 
variable 
Descriptive 
Group 1 and 2  
Prenatal diagnosis 
of hydronephrosis 
Baseline Treating Clinician Baseline 
comparison data 
Binary 




Baseline Treating Clinician Baseline 
comparison data 
Binary 








The chief investigator will perform all urine and tissue analysis within the laboratories at the Dorothy 
Hodgkin Building, Bristol.  All samples will be labelled with the individual patients’ numeric code 
and sample type and will be transferred to the laboratory on ice.  Samples will be processed in batches 











The chief investigator will be responsible for monitoring the accuracy and quality of data collection.  
Routine monitoring of trial progress will be made every 4 months, checking protocol compliance, 
accurate data collection form completion and monitoring of adverse events.  Telephone contact will 
be made with clinicians if incomplete data collection is noted. 
In order to ensure the study is run in accordance with ICH-GCP (ICH Harmonised Tripartite 
Guideline for Good Clinical Practice) certain essential documents will be compiled and retained at 
the study site within an investigator site file (ISF).  
Data will be collected and retained in accordance with the Data Protection Act 1998. 
 
Methods to Ensure Data Quality 
Data extracted by the treating clinician from the patient medical records will be recorded on specific 
paper data collection forms according to the group the patient is recruited to and which point of the 
study they are at.  These forms will contain clear instructions to minimize errors in data recording.  
In terms of measurements of kidney pressure, the instrument will first be calibrated and then the 
measurement will be recorded 3 times.  Tissue and urine samples will each be analysed twice in order 
to check the accuracy of the data.   
Medical and laboratory data will be entered by the chief investigator into a specially designed 
database created using Microsoft Access. Data entry will be performed via a standardized and 
consistent procedure.  Data checking will be performed by verifying random samples of the digital 
data against the original data, double entry of data and statistical analyses such as frequencies, means 
and ranges to detect errors and anomalous values.  
 
Data Security/Storage 
For the duration of the study patient identifiable data including only the patient name, date of birth 
and Bristol Children's Hospital Identification Number will be stored on a database on the secure 
Bristol Children's Hospital NHS Trust server. Each child will be assigned a unique numeric code on 
this database.  This network is only accessible to approved members of the NHS clinical workforce. 
Data extracted from the child's records (demographic data, results of ultrasound scans and x-ray tests) 
will be recorded on a paper data collection form as described above and the child's unique numeric 
code placed on the record.  No personal details of the child will be recorded on the data collection 
form and completed forms will be stored in a locked drawer in the Dorothy Hodgkin Building, 
University of Bristol. Only the chief investigator will have access to this drawer.  The building itself 
is very secure with swipe card and biometric authorisation necessary for access.   
Data Handling and Record Keeping 
362 
 
Data from the data collection form and laboratory sample analysis results will be stored on the secure 
password protected University of Bristol Local Research Data Storage System.  This data will only 
be accessible by the chief investigator. 
The University of Bristol provides a dedicated Research Data Service as part of the Library 
(http://data.bris.ac.uk/research/). The Service offers advice, support and training in all areas of 
research data management and is responsible for Bristol’s data.bris, Research Data Repository. The 
Service has it’s own Steering Group and is responsible for the University’s Research Data Principles 
(http://data.bris.ac.uk/research/support/). 
 
Long-term Data Storage/Archiving 
Following completion of the study, the data from the Bristol Children’s Hospital NHS system and 
the University of Bristol Local Research Data Storage System will be encrypted and stored within 
the secure University of Bristol Research Data Storage Facility (RDSF) for 20 years.  Dr Richard 
Coward will be the Data Steward and the chief investigator (Laura Jackson) and Mr Mark Woodward 
will also have access to the data.   
The University of Bristol Research Data Storage Facility (RDSF) provides secure, long-term storage 
for research data. This two million pound investment provides nightly backup of all data, with further 
resilience provided by three geographically distinct storage locations. A tape library is used for 
backup purposes and also for long-term, offline data storage. Only authorised users can access data 
stored within the RDSF. 
The RDSF is managed by Bristol’s Advanced Computing Research Centre (ACRC) which has a 
dedicated steering group and a rigorous data storage policy 
(https://www.acrc.bris.ac.uk/acrc/RDSF_policy.pdf). The RDSF upholds and reinforces Bristol’s 
wider Information Security Policy (www.bris.ac.uk/infosec/policies/docs/isp-01.pdf). 
 
Public Sharing of Non-Confidential Research Data 
Anonymous data will be stored on the University of Bristol long term Research Data Repository in 
order to publicly share research results. 
The data.bris Research Data Repository offers a means for Bristol’s researchers to openly share non-
confidential research data, without the need for external data users to undergo any form of 
authentication. Each deposit is accompanied by appropriate metadata and is assigned a unique Digital 
Object Identifier (DOI) via the DataCite scheme. All data published by the Repository is available 











The statistical requirements of this study have been discussed with Professor Tim Peters, Professor 
of Primary Care Health Services Research and Head of The School of Clinical Sciences 
All recruited patients will be included in the analysis.  Descriptive statistical analysis will be applied 
to the study in order to quantitatively evaluate the basic features of the data.  This will include 
measures of central tendancy (mean, median, mode), measures of dispersion (range and quartiles) 
and measures of variability (standard deviation). 
The distribution of the data will be assessed to determine normality of distribution which will impact 
on further choices of statistical test.  Anticipated statistical tests are listed below: 
 
Primary outcome measure will be analysed using: 
• Unpaired T-test/Mann-Whitney Test 
• Logistic regression model to generate receiver operating characteristic curve (ROC curve) 
which will allow the threshold to be determined for the urine biomarker test. 
Secondary outcomes measures will be analysed using: 
• Unpaired T-test/Mann-Whitney Test 





All adverse events will be recorded in the investigator site file, documenting when the event occurred, 
details of the adverse event, any potential relation to the study, action taken and resolution / closure 
of the adverse event.  An assessment of seriousness will be made and serious adverse events will be 
recorded and reported in accordance with UH Bristol’s Research Related Adverse Event Reporting 
Policy in line with University of Bristol guidance.  All serious adverse events will also be reported 
to the NHS Research Ethics Committee in the Annual Progress Report.  
 
The type and duration of follow-up will be specific to the adverse event and will be determined by 
the study investigators. However; all adverse events will be followed through to resolution or until 










Definitions of Study Completion and Premature Discontinuation of the Study: 
• Completion of the study will be achieved when all data collection and analysis has been 
completed for all patients enrolled in the study. 
• Premature discontinuation of the study will occur if patient recruitment is terminated before 
full recruitment is achieved.  The chief investigator, Research and Innovation Team and 
Research and Enterprise Development Team will discuss whether premature discontinuation 
is required following completion of the interim analysis. 
Routine monitoring of trial progress will be made every 4 months, checking protocol compliance, 
accurate proforma completion and monitoring of adverse events. An interim descriptive statistical 
analysis of the data will be performed at 1 year 
At study completion or if the study is prematurely discontinued, the Research and Innovation 
Department (NHS) and the Research and Enterprise Development Department (University) will be 
notified in writing.   A ‘Declaration of the End of a Study’ form will be completed and sent to the 
Research Ethics Committee (REC).  A copy will also be sent to the sponsor.  The funding body will 





The study will be monitored and audited in accordance with University of Bristol policies.  All trial 
related documents will be made available on request for monitoring and audit by UH Bristol, 
University of Bristol and the relevant Research Ethics Committee. 
The study will be performed subject to Research Ethics Committee (REC) approval and local 
Research and Development (R&D) approval. 
This study will be conducted in accordance with the Research Governance Framework for Health 
and Social Care and Good Clinical Practice. 
If any changes to the study are required, necessary amendments will be made in agreement with the 
sponsors following approval from the REC and R&D.  An annual report will be submitted to the 








Ethical Issues Related to the Study 
 
Consent  
Children in all groups will require consent from at least one parent/carer with parental responsibility.  
Due to the nature of the study consent will be obtained for the removal (consent under common law), 
storage (consent under Human Tissue Act), and use (consent under Human Tissue Act) of human 
tissue.  Consent will also be gained for access to medical records.  We aim to gain generic consent 
for the samples which means they can be used for ongoing/future research projects and this will be 
explained to the families. 
This study will involve recruiting children who are under the age of 16 years.  Valid informed written 
consent will therefore be obtained from one adult (parent or carer) with parental responsibility in 
addition to obtaining assent from the child if they have sufficient understanding.   
It will be emphasized to all families involved that they may withdraw their consent at any time during 
the process and this will not affect their ongoing treatment.  
If the child and family do not have adequate understanding of English due to linguistic or hearing 
issues then a qualified medical interpreter will be engaged to enable effective communication with 
the family.  Due to financial and logistical constraints it will not be possible to provide patient 
information leaflets and consent forms in languages other than English however an interpreter would 
be requested to read through these with the family to enable them to  be included if they wish. 
Risks, Burdens and Benefits 
Benefits of the Study to the Child 
The benefits of collecting and analyzing urine samples are far reaching if it leads to the generation 
of a new urine test to help diagnose PUJ obstruction earlier thus reducing the risk to the kidney. If 
the urine aquaporin test can then be implemented into clinical practice, children with hydronephrosis 
may benefit from using the test to help decide their ongoing managment. 
Although the study will not influence the frequency of outpatient clinic follow-up appointments it is 
reasonable to assume that those children in the study will benefit from slightly more attentive follow-
up than their counterparts.  
There are no other direct benefits of the study to the children's health however they may take personal 
pleasure from being able to participate in a study that will help future generations of children with 
the same condition as them. 
 
Risks/Burdens of the Study to the Child 
For children in Groups 2 and 3 the risks/burden relate to the inconvenience of spending time in the 
outpatient clinic providing a urine sample and discussing with the clinician whether to take part in 
the study.  As we are recruiting children their ability to provide a specimen on demand is very 
variable.  In order to minimise inconvenience families will be provided with patient information 
leaflets on arrival to outpatient clinic by the clinic nurse.  This will give them time to read and digest 
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the information before meeting the clinician for their appointment.  Water will be made available in 
the clinic to encourage the timely  production of a urine sample.   
Children in group 3 will only be asked to provide a urine sample on one occasion.  Children in group 
2 will be asked to provide a urine sample at each outpatient clinic appointment over a period of up 
to 4 years.  This will cause some inconvenience at each visit while obtaining a urine sample however 
the time spent should be shorter than the first visit.  This is because we hope to gain consent at the 
first visit for ongoing samples which means they will not need to go through the consent process 
each time.  
Children in group 1 undergoing a pyeloplasty will have the same burden of inconvenience as group 
2 in terms of providing urine samples for analysis and additionally they will be required to give urine 
samples while an inpatient in hospital.  
Confidentiality 
During this study the “Caldicott Principles” will be utilized as a framework when dealing with patient 
confidentiality issues.  In order to correlate the findings from laboratory tissue/urine analysis with 
knowledge of severity of hydronephrosis, kidney function and patient demographics, it will be 
necessary to access patient NHS records and use patient identifiable data.  Without this data it will 
be impossible to know whether there is any difference between those children with hydronephrosis 
who maintain their kidney function and those who don’t.   
With this in mind we propose to use linked-anonymised data.  In this way the data will be anonymous 
to the chief investigator (the researcher who will receive and hold the data) but it will contain a code 
that will allow the supplier of the data (NHS healthcare team) to identify people from it.  In this way 
it will also allow us to link data from before and after surgery for patients, and also provide an avenue 
for the healthcare team to contact participants at the end of the study with a copy of the study results.   
Patient identifiable data including only the patient name, date of birth and Bristol Children's Hospital 
Identification Number will be stored on a database on the secure Bristol Children's Hospital Network.  
Each child will be assigned a unique numeric code on this database.  This network is only accessible 
to approved members of the NHS clinical workforce. 
Data extracted from the child's records (demographic data, results of ultrasound scans and x-ray tests) 
will be recorded on a paper data collection form and the child's unique numeric code placed on the 
record.  No personal details of the child will be recorded on the data collection form.  The data 
collection form will be stored in a locked drawer in the Dorothy Hodgkin Building, University of 
Bristol. Only the chief investigator will have access to this drawer.  The building itself is very secure 
with swipe card and biometric authorisation necessary for access.  Information from the data 
collection forms and laboratory sample analysis results will be stored on the secure password 
protected University of Bristol Local Research Data Storage. Only the chief investigator will have 
access to this data. 
Families will be informed during the consent process that access to medical records will be required 
to complete the study.  Medical records will only be accessed by the healthcare team involved in the 
direct care of the patient and data extraction will be kept to the absolute minimum necessary.  
Families will also be informed that information gleaned from the study will ultimately be published 
in journal articles and presented to other health professionals and researchers at national and 
international meetings. All data will by anonymised at the time of publication and it will not be 














The University of Bristol has arranged Public Liability insurance to cover the legal liability of the 
University as Research Sponsor in the eventuality of harm to a research participant arising from 
management of the research by the University. 
This does not in any way affect an NHS Trust’s responsibility for any clinical negligence on the part 
of its staff (including the Trust’s responsibility for University of Bristol employees acting in 
connection with their NHS honorary appointments). 
The University of Bristol holds Professional Negligence insurance to cover the legal liability of the 
University, for harm to participants arising from the design of the research, where the research 
protocol was designed by the University. 
The University of Bristol’s Public Liability insurance policy provides an indemnity to our employees 
for their potential liability for harm to participants during the conduct of the research. 
This does not in any way affect an NHS Trust’s responsibility for any clinical negligence on the part 
of its staff (including a Trust’s responsibility for University of Bristol employees acting in connection 
with their NHS honorary appointments). 
Miss Laura Jackson, Mr Mark Woodward and Dr Richard Coward all hold substantive appointments 
with University Hospitals Bristol NHS Foundation Trust giving them the protection of the NHS 














Regular reports will be submitted to the NHS REC, to the funding body (The David Telling 
Charitable Trust) and to the sponsor during the running of the study.  Study results will be published 
in peer-reviewed scientific journals and presented at conferences, nationally and internationally.  
Anonymous data will be stored on the University of Bristol long term Research Data Repository in 
order to publicly share research results.  Additionally, a summary sheet of the study results will be 
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10.3.2 Patient information leaflets 
Patient information leaflets provided to parents, young adults and children recruited to 
groups 1-3 are presented in the following section. 
 




Do aquaporins protect against renal damage in PUJ obstruction? 
Information Sheet for Parents/Guardians of Children having a 
Pyeloplasty for PUJ Obstruction (Group 1) 
Your child is being invited to participate in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve for you and your child.  
Please take time to read the following information carefully and discuss it with others 
if you wish. If appropriate, please encourage your child to read their information sheet 
and discuss the study with them.  
Your child’s specialist doctor will explain if there is anything that is not clear or if you 
would like more information. Thank you for taking the time to read this. 
The purpose of this study 
Your child has been diagnosed with pelvi-ureteric junction (PUJ) obstruction which is 
the most common cause of obstruction (blockage) in the urinary tract.  Your doctor has 
recommended that your child has an operation called a pyeloplasty to treat this 
condition. 
The kidneys produce urine by filtering the blood and removing waste products and 
water.  The urine must then drain out of the kidney through a funnel shaped structure 
called the renal pelvis and into a tube called the ureter which transports urine to the 
bladder where it is stored. 
PUJ obstruction is caused by a narrowing at the point where the ureter joins the renal 
pelvis.  This obstruction, which forms before the baby is born, means that urine can’t 
drain out of the kidney as fast as it is produced.  Urine therefore accumulates inside the 
kidney causing the kidney to swell.  This swelling (dilatation) is seen on ultrasound 
scan and is called hydronephrosis.  Accumulating urine may increase the pressure 






The major issue for doctors is deciding which children require surgery to relieve PUJ 
obstruction and limit kidney damage, and which do not. This is because some children 
with PUJ obstruction do not damage their kidneys, do not require surgery and 
ultimately grow out of the problem.  
Our current ability to distinguish between those children with high pressure 
“damaging” obstruction and those with low pressure “safe” non-kidney damaging PUJ 
obstruction is limited.   
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  By 
reabsorbing water from the urinary tract, these channels may reduce the pressure in 
the system, and explain the mechanism behind “safe” and “damaging” PUJ obstruction.  
We want to learn more about these channels so in the future we can develop new 
treatments to help protect the kidneys of all children and young adults with PUJ 
obstruction. 
In addition, everybody sheds some of these water channels in their urine.  We want to 
collect these special proteins from the urine, measure their amount and show whether 
they are a good marker of high pressure and low pressure kidneys.  This will enable us 
to work out if a new type of urine test could help doctors decide which children with 
PUJ obstruction need an operation and which don’t.    
We hope that by improving our understanding of how the kidneys become damaged in 
PUJ obstruction we will be able to develop new tests and new treatments.  These will 







Why has my child been chosen? 
Every patient with pelvi-ureteric junction (PUJ) obstruction who attends the Bristol 
Children’s Hospital will be invited to participate. 
Does my child have to take part? 
It is up to you to decide whether your child takes part. If you decide they can take part 
you will be asked to sign a consent form. You are still free to change your mind and 
withdraw your child from the study at any time without giving a reason, and this will 
not affect the treatment your child receives. 
What will happen if my child agrees to take part? 
There are three parts to this study: 
Firstly, when your child is admitted to hospital on the day of their operation they will 
be weighed and measured. With your permission we would also like them to provide a 
urine sample into a pot, or in younger children this may be collected from their nappy.  
The urine sample will be sent to the research laboratory in Bristol where the levels of 
water channels will be measured. 
 
Secondly, during your child’s operation (pyeloplasty), with your consent, samples will 
be obtained and procedures performed while your child is under general anaesthetic.  
These are:   
 
• All children undergoing a pyeloplasty normally have a bladder catheter inserted 
at the beginning of the procedure.  We would like to take a urine sample from 
the bladder catheter for laboratory analysis for the levels of water channels.   
• We would also like to take a pressure reading from the obstructed kidney before 
the obstruction is relieved.  This involves inserting a small pressure probe 
through the piece of drainage tube tissue that will subsequently be removed as 
part of the operation.  Measuring the pressure in the kidney is an extra 
procedure for your child. 
• During pyeloplasty surgery urine is usually removed from the obstructed 
kidney to reduce the size of the renal pelvis and make surgery easier.  This urine 
is normally discarded however we would like to take a sample of this urine for 
laboratory analysis for the levels of water channels. 
• The narrow section of tube at the junction of the renal pelvis and ureter will be 
removed and then the tube will be joined back together.  Removing this 
narrowed piece of drainage tube is a normal part of the operation to correct PUJ 
obstruction and this piece of tissue is normally disposed of at the end of the 
operation.  We would like the doctor to send the narrowed piece of renal 
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pelvis/ureter to the research laboratory in Bristol where the levels of water 





After the operation the tube from the kidney will be joined together and urine will drain 






After your child’s operation we would like to collect a urine sample on a daily basis 
until they are discharged from hospital.  Initially this will be taken from the bladder 
catheter but once this is removed your child will be asked to provide a specimen into a 
pot.  In younger children the sample can be collected from the nappy. 
Thirdly, at each outpatient clinic visit your child will be weighed and measured and we 
would like them to provide a fresh urine sample into a pot, or in younger children it 
may be collected from their nappy.  This will be sent to the research laboratory in 
Bristol where the levels of water channels will be measured.  These results will help us 
to know whether treating the blockage in PUJ obstruction changes the amount of water 
channels shed in the urine. 
During each stage, with your permission, the doctor will record some information 
about your child which will be taken from their medical notes/results file.  These will 
include; their age, height and weight, any symptoms relating to PUJ obstruction, the 
results of their kidney scans and current medications. 
With your permission we would like to store the samples after this research is 
complete for use in future ethically approved kidney disease research.  
What will happen to any information about my child? 
Any medical information about your child will be kept private.  Limited personal details 
identifying your child as participating in the study will remain on the NHS computer 
system at the Bristol Children’s Hospital.  All children will be assigned a study number 
so that any samples and information collected about them is labelled with this number 
and no personal details when it is transferred to the research laboratory.  The 
information your doctor sends to the researchers and the results we have from sample 
analysis will be stored securely at the laboratory.  At the end of the study the 
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information will be encrypted and transferred to a secure storage facility within the 
University of Bristol called the Research Data Repository where it will remain for 20 
years.  At the end of this period of time the information will be destroyed. 
What will happen to my child’s samples? 
Once the narrowed drainage tube and urine samples have been analysed, they will be 
stored securely at the research laboratory in Bristol.  The samples will be labelled with 
your child’s unique study number so that their sample results can be linked with their 
medical information.  At the end of the study, with your permission, the samples will 
continue to be stored at the research laboratory pending further study.  Access to this 
building is limited to the laboratory staff and an identification card and biometric 
authorisation is required for access. 
What if new discoveries are made about PUJ obstruction?   
The research-group want to test for water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They also want to determine whether a urine 
test for these water channels will help doctors decide which children and young adults 
need an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your child’s 
samples to be stored and used for future research that’s ok, just inform your specialist 
doctor and we will dispose of them at the end of this study. 
How will I know the outcome of the research? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results please inform your specialist doctor.  
Will the results be published? 
All data collected will be collated and published in peer-reviewed scientific journals.  
The findings will also be presented at national and international scientific conferences.  
All this information will be anonymous and it will not be possible to identify your child 
from the data.    
 
Will my GP know about this research? 






How long will I have to decide? 
We would like to give you as much time as possible to discuss the study and decide 
whether you wish your child to take part.  However; your child’s ongoing medical 
treatment is our greatest priority and we wouldn’t want to delay their operation in 
order to accommodate the study.  Because of the type of samples and information we 
would like to collect, it is not possible to join the study after your child has had surgery.  
Considering all these factors we would need to know by the day of your child’s 
operation whether you would like to take part.  We will be extremely happy to answer 
any questions you may have in the meantime and we would ask that you please contact 
either your specialist doctor or email the researcher listed at the bottom of the leaflet.  
What if I wish to withdraw my child from the study? 
A participant may withdraw at any stage without having to give an explanation. You 
can do this via telephone, email, or in writing to your specialist doctor or directly to the 
research team if you wish. The results of any tests on samples already collected will be 
used but no further tests will be done on these samples and no further samples will be 
collected.  Any samples already held by the research team will be destroyed in an 
appropriate manner. 
What are the risks/benefits in participating in this study? 
This study does not require you to attend hospital more frequently however there is 
an extra procedure that would be undertaken during your child’s operation.  This is to 
measure the pressure in the kidney.  There are no risks associated with measuring the 
kidney pressure as the pressure probe is inserted through the piece of drainage tube 
tissue that is subsequently removed as a normal part of the operation. Measuring the 
pressure takes about 5 minutes to perform. 
The pyeloplasty operation will be performed in exactly the same manner as normal and 
the outcome of the surgery will not be changed by involvement in the study.   
At each outpatient clinic visit and during your child’s hospital stay your child will be 
asked to provide urine samples (or in younger children these would be taken from the 
nappy) for analysis.  Your child will also be weighed and measured at each outpatient 
clinic visit.  Some of these urine samples will be extra to normal requirements. 
The benefits of participating in the study are that it will increase medical knowledge 
about PUJ obstruction potentially leading to new treatments and the development of a 
new urine test.  We hope this urine test will allow earlier and improved detection of 
those children requiring surgery for PUJ obstruction.  
What do I do if I have concerns about the study? 
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If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 
Complaints Team within the Bristol Children’s Hospital.  
Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project.  
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West - Central Bristol Research Ethics Committee. 
 
Researchers Patient Support and Complaints 
Team 
Miss Laura Jackson, Mr Mark Woodward and 
Prof Richard Coward 
Patient Support and Complaints 
Team 
Academic Renal Unit  Trust Headquarters 
University of Bristol University Hospitals Bristol 
Dorothy Hodgkin Building, Level 1 Marlborough Street 
Whitson Street Bristol 
Bristol BS1 3NU 
BS1 3NY  














Do aquaporins protect against renal damage in PUJ obstruction?  
Information Sheet for Young Adults having a Pyeloplasty for 
PUJ Obstruction (Group 1) 
You are being invited to take part in a project. Before you decide, it is important for you 
to understand why we want to do it and what it means for you.  
Please take time to read this and chat about it with others if you want.  
Your specialist doctor will explain anything that is confusing, or give you more 
information. Thank you for taking the time to read this. 
The purpose of this study 
You have a blockage of your kidney called pelvi-ureteric junction (PUJ) obstruction 
which needs an operation known as a pyeloplasty to make it better.  PUJ obstruction is 
caused by a narrowing in the upper part of the tube that drains urine out of the kidney.  
Urine therefore builds up and can increase the pressure inside the kidney.  In some 
children and young adults this can cause the kidney to not work properly.   
 
 
Not all people with PUJ obstruction are at risk of kidney damage if they don’t have an 
operation.  Some children grow out of the problem and their kidneys continue to work 
normally.   
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Sometimes it can be difficult for doctors to figure out which children and young adults 
need an operation to protect their kidney and which will simply grow out of the 
problem. 
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  We 
want to learn more about these channels to see if we can develop new treatments to 
help protect the kidneys of all children and young adults with PUJ obstruction. 
In addition, everybody sheds some of these water channels in their urine.  We want to 
collect these special proteins from the urine and measure their amount.  This will 
enable us to work out if a new type of urine test could help doctors decide which 
children with PUJ obstruction need an operation and which don’t.    
Why have I been chosen? 
Every patient with pelvi-ureteric junction (PUJ) obstruction who attends the Bristol 
Children’s Hospital will be invited to participate. 
Do I have to take part? 
It is up to you to decide whether you take part.  You are still free to change your mind 
and leave the study at any time without giving a reason. If you decide not to take part 
or to come out of the study this will not affect the treatment you receive.  
What will happen if I agree to take part? 
There are three parts to this study if you decide you want to take part: 
Firstly, when you come in to hospital on the day of your operation we would like you 
to be weighed and measured and we would like you to provide a urine sample into a 
pot.  This will be sent to the research laboratory in Bristol where the levels of water 
channels will be measured. 
Secondly, during your operation (pyeloplasty), your doctor would like to take some 
samples and perform some procedures while you are asleep under general anaesthetic.  
These include: 
At the beginning of the operation your doctor would like to use a special machine to 
record the pressure in your blocked kidney.  They would also like to take a urine sample 
directly from the blocked kidney which will be sent to the research laboratory to 
measure the levels of water channels.   
The main part of the operation is when your doctor takes out the narrow piece of tube 
and joins the tube back together in order fix your kidney blockage.   Normally the 
removed section of narrow tube is discarded, but your doctor would like to send the 




be measured.  All of this will happen while you are under general anaesthetic, so you 




After the operation the tube from the kidney will be joined back together and urine will 





After the operation your doctor would like to collect a urine sample from you every day 
while you are in hospital. 
Thirdly, at each outpatient clinic visit we would like you to be weighed and measured 
and to provide a urine sample into a pot.  This will be sent to the research laboratory 
in Bristol where the levels of water channels will be measured.  
These results will help us to know whether treating the blockage in PUJ obstruction 
changes the amount of water channels shed in the urine. 
During each stage your doctor would like to record some information about you 
including; your age, your height and weight, the results of your most recent kidney 
scans, and if you are taking any medicines. 
With your agreement and your parents’ permission we would like to store your 
samples after this research is complete for use in future ethically approved kidney 
disease research.  
What will happen to any information about me? 
Any information about you will be kept private. The information your doctor sends us 
will be stored securely at the laboratory.  At the end of the study the information will 
be encrypted and transferred to a secure storage facility within the University of Bristol 
called the Research Data Repository where it will remain for 20 years.  At the end of 
this period of time the information will be destroyed. 
What will happen to my drainage tube and urine samples? 
Once the drainage tube and urine samples have been analysed, they will be stored 
securely at the research laboratory in Bristol.  At the end of the study, with your 
agreement, the samples will continue to be stored at the research laboratory in Bristol. 
Only people in the research group with special passes can get in. The samples are kept 
in a freezer until they are used.  
What if new discoveries are made about PUJ obstruction?   
The research-group want to test for water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They also want to determine whether a urine 
test for these water channels will help doctors decide which children and young adults 
need an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your samples to 
be stored and used for future research that’s ok, just tell us and we will dispose of them 




How will I know the results of the study? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results that’s fine just let us know.  
 
Will my GP know about this research? 
If you and your parents agree we will inform your General Practitioner of your 
participation in this project.  
How long do I have to decide? 
We would like to give you as much time as possible to discuss the study and decide 
whether you want to take part.  However; your medical treatment is our greatest 
priority and we wouldn’t want to delay your operation because of the study.  Since the 
samples and information we would like to collect are mostly obtained during your 
operation, it is not possible to join the study after you have had your operation.  
Considering all these factors we would need to know by the day of your operation 
whether you would like to take part.  We will be extremely happy to answer any 
questions you may have in the meantime.  Please contact either your specialist doctor 
or email the researcher listed at the bottom of the leaflet with any questions you have.   
What if I wish to leave the study? 
You can leave the study at any stage without having to give a reason. You can do this 
via telephone, email, or in writing to your specialist doctor or directly to the research 
team if you wish. The results of any tests on samples already collected will be used but 
no further tests will be done on these samples and no further samples will be collected.  
Any samples already held by the research team will be destroyed in an appropriate 
manner. 
What do I do if I have concerns about the study? 
If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 
Complaints Team within the Bristol Children’s Hospital.  
Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project. 
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West – Central Bristol Research Ethics Committee. 
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Studying Kidney Blockage 
Information Sheet for Children having an Operation for a 
Kidney Blockage (Group 1) 
 
Hello!  
Thank you for reading this.  You can ask someone to help you read it if you want. 
Please ask if you don’t understand. 
Your doctor thinks you have a blockage of your kidney which needs an operation to 
make it better.   We call this blockage pelvi-ureteric junction (PUJ) obstruction. It 
happens because part of the tube that drains wee out of the kidney is too narrow.  There 
are other children, just like you, in Bristol and the rest of the country who also have 
this problem. 
 
There is a group of doctors and scientists in Bristol who want to find out more about it. 
They want to try and find out why the blockage sometimes makes the kidney not work 
properly.  They also want to find out if a new test using a sample of wee can help doctors 




They will do this by asking all the children who come to Bristol Children’s Hospital with 
a kidney blockage to join in this project.  They would like to collect information about 
how old you are, how heavy you are and what tests and scans you’ve already had. 
The doctors would also like you to give them a sample of your wee each time you come 
to the hospital. The sample will be tested to see how much of a special type of protein 
is in your wee.    
When you have your operation to fix the kidney blockage your doctor will take out the 
narrow bit of tube and join the tube back together.  Your doctor would like to send the 
narrow bit of tube to the scientists to be tested just like the wee sample.  All this would 









After the operation the tube from the kidney will be joined back together and the kidney 






If you don’t want to take part that’s ok and it won’t affect your treatment. 
So that’s it!  
Do you want to ask any questions? 
 
Researchers 
Miss Laura Jackson, Mr Mark Woodward and Prof Richard Coward 
Academic Renal Unit 
University of Bristol 
Dorothy Hodgkin Building, Level 1 
Whitson Street 
Bristol, BS1 3NY 
Contact email: laura.jackson@bristol.ac.uk 
This study has been reviewed and approved by South West – Central Bristol Research 




Do aquaporins protect against renal damage in PUJ obstruction? 
Information Sheet for Parents/Guardians  of Children with 
Hydronephrosis (Group 2)  
 
Your child is being invited to participate in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve for you and your child.  
Please take time to read the following information carefully and discuss it with others 
if you wish. If appropriate, please encourage your child to read their information sheet 
and discuss the study with them.  
Your child’s specialist doctor will explain if there is anything that is not clear or if you 
would like more information. Thank you for taking the time to read this. 
The purpose of this study 
There a number of children and young adults who come to the Bristol Children’s 
Hospital because they have pelvi-ureteric junction (PUJ) obstruction which is the most 
common cause of obstruction (blockage) in the urinary tract. Some need an operation 
known as a pyeloplasty to treat this condition. 
The kidneys produce urine by filtering the blood and removing waste products and 
water.  The urine must then drain out of the kidney through a funnel shaped structure 
called the renal pelvis and into a tube called the ureter which transports urine to the 
bladder where it is stored. 
PUJ obstruction is caused by a narrowing at the point where the ureter joins the renal 
pelvis.  This obstruction, which forms before the baby is born, means that urine can’t 
drain out of the kidney as fast as it is produced.  Urine therefore accumulates inside the 
kidney causing the kidney to swell.  This swelling (dilatation) is seen on ultrasound 
scan and is called hydronephrosis.  Accumulating urine may increase the pressure 





The major issue for doctors is deciding which children require surgery to relieve PUJ 
obstruction and limit kidney damage, and which do not. This is because some children 
with PUJ obstruction do not damage their kidneys, do not require surgery and 
ultimately grow out of the problem.  
Our current ability to distinguish between those children with high pressure 
“damaging” obstruction and those with low pressure “safe” non-kidney damaging PUJ 
obstruction is limited.   
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  By 
reabsorbing water from the urinary tract, these channels may reduce the pressure in 
the system, and explain the mechanism behind “safe” and “damaging” PUJ obstruction.   
Everybody sheds some of these water channels in their urine.  We want to collect these 
special proteins from the urine, measure their amount and show whether they are a 
good marker of high pressure and low pressure kidneys.  This will enable us to work 
out if a new type of urine test could help doctors decide which children with PUJ 
obstruction need an operation and which don’t.    
In order to know whether the test correctly identifies which children need an operation 
we need to know what the levels of these water channels are in children who have a 
swollen kidney but no evidence of a kidney obstruction. 
For this reason the kidney research unit in Bristol is asking children who have a 





Why has my child been chosen? 
Every child/young adult with a swollen kidney (but not a kidney obstruction) who 
attends the Bristol Children’s Hospital surgery/urology clinics on specified 
recruitment days will be invited to participate. 
Does my child have to take part? 
It is up to you to decide whether your child takes part. If you decide they can take part 
you will be asked to sign a consent form. You are still free to change your mind and 
withdraw your child from the study at any time without giving a reason, and this will 
not affect the treatment your child receives. 
What will happen if my child agrees to take part? 
Your child’s scheduled appointment with the doctor will go ahead today as planned.  
With your consent at the end of the appointment your child will be weighed and 
measured and we would like them to provide a urine sample into a pot.  In younger 
children the sample can be collected from the nappy.  The urine sample will be sent to 
the research laboratory in Bristol where the levels of water channels will be measured. 
Subsequently each time you attend a urology appointment your child will be weighed 
and measured and we would like them to provide a fresh urine sample into a pot, or in 
younger children it may be collected from their nappy.  Again, this will be sent to the 
research laboratory where the levels of water channels will be measured.   
At each visit, with your permission, the doctor will record some information about your 
child which will be taken from their medical notes/results file.  This will include; their 
age, their height and weight, the cause of their swollen kidney, results of any kidney 
scans and current medications.  
With your permission we would like to store the samples after this research is 
complete for use in future ethically approved kidney disease research.  
What will happen to any information about my child? 
Any medical information about your child will be kept private.  Limited personal details 
identifying your child as participating in the study will remain on the NHS computer 
system at the Bristol Children’s Hospital.  All children will be assigned a study number 
so that their urine sample and information collected about them is labelled with this 
number and no personal details when it is transferred to the research laboratory.  The 
information your doctor sends to the researchers and the results we have from sample 
analysis will be stored securely at the laboratory.  At the end of the study the 
information will be encrypted and transferred to a secure storage facility within the 
University of Bristol called the Research Data Repository where it will remain for 20 




What will happen to my child’s samples? 
Once the urine samples have been analysed, they will be stored securely at the research 
laboratory in Bristol.  The samples will be labelled with your child’s unique study 
number so that their sample results can be linked with their medical information.  At 
the end of the study, with your permission, the samples will continue to be stored at 
the research laboratory pending further study.  Access to this building is limited to the 
laboratory staff and an identification card and biometric authorisation is required for 
access. 
What if new discoveries are made about PUJ obstruction?   
The research-group is interested in water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They want to determine whether a urine test 
for these water channels will help doctors decide which children and young adults need 
an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your child’s 
samples to be stored and used for future research that’s ok, just inform your specialist 
doctor and we will dispose of them at the end of this study. 
How will I know the outcome of the research? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results please inform your specialist doctor.  
Will the results be published? 
All data collected will be collated and published in peer-reviewed scientific journals.  
The findings will also be presented at national and international scientific conferences.  
All this information will be anonymous and it will not be possible to identify your child 
from the data.    
Can I have more time to decide? 
Yes. There is no time limit.   
What if I wish to withdraw my child from the study? 
A participant may withdraw at any stage without having to give an explanation. You 
can do this via telephone, email, or in writing to your specialist doctor or directly to the 
research team if you wish. The results of any tests on samples already collected will be 
used but no further tests will be done on these samples and no further samples will be 




What are the risks/benefits in participating in this study? 
This study does not require you to make an extra visit to the hospital however it does 
require your child to be weighed and measured and provide a urine samples at the end 
of each urology clinic appointment you attend. 
The benefits of participating in the study are that it will increase medical knowledge 
about PUJ obstruction potentially leading to the development of a new urine test.  We 
hope this urine test will allow earlier and improved detection of those children 
requiring surgery for PUJ obstruction.  
What do I do if I have concerns about the study? 
If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 
Complaints Team within the Bristol Children’s Hospital. 
Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project. 
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West - Central Bristol Research Ethics Committee. 
 
Researchers Patient Support and Complaints 
Team 
Miss Laura Jackson, Mr Mark Woodward and 
Prof Richard Coward 
Patient Support and Complaints 
Team 
Academic Renal Unit  Trust Headquarters 
University of Bristol University Hospitals Bristol 
Dorothy Hodgkin Building, Level 1 Marlborough Street 
Whitson Street Bristol 
Bristol BS1 3NU 
BS1 3NY  







Do aquaporins protect against renal damage in PUJ obstruction?  
Information Sheet for Young Adults with a Swollen Kidney 
(Group 2) 
 
You are being invited to take part in a project. Before you decide, it is important for you 
to understand why we want to do it and what it means for you.  
Please take time to read this and chat about it with others if you want.  
Your specialist doctor will explain anything that is confusing, or give you more 
information. Thank you for taking the time to read this. 
The purpose of this study 
There a number of children and young adults who come to the Bristol Children’s 
Hospital because they have a blockage of their kidney called pelvi-ureteric junction 
(PUJ) obstruction.  Some need an operation known as a pyeloplasty to make it better.  
PUJ obstruction is caused by a narrowing in the upper part of the tube that drains urine 
out of the kidney.  Urine therefore builds up and the kidney becomes swollen.  In some 
children and young adults this can cause the kidney to not work properly.   
 
Not all people with PUJ obstruction are at risk of kidney damage if they don’t have an 
operation.  Some children grow out of the problem and their kidneys continue to work 
normally.   
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Sometimes it can be difficult for doctors to figure out which children and young adults 
need an operation to protect their kidney and which will simply grow out of the 
problem. 
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  
Everybody sheds some of these water channels in their urine.  We are currently 
measuring the amount of these special proteins in the urine of children who have had 
an operation for PUJ obstruction.  The aim is to work out if a new type of urine test 
could help doctors decide which children with PUJ obstruction need an operation and 
which don’t.    
In order to know whether the test works properly we need to know what the levels of 
these water channels are in children/young adults who have a swollen kidney but not 
a kidney blockage.  
For this reason the kidney research unit in Bristol is asking children and young adults 
like you who have a swollen kidney if they’d like to take part in the study.   
Why have I been chosen? 
All children/young adults who have a swollen kidney (but not a kidney blockage) will 
be invited to participate if their clinic appointment at the Bristol Children’s Hospital 
falls on a specified recruitment day. 
Do I have to take part? 
It is up to you to decide whether you take part.  You are still free to change your mind 
and leave the study at any time without giving a reason. If you decide not to take part 
or to come out of the study this will not affect the treatment you receive.  
What will happen if I agree to take part? 
Your scheduled appointment with your doctor will go ahead today as planned.  At the 
end of the appointment we would like you to be weighed and measured and we would 
like you to provide a urine sample into a pot.  This will be sent to the research 
laboratory in Bristol where the levels of water channels will be measured.   
Subsequently each time you attend an appointment we would like you to be weighed 
and measured and to provide a fresh urine sample into a pot.   
At each clinic appointment your doctor would also like to record some information 
about you including; your age, your height and weight, the reason for your swollen 




With your agreement and your parents’ permission we would like to store your 
samples after this research is complete for use in future ethically approved kidney 
disease research.  
What will happen to any information about me? 
Any information about you will be kept private. The information your doctor sends us 
will be stored securely at the laboratory.  At the end of the study the information will 
be encrypted and transferred to a secure storage facility within the University of Bristol 
called the Research Data Repository where it will remain for 20 years.  At the end of 
this period of time the information will be destroyed. 
What will happen to my urine samples? 
Once the urine samples have been analysed, they will be stored securely at the research 
laboratory in Bristol.  At the end of the study, with your agreement, the samples will 
continue to be stored at the research laboratory in Bristol. Only people in the research 
group with special passes can get in. The samples are kept in a freezer until they are 
used.  
What if new discoveries are made about PUJ obstruction?   
The research-group is interested in water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They want to determine whether a urine test 
for these water channels will help doctors decide which children and young adults need 
an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your samples to 
be stored and used for future research that’s ok, just tell us and we will dispose of them 
at the end of this study. 
How will I know the results of the study? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results that’s fine just let us know.  
Can I have more time to decide? 
Yes.  There is no time limit.   
What if I wish to leave the study? 
You can leave the study at any stage without having to give a reason. You can do this 
via telephone, email, or in writing to your specialist doctor or directly to the research 
team if you wish. The results of any tests on samples already collected will be used but 
no further tests will be done on these samples and no further samples will be collected.  
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Any samples already held by the research team will be destroyed in an appropriate 
manner. 
What do I do if I have concerns about the study? 
If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 
Complaints Team at the Bristol Children’s Hospital.  
Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project.  
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West – Central Bristol Research Ethics Committee. 
 
Researchers Patient Support and Complaints 
Team 
Miss Laura Jackson, Mr Mark Woodward and 
Prof Richard Coward 
Patient Support and Complaints 
Team 
Academic Renal Unit  Trust Headquarters 
University of Bristol University Hospitals Bristol 
Dorothy Hodgkin Building, Level 1 Marlborough Street 
Whitson Street Bristol 
Bristol BS1 3NU 
BS1 3NY  











Studying Kidney Blockage 




Thank you for reading this.  You can ask someone to help you read it if you want. 
Please ask if you don’t understand. 
There is a group of doctors and scientists in Bristol who are trying to help children who 
have a blockage of their kidney.  We call this blockage pelvi-ureteric junction (PUJ) 
obstruction.  It happens because part of the tube that drains wee out of the kidney is 




The doctors and scientists want to find out if a new test using a sample of wee can help 
them decide which children need an operation to fix this problem.  The test will show 
how much of a special protein there is in the wee. 
To find out how good the new test is we need to know what the levels of this special 
protein are in wee from children like you who have a swollen kidney.  That’s why we’re 
asking you if you’d like to take part.  
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Taking part will mean that every time you come to see the doctor at the Children’s 
Hospital we would like you to give us a sample of your wee.  Each time the sample will 
be tested to see how much of the special protein it contains.    
 
Also, each time you come to the hospital the doctor would like to measure how heavy 
and tall you are and collect some information about how old you are, and if you take 
any medicines. 
If you don’t want to take part that’s ok and it won’t affect your treatment. 
So that’s it!  
Do you want to ask any questions? 
 
Researchers 
Miss Laura Jackson, Mr Mark Woodward and Prof Richard Coward 
Academic Renal Unit 
University of Bristol 
Dorothy Hodgkin Building, Level 1 
Whitson Street 
Bristol, BS1 3NY 
 
Contact email: laura.jackson@bristol.ac.uk 
This study has been reviewed and approved by South West – Central Bristol Research 









Do aquaporins protect against renal damage in PUJ obstruction? 
Information Sheet for Parents/Guardians of Children with 
Normal Kidneys (Group 3)  
 
Your child is being invited to participate in a research study. Before you decide, it is 
important for you to understand why the research is being done and what it will 
involve for you and your child.  
Please take time to read the following information carefully and discuss it with others 
if you wish. If appropriate, please encourage your child to read their information sheet 
and discuss the study with them.  
Your child’s specialist doctor will explain if there is anything that is not clear or if you 
would like more information. Thank you for taking the time to read this. 
The purpose of this study 
There a number of children and young adults who come to the Bristol Children’s 
Hospital because they have pelvi-ureteric junction (PUJ) obstruction which is the most 
common cause of obstruction (blockage) in the urinary tract. Some need an operation 
known as a pyeloplasty to treat this condition. 
The kidneys produce urine by filtering the blood and removing waste products and 
water.  The urine must then drain out of the kidney through a funnel shaped structure 
called the renal pelvis and into a tube called the ureter which transports urine to the 
bladder where it is stored. 
PUJ obstruction is caused by a narrowing at the point where the ureter joins the renal 
pelvis.  This obstruction, which forms before the baby is born, means that urine can’t 
drain out of the kidney as fast as it is produced.  Urine therefore accumulates inside the 
kidney causing the kidney to swell.  This swelling (dilatation) is seen on ultrasound 
scan and is called hydronephrosis.  Accumulating urine may increase the pressure 






The major issue for doctors is deciding which children require surgery to relieve PUJ 
obstruction and limit kidney damage, and which do not. This is because some children 
with PUJ obstruction do not damage their kidneys, do not require surgery and 
ultimately grow out of the problem.  
Our current ability to distinguish between those children with high pressure 
“damaging” obstruction and those with low pressure “safe” non-kidney damaging PUJ 
obstruction is limited.   
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  By 
reabsorbing water from the urinary tract, these channels may reduce the pressure in 
the system, and explain the mechanism behind “safe” and “damaging” PUJ obstruction.   
Everybody sheds some of these water channels in their urine.  We want to collect these 
special proteins from the urine, measure their amount and show whether they are a 
good marker of high pressure and low pressure kidneys.  This will enable us to work 
out if a new type of urine test could help doctors decide which children with PUJ 
obstruction need an operation and which don’t.    
In order to know whether the test correctly identifies which children need an operation 
we need to know what the normal levels of these water channels are as a comparison. 
For this reason the kidney research unit in Bristol is asking children who have normal 






Why has my child been chosen? 
Every child/young adult with normal kidneys who attends the Bristol Children’s 
Hospital surgery/urology clinics on specified recruitment days will be invited to 
participate. 
Does my child have to take part? 
It is up to you to decide whether your child takes part. If you decide they can take part 
you will be asked to sign a consent form. You are still free to change your mind and 
withdraw your child from the study at any time without giving a reason, and this will 
not affect the treatment your child receives. 
What will happen if my child agrees to take part? 
Your child’s scheduled appointment with the doctor will go ahead today as planned.  
With your consent at the end of the appointment your child will be weighed and 
measured and we would like them to provide a urine sample into a pot.  In younger 
children the sample can be collected from the nappy.  The urine sample will be sent to 
the research laboratory in Bristol where the levels of water channels will be measured.  
The doctor will record some information about your child which, with your permission, 
will be taken from their medical notes/results file.  This will include; their age, their 
height and weight, the reason for their hospital appointment and current medications.  
With your permission we would like to store the urine sample after this research is 
complete for use in future ethically approved kidney disease research.  
What will happen to any information about my child? 
Any medical information about your child will be kept private.  Limited personal details 
identifying your child as participating in the study will remain on the NHS computer 
system at the Bristol Children’s Hospital.  All children will be assigned a study number 
so that their urine sample and information collected about them is labelled with this 
number and no personal details when it is transferred to the research laboratory.  The 
information your doctor sends to the researchers and the results we have from sample 
analysis will be stored securely at the laboratory.  At the end of the study the 
information will be encrypted and transferred to a secure storage facility within the 
University of Bristol called the Research Data Repository where it will remain for 20 
years.  At the end of this period of time the information will be destroyed. 
What will happen to my child’s samples? 
Once the urine sample has been analysed, it will be stored securely at the research 
laboratory in Bristol.  The sample will be labelled with your child’s unique study 
number so that their sample results can be linked with their medical information.  At 
the end of the study, with your permission, the sample will continue to be stored at the 
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research laboratory pending further study.  Access to this building is limited to the 
laboratory staff and an identification card and biometric authorisation is required for 
access. 
What if new discoveries are made about PUJ obstruction?   
The research-group is interested in water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They want to determine whether a urine test 
for these water channels will help doctors decide which children and young adults need 
an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your child’s 
sample to be stored and used for future research that’s ok, just inform your specialist 
doctor and we will dispose of it at the end of this study. 
How will I know the outcome of the research? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results please inform your specialist doctor.  
Will the results be published? 
All data collected will be collated and published in peer-reviewed scientific journals.  
The findings will also be presented at national and international scientific conferences.  
All this information will be anonymous and it will not be possible to identify your child 
from the data.    
Can I have more time to decide? 
Yes. There is no time limit.   
What if I wish to withdraw my child from the study? 
A participant may withdraw at any stage without having to give an explanation. You 
can do this via telephone, email, or in writing to your specialist doctor or directly to the 
research team if you wish. The results of any tests on samples already collected will be 
used but no further tests will be done on these samples and no further samples will be 








What are the risks/benefits in participating in this study? 
This study does not require you to make an extra visit to the hospital however it does 
require your child to be weighed and measured and provide a urine sample at the end 
of today’s clinic appointment. 
The benefits of participating in the study are that it will increase medical knowledge 
about PUJ obstruction potentially leading to the development of a new urine test.  We 
hope this urine test will allow earlier and improved detection of those children 
requiring surgery for PUJ obstruction.  
What do I do if I have concerns about the study? 
If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 
Complaints Team at the Bristol Children’s Hospital. 
Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project. 
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West – Central Bristol Research Ethics Committee. 
 
Researchers Patient Support and Complaints 
Team 
Miss Laura Jackson, Mr Mark Woodward and 
Prof Richard Coward 
Patient Support and Complaints 
Team 
Academic Renal Unit  Trust Headquarters 
University of Bristol University Hospitals Bristol 
Dorothy Hodgkin Building, Level 1 Marlborough Street 
Whitson Street Bristol 
Bristol BS1 3NU 
BS1 3NY  







Do aquaporins protect against renal damage in PUJ obstruction? 
Information Sheet for Young Adults with Normal Kidneys  
(Group 3) 
 
You are being invited to take part in a project. Before you decide, it is important for you 
to understand why we want to do it and what it means for you.  
Please take time to read this and chat about it with others if you want.  
Your specialist doctor will explain anything that is confusing, or give you more 
information. Thank you for taking the time to read this. 
The purpose of this study 
There a number of children and young adults who come to the Bristol Children’s 
Hospital because they have a blockage of their kidney called pelvi-ureteric junction 
(PUJ) obstruction.  Some need an operation known as a pyeloplasty to make it better.  
PUJ obstruction is caused by a narrowing in the upper part of the tube that drains urine 
out of the kidney.  Urine therefore builds up and can increase the pressure inside the 
kidney.  In some children and young adults this can cause the kidney to not work 





Sometimes it can be difficult for doctors to figure out which children and young adults 
need an operation to protect their kidney and which will simply grow out of the 
problem. 
Current research suggests that special water channels (proteins called aquaporins) in 
the kidney and its drainage tubes may help to protect the kidney from damage.  
Everybody sheds some of these water channels in their urine.  We are currently 
collecting these special proteins from the urine of children with PUJ obstruction and 
measuring their amount.  The aim is to work out if a new type of urine test could help 
doctors decide which children with PUJ obstruction need an operation and which don’t.    
In order to know whether the test works properly we need to know what the normal 
levels of these water channels are as a comparison. 
For this reason the kidney research unit in Bristol is asking children and young adults 
like you who have normal kidneys if they’d like to take part in the study.   
Why have I been chosen? 
Every child/young adult with normal kidneys who attends the Bristol Children’s 
Hospital surgery/urology clinics on specified recruitment days will be invited to 
participate. 
Do I have to take part? 
It is up to you to decide whether you take part.  You are still free to change your mind 
and leave the study at any time without giving a reason. If you decide not to take part 
or to come out of the study this will not affect the treatment you receive.  
What will happen if I agree to take part? 
Your scheduled appointment with your doctor will go ahead today as planned.  At the 
end of the appointment we would like you to be weighed and measured and we would 
like you to provide a urine sample into a pot.  This will be sent to the research 
laboratory in Bristol where the levels of water channels will be measured.   
Your doctor would also like to record some information about you including; your age, 
your height and weight, the reason for your clinic appointment and if you are taking 
any medicines. 
With your agreement and your parents’ permission we would like to store your sample 
after this research is complete for use in future ethically approved kidney disease 
research.  
What will happen to any information about me? 
Any information about you will be kept private. The information your doctor sends us 
will be stored securely at the laboratory.  At the end of the study the information will 
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be encrypted and transferred to a secure storage facility within the University of Bristol 
called the Research Data Repository where it will remain for 20 years.  At the end of 
this period of time the information will be destroyed. 
What will happen to my urine sample? 
Once the urine sample has been analysed, it will be stored securely at the research 
laboratory in Bristol.  At the end of the study, with your agreement, the sample will 
continue to be stored at the research laboratory in Bristol. Only people in the research 
group with special passes can get in. The samples are kept in a freezer until they are 
used.  
What if new discoveries are made about PUJ obstruction?   
The research-group is interested in water channels (aquaporins) and their role in 
protecting the kidney in PUJ obstruction.  They want to determine whether a urine test 
for these water channels will help doctors decide which children and young adults need 
an operation for PUJ obstruction. 
In the future other proteins and substances may be found to be involved in PUJ 
obstruction.  The group would like to be able to test for new proteins and substances, 
if they are found, using the original stored samples.  If you don’t want your sample to 
be stored and used for future research that’s ok, just tell us and we will dispose of it at 
the end of this study. 
How will I know the results of the study? 
At the end of the study your doctor will send you a summary of the study results.  If you 
don’t want to receive a copy of the results that’s fine just let us know.  
Can I have more time to decide? 
Yes.  There is no time limit.   
What if I wish to leave the study? 
You can leave the study at any stage without having to give a reason. You can do this 
via telephone, email, or in writing to your specialist doctor or directly to the research 
team if you wish. The results of any tests on the sample already collected will be used 
but no further tests will be done on this sample.  The sample held by the research team 
will be destroyed in an appropriate manner. 
What do I do if I have concerns about the study? 
If you have any concerns or further questions about this study or the way it is carried 
out, you should contact the research team. You can also contact the Patient Support and 




Will this study have an educational role?  
This study is being undertaken as part of a higher degree educational project. 
Has this research study been approved by an ethics committee? 
All research in the NHS is looked at by an independent group of people, called a 
Research Ethics Committee, to protect your interests. This study has been reviewed 
and approved by South West – Central Bristol Research Ethics Committee. 
 
Researchers Patient Support and Complaints 
Team 
Miss Laura Jackson, Mr Mark Woodward and 
Prof Richard Coward 
Patient Support and Complaints 
Team 
Academic Renal Unit  Trust Headquarters 
University of Bristol University Hospitals Bristol 
Dorothy Hodgkin Building, Level 1 Marlborough Street 
Whitson Street Bristol 
Bristol BS1 3NU 
BS1 3NY  














Studying Kidney Blockage 




Thank you for reading this.  You can ask someone to help you read it if you want. 
Please ask if you don’t understand. 
There is a group of doctors and scientists in Bristol who are trying to help children who 
have a blockage of their kidney.  We call this blockage pelvi-ureteric junction (PUJ) 
obstruction.  It happens because part of the tube that drains wee out of the kidney is 
too narrow.  Sometimes the blockage makes the kidney not work properly.  
 
 
The doctors and scientists want to find out if a new test using a sample of wee can help 
them decide which children need an operation to fix this problem.  The test will show 





To find out how good the new test is we need to know what the normal levels of this 
special protein are in wee from children like you who don’t have blocked kidneys.  
That’s why we’re asking you if you’d like to take part.  
Taking part means we would like you to give us a sample of your wee.  The wee sample 
will be tested to see how much of the special protein it contains.    
Your doctor would also like to measure how heavy and tall you are and collect some 
information about how old you are and if you take any medicines. 
If you don’t want to take part that’s ok and it won’t affect your treatment. 
So that’s it!  
Do you want to ask any questions? 
 
Researchers 
Miss Laura Jackson, Mr Mark Woodward and Prof Richard Coward 
Academic Renal Unit 
University of Bristol 
Dorothy Hodgkin Building, Level 1 
Whitson Street 
Bristol, BS1 3NY 
 
Contact email: laura.jackson@bristol.ac.uk 
This study has been reviewed and approved by South West – Central Bristol Research 
Ethics Committee and is being undertaken as part fulfilment of an educational project. 
 
10.3.3 Study consent forms 





Do aquaporins protect against renal damage in PUJ obstruction? 
Consent Form for Parents/Guardians    Group 1 
(Name of Patient)   
(DOB) 
(Study Assigned ID Number) 
I confirm that I have read and understood the information sheet (PUJO Group 1 
Version 5) for the above study and I have had the opportunity to ask questions. 
I agree for my child to take part in the study. 
I understand my child’s participation is voluntary and that my child is free to 
withdraw at any time without giving any reason, and without my child’s 
medical care or legal rights being affected. 
I understand that sections of my child’s medical notes may be looked at by 
responsible individuals from the NHS Trust, Sponsor or from regulatory  
authorities where it is relevant to my child’s participation in research. I give 
permission for these individuals to have access to my child’s records. 
I agree that my child’s medical notes and test results can be looked at by 
Bristol Children’s Hospital NHS doctors.  I give permission for information 
relevant to the study to be collected for analysis. 
I agree for my child to be weighed and measured at each hospital attendance. 
I agree for my child to provide urine samples before, during and after their 
operation.  
I agree for my child to have the pressure within their obstructed kidney 
measured during their operation. 
I agree that the narrowed piece of drainage tube tissue (renal pelvis/ureter 
junction) removed during the operation can be tested in the laboratory. 
I agree that my child’s General Practitioner will be informed of their 
participation in this study. 
I agree that if new proteins and substances associated with PUJ obstruction 
were to be found that my child’s samples could be tested for these. 
I agree that the samples may be stored and used by researchers in future 









Name of parent/guardian.................................................          Date .............................. 
Signature............................................ 
 
Name of person taking consent........................................        Date............................... 
Signature............................................ 
 
Assent Form for Children/Young People  
For children/young people who would like to co-sign this form to confirm you want to take part, 
you can write your name here: 
Child (or if unable, parent on their behalf) /young person to circle all they agree with:  
 
 
Have you read (or had read to you) about this project?    Yes/No  
 
Has somebody else explained this project to you?    Yes/No  
 
Do you understand what this project is about?     Yes/No  
 
Have you asked all the questions you want to ask?   Yes/No  
 
Have you had your questions answered in a way you understand?  Yes/No  
 
Do you understand it’s OK to stop taking part at any time?   Yes/No  
 
Are you happy to take part?       Yes/No  
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
 
If you do want to take part, you can write your name below  
 
Your name.................................................................................................... Date .............................. 
 
Name of person taking consent........................................................... Date............................... 
Signature............................................ 
Thank you 





Do aquaporins protect against renal damage in PUJ obstruction? 
Consent Form for Parents/Guardians    Group 2 
 
(Name of Patient)  
(DOB) 
(Study Assigned ID Number) 
 
I confirm that I have read and understood the information sheet (PUJO Group 2 
Version 1) for the above study and I have had the opportunity to ask questions. 
I agree for my child to take part in the study. 
I understand my child’s participation is voluntary and that my child is free to 
withdraw at any time without giving any reason, and without my child’s medical 
care or legal rights being affected. 
I understand that sections of my child’s medical notes may be looked at by 
responsible individuals from the NHS Trust, Sponsor or from regulatory  
authorities where it is relevant to my child’s participation in research. I give 
permission for these individuals to have access to my child’s records. 
I agree that my child’s medical notes and test results can be looked at by Bristol 
Children’s Hospital NHS doctors.  I give permission for information relevant to 
the study to be collected for analysis. 
I agree for my child to be weighed and measured at every urology outpatient 
clinic attendance.  
I agree for my child to provide a urine sample at every urology outpatient clinic 
attendance.  
I agree that my child’s General Practitioner will be informed of their 
participation in this study. 
I agree that if new proteins and substances associated with PUJ obstruction 
were to be found that my child’s urine samples could be tested for these. 
I agree that the urine samples may be stored and used by researchers in future 










Name of parent/guardian................................................................  Date .............................. 
Signature............................................ 
 
Name of person taking consent....................................................  Date............................... 
Signature............................................ 
 
Assent Form for Children/Young People  
For children/young people who would like to co-sign this form to confirm you want to take part, 
you can write your name here: 
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with:  
 
 
Have you read (or had read to you) about this project?    Yes/No  
 
Has somebody else explained this project to you?    Yes/No  
 
Do you understand what this project is about?     Yes/No  
 
Have you asked all the questions you want to ask?   Yes/No  
 
Have you had your questions answered in a way you understand?  Yes/No  
 
Do you understand it’s OK to stop taking part at any time?   Yes/No  
 
Are you happy to take part?       Yes/No  
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
 
If you do want to take part, you can write your name below  
 
Your name.................................................................................................... Date .............................. 
Name of person taking consent........................................................... Date............................... 
Signature............................................ 
Thank you 






Do aquaporins protect against renal damage in PUJ obstruction? 
 
Consent Form for Parents/Guardians    Group 3 
 
(Name of Patient)  
(DOB) 
(Study Assigned ID Number) 
 
I confirm that I have read and understood the information sheet (PUJO Group 3 
Version 1) for the above study and I have had the opportunity to ask questions. 
I agree for my child to take part in the study. 
I understand my child’s participation is voluntary and that my child is free to 
withdraw at any time without giving any reason, and without my child’s 
medical care or legal rights being affected. 
I understand that sections of my child’s medical notes may be looked at by 
responsible individuals from the NHS Trust, Sponsor or from regulatory  
authorities where it is relevant to my child’s participation in research. I give 
permission for these individuals to have access to my child’s records. 
I agree that my child’s medical notes and test results can be looked at by 
Bristol Children’s Hospital NHS doctors.  I give permission for information 
relevant to the study to be collected for analysis. 
I agree for my child to be weighed and measured.  
I agree for my child to provide a urine sample.      
I agree that my child’s General Practitioner will be informed of their 
participation in this study. 
I agree that if new proteins and substances associated with PUJ obstruction 
were to be found that my child’s urine sample could be tested for these. 
I agree that the urine sample may be stored and used by researchers in future 









Name of parent/guardian...................................................................... Date .............................. 
Signature............................................ 
 
Name of person taking consent........................................................... Date............................... 
Signature............................................ 
 
Assent Form for Children/Young People  
For children/young people who would like to co-sign this form to confirm you want to take part, 
you can write your name here: 
 
Child (or if unable, parent on their behalf) /young person to circle all they agree with:  
 
 
Have you read (or had read to you) about this project?    Yes/No  
 
Has somebody else explained this project to you?    Yes/No  
 
Do you understand what this project is about?     Yes/No  
 
Have you asked all the questions you want?     Yes/No  
 
Have you had your questions answered in a way you understand?  Yes/No  
 
Do you understand it’s OK to stop taking part at any time?   Yes/No  
 
Are you happy to take part?       Yes/No  
 
If any answers are ‘no’ or you don’t want to take part, don’t sign your name!  
 
If you do want to take part, you can write your name below  
 
Your name................................................................................................. Date .............................. 
 
Name of person taking consent........................................................ Date............................... 
Signature............................................ 
Thank you 




10.3.4 GP letter for group 1 patients 
 
A copy of the covering letter overleaf was attached to a copy of the Group 1 parent patient 















































Academic Renal Unit 
University of Bristol 
Dorothy Hodgkin Building, Level 1 
Whitson Street 
Bristol, BS1 3NY 
Tel: 07930 868195 
Date............................................................................. 
Do aquaporins protect against renal damage in pelvi-ureteric 
junction (PUJ) obstruction?  
 
RE: Name:.................................................................................................. 
Date of Birth:................................................................................... 
 
Dear Dr....................................., 
I am writing to inform you that the above-named patient has been recruited to a study 
being undertaken at the Bristol Royal Hospital for Children in conjunction with the 
University of Bristol. This study is designed to investigate the mechanism of renal 
injury in PUJ obstruction, and to determine whether urine aquaporin measurement is 
a useful biomarker to direct the timing and necessity of surgical intervention.  I have 
enclosed a copy of the patient information leaflet detailing the study received by the 
child and their family. 
Please do not hesitate to contact me should you have any questions or require a copy 
of the scientific protocol. 
Yours Sincerely, 
 
Miss Laura Jackson 
Research Fellow in Paediatric Surgery 
Researchers: Miss Laura Jackson, Mr Mark Woodward and Prof Richard Coward 
Contact email: laura.jackson@bristol.ac.uk 
This study has been reviewed and approved by South West – Central Bristol Research 
Ethics Committee and is being undertaken as part fulfilment of an educational project. 
This study is sponsored by the University of Bristol. 
